Progress in Medicinal Chemistry 7
This Page Intentionally Left Blank
Progress in MedicinaI Chemistry 7 Edited by
G...
36 downloads
6876 Views
16MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Progress in Medicinal Chemistry 7
This Page Intentionally Left Blank
Progress in MedicinaI Chemistry 7 Edited by
G. P. ELLIS, B.SC., PH.D., F.R.I.C. Department of Chemistry, University of Wales Institute of Science and Technology. King Edward VII Avenue, Cardiff and G. B. WEST, B.PHARM.,D.SC.,PH.D., F.I.BIOL Barking Regional College of Technology, North-east London Polytechnic, Longbridge Road, Dagenham , Essex
LONDON BUTTERWORTHS
T H E BUTTERWORT11 GROUP ENGLAND Butterworth & Co (Publishers) Ltd London: 88 Kingsway, WC2B 6 A B AUSTRALIA Butterworth & (’0(Australia) Ltd Sydney: 20 Loftus Street Melbourne: 343 Little Collins Street Brisbane: 240 Queen Street CANADA Butterworth & Co (Canada) Ltd Toronto: 1 4 Curity Avenue, 374 NIlW ZliALAND Butterworth & C o (New Zealand) Ltd Wellington: 49/5 1 Ballance Street Auckland: 35 High Street
SOIITtI AI:RI(’A Butterworth & <‘o (South Africa) (I’ty) Ltd Durban: 33/35 Bench Grove 1,’irst published 1970
@ Ih~tterwortli& (’0 (Publishers) Ltd.. I 9 7 0 Suggested CJ.D.(’. number: 6 15.7:54 ISBN 0 4 0 8 70080 7
Printed by plioto-litliograpliy and tiiadc in (;reat Britain at the Pitnian Press. Bath
Preface
A nuniber of changes have been made in Volume 7 of the series, and each volume will henceforth be published in two paper-backed parts at approximately sixmonthly intervals. On publication of the second part a complete volume will become available in a single case-bound edition. We hope that the other minor changes will also be appreciated by our readers. As in previous volumes, we are grateful to reviewers and others for their encouragement, criticisms and suggestions. We hope that the new arrangement of six-nionthly issues wlll permit reviews to appear in print at a shorter interval of time between submission and publication than has been achieved in the past. Our thanks are due t o the staff of Butterworths and t o the authors, societies and publishers for permission t o use illustrations and tables.
G. P. E l L l S G. B. W r m
This Page Intentionally Left Blank
Contents 1 Some recently introduced drugs A. P. Launchbury, B.Sc., M.P.S.* Selly Oak Hospital, Birmingham, 29, England
2 The Biochemical Basis for the Drug Actions of Purines John A. Montgomery, Ph.D. Kettering-Meyer Labora tory, Sou thern Research La bora t o p , Birmingharn, Alabama 35205, U.S.A. 3 The Chemistry of Guanidines and their Actions a t Adrenergic Nerve Endings G. J. Durant, B.Sc., Ph.D., A.R.I.C. Smith Kline and French Research Institute, Welwyn Garden City, Hertfordshire A.M. Roe,M.A., D.Phil., F.R.I.C. Stnith Kline and Fretich Research Institute, Welwyn Garden City, Hertfordshire A. L. Green, B.Sc., P1i.D. Departrnent of Biocheni istry, University of Strathclyde, Glasgow
1
69
124
4 Medicinal Chemistry for the Next Decade W. S. Peart, F.R.S., M.D., F.R.C.P. Medical Unit, St. Mary's Hospital, London, W.2.
71 s
S Analgesics and their Antagonists: Recent Developments
729
A. F.Casy, B.Sc., Ph.D., F.R.I.C., F.P.S. Faculty of Pharinacy and Pharniaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada 6 Some Pyrimidines of Biological and Medicinal Interest - Part I1 C.C. Cheng, B.S., M.A., Ph.D. Midwest Research Institute, Kansas City, Missouri 641 l U , U.S.A. and Barbara Roth, B.S., M.S., Ph.D. Burroughs Wellcome and Co. (U.S.A.) lnc., Tuckahoe, New York I0707, U.S.A.
Index
* Present address:
285
343 Pharrnitalia (U.K.) Ltd., Kingmaker House, Station House, Barnet, Hcrts
CONTENTS OF EARLIER VOLUMES VOLUME 1 1 PHARMACOLOGICAL SCREENING TESTS-W. G. Smith 2 HYPOTENSIVE AGENTS-R. Wien 3 TRANQUILLIZERS-M. W. Parkes 4 DIURETIC DRUGS-H. Heller and M. Ginsburg 5 ORAL HYPOGLYCAEMIC DRUGS-J. D. H. Slater 6 ANTIFUNGAL AGENTS-E. P. Taylor and P. F. D’Arcy
VOLUME 2 1 THE PATENTING OF DRUGS-F. Murphy
2 THE TESTING AND DEVELOPMENT O F ANALGESIC DRUGS-A. H. Beckett and A. F. Casy 3 MECHANISMS 01: NEUROMUSCULAR BLOCKADE-W. C. Bowman 4 2-HALOGENOALKYLAMINES-J. D. P. Graham 5 ANAPHYLACTIC REACTIONS-G. E. Davies VOLUME 3 1 SOME CHEMICAL ASPECTS O F NEUROMUSCULAR BLOCK-J. B. Stenlake
2 THE CHEMOTHERAPY OF TRYPANOSOMIASIS-L. P. Walls 3 ANTITUSSIVE DRUGS-C. I. Chappel and C. Von Seeman 4 THE CHEMISTRY AND PHARMACOLOGY OF THE RAUWOLFIA ALKALOIDSR. A. Lucas 5 STATISTICS’ AS APPLIED T O PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING-G. A. Stewart and P. A. Young 6 ANTICONVULSANT DRUGS-A. Spinks and W. S. Waring 7 LOCAL ANAESTHETICS-S. Wiedling and C. Tegntr VOLUME 4 1 EXPERIMENTAL HYPERSENSITIVITY REACTIONS-P. S. J. Spencer and G. B. West
2 MECHANISMS O F TOXIC ACTION-J. M. Barnes and G. E. Paget 3 DRUG RECEPTOR INTERACTIONS-E. W. Gill 4 POLYPEPTIDES OF MEDICINAL INTEREST-H. D. Law 5 ANALGESICS AND THEIR ANTAGONISTS: BIOCHEMICAL ASPECTS AND STRUCTURE-ACTIVITY RELATIONSHIPS-A. H. Beckett and A. F. Casy VOLUME 5 1 POLYPEPTIDE ANTIBIOTICS OF MEDICINAL INTEREST-R. 0. Studer 2 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS-S. S. Adams and R. Cobb 3 T H E PHARMACOLOGY OF HEPARIN AND HEPARINOIDS-L. B. Jaques 4 THE HISTIDINE DECARBOXYLASES-D. M. Shepherd and D. Mackay 5 PSYCHOTROPIC DRUGS AND NEUROHUMORAL SUBSTANCES IN THE CENTRAL . I NERVOUS SYSTEM-J. Crossland 6 THE NITROFURANS-K. Miura and H. K. Reckendorf VOLUME 6 1 THE BRITISH PHARMACOPOEIA COMMISSION-G. R. Kitteringham
2 PHARMACOLOGICAL ASPECTS O F THE CORONARY CIRCULATION-J. R. Parratt 3 SOME PYRIMIDINES OF BIOLOGICAL AND MEDICINAL INTEREST-Part 1C. C. Cheng 4 THE MECHANISM O F ACTION OF SOME ANTIBACTERIAL AGENTS-A. D. Russell 5 THE BIOSYNTHESIS AND METABOLISM OF THE CATECHOLAMINES-M. Sandler and C. R. J. Ruthven 6 THE LITERATURE O F MEDICINAL CHEMISTRY-G. P. Ellis
1 Some Recently Introduced Drugs A. P. LAUNCHBURY, B.Sc., M.P.S. Selly Oak Hospital, Birmingham, 29, England * INTRODUCTION Some preliminary considerations MODIFICATIONS O F PHY SICO-CHEMICAL IMPORTANCE Penamecillin Prednisolone stearoylglycollate Doxycycline DRUGS OF NOVEL STRUCTURE OR ACTIVITY A curariform muscle relaxant: pancuronium bromide A non-addictive analgesic: pentazocine An intravenous anaesthetic: propanidid A psychotropic drug: oxypertine A tricyclic antidepressive: ipnndole An anti-hypertensive sympathetic neurone blocker: debrisoquine An adrenergic a-receptor blocker: thymoxamine Three phenylethylarnines with complex sympatholytic or spasmolytic effects: (a) prenylamine (b) verapamil (c) mebeverine A diuretic: ethacrynic acid (with notes on frusernide) Two hypotensive diuretics: (a) chlorexolone (b) clopamide A mucoid-secretion modifying agent: bromhexine
A pulmonary anti-allergic for asthma therapy: cromoglycic acid A terpenoid ester for gastroduodenal ulcer: gefarnate A broad-spectrum antimicrobial nitrofuran: nifuratel The f m t anti-pseudomonal penicillin: carbenicillin A new antibiotic of unusual structure: rifamide A new antitubercular drug: rifampicin A selective bronchodilator: salbutamol Concluding remarks References *Present address: Pharmitalia (U.K.) Ltd, Kingmaker House, Barnet, Herts. 1
7
2 3 3
5 8
12 12 16 20 23 25
27 29 31 31 34 35 36 40 43 44 45 46
49 50 52 54 55 56 51
-3
SOME RECENTLY INTRODUCED DRUGS
INTRODUCTION In this brief review the variety of drugs t o b e discussed precludes a completely systematic approach. The compounds t o be studied have therefore been grouped under two main headings: ( 1 ) those which are modifications, designed primarily to improve physicochemical characteristics, of pre-existing drugs; and (2) drugs which are either completely new in structure or activity or are sufficiently different from previously available agents t o warrant separate notice.
Substances included in (2) form the major part of this work, because of their number and variety, but drugs in ( 1 ) are n o less important therapeutically.
Some preliminary considerations
Before a drug produces an effect, it must interact with, or pass through, one or more biological membranes. In a very few cases, the drug is required t o produce a pharmacological effect on the first membrane encountered during its absorption, distribution and excretion within an organism; generally it must penetrate external (plasma) cell membranes, many cytoplasmic membranes (for example the endoplasmic reticulum) and often organelle (for example lysosomal, microsoma1 or nuclear) membranes before reaching its required site o f action; in addition, some drugs are particularly intended t o interact with one or more of these barriers. With some estimates [ 11 placing membrane mass as high as 80 per cent of the total dry mass of the cell, it is not surprising that increasing attention is being given to the study of biological membrane structures and functions [2-4) . Interaction between membranes and chemical compounds often yields information of particular application to pharmacology [ S ] . While the early concept of cell membrane as a simple lipid film is a gross oversimplification, it has none the less enabled the behaviour of many drugs t o be better understood, provided allowance is made for the effects of the pH of the aqueous phases, t h e pK, of the drug, and the lipid-solubility of the non-ionized species [ 6 ] .By processes which have been described as ‘drug latentiation’ [7, 81 , the absorption-distiibution characteristics of drugs are being modified to take advantage of the fact that an un-ionized, lipid-soluble molecule penetrates biological membranes much more readily than a polar ionized one. Esterification (often double esterification) is being increasingly employed t o yield compounds which can be more readily absorbed (usually from the alimentary tract), subsequent esterase-hydrolysis releasing the parent drug in the tissues. Well-known examples of this approach include methyl nicotinate, glycol salicylate, betamethasone 17-valerate, fluocortolone 2 1hexanoate and ditophal (for epidermal absorption), and triacetyloleandomycin and other macrolide esters (for alimentary absorption). Triclofas deviates from
A. P. LAUNCHBUKY
3
this scheme only in that the ester is ionic-it is, none the less, a bland ‘transport form’ of the highly irritant trichlorethanol. In the present review, two further examples will be discussed; both are double esters b u t one (penamecillin) is o f a pharmacologically-active acid, the other (prednisolone stearoylglycollate) of an alcohol. In addition, an example o f reduction of polarity (or increase in lipid solubility) by another method-the elimination of a hydroxyl group-will be noted in the section o n doxycycline.
MODIFICATIONS OF PHYSICO-CHEMICAL IMPORTANCE Penamecillin
Benzylpenicillin is still the most active penicillin against the classically penicillinsensitive organisms [9-121 . It is, however, only poorly utilized after oral administration partly because of destruction by gastric acid and gut flora, but more particularly because, being strongly anionic and therefore only very slightly lipophilic, it is poorly absorbed. Almost all t h e drug which achieves a therapeutic effect (during oral administration of the sodium, potassium or calcium salts) is absorbed in the duodenal region; some 70-80 per cent of each dose is lost by degradation or faecal elimination [ 131. Simple methyl, lower alkyl and benzyl esters show improved absorption, but are of little clinical value since they neither undergo spontaneous aqueous hydrolysis [ 141 nor cleavage to active antibiotic by an enzyme present in man [ I S ] (though rodents can perform this reaction). Some alkanolamine esters which d o hydrolyse spontaneously gave early promise [ 141 though, of these, only penethamate hydriodide [ 161 received clinical application (asan injection, Estopen)and even this drug hasnow fxllen into disuse. The solution t o this problem lay, in effect, in conversion of the penicillin anion t o an alcohol (i.e. t o an ester of a gem diol) which was then further esterified with a suitable acid-though this wasnot the method o f synthesis. The penicillin molecule is extremely labile and synthesis of its double esters has been achieved by the use of a-acyloxyalkyl halides; these readily form the required compounds by direct reaction with a benzylpenicillin salt [ 171 , the activation energy for this process being low enough to avoid excessive penicillin degradation. Such double esterification, in the case of the acetoxymethyl derivative of penicillin G, results in rapid biological availability of benzylpenicillin since non-specific acetic esterases are ubiquitous in mammalian tissues and serum [25] . Once the acetate moiety is removed the remaining compound (which can be considered t o be the ester of penicillin, G with methanediol) undergoes rapid and spontaneous decomposition to active antibiotic and formaldehyde [16, 171 (the latter being promptly metabolized t o less vigorously reactive substances). The acetoxymethyl ester of benzylpenicillin is penamecillin (Havapen, 1 ). It is an almost white, free-flowing powder lacking the characteristic odour 2nd taste which make penicillins generally unpalatable when administered in tablet or
4
SOME RECENTLY INTRODUCED DRUGS
liquid formulation 161. This is an important factor in determining patient coopera t ion in therapy. The initial pharmacological report on penamecillin [ 181 , while containing errors of deduction regarding the site and rate of hydrolysis of the drug, showed it to be superior to the anion with regard to stability in gastric juice and the COOCH2 -0OC Me
(I1
persistence of serum antibacterial levels after single doses. When given orally to dogs, penamecillin itself was not isolated from circulating blood, even from the hepatic portal vein. The method of recovery (extraction into chloroform which, in contrast to acetone. removes penamecillin selectively in the presence of benzylpenicillin) was verified by in virro checks. Other in uitro experiments showed that extremely rapid hydrolysis to benzylpenicillin was effected by exposure t o tissue hornogenates and the serum of various animals. The possibility that the fatsoluble ester is taken up in lipidsvia the lymphatics was eliminated by examination of the contents of the thoracic duct two hours after oral dosage; n o penamecillin was detected. A re-examination [ 191 of the data presented in the earlier paper cleared some o f the apparent anomalies by the use of pharinacokinetic analysis. For example, it had been observed that both benzylpenicillin and penamecillin appeared in the circulation only as benzylpenicillin yet the levels resulting from a single dose of panamecillin persisted (at 0.1 pg/ml or above) for 10 hourscompared with 5-6 hours for an equivalent dose (on a molar basis) of benzylpenicillin, though the latter drug produced much higher levels, more rapidly, than did penamecillin. This phenomenon was shown to be due to prolonged absorption of penamecillin from the gut (over a period of 10 hours or so) which contrasted sharply with benzylpenicillin for which little absorption was demonstrated beyond the first h o u r after administration. This is a classic example of biological half-life estimations having been invalidated by failure t o correct for the behaviour of a poorly and slowly absorbed drug. Clinically, penamecillin has exhibited the expected activity against infections normally responding to benzylpenicillin [20-221, with the advantage that doses can be given at 8-hourly (instead of 4-6 hourly) intervals and still provide relatively smooth blood-level curves. Organisms producing penicillinases, or those normally tolerant to penicillin G, d o not, of course, respond to penamecillin. The main advantage of penamecillin lies in its lipid-solubility and resistance to degradation until absorbed into the alimentary mucosa, though the potential inherent i n these properties has not been widely appreciated by clinicians [24] . Its mrliti drawback at present is its very poor water solubility which limits the rate of dissolution of the drug particles and thereby limits the amount of drug
A . P. LAUNCHBURY
5
presented to the mucosa for absorption at any one time. While this low aqueous solubility (approximately 4.5 mg/lOO ml [ 191 ) in large measure maintains the intestinal reservoir of the drug, a more favourable rate of dissolution would enable some of the 90 per cent of each dose at present eliminated to be utilized therapeutically. There seems to be room for development here, and in the application of this principle of double esterification to the formulation of improved depot penicillin injections-where penamecillin’s low water solubility may be an asset [231 . Prednisolone stearoylglycollate *
For the first decade or so after the introduction into medicine of cortisone and hydrocortisone, most research endeavour attempted to emphasize therapeutically desirable effects (and reduce the proportion of unwanted properties) by modifying and substituting the steroid ring-system. This process has indeed resulted in drugs with greatly increased specificity over a wide range of endocrine functions and, in the anti-inflammatory field, produced compounds such as prednisolone, triamcinolone, dexamethasone, paramethasoneand betamethasone-to name only a few. These coiticosteroids have, generally, been administered only as the 2 1-acetate or the corresponding free alcohol when used orally or parenterally, though other esters and some 1 6 ~ 117cy-‘acetonides’ , are widely used topically. Of recent years, however, more attention has been paid t o the potential latent in 21 -esterification as. a means of modifying corticosteroid activity. While propionates, benzoates, decanoates and hexanoates have been common among parenteral preparations of other steroid groups (mainly androgens, oestrogens and progestogens), such esters are only now being examined as rational modifications in the oral steroid treatment of systemic disease. A series of 21-esters of prednisolone has now been described [ 2 6 ] , screened by the classic Ungar [27] test. Chemically, the series consisted of two parallel lines of compounds; (a) simple 21 -esters of prednisolone with short (propionic) t o long (stearic) chain aliphatic acids and with one aromatic acid (benzoic), and (b) prednisolone-2 1-glycollate esterified with the same acids at the glycollic hydroxyl. Methods of preparation and purification have been briefly given. Pharmacologically, the Ungar test showed that short-chain simple esters displayed higher activity than the corresponding ‘glycollic bridge’ compounds; the more complex trimethylacetates and enanthates provided the ‘break even’ point where activity in the two series was approximately equal while esters of longer chain or aromatic acids were more active in the glycollate form. The simple 21-stearate showed high and prolonged activity but the 21 -stearoylglycollate (11, Sintisone) was even more interesting in both these aspects and was chosen for detailed examination and subsequent clinical use. The basic concept behind studies such as this is that esterification may modify corticosteroid activity by (1) increasing lipid solubility of the drug and thereby *Now often termed sfeaglate.
6
SOME RECENTLY INTRODUCED DRUGS
improving its absorption and distributlon after oral administration ( 2 ) ,modifying the rate of hydrolysis to active steroid alcohol by judicious selection of esterifying acid and ( 3 ) possibly introducing an element of selectivity for particular types of tissue (enzymes capable of regenerating the drug may not be equally active at all potential sites of action). As is indicated in the brief survey below, prednisolone-
(11)
21 -steaglate is rapidly and fairly completely absorbed from the gut, produces high, prolonged, blood levels (both in terms of drug present and of activity), and may possibly prove t o have some selectivity, though this awaits rigorous observation before warranting further comment. An early study [28] of the pharmacology of this prednisolone double ester examined the compound t o ascertain (a) its anti-inflammatory activity (intensity and duration), and (b) the degree t o which undesirable effects appeared a t dose levels ne-ded to achieve therapeutically interesting results. In both these respects, the drug was compared with prednisolone and the results, corrected for prednisolone content of the ester, are summarized in Table 1. I . The variations in Table 1.1.
Activity of prednisolone stearoylglycollate, corrected for prednisolone content, compared with prednisolone (activity = 1 ) [ 2 8 ]
Test Foreign-body granuloma Carageenin oedema Capillary protection Thymus involution Pituitary-adrenal inhibition Ulcerogenesis
I
Activity
0.75
relative potencies of the two drugs in the different tests are indicative of the complex effects of 21-double esterification on the activity (or susceptibility of tissues to that activity) of this type of drug. During the study it became apparent that absorption from the gut is little different from that of the free alcohol; the differences lie in the subsequent fate of the ester. There seems evidence of slower metabolic inactivation of the steroid, as might be expected, and hence a strong
A . P. LAUNCHBURY
I
probability that the greater activity of the double ester in many tests can be accounted for by more efficient utilization. In this respect the stearoylglycollate might be regarded as another example of ‘drug latentiation’-a circulating ‘depot’ from which prednisolone is steadily released. This interpretation is borne out by another study [29] which, as its prime objective, compared the blood-1evel:time relationships of prednisolone and its stearoylglycollate. The authors concluded that their results, showing consistently higher serum levels (the difference increasing progressively with time) after administration of the double ester, were only accounted for by reduction in the rate of inactivation of the ester compared with the parent steroid. The absence of any prolonged absorption from the gut was confirmed. Absorption was completed within two hours. Interference, by prednisolone and its stearoylglycollate, with the dynamics of calcium and nitrogen metabolism were compared [30] , using isotopic methods to measure calcium mobilization. As a by-product of this investigation, evidence was obtained that patients with impaired calcium absorption before treatment (‘hypoabsorbers’) show less disturbance of calcium balance during therapy than normal individuals. While both compounds accelerated calcium turnover in bone and increased its excretion, the ester produced significantly less effect than its parent. The loss of nitrogen characteristic of corticosteroid activity also appeared to be reduced. Both these advantages were apparent at dose levels adequate for therapy. Two further communications [3 1,321 reported that prednisolone stearoylglycollate, in substantial doses, was the least potent anti-inflammatory steroid (among the representative series studied) with respect t o pituitary-adrenal inhibition. The order of increasing suppressive potency in this test was: prednisolone stearoylglycollate, prednisolone, triamcinolone, dexamethasone, betamethasone. Techniques used in the comparative evaluations included the metyrapone test and gas-liquid chromatography. Clinically, the quantitative nature of spirometry led to its early use in evaluation of the effectiveness of the double ester in bronchial asthma [ 3 3 ] . By this method the newer drug was shown t o be twice as potent as prednisolone therapeutically. This is in terms of prednisolone equivalent (not a weight for weight compari5on with the ester which contains only 52.6 per cent steroid) and is an expression of the fact that the average daily suppressive dose, and the total drug consumed during the trial period, was only half that required by patients on the parent steroid. This, again, bespeaks better utilization of the administered steroid. Sideeffects, particularly fluid retention and steroid-induced glaucoma, were evaluated by other workers [34] in patients suffering from a wide range of disorders. No instance of steroid glaucoma and little fluid retention was detected during therapy with the double ester in clinically effective regimes. while prednisolone produced these complications in the familiar pattern. In this trial it was agreed that the approximate equivalence of 6.65 mg stearoylglycollate to 5 mg prednisolone alcohol was reasonable as a guide to therapy.
X
SOME RECENTLY INTRODUCED DRUGS
Dox ycycline
Hydrogenation of methacycline yields a t least two major products, the 6 a and 60 epimers of 6-deoxy-5-hydroxytetracyline. These were initially referred to, loosely, as ‘6-deoxyoxytetracylines’ but it soon became apparent that it could not be assumed that the configuration of the C6 methyl would necessarily be the same as in that of the parent 6-hydroxy compounds. Indirect evidence that the 6a epimer resulted from an improved hydrogenation reaction was obtained in early studies [35] in which it was also noted that one advantage accruing from 6-dehydroxylation was increased chemical stability; in the absence of the 6-hydroxyl, degradation t o anhydrotetracylines and isotetracylines is impossible. A further finding was that both the 6-methyl and the 6-hydroxyl groups may be removed without reduction in typical tetracyline activity-which was in fact increased t o the extent that 6-deoxy-6-demethyltetracyline was found t o be twice as active in v i m , weight for weight, as tetracyline. This compound, with only four remaining asymmetric centres, is the simplest molecule so far studied which retains typicd tetracyline-like activity and demonstrates that asymmetry a t c6 is not vital to such activity. None the less the actual configuration of the c6 substituents has quantitative consequences. This was clearly established by more detailed work [36] during the course of which both c6 epimers of doxycycline were synthesized. The 60 species was obtained by a stereospecific reaction involving Raney nickel desulphurization of the benzylmercaptan addition derivative of methacycline. Model studies confirmed the skeletal configuration. The 68 epimer was produced by noble metal catalytic hydrogenation of Ila-fluoro6-methylene-5-hydroxytetracycline.Bioassay of the two epimers against K. pneumoniue revealed that the 601 compound had almost three times the activity, weight for weight, of the 8 epimer; this has been confirmed against other organisms, and is in good accord with further studies of tetracycline [ 3 7 ] and derivatives possessing c6 asymmetry [38] ,
OH
CO-NH,
OH OH
0
OH
0
Doxycycline (6-deoxy-5-hydroxytetracycline,Vibramycin, 111) is, chemically, the most stable tetracycline in current use but its outstanding property is its high lipid solubility; these features combine to make it the most reliably and completely absorbed tetracycline derivative, with the longest half-life. The consequences of high lipid solubility were demonstrated in a comparison
A.
P. L A U N C H B U R Y
9
[39] of the distribution in dogs of various tetracyclines after oral dosage. This study did not assess rate of absorption from the gut since the prime objective was to study the differences of distribution of the drugs (i.e. from serum t o interstitial fluids to tissue depots) and their variation with lipid solubility once the equilibrium state had been reached by repeated administration. After making allowances for serum protein binding, metal chelating powers and pK, values, it was shown that the distribution o f the antibiotics between tissue depots and interstitial fluid correlated well with the partition coefficients in chloroform/ water (used as an assessment of lipid solubility as previously described [40] ). The similarity between dog and man with respect to the consequences of physicochemical properties o f drugs was evident in this case as in many others. Since cloxycycline has high lipid solubility (K, CHC13/H20 at pH 7.4 x lo3 = 475 as against 95 for tetracycline, 7 2 for demethylchlortetracycline and methacycline, and only 7.2 for oxytetracycline) it would be expected t o attain high concentrations i n . tissues (its serum protein binding is similar t o that of demethylchlortetracycline and 1.5 times that of tetracycline); this was confirmed by recovery from various tissue homogenates. A more detailed investigation [41] of the absorption (including the effect on this of the presence of various foods), renal clearance and anti-infective properties of doxycycline showed it to be the first clinically-available tetracycline t o be rapidly and almost completely absorbed even in the presence of food. Hitherto, tetracycline absorption had always been unpredictable (421 (owing, for example, to their tendency to form insoluble complexes with metals) 11' taken during o r after meals, or even with milk. In some circumstances (for example ingestion of a glass of milk with the drug) the levels attained were slightly reduced. In n o case was doxycycline affected by normal dietary substances to anything like the degree encountered with older tetracyclines. Aluminium hydroxide was the only substance tested which reduced absorption of doxycycline to negligible levels (as happens with all tetracyclines). This is to be expected and it should be routine practice t o avoid any antacid with high adsorptive capacity durliig therapy with any tetracycline (or indeed, with many other drugs). Administration of I00 mg doxycycline, in the absence of foods, led t o almost complete absorption from the gut and a peak blood level of 1.8 pg/ml two hours after ingestion. Three times this dose was required.to produce a similar blood level in four hours in the case of 300 mg demethylchlortetracycline. The plasma half-life (after single dose) was 15 hours in the case of doxycycline and 12 hours for demethylchlortetracycline. This means that the half-life of doxycycline is seven hours longer than that of tetracycline. Plasma protein binding, measured by an ultracentrifugation method, was estimated at 93 per cent. This is somewhat higher than the figure quoted by other workers [49] who also obtained lower figures for the serum binding of other tetracyclines. It may well be that the binding forces are weak and the degree of I,i~~clingtherefore variable according to conditions during estimation; certainly
the attachment to serum proteins is loose enough to permit rapid migration of the drug, in quantity, into tissue fluids as discussed below. Renal clearance of doxycycline was strikingly different from that of other tetracyclines (1 2 per cent of creatinine clearance, compared with 26 per cent for demethychlortetracycline) and was considered to be the principal factor in determining both the serum concentration and its duration. This is a likely explanation since, as briefly indicated earlier, highly lipid-soluble drugs penetrate cell membranes readily. I t follows that lipid soluble materials present in the glomerular filtrate diffuse back through the tubular walls and return to the general circulation. This has been demonstrated for many bases (for example amphetamines [43-45] narcotic analgesics [46] );the tactorS involved have been comprehensively reviewed 1471 and summarized [48]. This phenomenon, apparently due to the loss of tile hydrophilic C6 hydroxyl, coupled with the dependable alimentary absorption would account for the increase in plasma half-life to 22 hours on repeated dosage in man. I n a pliarmacokinetic study [49], this and related aspects of doxycycline were stiiclied in man. Although the degree of serum protein binding as estimated by these workers was lower than in the report [41] discussed above, the differences seem inadequate t o call in question the validity of their conclusions; in addition. serum levels and protein binding data are not, of themselves, reliable indicators of therapeutic potential. Serum levels of doxycycline wei-e shown to be proportional to the dose (oral) f o r the series 50. 100, 150 and 250 mg. This is in contrast to the effect ot increasing the oral dose of tetracycline and most other derivatives of it, for hitherto the proportion of drug absorbed decreased as the dose increased. Nor could any reliable figure be assigned to this proportion [SO]. The report at present under review [49] also advances reasons for believing that the alimentary absorption of doxycycline is almost, if not quite, complete. This is important since many of the common side-effects of tetracycline therapy (such as gastrointestinal disorders and proctitis), are generally held to be due in large measure to residual drug remaining i n the gut [42] . While overgrowth with non-susceptible inicro-urganisrns ( t o r example Candida) may account for some of the effects, much o f the alimentary intolerance may well be due t o a direct irritant effect of the drug on the mucosa; a strong hint of this lies i n the fact that intramuscular injections of tetracyclines are generally formulated with a local anaesthetic t o reduce pain on injection. Doxycycline may, if only negligible amounts remain in the gut. be free of most of the traditional complications of tetracycline therapy; in t h i s connection i t is interesting that nausea is the only side-effect so far reported 141 1 and this only occurred when the drug was given after an overnight fast and contact with gastric mucosa was therefore maximal. As indicated Irom a previous study [41] , repeated dosage leads to an increase i n half-life from about I 5 to 22 hours. It was also established that this increase in apparent half-life was not due to decreased urinary excretion or to unusual accumulation of the drug; once equilibrium with storage depots (which release
A. P. LAUNCHBURY
11
lipid-soluble drugs only slowly) was achieved-generally within t w o days-no further accumulation was detected. In this study 25-30 per cent of the administered dose was recovered from the urine ( 2 4 hours collection) and this proportion appeared t o be independent of dose (in single dose studies) and of time (in chronic, multiple dose experiments). Since patients can rarely be relied upon t o take (or be given) medication after fasting,and since itis common experience that dosesare omitted more or less frequently the properties of doxycycline make it appear a promising successor t o the ‘first generation’ tetracyclines. This is even more likely since the antibacterial spectrum and activity is at least equal to that of tetracychne, and in the case of certain tetracycline-resistant bacteria doxycycline has (of all derivatives tested) shown the highest activity [ 3 5 , 4 1 ] . Clinical reports, while still not numerous, appear t o bear out the optimism aroused by the drug’s unusual physico-chemical properties. An outstanding example isan evaluation of doxycycline in sinusitis [ S 11, an often intractable and potentially dangerous infective disease. Antibiotics are widely used systemically in this condition primarily as prophylaxis against possible meningitis or osteitis; it is not generally believed that the sinusitis itself is greatly affected. The few reported attempts t o detect antibiotics in purulent sinus secretions, during systemic therapy, have failed. This is not surprising since the usual antibiotics used in such diseases (penicillins, streptomycin) are generally highly polar, often ionic, and are not expected to penetrate well under these circumstances (just as their low lipid solubility prevents their traversing the ‘blood-brain barrier’). Doxycycline’s ability t o penetrate lipoid membranes would be expected t o increase its chance, at least, of significant penetration into infected sinuses though the authors concerned claim t o have selected doxycycline, not for this fundamental reason, but for one of its consequences-the prolonged half-life-of which they had read a report [ 5 2 ] . During the trial, (blood levels as high as those reported by previous workers were attained, and all 1 2 patients produced sinus secretion concentrations of doxycycline of 05-7.5 pg/ml-approximately tenfold higher than the M.I.C.’s reported for the organisms isolated before the trial commenced. Sinus secretion ceased-in 4-9 days. This work indicates that many conditions, for which current tetracyclines are considered unsuitable, may prove treatable with more lipophilic agents. A different approach [ 541 t o increasing tissue permeability t o antibiotics is discussed under bromhexine. A further example of the ability of doxycycline to penetrate into secretions is provided by a report”[53] of a comparative trial of the drug and ampicillin in acute exacerbations in chronic bronchitis. It was found that 100 mg doxycycline daily and ampicillin 250 mg four times daily were clinically equally effective. Bacteriologically, however, it was found that H. irzfluerzzae re-appeared in sputum more often during ampicillin therapy than y i t h doxycycline. This was attributed, following earlier workers, to the failure o f ampicillin (in the dose used) to reach adequate levels in sputum. By inference, therefore, doxycycline (at one tenth of the daily dosage) achieves adequate levels more readily.
12
SOME RECENTLY INTRODUCED DRUGS
It is interesting to observe that in penamecillin, prednisolone stearoylglycollate and doxycycline, pharmacological effects predictable on the basis of physicochemical data are being observed in clinical practice. There can be little doubt that modification of physico-chemical properties will be increasingly explored in the future as a means of improving old drugs and designing new ones.
2 . DRUGS OF NOVEL STRUCTURE OR ACTIVITY A curariforrn muscle relaxant Pancuronium bromide
For many years (+)-tubocurarine has remained the standard non-depolarizing drug for all but short operations, in spite of its side-effects. Predominantly, these consist of (1) histamine release (often leading to bronchospasm) and (2) hypotension (resulting, in large measure, from autonomic ganglion blockade). Although many potential competitors have been examined, few have stood the test of time. Gallamine triethiodide has a shorter duration of action but raises the blood pressure and induces tachycardia. Like tubocurarine, it is a histamine-releaser. Alcuronium chloride is the other main contender in this field but it too liberates histamine though only to about the same degree as gallamine, i.e. rather less powerfully than tubocurarine. It is apparent that if any real advance is to be made in this field, resulting in the production of a neuromuscular blocking agent lacking histamine releasing properties, without cardiovascular effects but with a predictable period of action (and readily reversible with neostigmine and atropine), then some fundamental study of this type of activity is necessary. Two excellent reviews of work in this field have already appeared in this series, one concerned mainly with the structureactivity relationships [55] , the other more with the drug-receptor interaction [56] . Both authors express dissatisfaction with the terms used to characterize types of neuromuscular block. It is pointed out [55] that many so-called curariform agents have ‘a dual mode of action’, first an apparently acetylcholinelike depolarization of brief duration followed by a competitive-type block. Further, many compounds produce these effects in varying proportions in different species and tissues, and since many substances have been examined and classified on the basis of results obtained with a single preparation many need reevaluation now that techniques and terminology are more refined. Several proposed alternatives to the term ‘non-depolarizing’ to describe curariform neuromuscular block have been discussed and the alternative term ‘competitive antagonism’ [56] proposed asmore accurately descriptive of what is now believed to occur. It is, however, pointed out that however careful the laboratory study may be, it is still impossible to determine in vivo if curare-like drugs fulfil all the criteria of block by competition.
A. P. LAUNCHBURY
13
For the purposes of the present discussion the term ‘curariform neuromuscular block’ will be taken to refer to a post-neural membrane effect, resulting in paralysis of striated muscle, having the following characteristics: (i) blockade can be reversed by anticholinesterases, for example neostigmine and edrophonium, (ii) suxamethonium can antagonize the effect, (iii) partial-block by the drug in question can be augmented by small doses of tubocurarine or gallamine (these doses being insufficient to initiate full blockade unaided), (iv) partial neuromuscular blockade can be reversed with potassium chloride, (v) partial-block is reversible by adrenaline, (vi) after reduction of the tension generated by indirectly elicited tetanus, during partial block, post-tetanic twitches are, briefly, of increased amplitude, (vii) the degree of block is reduced by fall of temperature (in mammalian preparations). Most drugs with this type of activity have non-rigid molecules and for some time it was assumed that the fullyextended configuration of decamethonium represented an optimum interonium distance of approximately 14 A. Doubt was aroused by studies [57-611 indicating that full extension is unlikely in aqueous solution (factors determining configuration were reviewed [ 621 earlier in this series) and by observations of high activity of this type with molecules incapable of such interonium distances (for example toxiferine I [63] ,gallamine triethiodide [64] ). From such considerations it seemed likely that maximum activity would be associated with an interonium distance of 9-10 A, though the work discussed below has shown that this value is not critical. Against this background, and in view of the growing clinical importance of a proper understanding of drugs of this type, a contribution already referred to [55] concluded: ‘ . . . studies must establish not only absolute stereochemical configuration, but also the most probable conformation of the molecule in the biological system in which it produces its effect. Many of the most interesting and most potent neuromuscular blocking agents have nonrigid molecules, and studies of the biological cation of both completely rigid molecules, such us those bused on the steroid nucleus, and on molecules of known cbnformation should provide fruitful areas of work ultimately leading to new advances’ (present writer’s italics). The first of these advances reaches clinicians in the form of the steroid, pancuronium. The steroid nucleus provides an excellent rigid lattice for the attachment of pharmacologically active groups plus, in many cases, a hydrophiliclipophilic balance favourable to the ready penetration of derived drugs to their sites of action. In the study of curariform neuromuscular blocking agents the steroid fused-ring system offered the advantage of providing compounds of fixed interonium distances, thus enabling variations of activity with structure, or
14
SOME RECENTLY INTROI)UCl
charge density, to be separated. The first series of compounds based o n this structure were monoquaternary, having acetylcholine analogues ‘built in’ to the steroid A ring, in a variety of a and 0 configurations. The reasoning behind this approach (including many references) is given in the report [65]which appeared some time later. All ten compounds tested exhibited typical non-depolarizing neuromuscular activity. Though this was weak (the most potent drug showed only one sixteenth of the potency of tubocurarine, on a molar basis) the work did confirm that steroids with this type of activity had clinical potential, as had been anticipated from studies of aminosteroid alkaloids (e.g. malouetine 1661. and derivatives of funtumine and funtumidine 1651) and communications from other workers. Unfortunately, all thesc mono-quaternary Sa-androstanes proved to be both sympathetic and parasympathetic ganglion blockers, as had been suspected. Attention then turned t o bisquaternaory Sa-androstanes, substituted 3a, 17a t o give an interonium distance of 9-10 A. Pharmacological testing showed such compounds t o be potent non-depolarizing curariform agents (up t o one half the potency of tubocurarine, o n a molar basis) with weak anticholinesterase activity. The published report of these studies [67]also discussed the implications o f work in hand in other laboratories. The accumulated evidence indicated that a , 0-stereoisomerism had little effect on neuromuscular activity, steric impedance from angular methyl groups on C l o and C 1 3was absent and confirmed that this type of activity was not dependent on a ‘fixed’ interonium distance but varied within a range of quaternary separations. The obvious pointers offered by the foregoing compounds led t o the synthesis of further derivatives, this time incorporating the feature present in the earlier monoquaternary agents (acetylcholine-like structures ‘built into’ the steroid A and D rings). The series, based on 2~,16~-diamino-5a-androstane-3a,l7~-diol dimethohalide, was described [68] and one compound selected for detailed comparison with tubocurarine. The steroid selected was pancuronium bromide (IV) (20,160-dipiperidino-SaMe
I
CO
I
2 Br-
MeCO.0‘ H
atrdrostane-.b.. 1 7fl-diol cliacetate dimethohi-omide, NA07. Pavulon). Detailed pharmacology. iiicluding structure-activity relationships within this group, has been presented [601 . Pancuronium is one of the most potent curariform
A.
P. L A U N C H B U R Y
15
neuromuscular blocking agents k n o w n . y e t its histamine-releasit~gand ganglionblocking activities are iicgligiblc. According to the conditiuns of test ~ ~ I I I ~ I I I - U I ~ ~ U I I I
shows u p to ten times tlie potency (molar comparison) of tubocurarine, with equal duration of activity and an apparently similar mechanism of action. Toxicity is found to be low and related only to the neuromuscular blocking effects. Provided that artificial ventilation is available, 10,000 times the normal effective dose evinces no acute toxicity in anaesthetized cats for u p to two hours after injection;as usual. species vary in susceptibility to toxic effects. As might be expected o f a highly-charged cation. absorption from the gut is poor. No I~ormonal effects have been detected. Further studies [70-731 of the properties of pancuroniurn have appeared while the clinical advantages of the drug over existing agents have been reported in a separate publication [74] . In these clinical experiments on anaesthetixd human patients an electromyographic technique was used t o record action potentials from tlie hypothenar muscles following supramaximal stimulation of the ulnar nerve at the elbow. The height of tlie action potential was found to be, as previously reported. closely related to the degree of paralysis of tlie muscles under study. The drug was injected intravenously at controlled rates via tlie opposite hand. In no case was any evidence of histamine release found (no broncliospasm or skin wheals occurred). Tlie onset of action was considered more rapid than that of tubocurarine. and a complete absence of cardiovascular side effects (even in the presence of halothane) was particularly commented upon. Weight for weight, this study indicated pancuronium to be about five times as potent as tubocurarine. Tlie above and reports from other workers (awaiting publication at the time of writing), strongly suggest that this type of neuromuscular blocking agent constitutes a notable advance in anaesthesia. Tlie properties of pancuronium. which make it of special value in the poor-risk or asthmatic patient may be briefly summarized as: (i) myoneural blockade, similar in intensity t o that effected by 1 0 - 1 5 mg of tubocurarine, is rapidly produced by 2-4 nig of pancuronium and may, i f required. be maintained by incremental doses of 1-2 mg. (ii) Paralysis thus induced is easily reversed by an ticlio linesterases ( lOi examplr neostigmine), plus atropine, without subsequent recurarization. (iii) Circulatory effects are unusual in that even if hypotension is produced by. for example, halothane, the blood pressure often returns t o normal when pancuronium is given. In a similar manner an elevated or depressed pulse-rate frequently stabilizes at 80 to 90 per minute after administration of tlie relaxant (it is of interest in this context t o note that the tachycardia normally following reversal of block with neostigmine and atropine is generally prevented by pancuron ium). (iv) No liberation of histarnine can be detected. Hazardous bronchospasm is therefore unlikely to occur.
16
SOME RI-CENTLY INTRODUCED DRUGS
(v) I n man, tlie drug appears to be approximately five times as potent (on a milligramme basis) as tubocurarine. (vi) Even in long operations no evidence of tachyphylaxis or of cumulation was discernible. (vii) Premedicants such as promethazine and atropine d o not appear to interact with pancuronium. Anaesthetics vary in this respect; ether strongly potentiates the drug while tliiopentone only moderately reinforces it, halothane also ‘increases block b u t (as mentioned above) was prevented by pancuronium from producing its cliarai teristic liypoterisive complications. It is ccrtain that pancuronium is but tlie first of a series of steroids of this type There is Iorexaniple. need f o r a n agent with its favourable properties but with the brevity 01. action of suxametlionium. Achievement of this aim may not be too distant siiicc quaternary derivatives of the alkaloid conessine, possessing (in cats at least) the required cliaracteristics have recently been described [ 7 5 ], and dacitroriium bromide is now under intensive study by the team responsible for tlie develupmeiit ot’ pancuronium. A ’non-addictive‘ analgesic Pentazocine
Until recently (the last decade or so) studies of enormous numbers of potent analgesics seemed to indicate that effective analgesia and drug dependence of the morphine type were inseparable. In addition. ‘addiction’, ‘habituation’ and similar terms were widely used with very loosely defined connotations, so that considerable confusion resulted. The World Health Organisation has now published [76] a system of description o f such conditions, based on the term ‘drug dependence of the (name of drug specified) type’, together with a review of developments which led to its adoption. The last few years have produced a voluminous literature on structure-activity relationships among potent analgesics and their antagonists especially since research received ( i n 1054) ‘near-maximal stimulus’ with the discovery that morpliiiie-antagoiiists (nalorphine i n particular) were potent analgesics in man (see below for detail). Since nalorphine was known t o precipitate theabstinence syndrome when administered to laboratory animals (and man) with established drug dependence of the morphine type it seemed probable that, if the undesirable subjective (mainly hallucinogenic) effects of nalorphine could be reduced or eliminated, clinically valuable analgesics (comparable to morphine in effectiveness) lacking significant ‘addiction potential’ could be produded. The present position can now be summarized (at the risk of oversimplification) by grouping the resultant compounds under three headings:
(i) Analgesics with dependence liability, for example morphine (V), levorphanol (VI), phenazocine (VII) and methadone (VIII);
A. P. LAUNCHBURY
17
(ii) Antagonist-analgesics which will generally reverse the actions of compounds under (i) but will, if given alone or with a similar drug provide effective analgesia, at least in man, for example nalorphine (IX), pentazocine (X, Fortral, Sosigon, Talwin, Win 20,228), cyclazocine (XI); (iii) Antagonists which not only reverse most activities typical of compounds under (i) but also those of agents under (ii). This type of drug appears t o have Me
R,
Me Me
(
VIII )
little if any pharmacological activity of its own (and may be regarded as approaching in properties the much-sought ‘silent antagonists’, i.e. antidotes with activity only in the presence of the drug(s) for which they may be specific), for example naloxone (XII, Narcone, Narcan) and diprenorphine (XIII, MSOSO).
Drugs grouped under (ii) are the primary concern of this review as pentazocine in particular has now received wide clinical as well as experimental use, but a few further points require mention by way of background. Only when pentazocine is viewed against the complex background of drug-cell interaction, will the historic nature of its introduction become clear. Pentazocine may not be ideal but it is at present the only clinically available analgesic t o emerge from the protracted search for a non-dependence producing, effective analgesic with an acceptably low incidence of side effects.
18
SOMI, K1:CLNTLY INTRODUCED DRUGS
Knowledge o f the mechanisms of drug-dependent states, while still far from complete, has advanced far enough for it to be obvious that, even for the supposedly single case of morphine-type dependence, refined techniques are necessary to evaluate the liability of drugs to produce it. These can often, for screening at any rate, be developments of fairly standard techniques. T w o reviews of the chemistry and pharmacology of potent analgesics, and their analgesicallyactive antagonists have already appeared in earlier volumes of this series. The first [77] included a survey of test procedures, the second [78] discussed in more detail mechanisms of action. drug-receptor interactions and studies o f structureactivity relationships with special emphasis on the agonist-antagonist phenomenon. A third review appears i n the present volume (Part 2). Since then compounds included under (iii) (above) have appeared. As these substances antagonize both groups ( i ) and (ii) further techniques have had to bedevised to assess their properties. Examples of such drugs include naloxone [79] ,which has been shown to bevirtually inactive as an analgesic [ 8 0 ] (its low activity varies with dose in an anomalous manner), to lack respiratory depressant effects, and to be of negligible hallucinogenic potency [81,82]. More interesting still, naloxone antagonizes the analgesic effects of antagonist-analgesics such as nalorphine, pentazocine and cyclazocine (83,841 and finally demonstrates its unusual character by apparently lacking any significant pharmacological effects (for example analgesia) when administered alone [84] . A second example of such silent antagonists of effective analgesics is diprenorphine, very much more potent than naloxone in reversing effects produced by drugs grouped under both (i) and (ii) [SS] . Diprenorphine is one of the latest novelties to emerge from the extensive series [86] (‘Bentley’s compounds’) of very active substances based on a bridged C-ring tetrahydrothe; baine structure [87] . The modified procedures required to evaluate antagonist drugs of type ( i i i ) are illustrated in the reports [84,85] above and in a slightly earlier description 188) and discussion of techniques adapted particularly to demonstrate the presence or reversal of antinociceptive properties. The above discussion has included many drugs which are incapable, so far as is known, of inducing morphine-like drug dependence; for example, substances under (iii) are apparently free from this drawback [89] while those under (ii) (including pen tazocine) are unusual i n that although a degree of physical dependence can be induced by them (contrary to earlier findings [90]) the resulting condition is qualitatively different from that following use of‘type (i) drugs, “9 1-71 . This is not surprising since most type (ii) compounds will, like nalorphine itself, precipitate the abstinence syndrome [94, 981 when administered to drug-maintained subjects physically dependent on type (i) drugs. An important point is that with type (ii) analgesics drug-seeking behaviour fails to appear even i f withdrawal symptoms follow abrupt termination of use. This separation of properties involving the loss of craving [92, 95, 961 should reduce the risk of illicit consumption after termination of therapy. In fact. continuous treatment with drugs such as cyclazocine may well be a valuable additional treatment for narcotic-dependence (in patients with adequate motivation), since stabilization
A . P. L A U N C H B U R Y
19
on such a drug largely inhibits any pleasurable experience if, for example heroin, methadone or morphine are subsequently taken. Drugs of this type are currently on trial for this purpose and are being advocated [95, 99, 1001 as a promising development, since no ‘liking’ for cyclazocine appears to have arisen throughout the period of experience. The introduction of pentazocine into clinical practice appears even more o f a significant step if recent studies of dependence (on drugs of group (i), i.e. morptiinetype) at cellular level are considered. Tissue-culture work [ 1011 has shown that such drugs can become essential for the continued existence of cultured human cells and that administration of an antagonist (or withdrawal of morphine) can lead to metabolic derangement or death-depending on the conditions of the experiment. Such a system of it7 vitro testing may foreseeably supplement, or even supplant, existing in vivo methods of assessment of addictive-liability. A conveniently analytical, but general, review of present methods has recently appeared [ 1021. Against this background of extensive metabolic involvement, at the cellular level, of earlier morphine-like drugs the development of the antagonist-analgesics was almost inevitable. The surprising aspect is that early leads [ 103-105] were so slowly followed, though it has been pointed out [ I061 that the entrenched conviction that potent analgesic activity was inseparable from physical dependence liability [ 1071 prevented many hints from being seen. The discovery [ 108, 1091 that nalorphine was equipotent, weight for weight, with morphine as an analgesic stimulated research which is now, at an everincreasing pace, producing compounds similar to those briefly reviewed above. One of the major obstacles (apart from physical dependence liability) is the persistent tendency of nalorphine-like analgesics to produce subjective, even hallucinatory, mental changes. The history of the development of pentazocine (and similar benzomorphans) and corresponding derivatives of other analgesic parent structures (for exaniple cyclorphan) has been told many times and from various angles [ I 10-1 12, 1 151 ,some stressing synthetic methods for pentazocine and its congeners 1061 and others their preliminary screening [ 106, 1 131 in animals. The fact that nalophine, and other drugs grouped here under (ii) failed to show analgesic effects in many animal tests [ 1 141 and the effect of this (and other qualitative differences between drugs of groups (i) and (ii)) on the development of more informative tests has been noted above. As both pharmacological and clinical studies indicated at an early stage that pentazocine lacked morphinelike addiction liability (it is a weak morphine-antagonist), but was none the less of analgesic potency somewhere between that of morphine and pethidine, workers on b o t h sides o f t h e Atlantic coinnieiiced a thorough investigation of the drug and, to date, close o n two hundred reports have already appeared. Of these, only representatives can be quoted here though these have been chosen to cover, with their references, as much of the field as possible. In 1906 the World Health Organisation Expert Committee on Dependence Producing Drugscleared 11 161 pentazocine of need for restriction under narcotics
20
SOME RECENTLY INTRODUCED DRUGS
regulations,a view shared by the U.S. Committee on Drug Addiction and Narcotics. The drug is now widely used and a general concensus of opinion, based on comparisons with older analgesics in a wide range of conditions seems to be that 30-60 mg by intramuscular injection is equivalent to 10 mg morphine sulphate given by the same route. Much seems to depend on the nature of the pain-inducing disease (myocardial infarction is an example of the more refractory algesic stimuli, closely iollowed by some types of cancer and surgical, especially urological, procedures) and, of course, on concurrent medication. All authors agree [ 117-1291 that pentazocine is an effective analgesic, the majority finding it to possess the advantage (for most indications) of producing more sedation than equieffective doses of pethidine or morphine though some [ 1 18, 1301 disagree on this. point-these latter significantly, using rather lower doses than average. Comparatively reduced respiratory depression and induction of nausea (with only occasional vomiting), little effect on blood pressure or heart rate (though some tachycardia may occur) and apparent absence of troublesome constipating effect are all points marking out pentazocine as an advance on' older potent analgesics. Respiratory depression, when it does occur, it not reversed by nalorphine (as might be expected) but methyl phenidate (Ritalin) has been shown [ 1311 t o provide a measure of slow reversal of this complication; it would seem reasonable to suppose that drugs under heading (iii), such as diprenorphine [86] might provide better control if introduced into clinical practice. Respiratory depression of the newborn following use of analgesics during parturition is an important example of older analgesics having proved unsatisfactory. Pentazocine has been demonstrated [ 1321 to have minimal effects on foetal heart rate and respiration (and, incidentally, an apparent facilitating effect on progress of labour) and this may well be related to the finding [133] that pentazocine passes across the placenta more slowly than pethidine, thus reaching lower concentrations in the neonatal circulation. Although pain at the site of injection has been reported [134] a recent investigation [ 1351 seems to prove that pentazocine does not release histamine. This is in marked contrast to morphine and older drugs of its type, and it has, in consequence, been suggested [135] that pentazocine is suitable for use in asthmatics and patients suffering from other allergic diseases. While, thus far, pentazocine appears on all counts t o mark a new phase of analgesic development, long-continued study will be required t o delineate its precise properties and place in therapeutics. An intravenous anaesthetic
Propanidid
Eugenol, the major constituent of clove oil, is a local analgesic and has been used as such in dentistry (inter a h ) for very many years. By a series of modifications (involving more than one laboratory) a number of general anaesthetics suitable
A. P. LAUNCHBURY
21
for formulation into intravenous injection solutions, have been evolved. As will be seen from the structures (XIVa), propanidid (Epontol, FBA 1420) and Estil ( X I n , G 29505)-the only other drug of this type to receive clinical evaluationare related to eugenol only nominally. The development of this group, and of propanidid in particular, has been described [ 1 3 6 7 1 . R
q
i
C
H
2 CO N E t 2
(XLVa), R = C H 2 CO 0 Pr (XIVb) EstlL,R=CH2 CH CH2
For about 30 years, the thio- and 0x0-barbiturates have been the only widely accepted induction agents for intravenous use. They have several disadvantages; for example, although they have often been described as ‘short acting’ it would be more appropriate to describe them as ‘rapidly acting’ since clinical anaesthesia is followed by a long period of somnolence. This may last up to 24 hours and is due to redistribution of the drug into tissue depots, including fat [ 138-1411, though the relatively minor role of fat in this respect was only recently established [ 1401. Further, thiobarbiturates, for example, thiopentone, are generally metabolized by the liver to the corresponding oxobarbiturates [ 1421 which are still anaesthetically active. The inactivation of barbiturates by side-chain oxidation is slow, generally about 15-20 per cent per hour. N-Methylated barbiturates (for example, methohexitone) have the additional disadvantage of producing a more marked excitatory phase (muscle twitches, laryngospasm, etc.) before the onset of anaesthesia. Finally, the very alkaline solutions of sodium barbiturates (required to achieve adequate concentrations) are extremely painful and damaging to tissue if allowed to escape from the vein at the site of injection. There is, therefore, a place for a drug which can be administered intravenously for the induction of anaesthesia which is not only rapidly acting but also subject t o rapid metabolic destruction so that no cumulation or ‘hangover’ can occur. Propanidid is, in many respects, just such a drug. After administration, n-propanol is quickly released (within minutes) by ester hydrolysis while a few per cent of the injected material may also suffer loss of diethylamine to give a dicarboxylic acid. Neither the mono- nor the dicarboxylic metabolites are anaesthetic. The first (and most important) hydrolysis appears to occur predominantly in the liver [ 143-41 though some destruction has been attributed [ 1471 to non-specific serum esterases previously described [ 145-61. Demonstration of the second metabolite and evidence for the pharmacological inertness of this compound and of the solubilizing agent, (‘Cremophor EL‘) necessitated by the low. water-solubility of propanidid, has been obtained by radioactive tracer studies [ 1481. The position with regard to the role of serum cholinesterase in the inactivation of propanidid is not yet entirely clear though
22
SOME RECENTLY INTRODUCED DRUGS
recent evidence and a re-examination of previous work, seems to show that this enzyme is involved to some extent [ 1491. This may be relevant to the study of propanidid-induced potentiation of suxamethonium (see below). The use of propanidid in anaesthesia for outpatients has been discussed in a detailed survey (based on both clinical and pharmacological data) of the subject [ 1501 , while the more general applications (including a further survey of experimental and clinical experience) have also been comprehensively reviewed [151]. The place of the drug in dentistry [153-41 and in electro-convulsive therapy [ 1541 (with a description of a technique t o surmount difficulties arising from the concurrent use ot suxamethonium) has been evaluated: A refined radio telemetric technique has enabled a detailed study [ 1551 of the cardiovascular effects of propanidid to be made, resulting in strong evidence for a transient procainamide- or quinidine-like depression of myocardial conductive tissue. The above publications [ 150-51 quote a large number of relevant references. The effects of propanidid, injected intravenously, may be summarized as follows: (i) Loss of conciousness within one arm-brain circulation time. (ii) Coincident with (i) marked hyperventilation occurs, apparently due to the local anaesthetic-type effects of the drug on lung-stretch receptors (this phase can be used, if necessary, to hasten intake of volatile anaesthetic or assist blind nasal intubation). (iii) After some 30 seconds, hypoventilation (or even apnoea), occurs which does not appear to result from the over-breathing, but rather from a ‘biphasic’ effect of the drug. (iv) During the above no laryngospasm has been reported even when attempts have been made deliberately to provoke the reflex. (v) Blood pressure falls during induction and, as anaesthesia proceeds, quickly rises again to near-normal levels. As noted above [ 1551 this appears t o be mainly due to a temporary decrease in the contractile force of the heart through a quinidine-like effect. This can be of value in poor-risk patients since the antiarrhythmic effect protects against possible ventricular fibrillation until adequate anaesthesia renders this unlikely. (vi) Recovery, due to metabolic destruction of the drug, begins within 5 minutes of injection (unless anaesthesia is maintained by subsequent doses or other agents) and is usually complete within 10 minutes. There is, by virtue of the mchanism of recovery, no after-effect except, of course, for possible sequelae of the operation itself. Even large doses, resulting from repeated injection, produce no cumulation of the drug. (vii) The action of suxamethonium is intensified and prolonged by propanidid. As indicated above [ 1491 ,this seems related to the interaction by both drugs with serum cholinesterase; there is good reason to believe that the neuromuscular junction is not involved [ 1561 ;This interactionis only inconvenient, or potentially dangerous, if the anaesthetist is unprepared for it. Techniques can be modified accordingly [ 154, 1571.
A. P. LAUNCHBURY
23
(viii) Barbiturates are often antanalgesic. Some premedicants (for example, atropine and promethazine) also heighten pain-sensitivity, while others (for example, pethidine) do not. Propanidid is at least not antanalgesic even though its analgesic potency is open to question. This means that the patient can at least bespared intensification of pain and benefit from subsequent analgesic medication. (ix) Unlike barbiturates, solutions of propanidid do not cause excessive tissue damage if allowed to leak into perivascular tissue; while the local anaesthetic effect of the drug undoubtedly reduces any discomfort, no residual damage follows initial hyperaemia in these circumstances. The preparation has been injected intra-arterially in man (both by intention and misadventure) and no adverse effects have been detected histologically although short-lived, but profound, vasodilation of the perfused limb followed its administration. Propanidid seems, therefore, to possess many advantages over former intra-. venous anaesthetics. In particular, procedures of short duration (especially under out-patient conditions [ 1581 and induction in many poor-risk patients), seem particularly suitable for exploitation of its properties. A psychotropic drug
Ox ypertine
The subject of neurohumoral substances in the C.N.S. and their probable (and sometimes hypothetical) interactions with drugs was reviewed recently in this series [ 1591 ;included in that survey was a discussion of indole compounds (some) physiological, others psychotogenic) t o which attention is drawn (with special reference to the genesis of schizophrenia and similar psychoses). A publication devoted solely to the pharmacology of the central nervous system, with 21 specialist contributors, has also recently appeared [ 159al . The complexity of psychotropic drug action is well demonstrated by a close study of oxypertine, with its unusual combination of effects on brain noradrenaline, dopamine and serotonin, especially in the context of its apparent qualitative change of activity with increasing dosage and against the background provided by the reviews above. The drug was introduced in preliminary communications [ 160-21 discussing structure-activity relationships within the 1-(3-indolyl)alkyl-4-arylpiperazines. Many tryptamine derivatives have been studied (as notea above) but in this new series the terminal amine group was incorporated into a 4-substituted piperazine ring, in much the same way that open side-chain phenothiazines (for example, chlorpromazine) led to the piperazine side-chain group (for example, trifluoperazine). Authors vary greatly in the degree of importance attached to the indole and piperazine moieties. From a group of drugs based on the above parent structure oxypertine (XV, Forit, Integrin, Opertil, WIN 18,50 1-2)-a reserpine-
24
SOME RECENTLY INTRODUCED DRUGS
like moleculewas selected for further study and is now available for clinical use. Screening and evaluation included the usual animal behaviour tests [ 162-61 ; early deductions from the results of these have been confirmed by subsequent more detailed biochemical findings. These indicate that, for example, oxypertine (like chlorpromazine) is adrenolytic yet a potent releaser of noradrenaline from
Ph
presynaptic vesicles [ 160, 16 1, 167, 1681 . This amine-depletion seems fairly specific since dopamine and serotonin appear to be affected little, if at all [ 161, 167-91, and evidence has been presented that oxypertine acts at the level of the catecholamine storage granules, rather than at the cell membrane, in preventing uptake and storage of noradrenaline [168, 170, 1711. This release of noradrenaline would seem, on theoretical and experimental [167, 168, 172, 1731 grounds, to contra-indicate the concurrent use of M A 0 inhibiters and oxypertine. The absorption and distribution of oxypertine has been studied using tritiated drug and autoradiographic techniques [ 1741. The high lipid solubility of the drug is suggested as an explanation of its rapid accumulation in the brain (and other vital organs) and its rapid traversal of the placental barrier into foetal organs. Retention of the drug in the spleen was shown to be due to its uptake by blood platelets. Metabolites provided virtually all the radioactivity found in bile and urine and a proportion of that in brain (after approximately three hours). The unusual combination of release and antagonism of noradrenaline has been noted above, while another property separating oxypertine from other major tranquillizers is that it does not potentiate the analgesia produced by morphine or pethidine [ 1611. The compound is anti-emetic and weakly antihistaminic [ 16&2]. While many of the experiments referred to above suggested that oxypertine would be an effective major tranquillizer, with perhaps some alerting effects in withdrawn cases, only experiments in man demonstrated that, in fact, this might be the case. A number of studies [ 175-71 have indicated that low doses of the drug may show stimulating, anti-withdrawal effects on patients previously very difficult to reach and communicate with, thus rendering them more amenable to psychotherapy, while higher doses appear to have a more typically tranquillizing effect (often accompanied by drowsiness) on patients who would otherwise have received substantial doses of phenothiazines. Other clinicians do not, however, consider this feature to have been adequately demonstrated [ 1781 while another review [ 1791 setting out some of the problems inherent in clinical studies of drugs
A.
P. LAUNCHBURY
25
of this type, has attempted an appraisal of experience obtained up to 1965. It concludes that the balance of clinical evidence, taking into account its striking correlation with animal work, is in favour of the view that oxypertine may activate the depressed yet quieten the overactive, the degree of stimulation being inversely proportional to the dose. Toxicity is remarkably low for a compound of such activity. In mice, the LD50 value isabout three times that of chlorpromazine [ 1661 while none of the effects of the latter drug on the myocardium, liver, skin or eye have appeared in the studies of oxypertine. It is, however, still too early to appraise its chronic toxicity in man. As indicated earlier, dangerous interactions are likely to follow concurrent use of a MA0 inhibitor, though simultaneous use of anti-Parkinsonism drugs, for example, to control the relatively minor extra-pyramidal symptoms seems to present no unusual problems. Hypotension may occasionally occur with high doses. Oxypertine, with its novel structure and apparently promising therapeutic characteristics is a drug worthy of further study. Its specificity for catecholamine storage granules has already been exploited as a research tool [167, 170-3, 180 1811 and its continued use for this purpose can be expected to yield further fundamental information. A tricyclic anti-depressive lprindole
The complexity involved in the study of psychotropic agents has been noted above. This aspect is even more clear when consideration is given to the specific topic of mood. A recent review [ 1821 of some current opinion (on ‘amines, alerting and affect’), discussion [ 183-41 arising therefrom, and the continued development of new hypotheses (some alluded to below [ 186-91 ) all serve to bring home the fact that although much has been learnt, much achieved in therapeutics, the fundamentals of mood control still elude us. Against such a background of discovery, controversy, and ignorance the therapeutic value of newly introduced anti-depressive drugs can only be assessed on results in man. Animal experiments involvingmodel ‘depressive syndromes’ may be useful screening dev&es but failures of correlation between animal and human studies are unfortunately common. The series of compounds from which jprindole was selected has been described [ 1851 , further pharmacological details (particularly of iprindole) being conveyed [ 186-81 as contributory to the development of a new theory of brain function (in the context of stimulation and depression) involving novel methods of drug evaluation. Chemically, iprindole (XVI, Prondol, Wy-3263, originally called pramindole) like oxypertine, is an indole derivative. The classic and standard tricyclic anti-depressive, imipramine, has an
26
SOME RECENTLY INTRODUCED DRUGS
iminodibenzyl ring system; the radical change of steric shape involved in substituting this for the hexahvdrocyclo-octindolesystem does not seem to have been commented upon (most authors, on the contrary, claim close similarity for the two compounds) though it is likely to be important in terms of receptor-drug interaction. The 3-dimethylaminopropyl side-chain is the familiar one common
CH2
I
(
XVI 1
CH 2
I
YHZ
N Me2
to many psychotropics, antihistaminics, anti-cholinergics, local anaesthetics, etc. This is mildly surprising since, in the anti-depressants, the monomethylamino derivatives (for example, desipramine, nortriptyline) are claimed t o be the active metabolites [ 1891 . Unfortunately, no great detail on animal studies is available; the drug does, however, appear to possess the general properties of imipramine in tests involving motor activity, morphine-and reserpine-induced states [ 1861 amphetamine potentiation 11881 and lack of MAO-inhibiting activity [ 1901 . The only major difference emerging from these animal tests seemed to be that iprindole lacked most of the anti-cholinergic activity of imipramine. The clinical confirmation of this, while not yet conclusive, seems to indicate that anti-depressive and anticholinergic properties are not inseparable, as once appeared. Iprindole has received close clinical scrutiny. It has been compared with a placebo [ 190, 1911 with imipramine [192-1951 and with both [196]. All were double-blind controlled evaluations and established iprindole as at least as effective as imipramine, and one study [ 1951 included an examination of the doctor-patient interaction as a factor in such work (a similar discussion was felt necessary, as noted above [179] in the evaluation of oxpertine). In only two [ 192, 1941 of the above reports is it possible to estimate the frequency and severity of anticholinergic side effects, though in the one case [192J the care taken in the experimental design and the number of patients observed leaves little doubt that the dry mouth, constipation, etc. characteristic of imipramine therapy is either greatly reduced or even absent during iprindole treatment. This point is confirmed in an extension of this team’s work to include a 12 month toxicity study I1971 which, in addition, failed to produce evidence of haemopoitic, hepatic, cardiac, ocular or renal damage. Similar results followed other work. Another recent review [198] of published material pointed out that the animal work on atropine-like side effects had still not been published in full and, in any case, required independent corroboration. None the less, it was agreed that the clinical evidence (in spite of the difficulties of evaluation) did point to
A.
P. LAUNCHBURY
21
fewer problems of this type and recommended that the drug be used in patients for whom such effects might involve risk. It would appear, from the above, that the novel tricyclic system of iprindole has conferred properties which prbmise more patient comfort, and therefore more cooperation, in the treatment of depressive illness.
An anti-hypertensivesympathetic neurone blocker Debrisoquine
Since the publication of the review [ 1991 (of drugs used to treat hypertension) which appeared in the first volume of this series an enormous increase in understanding of sympathetic nerve function, and of drugs to modify it, has occurred. That review could only mention guanethidine briefly as the drug was thennew but at about the same time another drug, bretylium, became available. Although bretylium is no longer used in therapy it stimulated a process of re-appraisal of knowledge of sympathetic nerve physiology, from which radical new theories emerged [200] . This momentum has been maintained as still more postganglionic sympathetic neurone-blockers continue to appear. It now seems clear that stores of catecholamines in postganglionic sympathetic nerve pre-synaptic vesicles can, for the purposes of the present disassion, be divided into two types: (i) loosely bound transmitter readily releasable by tyramine and other indirectly-acting sympathomimetics [201-71, (ii) more firmly bound material only released (with depletion of stores) by reserpine, guanethidine, etc [208-2121 .
Drugs used in the treatment of hypertension vary greatly in their mode of interference with sympathetic nerve function. In the case of methyldopa the mechanism is complex and still largely unknown. Others, such as guanoxan, guanochlor or bethanidine, involve varying degrees of, for example catecholamine depletion, blockade of subsequent release of noradrenaline and, occasionally, a weak receptor-blockade. Bethanidine is perhaps the best-known of this series and
is now otten preferred to guanethidine. Debrisoquine (XVII, Declinax, Ro 5-3307/ 1) is a very close chemical relative of bethanidine (XVIII) as will be seen
28
SOME RECENTLY INTRODUCED DRUGS
from their structures. They are also almost identical pharmacologically although, as has been pointed out in a recent review [213] this fact is surprisingly rarely mentioned. The synthesis [214] of debrisoquine, its cardiovascular effects (in animal preparations), acute toxicity and biochemistry [20 11 and clinical pharmacology [215] have been reported (see also p. 167-168 of this volume). Like bethanidine, intravenous injection of a single dose of debrisoquine (in normal individuals) releases the ‘loosely-bound’ noradrenaline of the sympathetic neurones resulting in a brief pressor response [201, 21 51 . Clinically this could be dangerous in hypertensive crises or in patients suffering from phaeochromocytoma. Oral administration does not lead to this response since catecholamines are released more slowly and inactivated before their effects become evident. This pressor response t o injected drug is abolished by pre-treatment with reserpine (which depletes the transmitter stores), while the ability of tyramine to elicit pressor effects after pre-treatment with debrisoquine demonstrates that, unlike reserpine and guanethidine, debrisoquine does not greatly reduce the neuronal catecholamine stores. On the other hand, administration (intravenously) of noradrenaline t o debrisoquine-pretreated subjects leads t o an exaggerated pressor response indicating that debrisoquine effectively prevents noradrenaline release leading t o receptor ‘denervation supersensitivity’. The rationale and techniques of the above tests have been discussed [206]. It has been claimed [201] that this ability to block sympathetic function without major depletion of transmitter is a clinical advantage, especially in maintenance of adequate cardiac function. It is difficult t o see, however, how such a point can be valid since catecholamines ‘locked’ in storage can no more influence cardiac function than can the traces remaining after extensive depletion. Toxicity of debrisoquine is low. The ‘explosive’ diarrhoea and abdominal cramps commonly encountered during guanethidine therapy are rarely encountered. In this respect, again, bethanidine is similar. Unfortunately, there is little published information on detailed toxicology of debrisoquine (apart from acute toxicity, referred to above [201], which appears t o be very similar t o that of bethanidine and related drugs) though the manufacturers report negative findings in a variety of chronic toxicity studies in animals-with the exception of unexplained thyroiditis in a few dogs after one year’s high dosage. The same source reports debrisoquine to be free of endocrine, muscle relaxant, anticonvulsant or analgesic effects. Some evidence of C.N.S. stimulation and particularly of imipramine-like potentiation of amphetamine and cocaine is recorded, though this does not seem to have been noticed clinically. Haeniatological, renal, hepatic and thyroid functions have been reported normal [215-71 during debrisoquine therapy, nor could blood-sugar abnormalities be detected. Clinical reports [215-2221 agree that debrisoquine is an effective antihypertensive agent with a duration of action of 8-1 2 hours, permitting flexibility of dosage. Like other similar drugs it is potentiated by thiazide-type diuretics and other anthypertensives. In all these respects it appears to be interchangeable
A.
P. LAUNCHBURY
29
with bethanidine so that patients intolerant t o the one may be transferred to the other.
An adrenergic a-receptor blocker
Thymoxamine
The theory, first proposed [ 2 2 3 ] in 1948, that responses to sympathetic stimulation are mediated through two types of receptor, a and 0 (permitting differing responses to a single transmitter) has, with various modifications, become accepted as a standard basis for discussion and study of sympathomimetic drugs and their antagonists. While fairly specific antagonists of 0-receptor effects have been developed (for example, pronethalol, propranolol), drugs available to block a-receptors (for example, dihydroergotaniine, phenoxybenzaniine, phentolamine, tolazoline) have lacked both potency and specificity. In addition some such drugs, especially the Iialoalkylamines (for example, phenoxybenzamine) exerted an irreversible effect by combining chemically with receptor material. Phentolamine has probably proved the most generally useful of the above; i t has, for example, been recommended a s routine antihypertensive treatment (given intravenously) in the acute pressor-crises of many M A 0 inhibitor-amine interactions and in the diagnosis of phaeochromocytoma. The drug is, however. of little value when given orally and is not specific for adrenergic a-receptors. Rather surprisingly, a much more specific, orally-active drug of this type has been available for at least 14 years. Largely unrecognized (for lack of detailed study) tliymoxamine (XIX, Arlytene, Carlytene, Moxisylyte. Opilon. Sympal) Me \
NMe2
has received sporadic use in Germany, over this period, as a ‘sympathicolytic’ for a variety of vascular disorders. Neither the original description [234] nor subsequent clinical recommendations (335A)j were sufficiently detailed t o indicate the mode ot‘ action of the drug, let alone its specificity. More recently the drug has been re-examined to elucidate its properties more thoroughly [23@1]. The first of these studies [230] demonstrated that thymoxamine satisfied the usual criteria [232-71 for competitive antagonism at a-receptor sites (against noradrenaline) but showed no 0-receptor blocking
30
SOME RECENTLY INTRODUCED DRUGS
activity (against adrenaline; guinea-pig auricle preparation) or anti-angiotensin or anti-serotonin activity. The potency, weight for weight, was judged to be intermediate between that of dihydroergotamine and piperoxan. Some an tihistaminic propertieswere detected but in this respect thymoxamine was of low potency when compared with mepyramine. The second study [ 2 3 1 ] , intended t o establish the quantitative aspects of thymoxamine a-blockade, compared it with phentolaniine. This paper is an example of the techniques required, and data evaluation problems encountered, during studies (in intact, concious animals) of drugs which produce a progressively lower baseline (in this instance, blood pressure). The first dose of either thymoxamine or phentolamine (into thejugular vein) resulted in a profound fall in blood pressure followed, in the case of thymoxamine, by a ‘rebound’ rise leading t o stabilization at below control level. After the complex dynamics of this initial adjustment subsequent admmistration of both drugs demonstrated a noradrenaline-antagonism with characteristics typical of competitive receptor block. A more general study [238] including postulated distributions of a,0 and myogenic receptors, also concluded that thymoxamine is a competitive antagonist of a-receptors of medium potency and with fewer other effects than any similar drug studied (tolazoline was found t o have the greatest variety of effects). The absence of 0-blockade and lack of effect on angiotensin or serotonin responses was confirmed. Clinical pharmacological work [ 2391 ,using plethysmography, showed that man responds t o thymoxamine as predicted from the animal work, and one such study [240] (again using plethysmography) challenged the widely held view that in occlusive arterial disease many non-atheromatous collateral vessels are always maximally dilated (before drug therapy) by demonstrating improvement in peripheral flow giving thymoxamine, bamethan, tolazoline and nicotinyl alcohol. Little effect on blood pressure has been observed after therapeutic doses of thymoxamine (orally) in man for treatment of Raynaud’s disease, labarinthine ischaemia (Meniere’s syndrome), various cyanotic states and excessively cold hands and feet. While its usefulness in these conditions is at least equal t o that of its predecessors, the role of thymoxamine as an adjunct t o orthopaedic and plastic surgery and in the diagnosis of phaeochromocytoma is still being investigated. Cutaneous blood flow and skin temperature have been shown t o be substantially increased (assessed against tolazoline) after application of a n ointment containing 10 per cent thymoxamine [240a]. Few toxic effects have emerged and such symptoms as diarrhoea, vertigo, headache and facial flushing are more likely t o be manifestations of profound a-blockade than of true toxicity. Since noradrenaline and thymoxamine compete for a-receptors overdosage with either drug can be countered by titrating the patient with the other. Thymoxamine is receiving increasingly wide attention as probably the most specific, non-toxic, a-receptor blocker currently available; many reports on experience with the drug are still awaiting publication.
A.
P. LAUNCHBURY
31
Three phenylethylamines with complex sympatholytic or spasmolytic effects
[240bl
(a)
Prenylamine
The original communication [241] describing prenylaniine ( X X , Coiontin, Incoran, Irrorin, Reocorin, Synadrin 60, Segontin) directed attention primarily to the coronary vasodilating effects of the drug and its consequent cardiovascular activity and this application of the drug has tended t o dominate studies to date. From the chemical and pharmacological points of view however, the drug is of
Q / Me
CH2-CH
\
I
Ph
(XX)
considerable interest in possessing reserpine-like ability t o deplete catecholamines, dopamine and serotonin from neural stores, in addition t o some 0-receptor blocking activity. Prenylamine should be regarded as yet another compound of ‘sympathomimetic-based structure’ which, like bamethan, buphenine (nylidrin), verapamil and mebeverine, adds t o the sum of knowledge of structure-activity relationships (affecting both neuronal and receptor structures) within this group. Indeed, this theme can be taken further and attention drawn t o the common factor linking the potent 0-blocker propranolol and the a-blocker thymoxamine; both can be regarded as derivatives of 2-aryloxyethylamine. The ether linkage is, however, absent from the compounds at present under study. The ‘sympathomimetics’have been subjected t o a detailed study [ 2 4 2 ] determining their ability to prevent uptake (by rat heart) of noradrenaline, this being taken as a measure of the affinity of compounds under test for the transmitter transport system. Such basic information is often lacking, though important, since compounds with affinity for the transport systems, approximating t o or exceeding that of the transmitter itself, generally reduce the availability of the transmitter by permitting its diffusion from the neurone with subsequent exposure t o deactivating enzymes. Affinity for neuronal transmitter uptake systems does not, however, bear any obvious relationship t o affinity for either a- or 0-receptors; quite different stereochemical requirements seem t o apply in these situations. A further con-
32
SOME RECENTLY INTRODUCED DRUGS
sequence of inhibition, by many ‘sympathomimetics’,of noradrenaline recovery by the efferent neurone is that the small amount of transmitter released by tyramine for instance may be greatly potentiated because of its longer period of availability to receptors. In the above study prenylamine was found to have greater affinity for the transport system than for example (-)-adrenaline or phenylethylamine though less than tyramine or (-Fnoradrenaline. Early studies, using rats [243] and golden hamsters [244] indicated that prenylamine reduced the noradrenaline content of brain and heart (rats) and of adrenal catecholamines in the hamster. These studies inspired more detailed work and it was subsequently demonstrated [245j that the compound possessed weak reserpine-like activity in reducing concentrations of noradrenaline, dopamine and (to a lesser degree)serotonin concentrations in rat brain. These workers inclined to the view that the amine release from adrenal medulla (observed by them and others [243, 2441 was an artefact resulting from tissue damage since irreversible non-responsiveness to dimethylphenylpiperazinium stimulation occurred. Further study [246] of brain monoamine metabolism confirmed the close similarity between the effects of reserpine and those of prenylamine (except that the latter is generally less potent) and produced evidence that these two drugs compete for the same sites of action. Peripheral reserpinelike effects have been observed in man [247-81 and, as noted below, the possibility of central reserpinelike activity (culminating in suicidal depression) should always be borne in mind during use of drugs of this type. Preliminary studies [241, 249, 2501 of the cardiovascular and sympatholytic properties of prenylamine demonstrated that coronary blood flow and oxygenation could be increased under experimental conditions (in dogs) and that the drug interacted in complex fashion with sympathetically innervated organs, but the picture presented was somewhat confused because of the many uncontrolled variables and limitations of the actual techniques used. Anti-arrhythmic activity of potency comparable with that of quinidine, plus local anaesthetic properties, were also demonstrated [25 11 but the same worker was not able to reproduce these effects in intact live animals with any consistency. Large doses of the drug actually provoked cardiac fibrillation in some cases. A more thorough study [252] showed that prenylamine consistently potentiated injected noradrenaline and adrenaline but reversed the hypotensive effect of isoprenaline to a pressor one-due, according to further studies in phentolamine-prernedicated rabbits and guinea-pigs, to the unmasking of a-receptor response to isoprenaline. As is implicit in this result, prenylamine demonstrated(as in other tests also) &receptor blockade which may be of clinical consequence. The potentiation of adrenaline and noradrenaline noted above appears to be specific to these compounds and related to the amine-depleting effects of prenylamine. The pressor response to tyramine is reduced by prenylamine pre-treatment indicating that the readily releasable pool of catecholamines (discussed under debrisoquine) is concerned. The potentiation of administered adrenaline and noradrenaline is largely attributable t o inhibition
‘
A.
P. LAUNCHBURY
33
of their incorporation into sympathetic neurone-stores. Study of the effect of prenylamine on sympathetic-neurone function has shown [253] that, in vitro, response to nerve stimulation is reduced by the drug but that this impairment can be reversed by addition of noradrenaline or dopamine (though function gradually declines with time). This is what would be expected of a drug which impairs the ability of neurones to store transmitter (as does reserpine, for example). In vivo studies failed to demonstrate consistent sympathetic neurone blockade though ‘releasable’ amine depletion occurred. Intact animals do, of course, present complicating, compensatory, difficulties t o such studies; such factors also complicate clinical research. At the other end of the scale of complexity the catecholamine storage granules of adrenal medulla have been separated and used [254-6] to study the effects of several amines on ability of the granules to take up and retain transmitter. From these results it was concluded that not only was prenylamine an extremely potent catecholaminereleaser but that its ability to inhibit catecholamine uptake was second only to that of reserpine. Laboratory evaluation [241] of acute and chronic toxicity of prenylamine indicates that, in high doses, convulsions accompanied by respiratory paralysis (often with pulmonary oedema) led to death. Doses inadequate to produce this result led only to phenomena characteristic of reserpine-like drugs. Chronic administration failed to produce recognizable changes in any organs or tissues studied. No toxic effects, unattributable to amine depletion, have appeared during several years’ clinical use. Prenylamine has been employed clinically mainly for the treatment of angina pectoris. The problems of evaluating effectiveness of drug therapy of this disease (with its psychic and vascular components) are freely discussed in two reports 1257-81 ;the benefit likely t o be observed with any medication (active or otherwise) is considered with the general conclusion that prenylamine is at least as effective as other drugs used in angina in reducing incapacitation and psychic stress. No objective improvement in the disease could be demonstrated in these and other studies [259, 2601 though these also reported the drug as beneficial in management of the disease. An interesting discussion of the probable mechanism of prenylamine’s relief of anginal symptoms proposes [252] that the coronary vasodilating activity is of minor importance. It is pointed out that marked increases in blood catecholamine levels have been observed in anginal patients after exercise and it is postulated that uptake of these agents by the myocardium increases its oxygen demand. Hypoxia resulting from this could well account for the pain experienced and such a mechanism is in accord with the finding that 0-blockers (for example propranolol) can provide relief. The observed inhibition of catecholamine uptake by prenylamine coupled with its moderate 0-blocking activity provide some basis for an explanation of its apparent effectiveness. In addition, the amine depleting effects (which also involve the myocardium) and central sedative properties (agnin due to amine depletion) must be contributory. A final note of caution may be based on the observation [260] of reserpine-
SOME RECENTLY INTRODUCED DRUGS
34
like side effects in some patients. A drug with such pharmacological similarities to reserpine could presumably produce a reserpine-like depression which might involve suicidal intent. While this has not yet been reported the psychology of angina patients is so complex that it may not be readily detected until well advanced. (b)
Verapamil
Though the drug has now been used to treat a considerable number of patients suffering from angina pectoris, verapamil (XXI, iproveratril, Isoptin, Cordilox)
CH, - CH,
\N-Me
suffers from a comparative paucity of published detail to define its properties. Verapamil was initially described [261-71 as a ‘benign’ coronary vasodilator, a specific cardiac sympatholytic, smooth muscle relaxant and anti-arrhythmic agent. Other workers [268] also claimed evidence of myocardial symparnetic blockade, of quinidine-like anti-axrhythmic effects [269] and freedom from t k occasional complication of coronary vasoconstriction attendant upon the use of potent &blockers (for example, propranolol) [270] . Particular emphasis has been laid on the claim that verapamil is a sympathetic &receptor blocker, but with activity of a low order so that the risks inherent in the use of potent agents of thb type (for example, propranolol) do not arise. The coronary vasodilating activity has not, as is now general practice, received stress. The view that the drug has indeed p-blocking activity has been strongly challenged [27 1] and t h i s aspect‘ will undoubtedly require further study. Clinically, the drug has been studied (for the most part) in poorly controlled trials with few precautions against subjective bias [272-4]. Two careful doubleblind assessmentshave however been reported, one [275] measuring reduction of weekly consumption of glyceryl trinitrate. The other [276], by far the most informative published to date, demonstrates the drug’s ability to increase the amount of exercise necessary to provoke an@ attacks,as well as its effectiveness in reducing the need for nitrate consumption. Clinically, this study failed to show any difference between propranolol and verapamil (in appropriate doses) and, in
A. P. LAUNCHBURY
35
discussing their findings, the authors attribute the beneficial effects of the drug in angina to a direct suppression of myocardial contractility consequent upon its quinidine-like properties. No details of toxicity appear in the literature; in clinical trials the only recorded adverse effects have been minor (nausea, dizziness etc.). It is amazing that verapamil, with an apparently interesting spectrum of activity and a chemical structure indicative of potentially wide-ranging effects, should have as yet received so little detailed published study. (c)
Mebeverine
The well known properties of reserpine (already reviewed in this series [277]) can be radically modified by reducing the molecule to fragments and then substituting in a variety of ways. A preliminary report [278] of work on these lines indicated that derivatives of 0-indolylethylamine generally exhibited reserpine-like activity while the related 8-phenylethylamines could be grouped into two series: (i) papaverine-like and atropine-like compopnds generally producing bradycardia and/or spasmolysis, (ii) adrenolytic C.N.S.depressants. The literature relative to this work was then reviewed [279] and the syvtheses and physical data on the compounds of these series published [280]. A more detailed examination of 71 phenylethylamines, clarifying the structural features required to produce shifts ofemphasis towards different types ofactivityhas followed [281 J ..It is clear from this work that spasmolytics with structure-activity relationships unusual among aminoakyl esters occur in this group, which is also structurally and pharmacologically a far cry from the original reserpine which inspired the work. From these esters, mebeverine (XXII, Colofac, Duspatalin, Duphaspasmin) was selected for
CGz CH2 I
,cH2-o~co~~--~Me
'C",
detailed pharmacological study. This showed [282] mebeverine to be some three times as potent as papaverine (against barium chloride induced spasm in isolated
36
SOME RECENTLY INTRODUCED DRUGS
guinea-pig ileum) and up to forty times as potent in relaxing the same organ in vivo. Peristalsis generally remained unaffected even when spasm was abolished; only very high doses caused intestinal paralysis. The same study examined the effect of mebeverine on the sphincter of Oddi (measured by bile flow and by muscle tone) and found a similar high activity (20-40 times that of papaverine) in this situation. The absorption (following administration by oral, intramuscular and intravenous routes), distribution and elimination of the drug has been studied by radiotracer techniques in rats and rabbits [283, 2841. The substituted benzoic acid was labelled with I 4 C and the alkanolamine remnant with 3H.Almost all radioactivity was recovered from the urine even after oral administration. Clinical pharmacological examination 12851 of mebeverine has utilized micro-balloon (for distal colon) and radio-'pill' (for small intestine) techniques. Radical reduction in colonic hypermotility (with persistence of a relatively normal peristalsis) without significant effect on small intestine function followed parenteral mebeverine (50 mg). The study then proceeded to a double blind trial, assessed by sequential analysis of objective criteria (frequency of defaecation, cramps). Mebeverine very soon demonstrated activity compared with placebo. Other studies have compared the drug with various anticholinergics and attempted assessment of its potential in paediatrics. While these confirm the lack of side effects and indicate relief of colonic spasm, little further light is shed on mechanisms of action or on potency-ratios against standard drugs in the clinical situation. Acute toxicity studies in mice reported by the manufacturers indicate a very low toxicity though further details on the reason for the unusually large difference between oral and intravenous LDS values (some 40-fold) would be interesting. Subchronic toxicity tests with oral and parenteral use of the drug in rats again indicate a low potential toxicity; no abnormalities were detected. Teratogenic activity could not be demonstrated in rats or rabbits; only limited experience of the drug in pregnant women is available but no complications have yet arisen. The structure of mebeverine suggests that investigation of its activity at sub-cellular levels (especially in relation to possible interactions involving catecholamines or serotonin) might be rewarding. It would also be of value to have details of activity (or lack of it) in organs and tissues other than the gut. A diuretic Ethacrynic acid (with notes on frusemide)
Knowledge of renal physiology, and to some extent of its modification by diuretics, has advanced considerably since the subject was reviewed in a previous contribution to this series [286]. Other work quoted [287] at that time strongly suggested that thiazides and diuretics of similar effectiveness exerted their primary
A.
P. LAUNCHBURY
37
effect on sodium reabsorption at the level of the proximal tubule. It is now clear that this is not so and a recent thorough review [288] of diuretics and renal function has concluded that drugs of the thiazide-type (and also chlorthalidone, chlorexolone, quinethazone and clopamide) act on the distal convoluted tubule of the nephron, probably at a point proximal to the exchange-site responsive to aldosterone. It has also become more evident that the loop of Henle is of major importance in the regulation of sodium and water balance, and in agreement with this, both frusemide (furosemide, fursemide, Lasilix, Lasix) and ethacrynic acid (XXIII
(XXIII)
Edecrin, Edecril, Hydromedin, Endecril, MK-595)-the most effective diuretics known (in terms of total sodium, chloride and water loss they can induce)-have been shown to exert most of their effects on this portion of the nephron. The main properties of the loop of Henle may be summarized by the statement that thisvery long structure, consisting of a descending limb and an ascending portion (linked by a ‘hairpin bend’) in close proximity to each other, exhibits the properties of a countercurrent multiplier system. Anatomically, the loops of various nephrons are of differing lengths and penetrate various distances into the renal medulla from the glomerular regions of the cortex but, in man, at least 250.000 (a quarter of the total per kidney) penetiate right down to the medullary papillae. This region of the renal medulla is strongly hypertonic relative to plasma (5-10 times the osmotic pressure of plasma, according to species and circumstances) as a direct result of the activity of the loops and the very limited rate of solute removal by blood vessels (which themselves function as countercurrent exchangers through following closely the loops of Henle). As a result, tubular fluid entering the descending portion of the loop is progressively concentrated (mainly by simple osmotic transfer of water from the lumen to the hypertonic interstitial fluid). As the fluid passes up the ascen$ng limb, sodium is actively reabsorbed(followed, of course, by chloride) but since this section of the nephron is impermeable to water the tubular fluid becomes progressively more dilute. This is an efficient arrangement since the one sodium transport region is thereby responsible for some of the diluting and the whole of the concentrating activity of the nephron. The development of the countercurrent concept of loop function [289-29 11 and its confirmation and discussion [292-41 have been summarized 129.5, 2961. One or two further points require mention before ethacrynic acid can be discussed in context. The ascending limb of Henle’s loop has the unusual property of reabsorbing a constant proportion (approximately two-thirds) of the sodium content of tubular fluid, regardless of the actual load involved [2971 . This
38
SOME RECENTLY INTRODUCED DRUGS
implies that the loop has an important role in sodium conservation in that if an unusually heavy sodium load escapes proximal tubular reabsorption, this load would be radically cut at the loop. Further, in contrast to distal tubule capability, it has not been found possible to saturate the sodium transport mechanisms of the ascending limb of the loop [298, 2991. Even with heavy sodium loading, fluid leaving the ascending limb remains at the hypotonicity characteristic of the nondiuretic state [297-3001. No single postulated mechanism satisfactorily accounts either for the activity of the loop or for its control. Since the moderately active diuretics (thiazide type) apparently exert all their effects upon the distal tubule, and .ethacrynic acid and frusemide may well have subsidiary effects at this level, brief reference to this structure is necessary. In the absence of ADH (antidiuretic hormone, vasopressin) the walls of the distal convoluted tubule and of the collecting tubules are relatively impermeable to water. At a point close to the junction with the ascending limb of Henle's loop there appears to be a length of distal tubule capable of considerable sodium reabsorption; this may be so rapid that not only is the tubular fluid further diluted but the steepest transtubular sodium gradients obtainable in the entire nephron may be set up [301]. However, the transport mechanism is quickly saturated by heavy sodium load [297] with the result that, as more and more sodium is presented to the proximal portion of the distal tubule, the proportion escaping reahsorption increases. After traversing this region the tubular fluid encounters the section of distal tubule which, in the presence of aldosterone, exchanges sodium for potassium (or H" ). This aldosterone-mediated secretion of potassium (and =absorption of sodium) accounts for much of the potassium loss, and its unpredictability, occurring during diuretic therapy. Since this is an exchange procedure the total potassium loss obviously depends upon an adequate tubular sodium load at this site-this is provided by diuretics. The effects of aldosterone can. be reversed by appropriate drugs (of at least two types, for example spironolactone and triamterene) but this is outside the scope of the uresent discussion. So too, beyond mere mention, is the action of ADH in rendering the distal and collecting tubular walls more permeable to water; as the tubular fluid traverses the increasingly hypertonic medullary regions, so final adjustment of urinary concentration occurs in proportion to the level, of circulating ADH. Drugs acting only on the distal tubule (however complete the resulting block of sodium resorption at that site) are limited, in the effect obtainable, by the comparatively small contribution to total sodium reclamation made by this portion of the nephron. For example, even at their activity peak, thiazide diuretics cause the elimination of only 8 per cent of the total filtered sodium [302,303] Very much higher proportions of filtered sodium would be expected to contribute to diuresis if the mechanisms of the loops of Henle could be blocked (this has, in fact, proved to be the case in that frusemide and ethacrynic acid are both capable of clearing up to 20 per cent of filtered sodium [302,304-6]).
A. P. LAUNCHBURY
39
It has long seemed reasonable to suppose that the mercurial diuretics achieved their intense action by reaction with protein-bound sulphydryl groups in renal tubular cells and this hypothesis has received experimental support [307]. In the search for diuretics more effective than thiazides, but less toxic than mercurials, it is therefore understandable that attention should be directed to organic compounds with high reactivity to sulphydryl groups. On this basis a series of a, 0-unsaturated ketone derivatives of aryloxyacetic acids was synthesized, screened for diuretic activity and reported [308] .From this group ethacrynic acid was selected, on the basis of structure-activity relationships initially only briefly outlined [308] but subsequently developed [309-3111. These reports indicated that ethacrynic acid had an effectiveness consistent with that predicted by the original concept of sulphydryl groups as essential for the major part of the nephron’s sodium reabsorbing function; the relationship between affinity for proteinaceous thiol groups and diuretic effectiveness then received further study. Several reports link these properties in the case of ethacryric acid [3 12-41 ,though other workers [ 3 151 believe inhibition of an adenosine triphosphatase (implicated in membrane ion-pump mechanisms) to be a more likely explanation of the drug’s activity-especially as mercurial diuretics have also been found to inhibit the enzyme [316]. It has, however, been stressed [288] that these isolated biochemical effects cannot be directly related to the diuretic activity of any given drug, and until more is known of the fundamentals of ion transport such mechanisms will remain hypothetical. Ethacrynic acid and frusemide are now widely used as the most effective diuretics available; both drugs are capable of producing a diuresis frequently described as ‘torrential’. Both may be given orally or parenterally according to need. Unlike previously available drugs these powerful agents are equally effective in acidosis or alkalosis [3 141 and hyponatraemia, hypochloraemia and changes in available potassium modify the diuresis but little [317-9] . This intense activity can, of course, be dangerous and caution to avoid potentially fatal hypovolaemia and electrolyte disturbance has been urged [320]. Further, while thiazides and mercurials become increasingly ineffective with falling glomerular filtration rate, this does not appear to be a factor with the potent agents at present under discussion [318, 3211. There seems little doubt that studies with ethacrynic acid have established that this astonishing potency is aspociated with abolition (or extreme reduction) of the urinary concentrating function of the loop of Henle [305] ;some [322] would go further and argue that the magnitude of the response indicates additional sites of action-probably distal to the loop. A recent communciation [323] suggests that ethacrynic acid may modify the course (for the better) of ischaemic acute renal failure; this is in line with other recent findings indicating that the drug increases renal cortical blood flow (while reducing medullary flow) [324] and that the sodium content of the renal medullary interstitial fluid influences afferent arterial flow to the kidney [325]. A point which does not seem to have attracted much attention is the reported increase in effect of ethacrynic acid if a thiazide has been given the previous day [326] -such
40
SOME RECENTLY INTRODUCED DRUGS
a ‘carry over’ could account for some of the occasionally reported unpredictability . Toxicity of the drug appears to be low in the sense that although the haemoconcentration, electrolyte disturbance, etc., possible during therapy with so potent a drug can of themselves be lethal, prolonged studies using animals given compensating fluids and electrolytes have revealed no evidence of hepatic, renal or haemopoietic toxicity. Clinicallv, most unwanted effects (for example, transient slight uraemia, hyperuricaemia, hypotension, haemoconcentration leading to occasional thromboembolism) are familiar results of intensive diuresis. A few cases of profuse watery diarrhoea have occurred [320] and the report suggests that in such instances the drug should be permanently withdrawn. No evidence of teratogenicity has appeared in animal tests covering three generations; clinical use in pregnancy has likewise failed to provide hint of such potential though it should, naturally, be borne in mind. Although the cellular basis for the action of ethacrynic acid may not yet be established its micro-anatomical effects on the nephron are well attested. The speed of onset and intensity of action make the drug (like frusemide) a valuable addition to existing compounds, especially where diuresis is urgently needed (for example, pulmonary oedema) or in patients resistant to milder drugs of the thiazide type.
Addendum on ethacrynic acid and frusemide
Since the major part of this section was written, evidence has been published [326a] demonstrating that the above diuretics are possibly even more diabetogenic than the thiazides (judged by inhibition of 14C-labelled glucose utilization in adipose tissue), with a mechanism of action probably similar to that of the earlier drugs. This work seems more enlightening on this controversial point than any hitherto presented.
Two hypotensivediuretics (a)
Chlorexolone
The thiazide diuretics possess antihypertensive properties, in part consequent upon electrolyte and plasma-volume changes but mainly resulting from a direct cardiovascular depressant effect. This is clearly illustrated by the non-diuretic thiazide, diazoxide, which is an effective hypotensive [326b, c ] . It is not therefore, surprising that both these properties should be found (in varying proportions) in other, structurally related, compounds. One particular line of research, aimed at modification of the thiazide heterocycle (the o-chlorobenzenesulphonamide moiety was untouched as it was believed essential to activity-the subsequent advent of ethacrynic acid questions this belief) examined first the corresponding
A.
P. LAUNCHBURY
41
thiatriazines [327] . Although some diuretic activity could be demonstrated, potency was low and some of the compounds chemically unstable. Further manipulation of the ring to give a range of basic structures (all involving replacement of the endocyclic sulphonamide group) indicated that, of the compounds studied, the isoindolines showed the greatest promise. From a further series chlorexolone (XXIV, Nephrolan) was selected as the most active (as a diuretic), subjected to preliminary pharmacological study, and the results briefly communicated [328] . Detailed synthetic methods and physical properties, with structure activity studies, were later reported in detail [329]. It is interesting, though not unexpected, that the corresponding 3-0x0 compound proved to be inactive. Pharmacological studies showed its carbonic anhydrase inhibiting activity to be weak and indicated that chlorexolone exerted its diuretic action upon the same sodium re-absorbing mechanism as did the thiazides (see above, under ethacrynic acid). Against this background it is understandable that the structural variants represented by the clinically useful compounds (Figure 1.I ) based on the original o-halobenzenesulphonamide, should show approximately the same limitation of peak effect. The outstanding exception is frusemide, which parallels ethacrynic acid in effectiveness, though bearing a close chemical resemblance to the earlier drugs. The elucidation of the mechanism of this unexpected extension of activity to include the loop of Henle should he fascinating. (So too, would be an explanation of the diabetogenic liability ot the above chemical types, especially of diazoxide (XXV, Figure 1.1) in view of their structural similarity t o the hypoglycaemic sulphonylureas, for example, chlorpropamide (XXVI); is an antihypertensive, diuretic, hypoglycaemic drug possible?). The hypotensive effect of chlorexolone was initially studied in the concious, normotensive dog (anaesthesia introduces complications into the experiment, asdiscussedby the authors) and compared with that of hydrochlorothiazide [330]. Both drugs produced a fall in blood pressure, with bradycardia (connection with the hypotension uncertain) and the authors suggest that their findings, compared with the lack of published success with anaesthetized animals [33 1-3331 , indicate that trained, conscious dogs may provide a sensitive means of detecting blood pressure changes induced by drugs-especially of this general type. The metabolism of chlorexolone to three monoh’ydroxylated derivatives (all apparently substituted in the cyclohexane ring) in both dog and man has been reported [334]. No storage in body tissues could be detected and elimination via the kidney appeared to follow oxidation to the polar metabolites (no unchanged drug could be recovered from urine). These findings contrast with those relating to thiazides which often appear unchanged in urine. Acareful study of the human and clinical pharmacology of chlorexolone [335] showed the drug to be capable of lowering the blood pressure of hypertensive patients at doses well below those required for diuresis. The duration of action appeared to be up to 48 hours, which some [336] consider a disadvantage
02
C hloro t h i az i de
Diazoxide
Hyd r oc hlorot hi az ide (substituted at position 3 t o give most thiazides i n current use)
(XXV)
&net
hazone
Chlorexolone
(XXIV)
Clopamide
Frusemide
(XXVII)
Chlort halidone
C hlor propam i de
(XXVI) Figure 1.1.
A. P. LAUNCHBURY
43
(especially because of sleep disturbance) though sub-diuretic, antihypertensive doses would seem free from this objection. Toxicity studies in animals have failed to show evidence of damage in any tissue examined after 3 months' administration to rats of daily doses up to 20 000 times that required to produce diuresis. Similar absence of effect on all vital organswas found in dogs and rhesus monkeys. No teratogenesis or impairment of fertility was detected. Very large doses (up to 10 000 mg/kg) failed to produce ill-effects in acute toxicity tests on rats, though intravenous LDS0 values were in the region of 230 mg/kg. Chlorexolone is thus another effective oral diuretic which may also form the basis of antihypertensive therapy. While many cases appear adequately controlled onchlorexolone alone [336] more severely ill patientsmay require its potentiation with specific antihypertensive drugs. (b)
Clopamide
This drug bears some formal chemical resemblance to the benzothiatriazines referred to above [327] in that a nitrogen atom occupies the position correwonding to C3 in the thiazide series. (XXVll, Figure I. 1 ) Clopamide (Aquex, Brinaldix) has obvious features in common with quinethazorie and chlorexolone for example and can be regarded either as a piperidinocarboxamide or a substituted carboxylic hydrazide of the familiar o-chlorobenzenesulphonamide. The series of compounds from which clopamide was selected has been described [337] and subjected to the usual evaluative tests to define properties and indicate the substances most clearly meriting development [338] . Detailed pharmacological study I3391 indicates that clopamide resembles the thiazides and their other analogues closely. For instance, the site of action appears to be identical with that of the thiazides (combination of maximum dose of clopamide with chlorothiazide failed to produce increase in diureses, though this was achieved by combination with spironolactone), there is no effect upon renal plasma flow, glomerular filtration rate and no carbonic anhydrase inhibition. An important qualitative difference is an apparently equal effectiveness in acidosis or alkalosis; the output of sodium and chloride can, in addition, be up to 30 per cent more than that achieved by thiazides-perhaps indicating' firmer binding to tubular sites. The effects of a single dose of clopamide can persist for up to 48 hours [340] and the hypertensive patients show up to 2 0 mmHg fall in diastolic pres sure [341]. The drug may be at least as diabetogenic as the thiazides [342-41 though further study is needed on this point. It is obviously not nearly as potent as frusemide and ethacrynic acid and is therefore unlikely to have any action on the loop of Henle. It is, however, a clinically useful diuretic [345-81 even though some feel that its long duration of action is a disadvantage and see no reason for preferring it to the thiazides [349]. Adverse or toxic effects are those associated with effective thiazide-type
44
SOME RECENTLY INTRODUCED DRUGS
diuretics. Acute toxicity tests in animals show it t o be of low toxicity, and chronic toxicity tests in dogs failed to show any detectable change in vital organs or any teratogenicity in rats or rabbits [339]. A mucoid-secretion modifying agent Bromhexine
It was recently observed that a plant,Adhutodu vusicu,long used in Indian herbal medicine (the source of many therapeutic leads) for the relief of cough and respiratory tract congestion, did appear to reduce the quantity and viscosity of sputum. The plant was studied and its active alkaloid named vasicine. The tricyclic quinazoline structure (XXVIII) was then reduced t o fragments and a series of derivatives prepared [350]. From these bromhexine (XXIX, Na 274, Bisolvon)
was selected [351] as the most active. As will be observed, its structure is but a dim reflection of that of the alkaloid from which it arose. The pharmacology of bromhexine is unusual and as yet incompletely known. The property which has received most attention is its apparent ability to disorganize radically the structure of viscid sputum. It has been shown 1352) that the adhesive, viscous, mucoid bronchial secretion characteristic of chronic bronchitis for example, derives these properties from a fibrous structure hitherto largely unsuspected. After staining with Toluidine Blue and observation by means of polarized light such sputum is seen to consist of a mass of interlacing fibres embedded in a gel-like matrix. These fibrous structures consist largely of acidic mucopolysaccharides, except when infection is prominent in the disease state when DNA becomes the dominant ‘fibrogen’. T’he importance of pathologicallyinduced sputum production in providing infection ‘reservoirs’, in reducing ventilation (especially of smaller airways) and in other ways contributing to irreversible lung damage is now recognized [353] . The effect of administration of bromhexine to patients suffering from excessive production of viscous sputum (due to a variety of pulmonary disorders) has now been. studied and reported [354] . It is assumed by the authors that the observed effects were directly due t o bromhexine though the possibility of activity via a metabolite seems worthy of study. During the study the viscosity of sputum and its fibrous structure were noted. Within five days of commencement of oral administration of bromhexine the fibrous structure was seen to be
A.
P. LAUNCHBURY
45
markedly disrupted, with reduction in the viscosity of the material. After 10 days only very small, dispersed fragments of fibrous material could be found but on cessation of treatment sputum viscosity rose rapidly and the ordered fibrous structure reappeared. The volume of sputum produced appeared to increase for the first few days of treatniznt and t o fall thereafter though this increase may be more apparent than real-previously immobile sputum would be expectorated during this early phase. The authors discuss their findings in relation to earlier, less detailed studies and suggested modes of action of the drug. Other workers have demonstrated improved lung function (including arterial oxygen level increase [355]) and increased response to bronchodilators [356] after bromhexine. Some evidence of weak activity against tubercle bacillus has appeared [357] ;this could complicate culture control of anti-tubercular therapy. An interesting report [54] of oxytetracycline levels in bronchial secretions has provided evidence that the drug often fails to reach therapeutic concentrations in sputum but that concurrent administration of bromhexine greatly increases its levels in such exudate. This property has been briefly alluded t o above in connection with penetration of doxycycline into sinus secretions. The authors [54] attribute this higher antibiotic concentration in sputum t o increased capillary permeability, without quoting authority. Toxicity of bromhexine appears to be low; the drug is accordingly recommended for long-term treatment of chronic bronchitis, for instance. Very occasionally a slight rise in serum transaminase levels is found early in treatment but as this is transient, even in patients with hepatic disease, its significance is doubtful. The drug can irritate the gastro-intestinal tract (and is therefore likely to aggravate gastric ulcer). This is interesting since earlier expectorants were often believed t o act through reflex secretion of watery bronchial mucus following gastric irritation; this cannot, however, be accepted as the primary mode of action of bromhexine which seems to be much more fundamental. Bromhexine is unlikely to exert its effects only on bronchial mucus; information regarding its activity in other organs and secretions involving acid mucopolysaccharides is awaited with interest. If its ability to enhance the diffusion of antibiotics (and possibly other drugs) is substantiated, a very wide scope for the use of bromhexine would be opened up. A pulmonary anti-allergic for asthma therapy Cromoglycic acid
The aetiology of asthma remains obscure but at least one type, extrinsic asthma, appears closely linked to allergy and provoking agents capable of initiating Type I reactions (involving reagin antibodies) can often be identified. This type often becomes evident early in life and typical allergens include pollens, cat hair, etc. Another common form of asthma is the socalled intrinsic type, often of late
46
SOME RECENTLY INTRODIJCED DRUGS
onset, in which provoking allergens can rarely be identified. Recipitin antibodies may be associated with these episodes; some unfortunates possess antibodies of both reagin and precipitin types. Reagin-mediated, extrinsic asthma tic episodes are mediated by substances such as histamine, serotonin and SRS-A (slow-reacting substance of anaphylaxis), and therapy often aims at modifying the responses to these products of antigen-antibody interaction. Cromoglycic acid interferes with the reaction mechanism apparently by preventing the release of histamine, and SRS-A, even though antigen-antibody association occurs. Chromones have found uses in medicine for many years and it is possible to see in cromoglycic acid (XXX, Intal, FPL 670) the end-product of a long series
including among its forerunners khellin and methylchromone. The observation that reaction t o inhaled antigen could be suppressed by chromones lacking bronchodlator (or vasodilator) properties provided the lead t o the bischromones. The structure, general pharmacology and toxicity of disodium cromoglycate have been the subject of a briefcommunication [358] . This indicated that cromoglycic acid is not a bronchodilator, or an anti-inflammatory agent, nor will it modify tissue reaction to injected histamine, serotonin, bradykinin or SRS-A. It does, however, modify or abolish reaction t o allergens in previously sensitized animals provided the drug i s administered prior t o the antigenic challenge. This was shown to involve inhibition of histamine, etc., release from mast (and probably other) cells as indicated above; the drug does not appear t o modify in any way antibody production. Very few general pharmacological properties could be found; minor cardiovascular effects (varying in character with species) followed large intravenous doses. Poor absorption from the gut led t o the development of a specially designed inha1er;most of the dose so administered reaches only the larger airways and the small quantity reaching peripheral lung was rapidly absorbed and excreted, largely unchanged, in urine and bile. Toxicity tests reported in the same communication failed to provide evidence of any effects of note, except at very high concentrations (in v i m ) or doses (in vivo). In a field as complex as that involving the treatment of asthma it is not surprising that the initial published clinical work [359] should have come in for more than the usual criticism and controversy. This reception is perhaps even more understandable in view of the fact that the trial material contained isoprenaline (to abolish non-specific bronchospasm due to the dry powder itself), that the
A.
P. LAUNCHBURY
47
value of objective spirometry (in particular, measurement of FEV, changes) as an indicator of clinical improvement was challenged, and that the mode of action claimed for the drug was novel. The initial publication was sharply criticized by other workers [360] who had reached diametrically opposed conclusions from their own studies and these, in turn, were examined and points of difference clarified by the original authors [36 1 ] . This exchange reveals the clinical evaluation of a new aid to asthma therapy a too complex for easy resolution of differences of approach and view. Two cautious, but hopeful, reviews [362,362a] concluded, from evidence then to hand that the currently available preparation of disodium cromoglycate with isoprenaline could benefit patients with allergic asthma, but both expressed the hope that results from cromoglycic acid without isoprenaline would soon clarify the position. Then came publication of detailed work on the involvement of cromoglycic acid in both reagin-(Type I) and precipitin-(Type Ill) mediated reactions to inhaled allergens [363]. Concurrently, the clinical status of the drug was re-reviewed [364] in a thorough discussion of the pathological background; the conclusion was the cromoglycic acid ‘represents a new phase of treatment’. Other clinical reports followed in quick succession [365-71 , all (including additional correspondents [368] ) o f the opinion that the drug showed considerable promise. The sole dissenters (the original critics) remained, however, unimpressed [ 3691 though their criticisms seem to have been fairly adequately answered [370]. In one study [367] a marked inhibiting effect on exercise-induced asthma was actually recorded as objective improvement in FEV, after exertion. Two reports [371, 3721 of trials using disodium chromoglycate without isoprenaline confirmed that the drug possessed the beneficial properties claimed and that the dry powder could, in the absence of isoprenaline, give rise to transient pulmonary irritation. The present position appears to be that the drug has been shown to inhibit release of allergic reaction tissue-mediators, that this probably accounts for its clinical effects, and that the drug is therefore primarily a prophylactic one. Corticosteroid dosage can be reduced, with precautions, during cromoglycate therapy which also often reduces bronchodilator consumption. The drug is not of use during an acute asthmatic attack and is of,limited value in late-onset intrinsic asthma. It is proving a valuable tool in the elucidation of sensitization and reaction mechanisms. A terpenoid ester for gastroduodenal ulcer Gefarnate
In spite of the extensive and time-honoured use of anticholinergics and antacids, the only agent hitherto shown t o be of significant value in promoting healing of
48
SOME RECENTLY INTRODUCED DRUGS
gastric and duodenal ulcers has been the triterpenoid, carbenoxalone. The drug has, however, sideeffects (including sodium and water retention); its properties and place in therapeutics have recently been thoroughly reviewed in a symposium [373].
In the search for new compounds with healing potential in gastro-duodenal ulcerative conditions, attention has been given to sporadic reports of weak variable activity of this type in many vegetables, notably in white-headed cabbage. A useful account of these studies and of the steps leading t o gefarnate (XXXI, Gefarnil, Gefarnyl) has appeared in the form of a historical review [374].
No active material was isolated from any plant though crude extracts did give evidence of activity from time to time. This activity was traced to the liposoluble fraction of the extracts and its disappearance during further processing was taken to mean that many weakly-active substances together probably provided the necessary potency (in crude preparations) which could not be maintained by separated, individual substances. Various tenuous threads of evidence suggested that Vitamin K-like compounds might be involved (though the actual vitamins proved inactive), and the terpenic (farnesylic and phytylic) side-chains were examined. Although phytol proved inactive farnesol showed promise; like the crude vegetable extracts it was demonstrably active given either orally or parenterally (to guinea-pigs with histamine-induced ulcers). Hydrogenation abolished activity (sometimes producing irritant, ulcerogenic, compounds) and the number, as well as the existence, of olefinic links appeared critical. Increase in polarity achieved by oxidation of farnesol t o the acid maintained activity while addition of a further carbon atom gave farnesylacetic acid with greatly increased activity. Ethyl farnesate retained the properties of the acid while esters formed from terpinols (for example, geraniol) provided the most active series studied. The synthesis of these esters has been described [375] and their initial screening, leading to the selection of gefarnate, reported [376, 3771. The main screening test was that of ability to heal gastric ulcers induced in guinea-pigs by repeated histamine administration [378] though more detailed and more broadly based studies followed. Gefarnate, a mixture of stereoisomers, was shown t o lack both water-retaining and diuretic activity, to have no effect on blood pressure, respiration, blood-sugar,
A. P. LAUNCHBURY
49
and to have no local or central analgesic activity. Gastric motility and acid secretion was unaffected by the drug. One action which is noted, but not followed up, is inhibition of hyaluronidase-this might seem to be relevant in the context of tissue integrity. Experimentally, gefarnate has protected rats against prednisolone-and phenylbutazone-induced ulcers [379] and similar properties have been observed in humans [380]. More detailed studies of the drug, involving complex trial design, have shown [381] an apparent remarkable superiority of gefarnate over conventional antacid-anticholinergic treatments in the clinical management of gastric and duodenal ulcers. Toxicity appears to be negligible to the extent that both in animals and in humans large doses for extended periods, orally and parenterally, have failed to provide evidence of abnormal function of any type [376, 377, 3821. As might be expected, large volumes of the oily ester initiated local tissue irritation. Clinically, results rivalling those obtained with other treatments in conjunction with complete rest have been obtained using gefarnate in ambulant cases [374,380,381,383], and other reports are in press. The route of administration appears immaterial in that approximately 80 per cent of gastric and 60 per cent of duodenal ulcers are reported as healed whether the drug was given intramuscularly or orally. The mode of action is unknown but current theories on the structure of cell membranes permit of speculation concerning action at this level. Further clinical trials and more detailed biochemical studies are required to elucidate the mechanism of action and to evaluate properly this interesting compound. A broad-spectrum antimicrobial nitrofuran Nifuratel
The nitrofurans, their syntheses, general properties and trends in development, were reviewed recently in this series [384]. In particular, the limited development of resistance and generally low toxicity were stressed. The addendum to that review noted a number of nitrofurans with antifungal and antitrichomonal activity, and from this line of development a series of compounds possessing antibacterial, antitrichomonal and anticandidal activity has emerged. Of these, nifuratel (XXXII, Macmiror, Magmilor, Polmiror) is the most active and its general properties, synthesis and pharmacology have been described [ 3851 .
I 4Na
dbSMe
I C
HN J y O 0
(xxxn)
50
SOME RECENTLY INTRODUCED DRUGS
A thioether oxazolidinone nitrofuran, the drug has an unusually wide spectrum of activity. Many Gram-positive and Gram-negative bacteria are sensitive, antitrichomonal activity appears to be at least 3-4 times (weight for weight) that of metronidazole while Cundidu species show anomalous behaviour in that only moderate sensitivity is demonstrable in vitro yet clinical results indicate elimination of Cundidu and prevention of overgrowth by this organism during therapy for infections caused by other microbes. This does not appear to result from active metabolite formation. The structure of the drug is unusual in possessing the thioether linkage; antimicrobial activity depends on this feature as oxidation to the sulphone or the dioxide radically reduces activity. Increase in size of the alkyl radical also diminishes activity, trichomonacidal activity being demonstrable only in the methyl ether. Toxicity is low in that acute and chronic animal tests agree with clinical pharmacological findings [3861 that no biochemical or histological changes in any vital organ could be detected following exposure t o the drug. One or two patients are reported to have experienced mild symptoms (probably due to acetaldehyde) after taking alcohol with the drug, though other reports indicate no such interaction. Under the circumstances (other nitrofurans, for example, furaltadone have provoked vigorous reactions in the presence of ethanol) it is probably wise to avoid concurrent consumption of the two drugs. Nifuratel is absorbed from the gut in amounts adequate to give systemic antibacterial and antitrichomonal activity though the main metabolite is bactericidal only. This systemic activity permits treatment of male partners who may be carriers of trichomonas-a frequent cause of re-infection in married women. Clinical trials t386-91 demonstrate that combined therapy (oral tablets and pessaries) gives the most predictable and rapid elimination of pathogens in vulvovaginitis due to bacteria, trichomonads or Cundidu spp., though good results have followed oral therapy alone. A further report [390] indicates that nifuratel may greatly simplify the treatment, in general practice (where pathological reports are rarely to hand), of vulvo-vaginitis of all likely aetiologies (except syphilis and gonorrhoea). Concurrent cystitis (presumably bacterial) also responded. Patients rarely required more than 14 days treatment to secure eradication of the three main pathogens noted above; in difficult cases one month’s treatment (with oral - , therapy of the partner where appropriate) sufficed. The advent of nifuratel is a reminder that the nitrofurans are by no means a spent force; much more will doubtless be heard of t h s drug and of congeners now under development. The first anti-pseudomonalpenicillin Carbenicillin
The number of penicillins synthesized and screened for activity has now reached astronomical proportions following the isolation [39 11 of 6-aminopenicillanic
A.
P. LAUNCHBURY
51
. acid
(in 1959) from which the semi-synthetic derivatives are obtained. It was soon observed that penicillin activity could be extended into the Gram-negative range by the introduction,at the a-carbon of the sidechain, of hydrophilic groups. Ionized radicals gave the greatest promise and ampicillin (the a-amino derivative) has now an accepted place in therapeutics for the treatment of infections due to Gram-negative bacteria. Further work, based on this approach, involved the a-guanidino analogue [392, 3931 but real progress came only when the a-substituent was made anionic rather than basic. Carbenicillin (XXXIII, Pyopen) 0
I
COOH
COOH I
H
exhibits a property, most unusual for a penicillin, of activity against Pseudomonus spp. Its general antibacterial spectrum resembles that of ampicillin, except that its activity is of a lower order, with the notable exception of the organisms named above (and of related, similarly difficult genera). Carbenicillin shares the remarkably low toxicity [394] characteristic of the penicillins; since it produces no physiological abnormality in mammals, it can be given intravenously in large doses in the treatment of severe Pseudomonas infections (20-30 g daily is not uncommon [395] ). The only problem likely to be encountered is that of convulsions, which have been reported after high doses of penicillins, but the likelihood of this complication occurring during carbenicillin therapy is small since the highly ionic molecule does not pass the blood-brain barrier in appreciable amounts. Intrathecal use (in meningitis) is more likely to carry this small risk. The absorption and excretion of carbenicillin in man has been reported [396]. The antibiotic is not absorbed intact from the gut; intramuscular injection (which is painful) often provides adequate serum levels (approximately 20 pg/ml) but infections with Pseudomonus strains having minimum inhibitory concentrations up to, or higher than, 100pg/ml require intravenous thkrapy to achieve such levels. No evidence of active metabolite formation has been obtained. Marked reductions in the half-life (and serum levels) of carbenicillin follow extracorporeal dialysis or peritoneal dialysis, the former producing the most striking effect [397]. These results were, of course, obtained in patients with severe renal failure. Patients with normal renal function rapidly eliminate the drug but, as with all penicillins, renal tubular secretion can be retarded by concurrent administration of probenecid. The assay of carbenicillin in biological fluids presents problems in that it may be accompanied by traces of benzylpenicillin (probably arising by a-decarboxylation of carbenicillin) to which the usual test organism, Surcinu lutea, is extremely
52
SOME RECENTLY INTRODUCED DRUGS
sensitive. Pseudomonas aeruginosa NCTC 10490 is used instead since it is unusually sensitive t o carbenicillin but relatively resistant to benzylpenicillin. Concentrations down to 2.5 pg/ml can be assayed in this way [ 3 9 6 ) . Microbiologically, interest is mainly directed t o carbenicillin for its activity against Pseudomonas aeruginosa, Proteus morgani, P. rettgeri and P. vulgaris [395, 3981, all more or less resistant t o ampicillin. Klebsiella and Strep. fuecalis are often resistant. While many other pathogens are sensitive to carbenicillin other penicillins are more effective against them. Carbenicillin, then, dovetails with ampicillin in the Gram-negative field. It is complementary t o methicillin or cloxacillin in that these drugs are competitive inhibitors of penicillinase (amidases and 0-lactamases) which would otherwise destroy carbenicillin. Not all Gramnegative bacteria are resistant to penicillins because of such enzyme production so that the enzyme-inhibiting penicillins have only a limited usefulness in potentiating ampicillin and carbenicillin. Synergism with other anti-pseudomonal agents such as gentamycin, polymixins Band E, and even streptomycin, has been reported and is currently receiving study [398, 3991. It may well be that, in difficult cases, treatment with a combination of gentamycin, carbenicillin and cloxacillin (or with a polymyxin and the penicillins) will be necessary. So far, clinical evaluation [396-91 has given hope of a measure of control of Pseudomonas with, for the first time, a non-toxic drug. In view of previous calamities a recent reviewer 14001 commented: ‘to make the best use of carbenicillin both the minimim inhibitory concentration for each strain of organism and the level of the antibiotic in serum must be established.’ Unfortunately, the next sentence reads. ‘We fear that in most hospitals this will remain a council of perfection’. It is to be hoped that this drug will not be squandered like so many of its predecessors.
A new antibiotic of unusual structure Rifamide
The rifamycins, like so many other antibiotics, have been developed semisynthetically over a period of some ten years. The isolation of rifamycin B, the clarification ,of its biological conversion products and their subsequent modification to rifamide (XXXIV, Rifocin-M) have been described [401, 4021. The drug is unusual in that a long complex aliphatic chain spans a hydroxylated napthalene system. Its antibacterial spectrum has been studied [403, 4041. It shows intense activity against many Gram-positive organisms, especially staphyloccocci, pneumococci and streptococci (against which it is often bactericidal) and, at higher concentrations, rifamide inhibits many Gram-negative bacteria including Esch. coli, Pseudomonas, Proteus, Salmonella and Shigella. Of particular interest is its high activity against Mycobaterium tuberculosis though other
A. P. LAUNCHBURY
53
rifamycins (including rifampicin), currently under study, show even higher activity against this organism. The mode of action [403-51 of rifamide is interesting in that i t appears to bring about a widespread disruption of bacterial metabolism. Protein and carbohydrate utilization is impaired [406] and R.N.A. polymerase inhibited, at least in vitro. Me
Me
MeCO 0 Me
(XXXW)
The in vivo distribution of rifamide has been studied in dogs and rats [407]. Following intravenous injection by far the highest concentrations of the drug were found in bile and urine; a fairly uniform distribution in most other tissues was noted with the exception of brain where the concentration was negligible. In the exudate of rat granuloma pouch high antibiotic concentrations occurred. Oral administration has been shown to give unpredictable blood levels [408] . The same study revealed that almost 80 per cent of parenterally administered drug was recoverable in bile (giving biliary concentrations above 1 mglml), while other workers [409] have demonstrated strongly antibacterial concentrations in the gall-bladder wall. Placental passage is negligible 14101 as might be expected from the blood brain barrier findings referred to above. The toxicity of rifamide has been studied [404,411] with almost consistently negative results. At very high doses, some species showed minor haemodynamic disturbances, whilst others showed minor renal or hepatic changes. No toxic effects have been observed in animals or humans at therapeutic doses. Pain may be encountered at the site of injection. In clinical experience the drug has shown the properties expected from earlier experimental work. I t has been studied in biliary disease [412, 4131 in general surgical work [414] andin a variety of pulmonary infections [415-81 .The results have justified early optimism; in particular the very high concentrations achieved in bile make the drug eminently suitable for infections of the biliary tract. Rifamide (and its analogues) would appear t o be a much-needed addition to the antimicrobial arsenal; because of its low toxicity and lack of cross-resistance with other anti-infectives it is t o be expected that much more will be heard of the
POM E RECENTLY INTRODUCED DRUGS
54
drug. Again it is hoped [418a] that the emergence of resistance will be delayed by the application of the basic principles of antibacterial therapy. A new anti-tubercular drug Ri farnpicin
The observation [403,404] that rifamide and its congeners showed activity against Mycobacteria led t o the synthesis of further members of this series. Kifampicin not only possesses this property t o a marked degree but also exhibits good absorption from the gut and prolongs serum levels [419-421]. Differing in structure from rifamide (XXXIV) only in the substituents on one benzene ring. rifampicin (rifampin, Rifadin, Rimactane, XXXV) is of considerable interest in
fi!:=N.N3Me OH
(XXXV)
H o - H 2 c q N H B " t
(XXXVI)
that it inhibits bacterial RNA synthetase (422-4231, and, more surprisingly, the RNA polymerase induced in mammalian cells by many DNA viruses 143-4-43-61. This implies that the viral-induced enzyme resembles bacterial RNA polymerase more closely than the mammalian enzyme of this type. It has been pointed out [427], however, that clinical exploitation of this effect is hampered by the relatively high concentrations required. In addition to its satisfactory absorption from the gut, rifampicin also appears superior to other rifamycins with regard to penetration into bone; in view of the high levels reached i n this tissue and the sensitivity of S. uureus t o the drug, rifampicin has been suggested as worthy of trial in osteomyelitis [428]. Experience in urinary tract infections has not been encouraging [429]. The activity of rifampicin against mycobacteria has been intensively studied [430-4321 both in vivo and in vitro, as has its activity i n combination with other drugs such as isoniazid [433] and ethambutol [434]. Rifampicin appears t o be particularly promising in the treatment of tuberculosis, especially in combination with isoniazid. The prolonged high blood levels attainable with a single daily dose should simplify therapy. The prospects, including questions still unresolved, have recently been reviewed [435]. It is t o be hoped that the usefulness of this effective, almost non-toxic addition t o the antitubercular range of drugs will not be jeopardized by injudicious use of other rifamycins since cross-resistance exists between all known members of this group-at least so far as mycobacteria are concerned.
A.
P. LAUNCHBURY
5s
A selective bronchodilator Salbu tarnol
The treatment of acute bronchospasm with the classic drug isoprenaline has a number of disadvantages. Relief of spasm is short-lived since the catecholamine is metabolized by catechol-o-methyltransferase to the inactive 3-methoxy derivative; cardiovascular responses may actually worsen hypoxaemia since cardiac output increases and pulmonary vasculature dilates. Ventricular arrhythmias leading t o fibrillation are consequent hazards. Bronchodilation and the cardiac effects described are usually designated P-adrenergic responses but evidence exists [436, 4371 that this group of receptors comprise at least two sub-groups. Marked correlations exist between lipolytic and cardiac stimulatory potencies 0-1)and between bronchodilator and vasodepressor activity @ 2 ) , when series of 0-activating sympathomimetics are examined. This indicates that drugs prefererentially active at one or other of these receptor sites might be found. In one series [437] it was found that the 3-hydroxyl group of catecholamines could be replaced by a hydroxymethyl with retention of much typical p-stimulant activity. The phenolic 4-hydroxyl was, however, found t o be essential for activity which was greatest (as might be expected) in amines with branched-chain N-substituents. Of these ‘saligeninamines’, salbutamol (Ventolin, AH 3365, XXXVI) was selected for further study and finally for clinical use. It exhibited [438] considerably more activity on bronchial smooth muscle than on other muscles affected by 8stimulants. For instance, the stimulant effect of salbutamol on isolated guineapig atria was only a two-thousandth of that of isoprenaline and the vasodilating effect, in the perfused dog limb, only one-tenth. The bronchodilator effect was, however, profound and prolonged. Metabolic studies indicated that at least 10 per cent of the drug is excreted as a glucuronide. that no detectable enzyme induction occurred over a three month period and that salbutamol is not affected by catechol-o-rnethyltransferase. Clinically, it has been confirmed that the drug is an effective bronchodilator with very little cardiovascular activity; it does not appear to increase hypoxaemia [439]. A more detailed study [ 4 4 0 ] , comparing salbutamol with isoprenaline and orciprenaline, demonstrated that 200 p g of sabutamol provided effective bronchodilation for a t least three hours without detectable cardiac stimulation. Equivalent bronchodilator doses of isoprenaline and orciprenaline were 1000 pg and 1500 pg respectively. The bronchial effects of isoprenaline, though initially intense, waned within one hour and cardiac effects were noted. In this trial little objective difference could be detected between salbutamol and orciprenaline at the dose levels used, though most patients expressed preference for salbutamol. By virtue of its prolonged effect and high degree of selectivity salbutamol may prove t o be a significant development in bronchodilators, apart from its intrinsic interest as a research tool.
56
SOME RECENTLY INTRODUCED DRUGS
Concluding remarks
In this brief survey of some recently introduced drugs, it is inevitable that some will not have received mention. The following brief notes are intended merely t o indicate the scope o f the subject. In an earlier review [441] the concluding paragraph alluded t o the need for, and difficulties in attaining, a long-acting local anaesthetic. The introduction of bupivicaine (Marcaine, AH 2250) which, with adrenaline, can give anaesthesia for up t o 10 hours, may be a step towards this goal [442] . The substituted procainamide, metoclopramide (Maxolon) as an anti-emetic [443] is worthy of note, while the findings of many workers [444-4471 that cyproheptadine (Periactin) stimulates appetite and can thereby increase body weight may solve some problems in paediatrics and geriatrics. In a completely different context, clomiphene (Clomid) [448] appears less likely than the gonadotrophins to lead t o multiple pregnancies in the treatment of some form of infertility in women. Drostanolone (dromostanolone, Drolban, Emdisterone, Masted, Methalone), offered as a palliative in the treatment of mammary carcinoma, has stimulated considerable research into anti-oestrogenic mechanisms [449], while the increasing use of allopurinal (Zyloric) in gout has revealed new aspects of purine metabolism [450]. Cholestyramine (Cuemid, Dowex 1-X2-C 1, Questran) is a quaternary ammonium cationic resin used primarily t o bind, in the gut, bile salts which appear t o be the main cause of pruritis in obstructive hepatic disease. Again, many unexpected facets of steroid and lipid metabolism are becoming clear following studies of the drug’s effects [45 1.4521. Polypetides of medicinal interest were reviewed earlier in this series (4531 and developments have continued apace. Angiotensinamide, pentagastrin, tetracosactrin and felypressin are now either widely used or growing in importance and serve t o illustrate how rapidly this branch of medicinal chemistry is expanding. An interesting example of the rare true synergy is t o be found in the combination of trimethoprim and sulphamethoxazole (Septrin, Bactrim). Since these two drugs attack sequential enzymes [454] involved in folate utilization, a large, almost irreparable, ‘metabolic crater’ results from the simultaneous use of the two drugs. Resistance to the combination is rare and feeble (so far) and it would seem reasonable t o expect that this principle of attacking sequential, rather than widely separated, enzymes will be developed further with other drugs. Other antiinfectives now gaining acceptance include capreomycin, ethambutol (both antitubercular), gentamycin (combining the spectrum of kanamycin and the polymyxins) and candidicin (for vaginal candidosis). Antibiotics with antineoplastic activity continue to appear and rubidomycin (daunomycin, daunorubicin) [455] is currently receiving wide study. The above, like the chapter it concludes, is not intended t o be comprehensive, but rather to pin-point areas which may be of particular interest requiring further study.
A. P. LAUNCHBURY
57
REFERENCES
1. 2. 3. 4. 5.
6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38.
J. S. O’Brien, J. Theor. Biol., 1967, 15, 307 G. M. W. Cook, Brit, Med. Bull., 1968,24,118 A. D. Bangham and D. A. Haydon, Brit. Med. Bull., 1968,24, 124 J. A. Lucy, Brit. Med. Bull., 1968, 24, 127 A. C. Allison, Brit. Med. Bull., 1968, 24, 135 B. B, Brodie, Absorption and Distribution of Drugs (Ed. T. B. Binns) E. & s. Livingstone, London, 1964, p.16 N. J. Harper, J. Med. Pharm. Chem., 1959, 1,467 N. J. Harper, Progr. Drug R e x , 1962,4,221 M. Barber and L. P. Garrod, Antibiotics and Chemotherapy, E. & S. Livingstone. London, 1963, p.32 M. Barber and P. M. Waterworth, Brit. Med. J., 1962, 1, 1159 M. Barber and P. M. Waterworth, Brit. Med. J., 1964, 2, 344. G. T. Sewart, The Penicillin Group of D r u g , Elsevier, Amsterdam, 1965,pp.108, 140 M. Gibaldi and M. A. Schwartz, Brit. J. Pharmacol., 1966, 28, 360 R. L. Barnden, R. M. Evans, J. C. Hamlet, B. A. Hems, A. B. A. Jansen, M. E. Trevett and G. B. Webb, J. Chem. SOC.,1953, 3733. A. P. Richardson, H. A. Walker, I. Miller and R. Hansen, Proc. SOC.Exp. Biol. M e d , 1945,60,272 H. P. K. Agersborg, Brit. J. Pharmacol., 1966,26,649 A. B. A. Jansen and T. J. Russel, J. Chem. SOC.,1965,2127 H. P. K. Agersborg, A. Batchelor, G. W. Cambridge and A. W. Rule, Brit. J. Pharmacol., 1966,26,649 M. Gibaldi and M. A. Schwartz, Brit. J. Pharmacol., 1966, 28, 360 G. Gomez and J. R. Gomez, Brit. J. Clin. Pracr., 1967, 21, 183 General Practitioner Research Group (D. P. Wheatley) Practitioner 1967, 198, 568 J. H. Sewart, J. Roy. Nav. Med. Sew., 1967, 53, 151 H. F. McDuffie and D. E. Cooper. Patent 2,650,218; Chem. Abstr., 1956,50,410 Drug Ther. Bull., 1967, 5 , 2 8 L. A. Mounter and V. P. Whittaker, Biochem. J . , 1963,54,55 1 P. N. Giraldi, G.Tosolini, G. Nanniniand A. Fojanesi,Arzneim-Forsch., 1966, 16, 162 G. Ungar, S. Kobnn and B. R. Sezesny, Arch. Int. Pharmacodyn Ther.,.1959,123,71 R. Tommasini, K. Bloch, J. Franceschini, A. Longoni, V. Mandelli, M. A. Parenti, N. Passerini and G. Valzelli, Arzneim.-Forsch., 1966, 16, 164 R. Tommasini, V. Mandelli, N. Passerini and G. Tosolini, Arzneim-Forsch., 1966, 16, 172 A. Caniggia, C. Gennari, B. Bencini, V. Palazzuoli and L. Cesari, Arzneim.-Forsch., 1967, 17,446 G . Sacchetti, G. Tosolini, S. Ezechieli and N. Bergamini, Lancet, 1966, 1, 1329 G. Sacchetti, G . Tosolini, S. Ezechieli and N. Bergamhi, Arzneim.-Forsch., 1968, 18, 336 G. Gunella, Arzneim.-Forsch., 1966, 16, 896 0. P. Sharma, S. S. Hayreh and D. G. James, Practitioner, 1968, 200, 542 J. R. D. McCormick, E. R. Jensen, P. A. Miller and A. P. Doerschuk, J. Amer. Chem Soc., 1960,82, 3381 M. Schach von Wittenau, J. J. Beereboom, R. K. Blackwood and C. R. Stephens, J. Amer. C h e m SOC.,1962, 84, 2645 R. M. Evans, The Chemistry of the Antibiotics used in Medicine, Pergamon, London, 1965, p.120 C. R. Stephens, J. J. Beereboom, H. H. Rennhard, P. N. Gordon, K. Murai, R. K. Blackwood and M. Schach von Wittenau, J. Amer. Chem. SOC.,1963,85, 2643
SOME RECENTLY INTRODUCED DRUGS
58
39. M. Schach von Wittenau and C. S. Delahunt, J. Pharmacol. Exp. Ther., 1966,152,164 40. B. B. Brodie and C. A . M. Hogben, J. Pharm Pharniacol., 1957,9,345 41. J. E. Rosenblatt, J. E,. Barrett, J. L. Brodie and W. M. M. Kirby, Antimicrob. Agents Clieniotlier., 1966,152,164 42. Today’s Drugs, Brit. Med. J . , 1968,2,609 43. A. H. Beckett and G. T. Tucker, J. Pharni. Pharmacol., 1968,20,174 44. A. H. Beckett, R. N. Boyes and G. T. Tucker,J. Pharm. Pharmacol., 1968,20,269 45. A. H. Beckett, R. N. Boyes and G. T. Tucker, J. Pharm. Pharmacol.,.1968,20, 277 46. A. H. Beckett and A. F. Casy, Progr. Med. Chern. 1965,4,172 47. I. M. Weiner and G. H. Mudge, Amer. J. Med., 1964,36,743. 48. L. S. Goodman and A. Gillman Eds. The Pharrnacological Basis of Therapeutics, 3rd Ed., Collier-Macmillan. London. 1965. 826 49. J. R. Migliardi and M. Schach von Wittenau, presented a t the 5th Int. Congr. of Chemotherapy, Vienna, 1967 50. C. M. Kunin and M. Finland Clin. Pharmacol. Ther. 1961,2, 51 51. C. Lundberg, K. Gullets and A. S. Malmborg, Lancet, 1968,2,107 52. J. Fabre, P. Pitton and J. P. Kunz, Cliernotlierapia, 1966,11, 73 5 3. W. R.C. Aitchinson, I. W. B. Grant and J. C. Gould, Brit. J. Clin. Pract., 1968,22,NO. 8 54. H. Burgi, A Kleber, J . Regli and M. Gent, Lancet, 1968,2,406 55. J. B. Stenlake, Progr. Med. C h e m 1963,3,1 56. W. C. Bowman, Progr. Med. Chern., 1962,2,88 57. 0. V. Brody and R. M. Fuoss, J. Pliys. Ciiem., 1956,60,156 58. S . A. Rice, J. Amer. C h e m SOC.,1956,78,5247 59. S. A. Rice, J. Amer. C h e m SOC.,1958,80,3207 60. P. H.Elworthy, J. Pharm. Pharmacol., 1963,15,Suppl. 137T 61. P. H. Elworthy, J. Pharrn. Pharrriacol., 1964,16, 375 62. E. W. Gill, Progr. Med. Chern. 1965,4,39 63. L. E. Craig, The Alkaloids (Ed. R. H . F. Manske), Vol. 5,Academic Press, New York, 1955,265 64. F. M. Carey, D. Edwards, J. J. Lewis and J. B. Stenlake, J. Pharm. Pliarmacol. 1959, 65.
11, 70T J. J. Lewis. M. Martin-Smith. T. C. Muir and H. H. Ross. J. Pharnr Pharrnacol. 1967,
19,502 66. 67. 68. 69. 70.
M. M. Janot, F. Laine and R. Goutarel, Ann. Pharm. Franc., 1960,18,673 M. Alauddin, B. Caddy, J. J. Lewis, M. Martin-Smith and M. F. Sugrue, J. Pharm Pharrnacol, 1965,17,57 W. R. Buckett, C. L. Hewett and D. S. Savage, Qiim. Ther., 1967,2,186 W. R. Buckett, C. E. B. Marjoribanks, F. A. Marwick and M. B. Morton, Brif. J. Pharmacol, 1968,32, 671 D. G. Bamford, D. F. Biggs, M. Davis and E. W. Parnel1,Brit. J. Pharmacol., 1967,3,
194
73. 74. 75. 76.
D. Busfield, Brit. J. Pharmacol., 1968,32,609 I . L. Bonta, W. R. Buckett, J. 1. Lewis and B. B. Vargaftig, Proc. 2nd Inr. Congr. on Horrnonal Steroids, Excerpta Medica, Amsterdam, 1966 W. R. Buckett and 1. L. Bonta, FedProc., 1966,25,718 W. L. M. Baud and A. M. Reid, Brit. J. Anaesthesia, 1967,39,775 D.Busfield, Brit. J. Pharmacol., 1968,33,609 N. B. Eddy, H . Halbach, H. Isbell and M. H. Seevers, Bull. World Health Organ, 1965,
77. 78. 79. 80. 81.
H.Beckett and A. F. Casy, Progr. Med. Chem. 1962,2,43 A. H.Beckett and A. F. Casy, Progr. Med. Chem., 1965,4,171 1,’. 1:. Foldes, J. N. Lunn, J. Moore and I. M. Brown, Amer. J. Med. S c i , 1963,245,23 L. Lasagna, Proc. R o y . SOC.M e d . , 1965,58,978 t:. F. Foldes, Med. Clin. N. A m e r . , 1964,48,421
71. 72.
32,721 A.
A. P. LAUNCHBURY 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129.
59
M. S. Sadove, R. C. Balagot, S. Hatano and E. A. Jobgen,J. Amer. Med. A s s , 1963, 183, 666 H. Blumberg, P. S. Wolf and H. B. Dayton,Proc. SOC.Exp. Biol. Med., 1965, 118, 763 H. Blumberg, H. B. Dayton and P. S. Wolf,Proc. SOC.Exp. Biol. Med., 1966, 123, 755 G. F. Blane and D. Dugdall, J. Pharm Pharmacol., 1968,20,547 K. W. Bentley and D. G. Hardy,Proc. Chem SOC.,1963,220 K. W. Bentley,J. Amer. Chern SOC.,1967,89, 3267 G. F. Blane, J. Pharm. Pharmacol., 1967, 19, 367 F. F. Foldes and T. A. G. Torda, Acta Anaesth. Scand., 1965, 9, 121 H. Isbell, Fed. Proc., 1956, 15,442 0. Schrappe, Arzneim.-Forsch., 1959, 9, 130 W. R. Martin and C. W. Gorodetzky, J. Pharmacol. Exp. Ther., 1965, 150,437 H. F. Fraserand D. E. Rosenberg, J. Pharmacol. Exp. Ther., 1964,143, 149 W. R. Martin, H. F. Fraser, C. W. Gorodetzky and D. E. Rosenberg, J. Pharmacol. Exp. Ther., 1965, 150, 426 L. Brill and J. H. Jaffe, Brit. J. Addict. 1967,62, 375 H. F. Fraser and L. S. Hams, Annu. Rev. Pharmacol., 1967,7, 277 L. Lasagna, Arch. Int. Med., 1954, 94, 532 H. F. Fraser, Med. Clin N. Amer., 1957, 47, 393 W. R. Martin, C. W. Gorodetzky and T. K. Clare, Clin Pharmacol. Ther., 1966, 7,455 V. P. Dole and M. E. Nyswander, J. Amer. Med. Ass., 1965, 193, 646 G. Gorssen and 1. A. Skora, J. Amer. Med. A s s , 1964, 187, 328 W. R. Buckett, Brit. J. Addict. 1967,62, 387 J. Pohl, Z. Exp. Pathol. Ther., 1914, 17, 370 J. Weijlard and A. E. Erickson, J. Amer. Chem. SOC.,1942,64,869 K. Unna, J. Pharmacol. Exp. Ther., 1943, 79.27 S. Archer, N. F. Albertson, L. S. Harris, A. K. Pierson and J. G. Bird, J. Med C h e m , 1964,7,123 0. Schaumann, Brit. Med. J., 1956,2, 1091 L. Lasagna and H. K. Beecher, J. Pharmacol. Exp. Ther., 1954, 112, 356 A. S. Keats and J. Telford, J. Pharmacol. Exp. Ther., 1957, 117, 190 N. B. Eddy, Brit J. Addict., 1966,61, 155 Lancet, 1967, 1, 1310 E. L. May, Brit. J. Addict., 1967,62, 197 L. S. Harris, Arch. Exp. Pathol. Pharmacol., 1964,248,426 L. S. Harris and A. K. Pierson, J. Pharrnacol. Exp. Ther., 1964, 143, 141 S. Archer and L. S. Harris, Yale Sci Mag., Feb. 1965 W. H. 0. Expert Committee on Dependence Producing Drugs: Fifteenth Report (1966), World Health Organ Tech. Rep., Ser. 343: 6 M. S. Sandove, R. C. Balagot and F. N. Pecora, J. Amer. Med. Ass., 1964, 189. 199 M. S. Sandove and R. C. Balagot, J. Amer. Med. Ass., 1965, 193,887 R . A. Gordon and J. H. Moran, Can. Anaesth. SOC.J., 1965,12,331 L. J. Cass, W. S. Frederik and J. V. Teodoro, J. Amer. Med. A s s , 1964, 188, 112 H. Erb, Gynaecologia, 1966, 162,275 J. L. Wilkey, L. J. Barson and F. H. Rowe, J. Urol. (Baltimore), 1967,97,550 R. Scott, R. J. Abernethy and H. S. Livingston, Clin. TrialsJ., 1966, 3, 395 N. McSwan, J. M. Reid, E. R. Matthews and E. M. Henderson, Clin. Tri3ls J., 1966, 3, 339 A. S. Keats and J . Telford, J. Pharmacol. Exp. Ther., 1964, 143, 157 V. K. Stoelting, Anaesth. Analg. Cum Res., 1965,44,769 J. P. Conaghan, Brit. J. Anaesthesia, 1966, 38, 345 M. Swerdlow and A. Dalal, Anaesthesist, 1966, 15,43 Drug Ther. Bull., 1967, 5 , 33
60 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 159a. 160. 161. 162. 163. 164. 165. 166. 167. 168.
SOME RECENTLY INTRODUCED DRUGS W. Norris and A. B. M. Telfer, Brit. J. Anaesthesia, 1968,40, 341 J. Telford and A. S. Keats, Clin. PharmacoL Ther., 1965,6, 12 W. W. Filler and N. W. Filler, Obstet. Gynaecol., 1966, 28, 224 A. H. Beckett and J. F. Taylor, J. Pharm Pharmacol., 1967, 19, Suppl. 50s W. T. Beaver, Clin. Pharmacol. Ther., 1966, 7 , 7 4 0 G . M. Halpern, Lancet, 1968,1,1205 M. J. Thuillier and R. Domenjoy, Anaesthesist, 1 9 5 7 , 6 , 163 R. Hiltmann, H. Wollweber, W. Wuth and F. Hoffmeister, Intravenose Kurznarkose mil dern neuen Phenoxyessigsaurderivat Propanidid (Epontol), (Eds. K. Horaz, R. Frey and M. Zindler) Springer-Verlag, Berlin, 1965, p.1 B. B. Brodie, L. C. Mark, E. M. Papper, P. A. Lief, E. Bernstein and E. A. Rovenstine, J. Pharmacol. Exp. Ther., 1 9 5 0 , 9 8 , 8 5 L. C. Mark, Clin Pharmacol. Ther., 1 9 6 3 , 4 , 5 0 4 H. L. Price, Anesthesiology, 1960, 21, 40 R. K. Richards and J. D. Taylor, Anesthesiology, 1956, 1 7 , 4 1 4 W. D. Winters, E. Spector, D. P. Wallach and F. E. Shideman, J. PharmacoL Exp. Ther., 1955, 114, 343 J. Putter, Die intravenose Kurznarkose mit dem neuen Phenoxyessigsaurederivat Propanidid (Epontol). (Eds. K. Horatz, R. Frey and M. Zindler) Springer-Verlag, Heidelberg, 1965, p.61 W. Wirth and F. Hoffmeister, Die intravenose KurznarkoFe mit d e m neuen Phenoxyessigsaurederivat Propanidid (Epontol). (Eds. K. Horatz, R. Frey and M. Zindler), Springer-Verlag, Heidelberg, 1965, p.17 W. N. Aldridge, Biochem J., 1953, 53, 110 K. B. Augustinsson,Acta Chem. Scand., 1959a, 13, 571 A. Doenicke, Acta Anaesth. Scand., 1965, Suppl. XVII, p. 21-5 B. Duhm, W. Maul, H. Medenwald, K. Patzschke and L. A. Wegner, Die intravenose Kurznarkose mit dern neuen Phenoxyessigsaurederivat Propanidid (Epontol), (Eds. Horaz, R. Frey and M. Zindler) Springer-Verlag, Heidelberg, 1965, p.78 A. Doenicke, 1. Krumey, J. Kugler and J. Klempa, Brit. J. Anaesthesia, 1968,40,415 M. Zindler, ed. Acta Anaesth. Scand., 1965, Suppl. XVII, R. S . J. Clarke and J. W. Dundee, Curr. Res. Anestha, 1966, 45, 250 D. R. Cadle, T. B. Boulton and M. S. Swaine, Anaesthesia, 1968, 23, 65 T. H. Howells, Brit. J. Anaesthesia, 1968,40, 182 P. W. Jackson and Z. M. Woodhead, Anaesthesia, 1967, 2 2 , 7 0 4 M. Johnstone and P. T. Barron, Anaesthesia, 1968, 23, 180 T. H. Howells, Acta Anaesth. Scand., 1965, Suppl. XVII, p.40 M. Zindler, Acta Anaesth. Scand., 1965, Suppl. XVII, p.41 Drug Ther. Bull., 1 9 6 6 , 4 , 9 7 J. Crossland, Progr. Med. Chem., 1967,5, 251 Various authors, Brit. Med. Bull., 1965, 21, 1 D. W. Wylie and S. Archer. J. Med. Pharm. Chenz., 1962.5, 932 S. Archer, D. W. Wylie, L. S. Hams, T. R. Lewis, J. W. Schulenberg, M. R. Bell, R. K. Kullnig and A. Arnold, J. Amer. Chem. Soc., 1962,84, 1306 D. W. Wylie and S. Archer, Fed. Proc., 1962, 21, 322 R. E. Edwards, L. E. Moon and J. Pearl, Pharmacologist, 1962,4, 161 J. 0. Cole and R. E. Edwards, Animal Behaviour and Drug Action, (Ed. H. Steinberg) J. and A. Churchill, London, 1964, p.286 J. M. A. Hameed and T. J. Haley, Proc. Western PhatWacol. SOC.,1965,8, I J. M. A. Hameed and T. J. Haley, Brit. J. Pharmacol., 1966,26,186 M. Matsuoka, Japan J. Pharmacol., 1964, 14, 181 K. Fuxe, H. Grobecker, T. Hokfelt, J. Johnsson and T. Malmfoss, NaunynSchmeidebergs Arch. Exp. Pathol. Pharmakol., 1961, 256, 450
A. P. LAUNCHBURY
61
169. J. P. McAuliff, F. J. Rosenberg, A. Arnold, L. S. Harris and S. Archer, Fed. Proc., 1963, 22,567 170. T. Itoh, J. Kajikawa, Y. Hashimoto, R. Yoshidaand Imaizumi, Japan J. Pharmacol., 1965, 15, 335 171. M. Matsuoka, S. Ishii, N. Shimiza and R. Imaizumi, Experientia, 1965,21, 121 172. R. Hassler, and I. J. Bak, Dei Nerv., 1966, 37,493 173. S . Spector, K. Melmon and A. Sjoerdsma, Proc. SOC.Exp. Biol. Med., 1962, 1 11,79 174. M. M. Airaksinsen and J. E. Idampaan-Heikkila, Psychopharrnacologica. 1967, 10,400 175. W. P. K. Calwell. M. Jacobsen and A. Skarbek, Brit. J. Psychiat., 1964, 110,520 176. J. Durell and W. Pollin, Brit. J. Psychiat., 1963, 109,687 177. L. E. Hollister, J. E. Overall, I. Kimbell, J. L. Bennett, F. Meyer and E. Caffey, J. New Drugs, 1963, 3 , 2 6 178. Drug Ther. Bull., 1967,5,51 179. A. Skarbek and M. Jacobson, Brit. J. Psychiat., 1965,111, 1173 180. A. Randrup and I. Munkvad, Acta Pharrnacol. Toxicol., 1964, 21,272 181. J. Kajikawa, T. Itoh, Y. Hashimoto, H. Yoshidaand R. Imaizumi, Japan. J. Pharmacol., 1965, 15,446 182. Anon., Lancet, 1968, 1, 1237 183. H. Weil-Maherbe, Lancer, 1968,2,219 184. W . G. Dewhurst, Lancet, 1968, 2, 514 185. L. M. Rice, J. Med. Chem., 1964,7,313 186. L. Stein, First Hahnemann Symposium on Psychosomatic Medicine, Lea & Febiger, Philadelphia, 1962, p. 297 187. L. Stein, Fed. Proc., 1964, 23, 836 188. L. Stein, Recent Advan. Biol. Psychiat., 1962, 4, 288 189. J. R. Gillette, J. V. Dingell, F. Sulser, R. Kuntzman and B. B. Brodie, Experimentia, 1961, 17,417 190. E. A. Daneman, Psychosomatics, 1967,8,216 191. J. T. Hicks, NlinoisMed. J., 1965, 622 192. N. W. Imlah, K. P. Murphy and C. S. Mellor, Clin. Trials J., 1968, 5 , 927 193. M. S. Sutherland, S. S. Sutherland and A. E. Philip, Clin. Trials J., 1967, 4, 857 194. J. Johnson and J. G. Maden, Clin Trials J., 1967,4,787 195. N. K. El-Deiry, A. D. Forrest and S. K. Littman, Brit. J. Psychint., 1967, 113,999 196. W. T. McClatchey, J. Moffatt and G. M. Irvine, J. Ther. Clin Res., 1967, 1, 13 197. N. W. Imlah, presented at 4th World Congress OfPsychiatry, Madrid, 1966 198. Drug Ther. Bull., 1968,6, 39 199. R. Wein,Progr. Med. C h e m , 1961, 1, 34 200. J. H. Burn and M. J. Rand, Adv. Pharmacol., 1962, 1, 1 201. R. A. Moe, H. M. Bates, Z. M. Palkoski and R. Banziger, Cum Ther. R e x , 1964,6, 299 202. N. Weiner, P. R. Draskoczy and W. R. Burak, J. Pharmacol. Exp. Ther., 1955, 137,47 203. J. R. Crout, A. J. Muskus and U. Trendelenburg,Brit. J. Pharmacol., 1962, 18,600 204. L. T. Potter, J. Axelrod and I. J. Kopin, Biochem. Phnrtncol., 1962, 11, 25 3 205. L. T. Potter and J. Axelrod, J. Pharmacol, Exp. Ther., 1963, 140, 199 206. W. M. Abrams,Amer. J. Cardiol., 1963, 12,711 207. M. L. Mashford, J. B. Philipson, D. A. Wolochow and W. A. Mahon, Proc. SOC.Exp. Biol. Med., 1962, 111, 308 208. J. H. Burn and M. J. Rand, J. Physiol., 1958, 144, 314 209. J. H. Bum and M. J. Rand, Brit. Med. J., 1958, 1,903 210. A. J. Plummer, Hypertension: Recent Advances (Ed. A. N. Brest and J. H. Moyer), Lea & Febiger, Philadelphia, 1961, 399 211. R. A. Maxwell, Hypertension: Recent Advances (Ed. A. N. Brest and J. H. Moyer), Lea and Febiger, Philadelphia, 1961, p.437 212. J. W. McCubbin, Y. Kaneko and I. H. Page, J. Pharmocol. Exp. Ther., 1961, 131, 346
62 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 240a. 240b. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262.
SOME RECENTLY lNTRODUCED DRUGS
Drug Ther. Bull., 1 9 6 7 , 5 , 4 4 W. J . Wenner, J. Med. Chem., 1965,8, 125 F. J . Talbot, Med, A n n District Columbia, 1965, 3 4 , 5 8 0 J . M. Bryant, J. Amer. Med. Ass., 1965, 193, 1021 M. H. Luria and E. D. Freis, Cum. Ther. Res., 1965,7, 289 F. A. Finnerty,Med. Clin. N. Amer., 1964,48, 329 N. Kakaviatos,Amer. J. Cardiol., 1964, 13, 111 A. H. Kitchin and R. W. D. Turner, Brit. Med. J . , 1966, 2, 728 D. Athanassiadis, Brit. Med. J., 1966, 2, 732 A. E. Gent and A. P. C. Bacon, Practitioner, 1967, 198,673 R. P. Ahlquist, Amer. J. Physiol., 1948, 153, 586 K. Greefand H. J . Schumann,Arzneim.-Forsch., 1953, 3, 341 H. Koch, Deut. Med. Wochenschr., 1954, 19, 176 F. Brauch, Deut. Med. Wochenschr., 1954, 17, 676 W. Lindenburg, Arztl. W., 1950, 25,434 W. Lindenburg,Med. K l i n , 1953, 18,633 G. Wichmann, Muench. Med. Wochenschr., 1953,95, 373 A. T. Birmingham and J . Szolcsanyi, J. Pharm. Pharmacol., 1965, 17, 449 A. T. Birmingham and J . Szolcsanyi, J. Pharm. Pharmacol., 1967, 19, 137 J. H. Gaddum, J. Physiol., 1937,89, 71 J . H. Gaddum, Pharm. Rev., 1957, 9, 211 H. 0. Schild, Brit. J. Pharmacol., 1947, 2, 189 H. 0. Schild, Pharrn Rev., 1957.9, 242 R. t:. Furchgott, Pharm Rev., 1955, 7, 183 0. Arunlakshana and H. 0. Schild, Brit. 1. Pharmacol., 1959, 1 4 , 4 8 G. Brownlee, Angiology, 1966, 17, 186 K. Myers, J . T. Hobbs and W. T. Irvine, ExcerptaMed. (Amsterdam) Congress Series, No. 126, 1966,80 S. S. Rose, Vascular Dis., 1967, 4 , 6 7 J . Harrison and A. P. Turner, J. Pharm. Pharmacol., 1968, 20, 161 See also J. R. Parratt, Progr. Med. C h e m , 1968,6, 11 E. Lindner, Arzneim.-Forsch., 1960, 10, 589 A. S. V. Burgen and L. L. lversen, Brit. J. Pharmacol., 1965,25, 34 H. H. Schone and E. Lindner, Anneim.-Forsch., 1960, 10,583 F. Wohlrab, Arch. Exp. Pathol. Pharmakol., 1962, 243, 382 A. V. Juorio and M. Vogt, Brit. J. Pharmacol., 1965,24,566 B. Werdinius, Acta Pharmacol. Toxicol., 1967, 25, 1 H. J . Kuschke, F. Eckmann. H. ldriss and P. Bieck, Verhandl. Deut. Ges. Med., 1964, 70, 191 I{. J. Kuschke. H. ldriss and F. Eckmann. Klin. Wochenschr.. 1965,43,617 W. Brassch and D. Fleck, Arzneim.-Forsch., 1961, 11, 336 E. Lindner, Arch. Int. Pharmacodyn Ther., 1963, 146,475 1 . Lindner, Arch. Int. Pharmacodyn Ther., 1963, 146,485 H . Obianwu, Acta Pharmacol. Toxicol., 1967,25, 127 H. Obianwu, Acta Pharmacol. Toxicol., 1967, 25, 141 A. Carlssen and B. Waldeck, J. Pharm Pharmacol., 1965, 17, 243 A. Carlss.cn, N. A. Hillarp and B. Waldeck, Acta Physiol. Scand., 1963,59, 215 A. Carlssen and B. Waldeck, Acta Physiol. Scand., 1 9 6 6 , 6 7 , 4 7 1 M. Neumann and A. A. Luisada, Amer. J. Med. S c i , 1964, 247, 156 K. Donat and C. A. Schlosser,Med. K l i n , 1966, 61, 352 A. Kappert, Z. nier., 1965,2, 82 J . A. Sosa and M. McCregor, Can Med. Ass. J., 1963,89, 248 E. Gerlach and B. Deuticke, Arzneitn-Forsch., 1963, 13, 177 M. Schlepper and E:. Witzleb, Arzneix-Forsch., 1962, 12, 559
..
A. P. LAUNCHBURY
263. 264. 265. 266. 261. 268. 269. 270. 271. 272. 273. 274. 215. 216. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290.
291. 292. 293. 294. 295. 296. 297. 298 299. 300. 301. 302. 303. 304. 305. 306.
63
H. Haas, Pharmaz. Ztg., 1964, 109, 1855 H. Haas, Arzneim.-Forsch., 1964, 14, 461 H.Haas, Deut. Med. Wochenschr.. 1964,89,2117 H. Haas and G. Hartfelder, Arzneim.-Forsch., 1962, 12, 549 A. Fleckenstein, Deut. Ges. Inn. Med., 70th Meeting, 1964 K. I. Melville and B. G. Eenfey, Can J. Physiol. Pharmacol., 1965,43,339 K. I. Melville, H. E. Shister and S. Huq, Can. Med. Ass. J., 1964,90, 76 E. D. Luebs, A. Cohen, E. J . Zaleski and R. J. Bing, Amer. J. Cardiol.. 1966, 17,535 R. H. E. Grant, D. G. McDevitt and R. G. Shanks, Lancet, 1968, I , 362 P. Hoffmann, Med. Klin. (Muench), 1964, 59, 1387 K. Hofbauer, Wien. Med. Wochenschr., 1966, 116,1155 K. Fischer,Med. Klin. (Muench), 1965,60,841 M. Neuman and A. A. Luisada, Amer. J. Med. S c i , 1966,251,87 G. Sandler, G. A. Clayton and S . G. Thornicroft, Brit. Med. J . , 1968, 3, 224 R. A. Lucas, Prog. Med. C h e m , 1963, 3, 146 T. Kralt ,H. D. Moed, V. Claassen, T. W. J. Hendriksen, A. Lindner, H. Selzer, F. Brucke, G. Hertting and G. Gogolak, Nature, 1960, 188, 1108 T. Kralt, W. J . Asma, H. H. Haeck and H. D. Moed, Red. Trav. Chim. Pays-Bas. 1961, 80, 313 T. Kralt, W. J. Asma and H. D. Moed, Reel. Trav. Chim. Pays-Bas, 1961, 80, 330 A. Lindner, V. Claassen, T. W. J. Hendriksen and T. Kralt, J. Med. Chem., 1963,6, 97 A. Lindner, H. Selzer, V. Claassen and P. Cans, Arch. Int. Pharmacodyn. Ther., 1963, 145,378 A. C. Houtman, Isotope Laboratory. Weesp. Holland, 1964 P. Crosti, Instituto di Semeiotica Medica della Universita di Milano, 1964 A. M. Connell, Brit Med. J., 1965, 2, 848 H. Heller and M. Ginsburg, Progr, Med. Chem., 1961, 1, 132 R. H. Kessler, K. Hierholzer, R. S. Curd and R. F. Pitts, Amer. J. Physiol., 1959, 196, 1346 M. Goldberg, (Ed., W. F. M. Fulton), Butterworths, London, 1967, p. 42 W. Kuhn and K. Ryffel, Z. Physiol. Chem., 1942,216, 145 B. Hargitay and W. Kuhn, Z. Electrochem., 195 1,55,539 H. Wirtz, B. Hargitay and W. Kuhn, Helv. Physiol. Pharmacol., 1951. 9, 196 C. W. Gottschalk and M. MyUe, Amer. J. Physiol., 1959, 196, 927 K. J. Ullrich, K. Kramer and J. W. Boylan, Renal Disease (Ed. D. A. K. Black), Blackwell, Oxford, 1962, p. 49 C. W. Gottschalk, Amer. J. Med., 1964,36,670 R. W. Berliner, N. G. Levinsky, D. G. Davidson and M. Eden, Amer. J. Med., 1958, 24,730 R. W. Winters and R. E. Davies, Ann. Intern Med., 1961,54, 810 G . Giebisch, R. M . Klose and E. E. Windhager, Amer: J.'Physiol., 1964, 206,687 M. Goldberg, D. K. McCurdy and M. A. Ramirez,J. Clin Invest., 1965.44, 182 V. M. Buckalew, M. A. Ramirez and M. Goldberg,Amer. J. Physiol., 1967, 212,381 M. A. Cortney, M. Mylle, W. E. Lassiter and C. W. Gottschalk, Amer. J. Physiol., 1965, 209,1199 G. Giebiech and E. E. Windhager, Amer. J. Med., 1964, 36,643 R. F. Pitts, The Physiological Basis of Diuretic Therapy., Thomas, Springfield, IU., 1959, p. 55 L. E. Earley, M. Kahn and J . Orloff, J. Clin Invest., 1961,40,857 W. Suki, F. C. Rector and D. W. Seldin, J. CIin Invest., 1 9 6 5 . 4 , 1458 M. Goldberg, D. K. McCurdy, E. L. Foltz and L. W.Bluemle, J. Cfin. Invest., 1964.43, 201 L. E. Earley and R. M. Friedler, J. Clin. Invest., 1964,43, 1495
64
SOME RECENTLY INTRODUCED DRUGS
A. Farah, C. H. Bender, R. Kmse and E. Cafruny, J. Pharniacol. Exp. nier., 1959, 125, 309 308. E. M. Schultz, E. J . Cragoe, J . M. Bicking, W. A. Bolhofer and J . M. Sprague, J. Med Pharrii. C h r m . , 1962, 5 , 660 309. 3. E. Baer H. E. uss so, J. K. Michaelson and K.H.Beyer,Pharmacologist, 1962,4. 158 310. J. E. Baer, J. K. Michaelson, H. F. Russo and K. H. Beyer, Fed. Proc., 1963, 2 2 , 5 9 8 311. P. J. Cannon, R. P. Ames and J . H. Laragh, J. Amer. Med. Ass., 1963, 185, 854 312. R. M. Komorn and E. J. Cafruny, Science, 1964, 143, 133 313. R. M. Komorn and E. J. Cafruny, J. Pharniacol. Exp. Ther., 1965, 148, 367 314. K. H. Beyer, J. E. Baer, J. K. Michaelson and H. F. Russo, J. Pharrnaco/. E-rp. Ther., 1965, 147, 1 315. D. E. Duggan and R. M. Nol1,Arch. Biocheni. B i o p h j x , 1965, 109, 388 3 i 6 . V. D. Jones, G. Lockett and E. J. Landon, J. Pltarniacol. Exp. Ther.. 1965, 147, 23 317. P. J. Cannon, H. 0. Heinemann, W. B. Stasonand J.H. Laragh, Circulation, 1965, 3 1 , 5 318. J . F. Maher and G. t.Schreiner,Ann. Intern. Med., 1965,62. 15 319. H. H. Wayne, S . A. Kotler, P. S . McGirr and R. D. Stoike,Amer. J. Cardiol., 1965, 16, 7 29 320. Drug Ther. Bull., 1 9 6 6 , 4 , 6 321. L. B. Berman and A. Ebrahimi, Proc. SOC.Exp. Biol. M e d . , 1965, 1 1 8 , 3 3 3 322. K. McGaffey, L. A. Lezotte, J. H. Snyder, E. W. Moore and H. Jick, Proc. Soc. Exp. Med., 1964, 116, 11 323. M. Kaye, L. Dufresne and D. McDade, Lancet, 1968, I . 1255 324. K. Thurau, Int. Congr. Nephrol., 1966, 1, 162 325. A. G. Birtch, R. M. Zakheim, L. G. Jones and A. C. Barger, Circ. R e s . , 1967, 2 1 , 8 6 9 326. K. E. W. Melvin, R. 0. Farrelly and J. D. K. North, Brit. Med. J., 1963, 1, 1521 326a. F. Fallucca, G. Aliberti, G. Tamburrano and G. Menzinger, Lancer. 1968, 2, 874 326b. N. Kakaviatos, M. Davidov, L. Garvilovic and F. A. Finnerty, Lancet, 1967, 2, 725 326c. L. S. Goodman and A . Gilman, Eds. The Pharmacological Basis of Therapeurics 3rd Edition, Collier-Macrnillan, New York 1965, p. 723 327. G . E. Lee and W. R. Wragg, J. Pharm. Pharniacol., 1 9 6 3 , 1 5 , 5 9 0 328. E. J . Cornish, C . E. Lee and W. R. Wragg, Nature, 1963, 197, 1296 329. E. J . Cornish, G. E. Lee and W. R. Wragg, J. Pharm Pharmacol., 1966, 1 8 , 6 5 330. D. R. Maxwell and J . M. McLusky, Nature, 1964,202, 300 331. W. E. Barrett, R. A. Rutledge, H. Sheppard and A. J . Plummer, Toxicol. Appl. Pharniacol., 1959, 1, 333 332. H. L o w and H. Wehmeyer, Diuresis and Diuretics (Ed. H. Schwiegk), Springer Verlag, Berlin, 1559, p.313 333. P. Preziosi, E. Marmo and E. Miele,Arch. Int. Pharmacodyn Ther., 1961, 131, 355 334. K. Corbett, S. A. Edwards, G. E. Lee and T. L. Threlfall, Nature, 1965, 208, 286 335. F. 0. Simpson, Curr. Ther. Res., 1 9 6 4 , 6 , 21 336. A. P. Albert, P. D. Beck, G. L. Becker, A. G. C. Ffolliott, R. E. Gilmer, M. Coldblatt, .- * and W. W. Worthington,Med. Proc., 1965, 1 I , 196 337. E. Jucker and A. Lindemann, Helv. Chirn. A c t a , 1962,45, 2316 338. E. Jucker, A. Lindemann, E. Schenker, E. Fliickiger and M. Taeschler, ArzneimForsch., 1963, 13, 269 339. E. Fliickiger, W. Schalch and M. Taeschler, Schweiz. Med. Worltenschr., 1963, 93, 1232 340. J. D. Brigs, R. N . M. McSween and A. C. Kennedy, Postgrad. Med. J., 1 9 6 5 , 4 1 , 1 9 3 341. H. Duner and 1. Sundberg, Lakartidningeii, 1 9 6 5 . 6 2 (Suppl. l.), 7 3 342. F. Durr and W. Kaufmann, Deur. Med. Wocherischr.. 1 9 6 6 , 9 1 , 1339 343. H. Frank and H. Dentler, Muench. Med. Woclierischr., 1966, 108, 2235 344. M. Zimmermeier,Med. Welt., 1966, 17, 1377 345. V. Parsons and R. K. Price, Practitioner, 1965, 195, 648 346. P. H. J. Theobald, Med. J. Ausr., 1967, 2, 15 347. E. Hohnloser, Med. Klin. Muench., 1964, 59, 1423 307.
A. P. LAUNCHBURY
348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 362a. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 378a. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 389a. 390. 391. 392. 393. 394.
65
1'. Schmuziger. Praxis, 1963,52, 1066
Dnrg Ther. Bull., 1 9 6 8 , 6 , 4 3 J . K e c k , J u m s Liebigs Ann. Chem., 1963,662, 171 F. Arch,nr,-iieim.-Forsch., 1963, 13, 480 H. Burgi, Lancet, 1964, 2, 644 C. R. Lowc, Chest Heart Bull., 1962, 179 R. A. Bruce and V. Kumar, Brit. J. Cliri. fract., 1968, 22, 289 W. Guenthner, Fortsclir. Med.. 1965, 83. 701 U. Seith,Med. Welt,. 1966. 37, 1982 I,'. Piacenza. Detrt. Med. J . , 1966, 17. 226 J. S. G. Cox, Nature, 1967, 216, 1328 J . B. L. Howell and R. E . C. Altounyan, Lancet, 1967, 2.5 39 I. W. B. Grant, S. Channell and J . C. Drever, Lancet, 1967, 2, 673 J . B. L. Howell and K. E. C. Altounyan, Lancet, 1967, 2 , 7 7 7 I.ancet, 1968, 1, 1362 Drug Ther. Bull.. 1968, 6, 37 J . Pepys, F. E. Hargreave, M. Chan and D. S. McCarthy, Lancet, 1968.2, 134 Lancet. 1968, 2, 160 1,'. Moran, J. D. H. Bankier and G. Boyd, Lancet, 1968, 2, 137 J . M. Smith arid G. 1:. Devey, Brit. Med. J . , 1968, 2, 340 S. F. Davies,Brit. Med. J., 1968, 2, 593 I. Gregg, Lancet, 1968, 2, 350 I. W. B. Grant, Lancet, 1968, 2, 282 1;. Moran, J . D. H. Bankier,and G. Boyd, Lancet, 1968, 2, 351 A. Minctte, Lancer, 1968, 2, 168 P. H. Kidner, P. Meisner, N. B. Pride and R. S. Bruce-Pearson, Lancet, 1968, 2, 655 W. Hausmann and A. L. Tarnoky, A Symposium on Cnrbenoxolone Sodium (Ed. J . M. Robson and 1;. M. Sullivan), Butterworths, London, 1967, p. 164 E. Adami, Clin. Europea, 1964, 3, 1 C. Cardani, B. Cavalleri and E. Adami, J. Med. Chem., 1 9 6 3 , 6 , 4 5 7 E. Adami, Experientia, 1962, 18, 461 E. Adami, E. Marazzi-Uberti and C. Turba, Med. Exp., 1962, 7, 171 E. Marazzi-Uberti and C. Turba,Med. Exp., 1 9 6 1 , 4 , 248 E. Marazzi-Uberti and C. Turba,Med. Exp., 1 9 6 1 , 5 , 9 G. Murari,Med. E x p . , 1964, 11, 361 A. L. Wissmer and E. Adami, C u r . Tller. Res. 1965, 7, 475 0. Ponari, Arzneirn-Forsch., 1964, 14, 207 E. Adami, E. Marazzi-Uberti and C. Turba, Arch. Int. fharmacodvrr Ther., 1964, 147, 113 C. Giovannelli, Settirn. Med., 1963, 5 1 , 787 K. Miura and H. K . Reckendorf. f r o g . Med. Chern, 1967.5, 320 British Patent, 969,126; Belg. P. 635,608; Chein. Abstr., 1964,61, 16069 I. Sagone, Minenta Gynecol., 1965,17, 13 M. Arnold and J. Delnon, Rev. Ther., 1965, 10, 490 R. Leoni, Rev. Obstet. Ginecol., 1964, 19, 120 G. Chappaz and P. Bertrand, Gvnackologica, 1965, 160, 17 G. Chappaz and P. Bertrand, Gynackologica, 1966, 1 6 1 , 3 6 J . E. Murphy, Brit. J. Clirr fract., 1968, 20, 431. I:. R. Batchelor, F. B. Doyle, J. H.C. NaylerandG. N. Rolinson, Nufure, 1959, 183, 257. W. J . Leanza, B. G. Christensen, E. F. Rogers and A. A . Patchett, Nature, 1965, 207, 1395 E. H. Thiele and H. J . Robinson, Appl. Microhiol., 1968, 16, 228 P. Acred, D. M. Brown, E . T. Knudsen, G . N . Rolinson and R. Sutherland, Nature. 1967, 215, 25
66
SOME RECENTLY INTRODUCED DRUGS
395. Drug Ther. Bull., 1968, 6 , 77 396. E. T . Knudsen, G. N. Rolinson and R. Sutherland, Brit. Med. J . , 1 9 6 7 , 3 , 75 397. J. B. Eastwood and J. R. Curtis, Brit. Med. J . , 1, 486 398. W. Brumfitt, A. Percival and D. A. Leigh, Lancet, 1967, 1, 1289 399. R. J . Jones and E. J . L. Lowbury, Brit. Med. J . , 1967, 3 , 7 9 400. L a m e t , 1967, I , 1313 401. P. Scnsi. Rex. P r o p . Orx. Biol. Med. Clretn.. 1964. 1, 337 402. N. Begamin1 and G . Fowst, Arznebn-b’orsch.. 1965, 8a, 951 403. R. Pallanza, S. Furesz, M . T. Timbal and G. Carniti, Arzneirn-Forsch.. 1965, 15, 800 404. B. C. Stratford and S. Dixson, Med. J. Aust., 1966, 1, 1 405. G. Hartmann, K. 0. Honikel, F. Knusel and J . Nuesch, Bioclrern. Biophys. Acfa, 1967, 145,843 406. L. Frontali, L. Leoni and G. Tecce, Nature, 1964, 203, 84 407. G. Maftii and P. Schiatti, Toxicol. Appl. Pharniacol., 1966, 8 , 138 408. S. Furesz, V. Arioli and R. Scotti, Arzrieim.-Forsclr., 1965, 15, 802 409. G. Acocella, F. Lamarina, L. T. Tenconi and F. B. Nicolis, G u t , 1 9 6 6 , 7 , 380 410. L. Mainardi and G. Sacchetti, Ann. Ostef. Ginecol., 1966, 88, 27 411. v. Dezuhan,M.G. SerralungaandG.Maffii, Toxicol. .4ppl. Phartnacol.. 1966. 8.126 412. B. C. Stratford, Med. J. A u s t . , 1966, I , 7 413. G. A. Khan and A. J. Scott, Brit. J. Pharinacol.. 1967, 31. 506 414. J . Mattelaer, Ext. ‘Mouvernent m e r ’ . . 1967, 12, 1 415. R. Carazzi and V. Carreri, Rifornia Med., 1966, 29. 3 416. A. M. Gaetini and M. Dei Poli, Boll. SOC. Pieniont. Chir., 1965, 35, 1 417. L. C. De Barros, 0. Hellmeister and G. A. Lima, 0.Hospital, 1966, 70, 9 7 418. G. Acocella and U. Scalfi, Wien. Med. Ir’ocherrschr.. 1967, 117, 1 418a. Drug Ther. Bull., 1 9 6 8 , 6 , 8 6 419. V. Arioli, R. Pallanza, S. Furesz and G. Carniti, Arzneirn-Forsch., 1967, 17. 523 420. R. Pallanza, V. Ario1i.S. Furesz and G. Bolzoni, Arzneirn.-Forsclr., 1967, 17, 529 421. S. Furesz, R. Scotti, R. Pallanza and E. Mapelli, Arzneirn-Forsch., 17, 534 422. G . C. Lancini and G. Sartori, t‘.uperierrtia. 1968, 24, 1105 423. G. Hartmann, K. 0. Honikel, F. Knusel and 1. Nuesch, Biochirn. Biophj3s. A c f a . 1967, 145,843 424. E. Heller, M. Argaman, H. Levy and N. Goldblum, Nature. 1969, 222. 273 425. Anon, Nature, 1969, 222, 218 426. J. H. Subak-Sharpe, M. C . Timbury and J . F. Williams, Nature. 1969. 222. 341 427. Anon., Lancet, 1969, 1, 976 428. V. Arioli. R. Pallanza and S. Furesz, Fifth Int. Congr. Chetnother., June 26-July 1. 1967, Vienna 429. J. MacC. Murdoch, C. F. Spiers, N. Wright and E. T. Wallace, Lincet, 1969, I , 1094 430. M. Lucchesi, G. Pallotta, P. Rossi and M. Sbambate, Ann. I s f . Carlo Forlanini, 1967, 27, 1 431. J . Clark and A. Wallace, Tubercle, 1967,48, 144 432. L. Verbist and A. Gyselen, Amer. Rev. Resp. Dis., 1 9 6 8 , 9 8 , 9 2 3 433. G. Canetti, M. Le Lirzin, G. Porven, N. Rist and F. Grumbach, Tubercle, 1968,49, 367 434. A. Gyselen, L. Verbist, J . Cosemans, L. M. Laquet and E. Vandenbergh, Amer. Rev. Resp. Dis., 1968, 98, 933 435. Anon., Lancet, 1969, 1, 1081 436. A. M. Lands, A. Arnold, J. P. McAuliff, F. P. Lunduena and T. G. Brown, Nature. 1967, 214, 597 437. D. Hartlcy, D. Jack, L. H. C. Lunts and A. C. Ritchie. Nature, 1968, 219, 86 438. R. T. Brittain, J . B. Farmer, D. Jack, L. E. Martin and W. T. Simpson, Nature, 1968, 219,862 439. K. N. B. Palmer and M. L. Diamant, Brit. Med. J . , 1969, I , 31 440. W. F. J. Choo-kang, W. T. Simpson and I . W. B. Grant, Brit. Med. J . , 1969.2.287
A. P. LAUNCHBURY
67
S. Weidling and C. Tegner, Prog. Med. Chem., 1963,3, 332 Drug. Ther. Bull., 1967, 5 , 81; British Patent, 869, 978;Chem Abstr., 1962, 5 6 , 11575 443. Drug. Ther. Bull., 1961, 5 , 72 444. A. F. Lavenstein, E. P. Decaney, L. Lasagna and T. E. Van Metra, J. Amer. Med. Ass., 1962, 180,912 445. S. S. Bergen, Anier. J . Dis. Childreri. 1964, 108. 270 446. P. Naranjo, Allergic Asthma, 1962, 8, 248 447. A. Drash, Chi. Pharmacol. Ther., 1966,7, 340 448. Drug Ther. Bull., 1967,5, 3 449. N . Deshpande, The Trearmeritof Carci,io,naofrlie Breast (Ed. A . S. Jarrett), Excerpta Medica Foundation, Amsterdam, 1968, p. 45 450. Laricet, 1968, I , 1239 451. Lancet, 1968, 2, 444 452. Drug. Ther. Bull., 1968, 6 , 81 453. H. D. Law, Progr. Med. Cliein., 1965, 4 , 81 454. Brif. Med. J., 1968, 2, 380 455. J. S. Maplas and R. B. Scott, Brit. Med. J . , 1968, 3, 227 441. 442.
This Page Intentionally Left Blank
The Biochemical Basis for the Drug Actions of Purines 2
JOHN A. MONTGOMERY, Ph.D. Kettering-Meyer Laboratoory, Southern Research Institute, Birmingham, Alabama 35205, U.S.A.
I NT RO DUCT1ON
i0
METABOLISM Anabolism The phosphoribosyltransferases The nucleoside kinases Nucleoside phosphokinases Nucleotide reductases Methylases and demethylases Other anabolic enzymes Catabolism F’hosphatases and nucleotidases Nucleoside phosphorylases and hydrolases Deaminases Oxidases Summary
14 14 14 80 80 83 83 84
MECHANISM OF ACTION Enzyme inhibition The de ~ O Y Osynthesis of inosinic acid The ‘salvage’ pathways Purine nucleotide interconversions Other enzymes Incorporation into nucleic acids Inhibition of protein synthesis Interference with co-factors Summary
91 93 93 96 91 99 99 100 101 102
69
85 85 86 81 88 91
I0
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
EFFECTS On the host Toxicity Embryonic tissue Immune response Platelet aggregation Gout On Invading organisms Micro-organisms (bacteria and protozoa) Viruses and cancer
102 102 102 104 104 105 105 105 105 106
THE PROBLEM OF RESISTANCE Mechanisms Circumventions
109 109 110
ACKNOWLEDGMENTS
111
REFERENCES
111
INTRODUCTION
An analogue of a naturally occurring purine, purine nucleoside, or a metabolic product of either, is potentially a substrate for and/or an inhibitor of any of the enzymes necessary for the reactions depicted in Figure 2.1. In addition certain analogue nucleoside mono-, di-, and triphosphates can, by negative pseudofeedback [l-31, inhibit the de n o w synthesis of purine nucleotides. Thus the problem of the biological activity of purines is a complex one based on the normal metabolism of the natural purines. Although a detailed discussion of the metabolism of the natural purine nucleotides is beyond the scope of this review, the general scheme is shown in Figure 2.1, and references t o reviews and recent original literature on the enzymes involved are given. The general subject of purine nucleotides and their metabolism has recently been the subject of an excellent review [ 4 ] , and numbers of earlier reviews dealing in part with this topic have appeared [S-131. With a few notable exceptions-such as puromycin and its relatives, psicofuranine and decoynine, and certain 9-alkylpurines-which will be discussed later, purines and their nucleosides must be anabolized t o nucleoside phosphates in order t o exert their biological effects. This type of metabolic event has been called a ‘lethal synthesis’, because it results in the death of cells that carry it out. Enzymes in general vary widely in their substrate specificity, and this wide variation is found in the purine-metabolizing enzymes, as will be seen from the
1, i
,Co-factors
6
in
12
11
t HvDoxanthine
t
1.7
lnosine
. r
21
I
Uric acid
Allantoin
*
\\*
Xanthin-e
=
1
F
27 Guanine
20
-
IMP:
RNP
t
-
2L b Xanthosine 1
1.7
Guanosine
22
19 dGTP
281'- --
* 29L
GMP
1 3 0
3
2' Deoxyguanosine
l L \ I 1 10 GDP
co:facJ
dGMP L
Figure 2.1. Cellular metabolism of purine nucleotides. The meaning of the numbers over the arrows is explained on the next page.
dGDP
12
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
ENZYMES A N D REFERENCES 1.
2. 3. 4.
5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30.
Nucleoside phosphorylase [ 14-2 1b] Pentosyltransferase [ 14, 19, 22-26] Nucleoside kinase [27] S’-Nucleotidase or nucleotide phosphatase [28-37a] Nucleotide kinase [38,39] Adenine phosphoribosyltransferase [40-45a] Nucleoside hydrolase (bacteria) [ 14,46,46aJ Adenosine kinase [27,47,48] Adenylate kinase (myokinase) [39, 49-52] Nucleoside diphosphate reductase [53, 541 Adenine deaminase (bacteria) 155, 561 Adenosine deaminase [57-64a] Adenylosuccinate lyase [65+7] Nucleoside diphosphokinase [68-7 1] Myosin adenosine triphosphatase [72] Adenylate deaminase [73-771 Adenylosuccinate synthetase [65,67,78] RNA polymerase [ 791 DNA polymerase [ 79-8 1 1 Inosine kinase [82,83] Xanthine oxidase [84] Hypoxanthine-guanine phosphoribosyl transferase [ 43,85-8 Sb] Inosinic dehydrogenase [6S, 85c] Xanthine phosphoribosyltransferase (bacteria) [8] GMP reductase [86] Uricase [87] Guanine deaminase [88] GMP synthetase [65, 89,901 Guanosine kinase (bacteria, fish) [82,83] Guanylate kinase [9 1]
discussions in the sections that follow. There are in many cases, however, clearly delineated structural requirements for substrates. The natural purine nucleotides can be placed into two groups based on structure, and it is logical t o discuss the metabolism of a purine analogue, according t o the group in which it best fits, based on the data we have at hand. The two structural groups are pictured in Figure 2.2. The dotted areas represent the parts of the purine nucleotide structure that determine its ability t o serve as a substrate for the various cellular enzymes. The structure of the 1-2-3+ positions o f the pyrimidine ring* is the primary determinant, and it is surely not by chance that this same portion of folic acid and the folic reductase inhibitors (for example, methotrexate
JOHN A. MONTGOMERY
73
and daraprin) (bigure 2.3) is critical t o their activity also. The hydroxyl or hydrogen a t C-2’ of the sugar moiety (ribose or 2‘-deoxyribose) is important to the metabolism of nucleosides and nucleotides. Thus analogues resemble either adenine compounds on the one hand or hypoxanthine-guanine compounds on the other (the amino or oxy group* at C-2, N-3 can also be determinant). In some cases, such as 2-fluoroadenosine, the classification of an analogue is obvious and predictable; but in others, such as 6-(methy1thio)purine ribonucleoside, the classification is deceptive and was correctly made in retrospect. Specific structural features also determine the deactivation or destruction by catabolic enzymes of purine analogues. Selective destruction of these toxic materials may, in fact, be the single most important factor relating to their activity . *For convenience the group at C-2 of xanthylic acid is represented here as an hydrosyl group, although it actually exists in the carbonyl or lactam form. This liberty is taken with other structures throughout this chapter.
I------
HO
HO
X
-
Adenylic acid: X OH 2’ - Deoxyadenylic acid X
-
H
-I
X
Inosinic a c i d : R -H.X - O H Xanthylic acid: R-X -OH Guanylic acid : R=NH,. X-OH 2’- Deoxyguhnylic acid: R -NH2, X-H
Figure 2.2. Purine nucleotfdes
In the sections that follow, the metabolism of the various purine analogues is presented first, followed by a discussion of the current status of our knowledge about the mechanism of action of these compounds. Next the distribution and effects of these drugs on the host and invading organisms is considered with some concluding remarks o n the ever present problem of resistance.
14
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
F o l i c acid
Methotrexate
Pyrimethamtne PMC (23)
Figure 2.3. Folic acid and inhibitors METABOLISM Anabolism The phosphoribosyltransferases
The reactions of purine bases with phosphoribosylpyrophosphate (PRPP)[92] t o form ribonucleotides are catalysed by purine phosphoribosyltransferases (purine nucleotide pyrophosphorylases)[93-96~], four of which have been identified in bacteria for the natural purines adenine, hypoxanthine, guanine, and xanthine by protein fractionation procedures [97] and by analysis of bacterial mutants [98-1001 . In mammalian cells, however, high levels of only two separate enzymes have been identified, adenine phosphoribosyltransferase [93, 96, 96a] and hypoxanthine-guanine phosphoribosyltransferase [96-96c, 101] . Although it has been suggested that the hypoxanthine and guanine phosphoribosyltransferase activities are separate enzymes [102, 1031, their separation has not been achieved and the many examples of mutant cells lacking both activities [ 8 ] , and no example of a mutant lacking only one, argue against this view. Recently, evidence has been presented supporting the view that not only is a single enzyme involved,
JOHN A. MONTGOMERY
15
but also that hypoxanthine and guanine bind to the same site on this enzyme [96b, 9 6 ~ 1When . the catabolism of xanthine was retarded by pre-treatment with 4-hydroxypyrazolo [3, 4-d] pyrimidine, a potent inhibitor ot xanthine oxidase (vide infru), its incorporation into nucleic acid purines in mice could be demonstrated [ 1041, and a very low level of xanthine phosphoribosyltransferase activity has been observed in man [ 1051 . Xanthine was later shown to be a poor substrate for hypoxanthine-guanine phosphoribosyltransferase [85a]. Adenine phosphoribosyltransferase (41-44, 103, 1061 and hypoxanthineguanine phosphoribosyltransferase have both been investigated in some detail [85a, 85b, 96b]. It has been suggested that in the case of adenine phosphoribosyltransferase, PRPP reacts with the enzyme t o form an enzyme-ribose-5phosphate complex, which then reacts with adenine to form AMP [41]. The mechanism of the hypoxanthine-guanine phosphoribosyltransferase appears more complex [85b, 9 6 b J . Initial velocity analyses suggest that a t relatively high magnesium concentrations the predominant reaction sequence for IMP synthesis is also one involving an enzyme-phosphoribosyl intermediate, whereas at low magnesium concentrations the predominant mechanism is one involving a ternary complex, although admittedly IMP synthesis by the latter sequence would be relatively slow [85b]. A number of purine nucleoside phosphates have been found to inhibit and to stimulate the enzymes 142-44, 85b, 96b, 103, 1061. It has been postulated that at low concentrations ATP is bound t o an activator site on adenine phosphoribosyltransferase which is separate from the substrate site and that at high concentrations it competes with PRPP for the active site [41] It has been further suggested that exogenous adenine is converted to AMP and assimilated into nucleic acid at a discrete locus separate from the pathway immediately accessible t o endogenous purines [ 1061, a point which could have important bearing on the biologic activity of adenine analogues. The enzymatic conversion of many analogues of the naturally occurring purines directly t o their biologically active form, the ribonucleotides, in vivo [ 5 , 8 , 10, 13,391 underlines the importance of these enzymes t o the drug action of this class of compounds. 2-Aminoadenine (2, 6-diaminopurine. 1) [ 1071, 2-fluoroadenine (11) [ 1081 , 4-aminopyrazolo [3, 4-d] pyrimidine (VIII) [ 109). and 2- and 8-aza-adenine (IX and X) [ I 10, 1 1 I ] have all been shown to be substrates for the adenine phosphoribosyltransferase [I 12, 1 1 31 . Extensive studies on the metabolism of 2-aminoadenine (I) in E. coli [ I 14, 1 151, L cells [ 1161, and mice [ 1 171 have also shown its conversion by this enzyme t o the ribonucleotide. Conversion of 4-aminopyrazolo [3,4-d] pyrimidine (VIII) to its ribonucleotide by mouse tumours and host tissues has been observed [ 1 18, 1191. Although no evidence of the anabolism of N-methyladenine (111) [ 1201 t o the ribonucleotide was obtained in mice with Ehrlich ascites carcinoma [ 121, 1221, it is anabolized by bacteria [ 123. 1241 : and the enzyme responsible was partially purified from Salmonella ryphimurium [ 1251 . Human epidermoid carcinoma No. 2 cells resistant t o 2-fluoroadenine (H.Ep.-2/FA) have lost adenine phosphoribosyl-
76
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS 01 PURINES
(1x1 X
= N; Y = C H ( X ) X = CH; Y = N
( I ) R1 =NH ; R zNH, (11) R, :F; =kHz ( I l l ) R1 = H; R2 = MeNH (IV) R1 = C I ; R , NH, ( V ) R1 = R z = H (VI) R1 = H; Rz =Me (V11) R1 Hi Rz C I
k,
y 2
ON> N
H
( X I I ) R = H. X S,Y = CH (XIII) R = NH,,X =S,Y =CH (XVI) R = H,X =O,Y = N (XVII) R NH,, X =O,Y:N
(XIV) R = H ( X V ) R =NH,
(XVII1)R =OH,X=O,Y=N
transferase, and cross resistance studies with these cells have provided indirect evidence that, in addition t o the purine analogues named above, 2-chloroadenine (IV) [ 126],4-aminoimidazo [4, 5-d] pyridazine (XI) [ 1271 , and 6-methylpurine (VI) are also converted to their nucleotides by this enzyme [13, 1281. Studies with ''C-labelled analogues showed that purine ( V ) was not anabolized to its ribonucleotide by mice 11291 , whereas 6-chloropurine (VII) and 6-methylpurine (VI) were (by S180 ascites cells in vivo [ 1301 and by rats [ 1 3 1 ] , respectively). 6-Chloropurine (VII) also reacted with PRPP in the presence of an extract from S180 cells [130]. Compounds more closely resembling hypoxanthine or guanine, such as 6-mercaptopurine (MP. XII) [ 1201, 4-hydroxypyrazolo [3, 4-d] pyrimidine (XIV) [ 1091, thioguanine (TG, X l l l ) [ 132],8-azaguanine (AzaG, XVII) [ 1 1 I ] , and 4-hydroxy-6-aminopyrazolo [ 3, 4-d] pyrimidine ( X V ) [ 1331 are substrates for hypoxanthine-guanine phosphoribosyltransferase [7, 8, 85a, I 12, 134, 1351, and the fact that 6-mercaptopurine-resistant neoplasms are cross resistant to 6-chloropurine [8] , whereas H.Ep.-2 cells lacking adenine phosphoribosyltransferase are not [ 1281, indicate that 6-chloropurine may also be anabolized by liypoxanthine-guanine phosphoribosyltransferase; although its binding constant is high [85a]. Low concentrations of ADP or ATP inhibit the formation of 8-azaguanylic acid by hog liver extract [ 1 121 , whereas pre-conditioning Ehrlich cells in vivo with a series of doses of non-radioactive 6-mercaptopurine stimulated
77
JOHN A. MONTGOMERY
the conversion of labelled 6-mercaptopurine to thioinosinic acid [ 136, 136a] Presumably 2- and 8-azahypoxanthine [ I 1 I . 1371 are also substrates for this enzyme, but 8-azaxanthine (XVIII) [ 1371 is not and is not anabolized in mammalian cells, which apparently convert xanthine to its nucleotide poorly be means of the hypoxanthine-guanine enzyme. On the other hand, bacteria have a xanthine phosphoribosyltransferase and can anabolize 8-azaxanthine [98] . In fact, bacterial cells lacking the hypoxantliine-guanine enzyme and resistant to MP and AzaC are sensitive t o 8-azaxanthine, which is converted to the nucleotide and thence t o 8-azaguanylic acid (981. Little quantitative work has appeared on the determination of the rate of conversion of the various purine analogues to their nucleotides with highly purified phosphoribosyltransferases from mammalian cells or any other source, but there would appear to be a rough correlation between the cytotoxicity of theseanaloguesand their ability t o serve as substrates ( t h e K; values for a number of purines and purine analogues have been determined [45a, M a ] but this value is not a measure of conversion t o nucleotide). Table 2.1 lists a number of purine analogues and an estimate of their ability to serve as substrates for the phosphoribosyl transferases. The ribonucleotides of 6-mercaptopurine. 6-thioguanine, 6-chloropurine, and purine have been prepared chemically for biochemical investigations [ 138-1 4 I ] . Table 2. I . Substrates for adenine phosphoribosyltransferase Estiriiated activitJ*
2-F:luoroadenine 2Chloroadenine 2-Aminoadenine (2, 6-DAP) 4-Aminopyrazolo [ 3, 4-d] pyrimidine 4-Aminoimidazo [ 4 , 5 4 1 pyridazine 2-Aza-adenine 8-Aza-adenine 6Chloropurine N-Aminoadenine N-Hydroxyadeninc N-ally ladenine
N-Me thyladcnine Purine 1-Methyladenine 2-Hydroxyadcnine
Good Fair Fair Fair Good Fair Poor Poor to none Poor to none Poor to none Fair to poor Poor to none None None
Substrates for hypoxanthine-guanine phosphori )syltransferase 6-Mercaptopurine 6-Thioguanine 8-Azaguanine 4-Hydroxypyrazolo [ 3, 4-d] pyrimidine 4-Hydroxy-6-aminopyrazolb [ 3, 4-d] pyrimidine 6Chloropurine
Good Good Fair Poor Poor ?
Table 2.2. SUBSTRATE SPECIFICITY OF ADENOSINE KINASE* A. Variation of substituents on purine ring
Mp moles nucleotide formed min? mg-’ p-otein
Cornpou nd Adenosine AdenoFine-1-oxidc 1-Methyladenosine 2-Fluoroadenosine 2-H ydrazinoadenosine
2-Aminoadenosine 2Chloroadenosine 2-Bromoadenosine 2-Methyladenosine 2-Methoxyadenosine 2-Dime thy laminoadenosine N-Methyladenosine N . N-dimethy ladenosine N-Aminoadenosine N-Allyladenosine N-Hydroxyadenosine Purine ribonucleoside 6-(Xlethylthio)purine ribonucleoside 6-Methylpurine ribonucleoside 6
148 597 158 349 68 54 10 10 10 10 10 571 235 216
< < < < <
55 30 510 487 468 4 24 309
B. Variations in the purine ring Tubercidin (7-deaza-adenosine) 1P-D-Ribo furanosyl-4-aminopyrazolo [ 3, 4-d ] pyrimidine 8-Aza-adenosine Formycin [ 7-amino-3~D-ribofuranosyl)pyrazolo[4,3-d] pyrimidine] l-Dea7a-6-me thylthiopurine ribonucleoside 3-Deaza-6-methylthiopurine ribonucleoside
643 460 279 149
< 20 < 10
C. Variation in the sugar moiety
9-[fl-DL-2Lu,3c~-dihydroxy-4~(hydroxymethyl)cyclopentyl] adenine Cordycepin ( 3 ‘deoxyadenosine) 2 ‘-1)eoxyadenosine 9P-L,-Ararbinofuranosyladenine 2-l:luoro-3:-deoxyadenosine 6-(Methy1 thio)purine-2’-deoxyribonucleoside 6-(Methylthio)-9$-D-arabinofuranosylpurine 6-(Methyl thio)-9$-L)-xyIofuranosyIpurine
*Liata f r o m reference 47.
?Data from reference 2 5 3
< < < < < <
60t 20 10 10 10 10 10 20
OH
OH
HobJ "kiJ Hok! OH OH
OH
(XXII)
(M I 1 1)
NH Me
I
How Rl
Rz
(XXIV) R2
I
The nucleoside kinases
Although the importance of pyrimidine nucleoside kinases has been recognized for some time, the importance of the purine nucleoside kinases, which phosphorylate purine nucleosides, has only recently become apparent. Although inosine and guanosine kinases have not been isolated and characterized [ 1421, evidence for their existence has appeared [82, 83, 143-1451. Adenosine kinase, which has been known for some time, has been purified 20-fold from homogenates of rabbit liver and Ehrlich ascites cells [48] and 175-fold from human epidermoid carcinoma No. 2 cells in culture [ 4 7 ] . In the latter case the preparation was free of adenosine deaminase and AMP kinase activities. Table 2.2 shows the substrate specificity of the kinase from H.Ep.-2 cells for purine nucleosides and ring analogue ribonucleosides. Most of the nucleosides used in this study were evaluated earlier for cytotoxicity [ 128, 1471. All of the nucleosides that are highly cytotoxic are good substrates for adenosine kinase, a finding in accord with other evidence that nucleotide formation is requisite for toxicity [8, 1 3 , 4 7 1 . At the same time it should be pointed out that, although compounds such as 9-/3-~1-arabinofuranosyladenine(XIX) [ 148, 1491 and 9-/3-D-xylofuranosyladenine (XX) [ 150, 15 11 are not good substrates for adenosine kinase (47, 481 and arc not very cytotoxic, they are, in fact, phosphorylated (48, 152, 1531 and are biologically active [ 154-157] , I t is particularly interesting that 6-mercaptopurine ribonucleoside (XXI) [ 1581 is an inhibitor of, but not a substrate for, the kinase [47] ; but 6(methy1thio)purine ribonucleoside (XXII) [ 159, 1601, resulting from the S-methylation of XXI, is an excellent substrate [47] and is readily phosphorylated in vivo [ 161, 1621 . The distribution of adenosine kinase in various normal and neoplastic tissues of man and mouse has been determined by using 6-(methylthio) purine ribonucleoside -3sSas substrate [ 162a].
Nucleoside phosph ok inases
In the preceding sections the conversion of purines and purine nucleosides to purine nucleoside monophosphates has been discussed. The monophosphates of adenosine and guanosine must be converted t o their di- and triphosphates for polymerization to RNA, for reduction to 2’-deoxyribonucleoside diphosphates, and for the many other reactions in which they take part. Adenosine triphosphate is produced by oxidative phosphorylation and by transfer of phosphate from 1,3-diphosphoglycerate and phosphopyruvate t o adenosine diphosphate. A series of transphosphorylations distributes phosphate from adenosine triphosphate to all of the other nucleotides. Two classes of enzymes, termed nucleoside monophosphokinases and nucleoside diphosphokinases, catalyse the formation of the nucleoside di- and triphosphates b y the transfer of the terminal phosphoryl group from adenosine triphosphate. Muscle adenylate kinase (myokinase)
81
(XXXIV) R = H (XXXV) R=CN
(XXXVI)
(XXXVII) R = H (XXXVIII) R-Me
82
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
specific for adenine nucleotides was the first phosphokinase t o be discovered. A large number of nucleotide phosphokinases have been described since with varying specificities toward nucleotide acceptors and phosphoryl donors. Further phosphorylation of nucleoside 5'-diphosphates has been attributed t o the action of nucleoside diphosphokinases, a representative of which has recently been purified 1400-fold from human erythrocytes and characterized [69-711. For detailed discussions of the phosphokinases the reader is referred t o a number of excellent reviews [38, 39, 68, 79, 1631. Although little work has been reported on the conversion of adenylic acid analogues to the di- and triphosphates by purified enzymes, a number of studies have been carried out on the metabolism of adenine and adenosine analogues by whole cells. A variety of adenine nucleosides are converted t o the di- and triphosphates: cordycepin (3 '-deoxyadenosine, XXIII) [ 164-1 691 , 3 '-deoxy3'-aminoadenosine (XXIV) [ 170-1 731 ,9-fl-D-xylofuranosyladenine (XX) [ I531 and 9-fl-D-arabinofuranosyladenine (XIX) [ 1521. Methylation of the 6-amino group, however,prevents the action of the phosphokinases so that only the monophosphates of N-methyladenosine (XXV) [ 1741 , N-methyl-:! '-deoxyadenosine (XXVI) [ 1751 and N-methyl-3'-deoxyadenosine(XXVII) [ 1761 are obtained, and the compounds are not substrates for crystalline rabbit muscle myokinase [ 1771 . Even so, purine ribonucleoside (XXVIII) [ 178, 1791 and 6-methylpurine ribonucleoside (XXIX) [ 13 I ] are both converted to mono-, di-, and triphosphates by rodents, and purine ribonucleotide was a substrate for myokinase [ 1801, but no evidence has been presented that 6-chloropurine ribonucleotide is further phosphorylated [ 1811. Substitution of a fluorine or an amino group at C-2 of adenylic acid does not interfere with phosphorylation and the higher phosphates of 2-fluoroadenosine (XXXI) [ 108, 1821, 2-aminoadenosine (XXXII) [ I 13, 183-1 851, and 2-methylaminoadenosine (XXXIII) [ 1 14, 1861 are formed. Changes in the ring also appear unimportant since the high phosphates of tubercidin (XXXIV) [ I 87-1901 . toyocamycin (XXXV) [191-193], 4-aminopyrazolo [3, 4-d] pyrimidine (VIII) [ 1 191 , and 2-aza-adenine (IX) [ 1851 have all been isolated from mammalian cells. Thus a surprising variety of changes can be made in the structure of adenylic acid without destroying the ability of the analogues to serve as a substrate for cellular phosphokinases, although bulk tolerance at C-6 would appear to be critical on the basis of the information at hand. 8-Azaguanosine 5 '-mono-, di-, and triphosphates have been isolated from the soluble fractions of micro-organisms [98, 194-1961 and of mouse tissues and neoplasms [ 1011 and 8-azaguanylic acid was shown to be a substrate for the phosphokinases of hog kidney and beef liver [ 1401 . 8-Azaguanosine mono-, di-, and triphosphates have also been synthesized chemically [138, 1 4 0 b l . Chromatographic evidence has been obtained for the formation of 6-thioguanosine di- and triphosphates in Ehrlich ascites cells [ 1971 and their formation is supported by the demonstrated incorporation of thioguanine into nucleic acids as thioguanylic acid (1981. The incorporation of both the a- and fl-anomers of 2'-deoxythioguanosine (XXXVI) [ 1991 into DNA without
JOHN A. MONTGOMERY
83
separation of the sugar from the base indicates that these nucleosides are substrates for a nucleoside kinase and that the nucleotides are substrates for phosphokinases [ 1441 . Proof of the incorporation of 6-mercaptopurine into RNA as the nucleotide, and thus as an integral part of the macromolecule, has not been presented [200] ,although its incorporation into DNAas 2’-deoxythioguanylicacid has been demonstrated [101] .Despite these reports, other investigators have been unable to demonstrate the incorporation of 6-mercaptopurine or thioguanine into nucleic acid or their conversion to the di- and triphosphates in viuo [8]. Furthermore, it seems abundantly clear that a number of adenylic acid analogues and 8-azaguanylic acid are readily phosphorylated and incorporated into nucleic acids of many types of cells, whereas the monophosphates of 6-mercaptopurine and thioguanine accumulate with little or n o further phosphorylation, and this rather clear difference in metabolism could explain the contrasting effects observed with these different types of compounds.
Nucleotide reductases
During the past 15 years data from experiments with different types of animal tissues and micro-organisms, using intact cells, crude extracts or purified enzymes, have firmly established the general occurrence of nucleotide reductases and have stressed their importance for DNA synthesis in essentially all types of rapidly growing cells [ 541 . It has been proposed that ribonucleotide diphosphates lose a hydroxide ion from C-2‘ to form a carbonium ion which is then sterospecifically reduced by a ‘hydride’ ion derived from thioredoxin 1541. Adenosine diphosphate and guanosine diphosphate (as well as uridine and cytidine diphosphates) are reduced in this manner. There is n o direct evidence for the reduction of analogue ribonucleoside diphosphates to the 2’-deoxyribonucleoside diphosphates by cells, but the incorporation of analogues, such as 6-mercaptopurine [201] or thioguanine [ 1981, into DNA as 2‘-deoxythioguanylic acid would seem likely to proceed by such a reduction, although a nucleoside deoxyribosyltransferase could be involved instead. Recently the triphosphates of tubercidin, toyocamycin. and sangvamycin [202a] were found to be substrates for the ribonucleotide reductase from bacteria [202b, c] . Tubercidin is also incorporated into DNA, presumably in the same way as thioguanine [ 190, 2021 .
Methylases and demeth ylases
The presence of small quantities of methylated purine and pyrimidine bases in nucleic acid of micro-organisms and animals has been widely documented. The methyl group is transferred frbm S-adenosylmethionine to these bases, and methylation occurs at the polynucleotide level rather than by transfer to the acid-
84
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
soluble nucleotide precursors with subsequent incorporation into DNA and RNA. The methylation of 2-aminoadenine in E. coli, however, takes place at the ribonucleoside phosphate level (XXXVII) to give 2-methylaminoadenosine mono-, di-, and triphosphates (XXXVIII), and the reaction is mediated by S-adenosylmethionine: 2-aminopurine N-methyltransferase [ 1 14, 1 15, 2031, which also catalyses the N-methylation of 2-aminoadenine itself, 2-aminopurine, 2-amino-6-methylpurine, and 2-amino-8-aza-adenine [203] . An S-adenosylmethionine-sulphydryl transmethylase system, present in tissues of a variety of mammalian species, particularly in the kidney, catalyses the S-methylation of 2-thiopyrimidines and 6-thiopurines [ 2041 . Methylation of 6-mercaptopurine to 6-(methy1thio)purine (XXXIX) has been found t o occur in the rat [205], and -6-mercaptopurine and its ribonucleoside are converted t o 6-(methylthio) purine ribonucleotide (XL) in H.Ep.-2 cells [206]. This latter methylation presumably occurs at the nucleotide level; otherwise 6-mercaptopurine ribonucleoside would inhibit cells resistant to 6-mercaptopurine. Although demethylation, which occurs in the liver, is normally considered t o be a catabolic process, it may result in conversion of an inactive form of a drug to the active form. Thus 6-(methy1thio)purine (XXXIX) is demethylated by the rat to 6-mercaptopurine [205]. This demethylation occurs in the liver microsomes and is an oxidative process which converts the methyl group t o formaldehyde [204, 2071. The 1-methyl derivative of 4-aminopyrazolo[3,4-d] pyrimidine (XLI) is demethylated slowly, but 6-mercapto-9-methylpurine (XLII) not at all [208]. The N-demethylation of puromycin (XLIII) [209, 2101, its aminonucleoside (XLIV) [2 1 11 ,and a number of related compounds, including N-methyladenine and N,N-dimethyladenine, occurs in the liver microsomes of rodents [212]. In the guinea-pig the rate-limiting step in the metabolism of the aminonucleoside appears to be the demethylation of the monomethyl compound, which is the major urinary metabolite [213] . The relationship of lipid solubility t o microsomal metabolism [21.4], and the induction of these demethylases in rats by pre-treatment with varibus drugs have been studied [215]. Apparently N-demethylations can occur in cells other than liver microsomes, since the demethylation of N-methyl-3 -deoxyadenosine (XXVII) to 3'-deoxyadenosine (XXIII) in K B cells [216] and of the aminonucleoside of puromycin (XLIV) t o 3 '-amino-3'-deoxyadenosine (XXIV) in L cells have been reported [217].
Other anabolic enzymes
Evidence for the formation of analogues of nicotinamide adenine dinucleotides, in which the adenine moiety is replaced by 2-aminoadenine (XLV) and 7-deazaadenine (XLVI), from 2-aminoadenine [218] and tubercidin [202] has been presented, but the details of these biosyntheses have not been investigated. Inosinic acid dehydrogenase converts inosinic acid to xanthylic acid which in
JOHN A. MONTGOMERY
85
OH OH (XLV) R=NH, (XLVI) R=H;
OH
OH
(XLVII)
; X=N
X=CH
OH (XLVIII)
turn is aminated to guanylic acid. The formation of 6-thioxanthylic acid (XLVII) from 6-mercaptopurine in Ehrlich cells [219] would seem likely t o occur via the dehydrogenation of thioinosinic acid. Cordycepin- I-oxide (XLVIII) is activated in Ehrlich ascites cells by reduction t o cordycepin [220] and a similar N-oxide reduction probably underlies the action of 6-mercaptopurine-3-oxide(XLIX) [221] . Catabolism Phosphatases and nucleotidases
In addition to the enzymes that catalyse the formation of nucleotides and polynucleotides, a large number of catabolic systems exist which operate at all levels of the internucleotide pathways. The ribonucleases and deoxyribonucleases that degrade polynucleotides are probably not significantly involved in purine analogue metabolism, but the enzymes which dephosphorylate nucleoside 5 '-monophosphates are known t o attack analogue nucleotides and may be of some importance t o their in vivo activity. Phosphatases of low specificity are abundant in many tissues [38], particularly the intestine [29]. Purified mammalian 5 '-nucleotidases hydrolyse only the nucleoside 5 'monophosphates [ 281 and
86
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
could be important to the activity of purines, such as 6-mercaptopurine, that are anabolized primarily to the 5 ‘-monophosphate level, since dephosphorylation must occur prior to cleavage of the nucleoside to the free base by a phosphorylase. A number of analogue nucleotides have been shown to be substrates for calf intestine phosphatase or snake venom S’-nucleotidase [ 112, 161, 2181.
Nucleoside phosphorylases and hydrolases
Nucleoside phosphorylases that catalyse the reversible cleavage of purine nucleosides to the free bases and ribose-I-phosphate are found in most cells, although a phosphorylase that will cleave adenosine has so far been identified only in bacteria. Recent studies have shown that ribo- and 2’-deoxyribofuranosyltransferase activity is associated with phosphorylase activity [ 19, 23.. 2221 and that both activities reside in one enzyme, which can be converted from one form to the other by substrate o r product binding [ 2 0 ] . Upon crystallization of the enzyme from human erythrocytes a marked decrease in the ribosyl transfer reaction was observed [ 21 b] . Purified enzyme extracts have been used to biosynthesize the ribonucleosides of 6-mercaptopurine, 8-azaguanine. 8-aminoadenine, 4-hydroxypyrazolo [ 3 , 4 - d ] pyrimidine, 6-methylpurine [ 15, 20, 2 1, 2231, and the 2’-deoxyribonucleosides of 6-mercaptopurine, 6-methylpurine, 8-azaguanine, and 2-aminoadenosine [ 15, 2241 ; since in vivo and in whole cells the equilibrium is shifted toward purine formation [ 18, 2251, these conversions can be viewed as evidence that these purine analogue nucleosides are subject to cleavage in whole cells. Ribonucleoside derivatives of 6-mercaptopurine and other purine bases are rapidly cleaved by Ehrlich ascites cells in vitro [ 2 2 6 ] . Nucleoside phosphorylase troin human erythrocytes cleaves 6-mercaptopurine ribonucleoside readily, but 6-methylthiopurine ribonucleoside only slowly [21 a] . In another study the phosphorolytic cleavage of the ribo- and 2‘-deoxyribonucleosides of adenine, 6-mercaptopurine, and thioguanine was observed [ 2 2 7 ] . Changes in the sugar moiety to xylose, arabinose, 3’-deoxyribose, 5 -deoxyallose. or 6’-deoxyallose preventedcleavage [ 1 73,2271 . Furthermore, 9-0-D-arabinofuranosylhypoxanthine and 9Q-~-xylofuranosylhypoxanthine, resulting from the deamination of the corresponding adenine nucleosides, are excreted in the urine of treated mice indicating that these nucleosides are not substrates either [ 152, 1531. The phosphorolysis of cordycepin, 3’-amino-3‘-deoxyadenosine, 2-fluoroadenosine 2-aminoadenosine, and 9Q-D-arabinofuranosyladenine, but not tubercidin, by an extract from S. faecalis [228] and of cordycepin by B. subtilis [229] has been reported. Studies with resistant H.Ep.-2 cell lines lacking adenosine kinase and adenine phosphoribosyltransferase indicate that 2-fluoroadenosine [ 128. 1471, 2-fluoro-3 -deoxyadenosine [ 1471 , and 6-methylpurine ribonucleoside [ 2301 are also cleaved to some extent in these cells, whereas tubercidin, 4-aminopyrazolo [ 3 , 4 - d ] pyrimidine ribonucleoside [23 1, 2321 , N-allyladenosine [ 2 3 3 ] ,
JOHN A. MONTGOMERY
87
N-aminoadenosine [ 1741 , 2-chloroadenosine [ 176. 2341 , 6-chloropurine ribonucleoside [ 178,235,2361 ,purine ribonucleoside [ 1781, and the (alkylthi0)purine ribonucleosides [I601 d o not appear t o be cleaved t o any appreciable extent [ 128, 1471. Irreversible hydrolytic cleavage of nucleosides catalysed by hydrolases has been observed in bacteria but not in mammalian cells [ 4 6 ] .
Dearninases
Adenine aminohydrolase has been found in micro-organisms, but not in mammalian cells, and the substrate specificities of the enzymes from Azotobacter vinelandii and Candida utilis were found t o be similar [55, 561. Among other purines, 2-aminoadenine, N-aminoadenine, and 6-chloropurine were found to be substrates 1551 Adenosine aminohydrolase (adenosine deaminase) is found in all types of cells and is apparently an important catabolic enzyme for the regulation of cellular metabolism. It has been isolated from a number of sources and the substrate specificities of the various enzymes are similar, since a low degree of specificity R
y
d
HOCH2
2
0
OH OH
OH R
(L)
RzNHNH,,R’:H
( L V I ) R z H , Y:N
(Li)
R:NHOH,
( L V I I ) R =OH, Y: CH
(LII)
R = O M e , R’zH
R’:H
(LIfI) RzNH,, R’zOH ( L I V ) RzNH,,
R’ZCi
( L V ) R = NH,,
R’ZMeS
is generally observed. Not only is the 6-amino group of adenosine hydrolysed, but the methylamino [59, 63, 237, 237a], hydrazino [ 5 9 ] , hydroxylamino [61, 63, 237a], methoxy [59, 2371, and chloro groups [59, 61, 6 3 , 64, 237, 238-2411 are all hydrolytically removed from the corresponding 6-substituted purine ribonucleosides (XXV, XXX, L-LII). 2-Fluoroadenosine (XXXI) has been reported by some investigators [ 2 4 0 , 2 4 2 ] to be very slowly deaminated and by others not a t all [239, 241 1 . Crotonoside (LIII), 2-chloroadenosine (LIV), and 2-(methylthio)adenosine (LV) are neither substrates nor inhibitors of adenosine
**
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
deaminase [ 2431 , but 2-aminoadenosine (XXXII) is deaminated to give guanosine [57, 61, 64, 237a, 2411. Changes in the purine moiety have an unpredictable effect on substrate specificity: 8-aza-2 -deoxyadenosine (LVI), 8-aza-adenosine [237a] , and formycin (LVII [244-2461 are deaminated [247-2491 whereas tubercidin (XXXIV) is not 2411. Though changes in the sugar moiety effect binding t o adenosine deaminase, many adenosine analogues are fair substrates. Thus, 2'-deoxyadenosine [ 571 , 3'-deoxyadenosine (XXIII) 157, 64, 239, 240, 248, 2501 , 3'-amino-3'-deoxyadenosine (XXIV) [216, 239-2411, 94-D-xylofuranosyladenine (XX) [227, 239, 240, 2501 , 9$-D-arabinofuranosyladenine (XIX) [227, 239, 240, 2501, 4'-thioadenosine [240, 2511 and ~ - [ P - D L - ~ O I . 301-dihydroxy-4~-(hydroxymethylcyclopentyl] adenine [ 252, 2531 are all deaininated and at rates that appear to affect their activity (since the inosine analogues that are formed are generally inactive). N-Methyladenosine (XXV) 1227, 239, 2501 , N-methyl-2'-deoxyadenosine (XXVI) [ 571 , 3 '-amino-N-methyl-3'-deoxyadenosine [ 2541 , and 6-methoxypurine ribonucleoside (LII) [63, 234, 2411 are all good inhibitors of adenosine deaminase and N-methyladenosine (XXV) has been used in combination with 94-D-arabinofuranosyladenine (XIX) t o increase its activity [255] . A number of 2-substituted N-methyladenosines [6 11 and 9-substituted adenines (see reference 256 and earlier papers by Schaeffer) are also inhibitors of the enzyme. Although adenylic acid deaminase is a well-known enzyme that has been isolated in crystalline form, little work has been reported on its substrate specificity; evidence for the deamination of 4-aminopyrazolo [3,4-d] pyrimidine ribonucleotide has been presented [ I 181, but it is not known if it catabolizes any of the other intracellularly formed adenylic acid analogues. Guanine aminohydrolase (guanine deaminase) was discovered in rabbit liver and is present in the tissues of other animals, in certain bacteria and in yeast [88]. The conversion of 8-azaguanine to 8-azaxanthine in vitro [257] and in vivo [258] is catalysed by guanine deaminase. Thioguanine is also a substrate for the enzyme purified from rabbit liver [88] .4(5)-Aminoimidazole-5(4)-carboxamide inhibits guanine deaminase [259] ; and, when coadministered with 8-azaguanine, it increases the anabolism of the latter 12601, resulting in increased toxicity and antitumour effectiveness with no net benefit. A search for an inhibitor that will selectively inhibit guanine deaminase of cancer cells has been undertaken [ 26 1 1.
r'
Oxidases
The literature on xanthine oxidase [84] and its companion catabolic enzyme uricase [87] has been extensively reviewed. Many purine analogues, with the exception of most 9-substituted purines [262], serve as substrates for xanthine oxidase both in vitro and in vivo, and if the product is a substrate for uricase, in species that possess this enzyme, the ultimate product is allantoin (LVIII). Thus 2-aminoadenine [S] ,N-methyladenine [ 1221, and purine [ 1291 are all catabolized
R
R
A )*
(LXX) R (LXXI)R
H2CQ C
H =H
=NH,
R
l+oH OH OH
(LXXII)R = Et, Bu
(LXXI I1 1
90
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
by rodents to allantoin, although intermediate oxidation products are also found. 6-Chloropurine is oxidized in vitro [263] and in vivo [264] to ‘6-chlorouric acid’ (LIX), which inhibited uricase in slices and homogenates of rat liver [264], but the major catabolic pathway for this analogue in the rat involves the loss of the 6-chloro group [264] . Other cytotoxic 6-substituted purines are also substrates for xanthine oxidase [ 265,265al. 4-Aminopyrazolo [3,4-d] pyrimidine is oxidized to 4-amino-6-hydroxv~vrazolo[3, 4-d] pyrimidine (LXI) 1266, 2671 , and its deamination product, 4-hydroxypyrazolo [3,4-d] pyrimidine, is oxidized to 4, 6-dihydroxypyrazolo [3,4-d] pyrimidine (LXII) [267,267a] . The catabolism of the thiopurines is complicated by the fact that in addition to ring oxidation, methylation and oxidation of the mercapto group also occurs. Since this subject has been amply reviewed [5, 12,2681 ,it will be discussed briefly here; the reader is referred to the reviews for most of the references to the original literature. Both 6-mercaptopurine and thioguanine, after deamination to 6-thioxanthine (LXIII), are further oxidized to 6-thiouric acid (LXIV), and thence to sulphate, and unidentified products. In the rat 6-mercaptopurine is in part methylated to 6-(methylthio)purine (see above), which is converted to hypoxanthine and inorganic sulphate. In rodents sulphate arises from 6-mercaptopurine via thiouric acid (LXIV), but in man, lacking uricase, it is probably formed via 6-(methy1thio)purine. Since 6-(methy1thio)purine ribonucleoside is not cleaved by nucleoside phosphorylase, its catabolism (and that of the nucleotide) must involve demethylation, which is known to occur in the case of 6-(methylthio)purine, in the rat (see above). S-Methylation of some form of 6-mercaptopurine in man has been established by the identification of 6-(methylsulphinyl)-8-hydroxypurine (LXV), ‘6-(methy1thio)uric acid’ (LX), and 6-(methylthio)-8-hydroxy-N-glucuronide (LXVII). The oxidation of 6-(methy1thio)purine to 6-(methylthio)-8-hydroxypurine (LXVI) is mediated much more rapidly by rabbit liver aldehyde oxidase than by xantliine oxidase, and the oxidation is not inhibited by 4-hydroxypyrazolo[3,4-d] pyrimidine [269] , which is known t o be an effective inhibitor of xanthine oxidase, and consequently, of the oxidation of 6-mercaptopurine [ 12,2681 . S-Methylation of thioguanine t o 2-amino-6-(methylthio)purine (LXVIll), which is deaminated to 2-hydroxy-6-(methyIthio)purine (LXIX) and may give rise to inorganic sulphate, the major end product of thioguanine catabolism, occurs to a much greater extent in man than in the mouse, in which deamination and oxidation to thiouric (and thence to sulphate) is the main pathway [ 12, 2681 6-Mercaptopurine and thioguanine have been converted t o S-heterocyclic derivatives (LXX and LXXI) [270, 2711 that are protected from rapid methylation and oxidation in vivo, and are split nonenzymatically t o the purinethiones by sulphydryl groups. Certain S-alkyl derivatives [272] of the purinethiones are metabolized like 6-(methylthio)purine, but the 9-alkyl derivatives [273-2751 are metabolized only to some extent t o their S-glucuronides (LXXII) [276, 2771 and are not affected by xanthine oxidase.
JOHN A. MONTGOMERY
91
Summary
2-Fluoroadenine, 2-chloroadenine, 2-aminoadenine, 2- and 8-aza-adenines, 4-aminopyrazolo [3, 4-d] pyrimidine and 6-methylpurine are converted to their ribonucleosides by adenosine phosphoribosyltransferase, and their ribonucleosides are converted to the ribonucleotides by adenosine kinase; most of the ribonucleotides are then converted to the di- and triphosphates. N-Aminoadenine, N-hydroxyadenine, N-methyladenine, purine, 7-deaza-adenine, and 7-aminopyrazolo[4, 3-d] pyrimidine are either not substrates or are very poor substrates for the phosphoribosyltransferase, but their ribonucleosides are excellent substrates for the kinase. The ribonucleotides of purine, 7-deaza-adenine and 7-aminopyrazolo [4, 3-d] pyrimidine are further phosphorylated to the di- and triphosphates, but the N-substituted adenylic acids are not. The nucleosides of adenine-cordycepin, 3'-amino-3'-deoxyadenosine, 9-fl-~-arabinofuranOsy1adenine, and 9-fl-D-xy~ofuranosy~adenine-are phosphorylated with varying degrees of ease and the resulting nucleotides are readily converted t o the di- and triphosphates. With the exception of 2-fluoro- and 2-chloroadenosine, tubercidin, and, obviously, purine and 6-methylpurine ribonucleosides, the adenosine analogues, whether they are presented to the cell as such or result from dephosphorylation of the nucleotide, are catabolized by adenosine deaminase to the corresponding inosine analogues, which, with some exceptions, have a low level of biologic activity, although the rate of catabolism varies a great deal. Most of the hypoxanthine analogue ribonucleosides are cleaved by nucleoside phosphorylase to hypoxanthine, which can be further degraded by xanthine oxidase and uricase. Most of the other hypoxanthine nucleosides are not further catabolized. Analogues of hypoxanthine or guanine such as 6-mercaptopurine, thioguanine, and 8-azaguanine are converted to their nucleotides by hypoxanthine-guanine phosphoribosyltransferase, but their ribonucleosides appear to be cleaved by nucleoside phosphorylase to the free bases rather than phosphorylated t o the ribonucleotides. 8-Azaguanylic acid is largely converted to the di- and triphosphate, whereas thioinosinic acid and thioguanylic acid for the most part are not. 8-Azaguanine and thioguanine are catabolized by guanase, and both the purinethiones are degraded by xanthine oxidase. Methylation and demethylation is an important factor in the activity of the thiopurihes and certain adenine or adenosine analogues also. MECHANISM OF ACTION
Most biologically active purines or purine nucleosides must be anabolized to 5'-nucleotides t o exert their effects. The 5 hucleotides are in some cases further phosphorylated to the di- and triphosphates and the number of potential sites of action of these compounds is obviously greater than the number of potential sites of action of compounds metabolized only to the monophosphate level. But even
=
Glycine +ATP
OH OH
OH OH
OH OH
I
I
OH OH
1
,Aspartate
Figure 2.4. The de novo synthesis of inosinic acid
AOP +HPOi-
CoF
OH OH
I
OH AH
JOHN A. MONTGOMERY
93
the latter compounds have been shown to be capable of interfering at multiple sites. It is the concensus of opinion today that, in fact, there may be no one metabolic block that can explain all the biological effects of most of the purine analogues and their metabolites. In the sections that follow all the biological effects of the various analogues that have been observed are discussed with emphasis on those that, in the opinion of the author, appear to be the most important to the drug action of these compounds. Enzyme inhibition The de novo synthesis of inosinic acid
The elucidation of the steps by which cells synthesize inosinic acid d e novo for purine nucleotide interconversions is largely due to the brilliant work of Buchanan and his co-workers [ 6 5 ] . The biosynthetic scheme as it is currently envisioned is shown in Figure 2.4. The first step of this sequence, which is not unique to d e novo purine nucleotide biosynthesis, is the synthesis of 5-phosphoribosylpyrophosphate (PRPP) from ribose-5-phosphate and adenosine triphosphate. Phosphoribosylpyrophosphate synthetase, the enzyme that catalyses this reaction [ 2781 , is under feedback control by adenosine triphosphate [279] . Cordycepin interferes with thede novo pathway [229, 280, 2811, and cordycepin triphosphate inhibits the synthesis of PRPP in extracts from Ehrlich ascites tumour cells [282]. Formycin [ 2831 ,probably as the triphosphate, 9-~-D-xylofuranosyladenine[ 1571 triphosphate, and decoyinine (LXXIII) [284-2861 (p. 89) also inhibit the synthesis of P W P in tumour cells, and this is held to be the blockade most important t o their cytotoxic action. It has been suggested but not established that tubercidin (triphosphate) may also be an inhibitor of this reaction [ 1931. The first irreversible reaction peculiar t o the d e novo purine nucleotide pathway, the formation of 5-phosphoribosylamine from PRPP and glutamine,,is also subject t o end product or feedback inhibition by the natural purine nucleotides, inosinic, guanylic, and adenylic acids and their higher phosphates [287] ; The regulation of phosphoribosylpyrophosphate amidotransferase, the enzyme that catalyses this reaction [ 2 8 8 ] , is allosteric in nature [ I ] . There are at least two separate allosteric binding sites on the' enzyme, one for inosineguanosine phosphates and one for adenosine phosphates, and both types of compound can act on the enzyme simultaneously [287, 2891. The inhibition is competitive against PRPP and mixed competitive-noncompetitive against glutamine. The ribonucleotides of the unnatural purine analogues, 6-mercaptopurine, thioguanine, and 4-hydroxypyrazolo[3, 4-d] pyrimidine, are good inhibitors of this enzyme [287, 2901. This feedback inhibition may be primarily responsible for the in vitro [291] and in vivo [290, 2921 activity of the purinethiones (for a review of the effects of anticancer agents on biochemical control mechanisms see reference 2).
94
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
The effect of 6-mercaptopurine on the incorporation of a number of I4Clabelled compounds into soluble purine nucleotides and into RNA and DNA has been studied in leukemia L1210, Ehrlich ascites carcinoma, and solid sarcoma 180. At a level of 6-mercaptopurine that markedly inhibited the incorporation of formate and glycine, the utilization of adenine or 2-aminoadenine was not affected. There was n o inhibition of the incorporation of 5(or 4)-aminoimidazole4(5)-carboxamide (AIC) into adenine derivatives and n o marked or consistent inhibition of its incorporation into guanine derivatives. The conversion of AIC to purines in ascites cells was not inhibited at levels of 6-mercaptopurine 8-20 times those that produced 50 per cent or greater inhibition o f d e novo synthesis [292]. Furthermore, AIC reverses the inhibition of growth of S180cells (AH/5) in culture by 6-mercaptopurine [293]. These results suggest that in all these systems, in vitro and in vivo, the principal site a t which 6-mercaptopurine inhibits nucleic acid biosynthesis is prior to the formation of AIC, and that the interconversion of purine ribonucleotides (see below) is not the primary site of action [292]. Presumably, this early step is the conversion of PRPP to 5-phosphoribosylamine inhibited allosterically by 6-mercaptopurine ribonucleotide (feedback inhibition is not observed in cells that cannot convert 6-mercaptopurine to its ribonucleotide [244]. Yet another piece of evidence that supports the allosteric inhibitor theory for 6-mercaptopurine was obtained from a study of the inhibition of adenocarcinoma 755 and sarcoma 180 cells in culture [295]. Ad755 cells are more sensitive t o inhibition by 6-mercaptopurine than S180 cells, and this sensitivity appears to be unrelated t o the ability of these cells t o anabolize 6-mercaptopurine to its ribonucleotide, since both cells exhibit this enzymatic capacity. But 6mercaptopurine is ten times more effective in inhibiting de novo synthesis in Ad755 cells than in S180 cells, whereas the EDs0 for growth inhibition is four times more for SI 80 than Ad755 cells. Studies on the mechanism of action of 6-mercaptopurine are complicated by the fact that its anabolic product, thioinosinic acid, is further metabolized by oxidation to 6-thioxanthylic acid [219] and by methylation t o 6(methy1thio)purine ribonucleotide [206, 2961 . the effects of which could be even more important than those of thioinosinic acid itself, since the methylthio compound is about 20 times as potent as a feedback inhibitor [289]. I t has been suggested that thioguanine’s multistep inhibition, one step of which is the inhibition of phosphoribosylpyrophosphate amidotransferase, results in a profound lowering of the intracellular concentration of guanine nucleoside phosphates and that this depletion causes a marked depression in cellular metabolism that presumably would lead t o cell death [91]. A number of other purines, purine ring analogues, and their ribonucleosides have been evaluated as feedback inhibitors [13, 173, 294, 297, 297a] by a modification [294] of the method of LePage andco-workers [291,298,299,300]. This method utilizes azaserine t o isolate the first few steps of the de novo pathway in whole cells by the specific blockade of the conversion of formylglycinamide
JOHN A. MONTGOMERY
95
ribonucleotide (FGAR) to the corresponding amidine. Compounds that can, after conversion to their nucleotides, act as feedback inhibitors of purine biosynthesis decrease the amount of FGAR accumulation in azaserine-treated cells; the extent of this decrease is a measure of the ability of an agent to inhibit by feedback. Using this technique,the EDso values for FGAR-accumulation inhibition in H.Ep.-2 cells for a number of purine analogues have been obtained. Table 2.3. CORRELATION OF THE CYTOTOXICITY OF CERTAIN PURINE ANALOGUES AND THEIR RIBONUCLEOSIDES WITH THEIR INHIBITION O F FGAR ACCUMULATION Base Nome cy t o toxicity
2-Fluoroadenine 1.4 2Chloroadenine 11.0 2-Aminoadenine 20 6-H ydrazinopurine 20 N-Methyladenine 1-Methyladenine >670 Adenine-1-oxide N-Allyladenine 4-Aminopyrazolo[ 3,441 pyrimidine 1.2 4-Aminoimidazo[ 4,541 pyridazine 23 7-Deaza-adenine? 20 8-Aza-adenine 21 2-Axa-adenine 5.2 Purine 80 6Chloropurine 214 6-Methylpurine 1.6 6-Methoxypurine >670 8-Azaguanine 3.4 6-Mercaptopurine 1.2 6-Thioguanine 0.14 6-(Methy1thio)purine 4 00 6-(Benzylthio)purine
>
EDSO(p molell) * ___Ribori leoside -FGAR FGAR Accumu. c y toAccumutoxicity latiori lation 1.8 16.6 35 1.8 14 18 1.8 6.4 0.1 >56 0.05 0.8
2.3
> 38 70 > 37 34
222 15
> 74 7.4 42 322 >400
> 33 0.6
ca
0.08 15.4 0.38 65 1.2 1.2 1.3
2.9 11.8 < 37 7.3 7.5 14.7 < 7.4 36 3.8
< < <
>so
3.8 3.7
< <
3.8 <7.7 3.7 10.4 >32 3.0 0.6 <0.3 15
<
<
* See text. 7 The aglycone of tubercidin.
A comparison of EDs0 values for feedback inhibition and for growth inhibition in H.Ep.-2 cells in culture is shown in Table 2.3. It is readily apparent that t o r most of the purine analogues listed, the correlation between feedback inhibition and cytotoxicity is good. The few discrepancies may be due to the fact that these particular compounds are not ieedback inhibitors, but metabolism (or lack of it) of the analogue in question may be important. In comparing these ED5, values, the difference in experimental conditions for cytotoxicity determination (long
96
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
exposures to drug, 96-1 20 h) and feedback inhibition (2-5 h exposure to d r u d must be considered. If both inhibition of growth and FGAR accumulation require the formation of a fraudulent nucleotide and its maintenance at a minimum intracellular concentration, discrepancies may result. Thus, although 4-aminopyrazolo [3, 4-d] pyrimidine does not appear to be a feedback inhibitor, its ribonucleoside is, and yet they are both converted intracellularly t o the ribonucleotide, which appears to be the true inhibitor. It seems reasonable to assume that long exposure to the base allows a sufficient conversion to nucleotide to inhibit cell growth, but if 4-aminopyrazolo[3, 4dlpyrimidine is not a good substrate for adenine phosphoribosyltransferase, enough nucleotide may not be formed in the short exposure period t o show feedback inhibition. On the other hand, the ribonucleoside is known to be an excellent substrate for the kinase (see above);soit is more cytotoxic than the base and is a good feedback inhibitor. In contrast, 8-azaguanine and its ribonucleoside [301] are about equitoxic, but neither acts as a feedback inhibitor and their biologic activity is most likely due to a different phenomenon (i.e., nucleic acid incorporation, see below). In addition to the analogues listed in Table 2.3, cordycepin [302] .3'-amino3'-deoxyadenosine [ 1731, and formycin [303] can inhibit the de nova pathway by blocking the phosphoribosylpyrophosphate amidotransferase. Thus, a number ofpurine analogues-after anabolism to nucleoside phosphates-can act as feedback inhibitors, and this inhibition may be the primary cause of their cytotoxicity.
The Salvage' path ways
Although cells synthesize inosinic acid de now for purine internucleotide conversions, they also utilize exogenously supplied adenine, hypoxanthine, and guanine by converting them directly to their ribonucleotides (see section or1 phosphoribosyltransferases, p. 74). The utilization of adenosine appears to involve this reaction also since it is largely deaminated to inosine which is cleaved to hypoxanthine, even though it can be phosphorylated directly to adenylic acid [ 147,3041 . Since inosine-guanosine kinase activity is low or missing in many cells, the utilization of inosine and guanosine must also involve cleavage to the bases, which are converted by the phosphoribosyltransferpe to ribonucleotides. Thus, these salvage pathways are of importance t o the economy of cells and their inhibition could be of some consequence. In this connection, a specific loss of hypoxanthine-quanine phosphoribosyltransferase activity has been observed in cases of gout associated with the overproduction of uric acid [305] and in a neurological disorder, the Lesch-Nyhan syndrome [306]. Although a causa! relationship has not been established, these disorders could be indicative of the importance of these enzymes. 6-Mercaptopurine is a competitive inhibitor of phosphoribosyl transfer from PRPP to guanine and hypoxanthine, [85a] but does not affect the reaction with
JOHN A. MONTGOMERY
97
adenine, which is catalysed by a different enzyme [ 102, 3071. 6-Mercaptopurine also inhibits the cleavage of inosine and guanosine preventing their utilization by the phosphoribosyltransferases, although in bacterial cells this inhibition results in greater utilization of the ribonucleosides indicating their phosphorylation by a kinase [308] . Competitive inhibition of adenine phosphoribosyltransferase by certain adenine analogues has been observed, but only at relatively high levels of these analogues [45a, 308a] . Even so this enzyme is inhibited competitively, with respect to PRPP, by AMP, ADP, and ATP [42, 43, 1031, and thus it is another potential site for the action of adenine analogues that are converted to ribonucleoside phosphates, particularly ones that are not incorporated into nucleic acid or easily degraded. Purine nucleotide in terconversions
The conversion of inosinic acid t o adenylic acid is a two-step process [651 The first step, the conversion of inosinic acid to adenylosuccinic acid, is mediated by adenylosuccinate synthetase [65] , which is inhibited by 6mercaptopurine ribonucleotide 1309-31 11 in a non-competitive manner, although the exact nature of this inhibition is not known [67]. The second step of the sequence, the conversion of adenylosuccinic acid t o adenylic acid, is also inhibited by 6-mercaptopurine ribonucleotide [66, 31 11, and in this case the inhibition is competitive with respect to the substrate [67]. Although tumour growth inhibition by 6-mercaptopurine has been attributed to the inhibition of the conversion of inosinic acid to adenylic acid [3@, 310, 3121, probably at the first step, this conversion by cell-free extracts from the exquisitely sensitive tumour adenocarcinoma 755 was inhibited only at high levels of 6-mercaptopurine ribonucleotide (3 131 . Furthermore, hadacidin (N-formylhydroxyaminoaceticacid) is an excellent inhibitor of adenylosuccinate synthetase [314, 3151, and yet it has little antitumour activity and is not cytotoxic, showing that this inhibition may be relatively unimportant to cells. Although 6-chloropurine ribonucleotide has little inhibitory effect on the enzymatic conversion of inosinic acid to adenylic acid, it markedly inhibits the conversion of inosinic acid to xanthylic acid by inosinic acid dehydrogenase [3 1 6 , 3171 . Evidence has been presented that the nucleotide combines reversibly with the enzyme in place of the normal substrate and then reacts, at its 6-carbon, with a sulphydryl group of the enzyme active site to form a stable thioether thus irreversibly inactivating the enzyme [3 17,3 17aJ . 6-Mercaptopurine ribonucleotide inhibits the enzyme in a similar manner through the formation of a disulphide bond between the mercapto group of the enzyme and the mercapto group of the nucleotide. In this case the reaction is reversible in the sense that the addition of glutathione slowly reactivates the inhibited enzyme by cleavage of the disulphide bond. If the enzyme is fully activated by glutathione before the inhibitor is added, the inhibition is purely competitive and a sevenfold excess of thioinosinic acid over inosinic acid is required for 50 per cent reduction in initial rate.
98
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
6-Chloropurine ribonucleotide and thioinosinic acid also react covalently with GhlP reductase, the enzyme that converts guanylic acid t o inosinic acid and ammonia [3 181 . The significance of these in uitro enzyme inhibition studies is uncertain, in view of the evidence that has been presented concerning the sensitivity of cancer cells t o feedback inhibition by these nucleotides. O n the other hand, 6-chloropurine inhibits the de nouo biosynthesis of nucleic acid guanine but not of nucleic acid adenine in sarcoma 180 ascites cells [3 191 . The second step in the conversion of inosinic acid to guanylic acid is the aminolysis of xanthylic acid with glutamine by xanthosine-5 ’-phosphate aminase [ 6 5 ] . Thisaminase, isolated fromE. coli B, is inhibited allosterically b y adenosine and adenylic acid [320], and it is also inhibited by psicofuranine (9-/3-Dpsicofuranosyladenine) (LXXIV) [284, 32 1-3261 , which apparently is not y
2
(LXXV) R -A -0-arabinofuranosyl,R’=H (LXXVI) R - Bu, R’-NH, ILXXIV)
metabolically activated [327] ; and this inhibition, which takes place only in the presence of xanthylic acid and inorganic pyrophosphate, is irreversible [328] . Psicofuranine(LXX1V) inhibition of an altered aminase from a resistant E. coli B mutant is readily reversible and dependent only on pyrophosphate. These observations indicate that psicofuranine inhibition is a two-step process. The first step-a pyrophosphate dependent, reversible reaction between the inhibitor and the enzyme-is followed by an irreversible step requiring xanthylic acid. The altered aminase is presumed t o have lost the ability t o undergo the second step. Binding studies show that the primary interaction of the aminase with psicofuranine is non-competitive and s u a e s t that it is allosteric at a site normally occupied by a metabolic regulator [89, 3281 . The psicofuranine-inhibited aminase cannot catalyse the formation of the adenyl xanthylic acid intermediate from adenosine triphosphate and xanthylic acid, nor can it catalyse its aminolysis t o guanylic acid [90]. The related antibiotic decoyinine (angustmycin A , LXXIII) [285] also inhibits xanthosine-5 ‘-phosphate aminase [329] , presumably in the same manner as psicofuranine (LXXIV), but less effectively. There is evidence that psicofuranine (LXXIV) and decoyinine (LXXIII) may be interconvertible in cells 13291.
JOHN A. MONTGOMERY
99
Other enzymes
ATP-GMP phosphotransferase is a highly specific enzyme that catalyses the phosphorylation of guanylic acid and 2'-deoxyguanylic acid by adenosine triphosphate. Of' the purine analogue nucleotides tested, only 8-azaguanylic acid was a good substrate; thioinosinic acid was neither a substrate nor an inhibitor. Thioguanylic acid was a competitive inhibitor of the enzyme and was itself phosphorylated only to a small extent [91,329a]. Cytidylate reductase, the enzyme that reduces cytidine diphosphate to 2 '-deoxycytidine diphosphate is inhibited not only by 1~-D-arabinofuranosylcytosine, but also by 9-0-D-arabinofuranosyladenine[330] and 9-0-D-arabinofuranosylpurine-6( 1H)-thione(LXXV) [33 1-3331 .9-Butylthioguanine (LXXVI), which is catabolized to unidentified excretion products but which is not debutylated, blocks the incorporation of adenine into DNA, but the exact mechanism of this action is unknown [334]. 9$-D-Arabinofuranosyladenine, presumably as the triphosphate, inhibits the incorporation of precursors into DNA [ 1541 , and the triphosphate inhibits noncompetitively the incorporation of thymidine triphosphate into DNA in extracts of ascites cells, suggesting a direct interaction with DNA polymerase, possibly at an allosteric site [ 1551. Other studies have confirmed the inhibition of DNA synthesis catalyzed by DNA polymerase [335,335a]. Incorporation into nucleic acids
The subject of the incorporation of anticancer agents into macromolecules [ 131 and other compounds [336] has been reviewed. A number of purine analogues are incorporated into nucleic acid, but the incorporation of these compounds requires that they be anabolized to nucleoside mono-, di-, and triphosphates, and it is difficult to separate the metabolic effects of the nucleoside phosphates from the metabolic effects of the fraudulent polynucleotides. 8-Azaguanine was the first purine analogue shown to be incorporated into polynucleotides [337] and, since its primary metabolic effect is on protein synthesis, the incorporation into RNA is considered the basis for its biologic activity [338] . In microbial systems 8-aza-adenine, 8-azahypoxanthine, 8-azaxanthine, and S(4)amino- 1H-1, 2, 3-triazo~e~4(5)-carboxamideare all incorporated into RNA as 8-azaguanylic acid [336]. Another guanine analogue, thioguanine, is also incorporated into both DNA and RNA of mammalian cells [ 1981, and a correlation between its antitumour activityand the extent of its incorporation into DNA has been observed [339,340], although some investigators feel that the metabolic effects of thioguanylic acid may be more universally important [ 13, 91, 3411 . The incorporation of a-and P-2'-deoxythioguanosine into DNA has also been reported [ 144. 144al. 'The incorporation of 6-mercaptopurine into DNA as 2 '-deoxythioguanylic acid has been observed but in cells resistant to the action of the drug, which makes the meaning of this observation unclear [201].
100
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
Several analogues of adenine or adenosine are reported to be incorporated into nucleic acids: 2-fluoroadenosine 13421, tubercidin 190, 192, 342a], toyacamycin [ 193,342a1, sangivamycin [342a, b] , cordycepin [ 168,343,3441, 4-aminopyrazolo[3, 4-d] pyrimidine [ 1 191 , formycin [344a] , . and 9-0-Darabinofuranosyladenine [ 152, 1541. The evidence for the incorporation of 9-0-D-arabinofuranosyladenine has been questioned [345] .
Inhibition of protein synthesis
I n the preceding section. the incorporation of 8-azaguanine into RNA was discussed. How this incorporation inhibits protein synthesis is not certain, but synthetic polymer or triplet nucleotides containing 8-azaguanine are less active in stimulating polypeptide tormation in vifro than the corresponding guanine compounds, even though no miscoding was detected [346, 347, 3 4 7 a l . Thus inhibition of protein synthesis by the analogue may be a result of the formation of 8-azaguanine-containing messenger RNA with altered template activity [ 3381 . The effects of puromycin (XLIII) on the synthesis of macromolecules has been studied in intact bacteria, mammalian cells, and whole animals. Puromycin (XLIII) was shown to inhibit protein synthesis immediately while DNA and RNA syntheses continue for a while at near normal rates. This pattern of macromolecular synthesis is now recognized as characteristic of inhibition of protein synthesis at a step subsequent to the formation of aminoacyl-sRNA. The studies leading to our present understanding of puromycin (XLIII) inhibition have been adequately reviewed [348] and will not be discussed in detail here. Puromycin, because of its resemblance to aminoacyl-sRNA (LXXVII), attaches t o the acceptor sites of the ribosome-messenger RNA complex adjacent to the sRNA's to which growing peptide chains are attached (the donor sites). Each carboxylactivated peptide is then transferred to the free amino group of puromycin, which subsequently detaches from the ribosome. Thus, the growing polypeptide chains are prematurely released from the ribosomes and protein synthesis is inhibited. In addition to the inhibition of protein synthesis, there is evidence that puromycin affects nucleotide metabolism and RNA synthesis, but thesc effects are probably due, at least in part, to breakdown to the aminonucleofide and demethylation of the aminonucleoside to 3 '-amino-3 -deoxyadenosine (see p. 84). Homocitrullylaminoadenosine (LXXVIII) [349] also inhibits protein synthesis, presumably in the same way that puromycin does [350]. A similar mode of action has been suggested for lysylaminoadenosine (LXIX) [ 3 5 1 , 3 5 2 ] . Nucleocidin (LXXX) [353] , an adenine nucleoside antibiotic whose structure has recently been elucidated, is also a potent inhibitor of protein synthesis. Studies with this compouna have led t o the conclusion that nucleocidin forms a complex with ribosomes which is inactive in peptide bond formation. Binding
JOHN A. MONTGOMERY
101
of either soluble RNA or messenger RNA to this complex is apparently not inhibited, nor is progression of the ribosomes down the messenger RNA molecule. The specific aspect of peptide bond formation which is inhibited in the complex has not been determined [354].
. ,N +L N H O c H ;
M~o
0
I c=o
I
CH,CHNH,
N b N5 ) ) -03
%d
POCH2
I
c=o I
R - CHNH,
Interference with co-factors
Tubercidin 5 ‘-monophosphate is converted to the ‘corresponding analogue of NAD when incubated with cell free extracts of S.fueculis (see above). Furthermore, the inhibition of S. fueculis by tubercidin can be prevented by a mixture ot amino acids, nucleosides, ribose-5-phosphate, and pyruvate suggesting that the primary action of the antibiotic is due to interference with N AD-dependent reactions [202]. This protective effect is not seen in mammalian cell systems [ 1931. Formation of the 2-aminoadenine analogue of NAD by H.Ep.-2 cells in culture has been demonstrated, and it appears quite likely that dinucleotides containing 2-aminoadenine and nicotinic acid or nicotinamide can be formed in living
102
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
animals. Whether this NAD analogue plays a significant role in the inhibition of biological systems by 2-aminoadenine is not known at present [218]. 6-Mercaptopurine ribonucleoside triphosphate is a potent inhibitor of adenylyl transfer to nicotinamide mononucleotide and is itself converted to the NAD analogue in vifro [355, 3561. Since it has not been established that 6-mercaptopurine is converted to its triphosphate in vivo, the significance of these observations is uncertain. It has also been suggested, but not established, that 6-mercaptopurirfe may interfere with co-factor A [357,358]. Summary
Certain purine analogues such as psicofuranine and puromycin are known to inhibit per se a specific metabolic event-the aminolysis of xanthylic acid and the formation of peptide chains, and these specific inhibitions are thought to be the basis of their biologic activity. In contrast, 6-mercaptopurine is known to interact with a number of enzymes and to be incorporated to a small extent into DNA. Some of these interactions result in the catabolism of the drug, and others in its anabolism to at least three biologically active forms-6-mercaptopurine ribonucleotide, 6-methylthiopurine ribonucleotide, and 6-thioxan thylic acid. These active forms are capable of interacting with still other enzymes. Many of the interactions of 6-mercaptopurine and its anabolities are enzyme inhibitions, any one of which could be responsible for cell death, although today it appears more likely that it is the simultaneous inhibition of two or more of these enzymes by the multiple active forms that results in the potent effects of this drug. Other compounds such as 8-azaguanine almost surely owe their effects to incorporation in macromolecules such as RNA, which in turn interferes with the normal function of this material in the direction of protein synthesis. Thus there are a number of metabolic events that are interfered with by the various purine analogues. The biological consequences of these interferences are discussed in the sections that follow. EFFECTS On the host Toxicity
Table 2.4 lists the LDlo values for the acute toxicity of a number of purine analogues for BDFl mice [359]. In general the values agree fairly well with the cytotoxicity values for the same compounds. Some of the discrepancies are easily explained. For example, 6-chloropurine ribonucleoside is nndoubtedly more readily converted to inosine in vivo accounting for its high LDlo value, whereas 6-(methy1thio)purine is demethylated t o 6-mercaptopurine (see above). The high LDlo value for 6-mercaptopurine ribonucleoside, however, is not easily understood, since it is readily cleaved t o 6-mercaptopurine. Studies on the toxicology of some of these purine analogues in rodents and dogs at sublethal doses showed that rapidly dividing tissues, especially the intestinal mucosa and bone marrow, are most sensitive to these compounds
JOHN A. MONTGOMERY
103
Table 2.4. A COMPARISON OF THE TOXICITY OF SOME PURINE ANALOGUES
Compound 2-Fluoroadenosine 4-Aminopyrazolo[ 3 , 4 d ] pyrimidine N-Aminoadenine 2-Aminoadenine 3 :Amino-3 Ideoxy-N, N-dimethyladenosine Purine 6-Methylpurine 6Chloropurine 6Chloropurine ribonucleoside 6-Mercaptopurine 6-Mercaptopurineribonucleoside 6-(Methylthio)purine 6-(Methylthio)purine ribonucleoside 6-(Benzylthio)purine ribonucleoside 9-Ethyl-6-mercaptopurine 9-Butyl-6-mercaptopurine Thioguanine Thioguanosine 8-Azaguahine 8-Azaguanosine
1
ca 15 ca 75 70 34 ca 400 1.7 230 550 40 250 94 20 150 52 250 1.6 1.7 90 17
>
In BDFl mice qd 1-1 1, observed 1-12.
[360] (as well as all other anticancer agents). However, the relative effects of these drugs on the two tissues vary. For example, 6-mercaptopurine, 2-aminoadenine, and 6-chloropurine produce similar lesions in the intestinal epithelium when given in doses that cause bone-marrow depression; the effects of thioguanine are largely limited to the bone marrow, in which most haematopoietic elements are susceptible. 6-Methylpurine appears to selectively depress erythrogenesis. The xanthine oxidase oxidation products of purine and 2-chloroadenine crystallize in the renal tubules causing kidney damage [360]. Hepatic damage occurs with many analogues, but is particularly prominent with Caminopyrazolo [3, 4-dlpyrimidine [361]. These various toxicities, and skin rashes [362, 3631 are also observed clinically along with anorexia, nause?, vomiting, and diarrhoea. The limiting clinical toxicity with 6-(methy1thio)purine ribonucleoside is gastrointestinal toxicity, particularly of the upper tract [364] , whereas bonemarrow toxicity is usually limiting with 6-mercaptopurine and thioguanine. Administration of 3 '-amino-3 '-deoxy-N,N-dimethyladenosine(the aminonucleoside of puromycin) to rats produces a nephrotic syndrome that is clinically indistinguishable from the nephrotic syndrome of unknown origin frequently observed in children [365] . Rats, monkeys, and humans are susceptible to this nephrotoxicity and susceptibility has been related to specie ability to demethylate the aminonucleoside [ 2 131. N6-Methyladenosine prevents development of this syndrome [365a].
104
THE BIOCHEMICAL BASIS FOR T H E DRUG ACTIONS OF PURINES
Embryonic tissue
Because of their effects o n rapidly dividing tissue, the purine analogues have a marked effect on the developing embryo. The analogues differ not only in the amounts required to produce toxicity in the embryo but in their teratogenicity. I t is possible t o produce teratogenic effects in the chick embryo with a sublethal amount of 8-azaguanine but not with 6-mercaptopurine [366]. Compounds such as 6-mercaptopurine and thioguanine affect both cellular multiplication and differentiation [367] . The abilityofpurine analogues to affect rodent embryos in ufero at doses that are non-toxic to the mother is well documented. When 6-mercaptopurine [368], thioguanine [369], some of their S-substituted derivatives [370, 3711, and 6-chloropurine [373] are given to the rat at the time o f implantation of fertilized ova, a high percentage of the foetuses are destroyed. To exhibit peak activity, 2-aminoadenine must be given before implantation [369] . 6-Mercaptopurine, 6-mercaptopurine ribonucleoside, h-mercaptopurine-3-oxide, and N-hydroxyadenine are teratogenic when administered on the eleventh day of gestation [373a]. The teratogenicity of 8-azaguanine in mice depends o n the timing and amount of the dose [ 3731 . Immune response
The finding that the administration of 6-mercaptopurine to rabbits following exposure to bovine serum albumin prevented antibody formation 13741 formed the basis for a new area of chemotherapy for purine analogues and other antimetabolites and was soon followed by the use of these drugs for the therapy of autoimmune disease and the suppression o f homograft rejection. This subject has been reviewed in depth [ 12, 375, 375al , has occasioned a symposium [376], and has received much recent publicity as a result of human heart transplants. Certain purines are capable of specifically inhibiting the immune response during the induction period of the response, and the inhibition is increased by increasing the antigenic stimulus. There is a close resemblance between druginducedand antigen-excess repression of the response, and although the mechanism by which these compounds suppress is not clear, the suggestion has been made that it is probably related to their cytotoxic nature [ 121. Fortunately for the potential of immunosuppressive agents in the treatment of homograft rejection, they have much less effect on a secondary than o n a primary immune response, although they are useful in the treatment of a number of autoimmune diseases such as psoriases, and undesirable effects have been reported [ 3 7 5 ] . A number of thiopurines (thioguanine, 6-mercaptopurine, 6xmethylthio) purine) [ 121 ,and purine, azathioprine (6(( l-methyl-4-nitro-5-imida~olyl)thio] other derivatives o t 6-rnercaptopurine [377] ) have all been used to successfully prolong homografts, and azathioprine (Imuran) appears t o be superior in its action [ 2 6 8 ] .
JOHN A. MONTGOMERY
105
Pla tele t aggrega tion
Circulating platelets adhere to the site of damage of blood vessels aggregating into clumps or white bodies, which stop the flow of blood causing clots. Adenosine diphosphate causes the aggregation of platelets in blood plasma both in vitro [378] andin vivo [379], and this effect is antagonized by adenylic acid and even more by adenosine. Of the thirty odd purine nucleosides that have been evaluated as platelet aggregation inhibitors [ 3 8 E 3 8 2 ] only 2-aza-adenosine and the 2-haloadenosines showed significant activity. 2-Chloroadenosine was more active than adenosine, but also caused respiratory arrest in rabbits [383]. A correlation has been noted between the ability of these compounds to inhibit platelet aggregation and their vasodilator activity [382] . Gout
The pyrazolo[3, 4-d] pyrimidines are substrates for and inhibitors of xanthine oxidase [ 266,267].4-Hydroxypyrazolo[3,4-d] pyrimidine was first investignted for its ability to protect 6-mercaptopurine and other analogues from oxidation by xanthine oxidase [384], but it also inhibits the oxidation of the natural purines, hypoxanthine, and xanthine. Its profound effect on uric acid metabolism made it an obvious choice for the treatment of gout and its utility in the control of this disease has been demonstrated [385,386]. On invading organisms
Micro-organisms (bacteria and protozoa)
Much information on the mechanism of action and cross-resistance of purine analogues has been obtained in bacteria, some of which are quite sensitive to certain of these compounds in vitro. There is a great deal of variation in response of the various bacteria to a particular agent and of a particular bacterium to the various cytotoxic purine analogues. Some, if not most, of these differences are probably due t o differences in the anabolism of the various compounds. Despite the fact that certain purine analogues have quite a, spectrum of antibacterial activity in vitro, none has been useful in the treatment of bacterial infections in vivo because their toxicity is not selective-the metabolic events whose blockade is responsible for their antibacterial activity are also blocked in mammalian cells and thus inhibition of bacterial growth can only be attained at the cost of prohibitive host toxicity. In contrast, the sulpha drugs and antibiotics such as penicillin act on metabolic events peculiar to bacteria. It is of historical interest that Tetrohyrnenagelii, whose metabolism has been described in detail [387], is inhibited by 8-azaguanine [388] and other purine analogues [389, 3901. Of more importance to chemotherapy is the fact that pathogenic protozoa such as the trypanosomes respond in vitro to a number of
106
THE BIOCHEMCAL BASIS FOR THE DRUG ACTIONS OF PURINES
purines such as 6-mercaptopurine [39 11 , thioguanine 139 11, and 2-aminoadenine [392]. More active than these compounds, in vitro and in vivo, however, is the aminonucleoside of puromycin, 3 '-amino-3 '-deox y-N,N-dimethy ladenosine, which is more effective than puromycin itself [ 39 1,3931 . Primaquine appears to be more effeGtive than the aminonucleoside on the flagellate forms of T. cruzi; so the combination was tested in mice and found extremely effective [394]. Puromycin alone was not effective against T. cruzi in humans [395], but was effective against early infection of T. gambiense [396]. T. equiperdum and T. gumbiense in mice respond to both puromycin and the aminonucleoside [397-4001. Puromycin was also effective in suppressing T. equiperdum, T. equinum. T. Evansi, and T. rhodesiense in mice, but was ineffective against T. congolense [398]. T. equiperdum infections in mice 14011 and T. congolense, T. gambiense, and T. equinum in mice and rats are cured by treatment with nucleocidin [4021. Although inferior to pyrimethamine plus sulphonamides, both puromycin and the aminonucleoside are active against Toxoplasma gondii in vivo [403]. These drugs are also effective against Endamoeba histolytica in vifro [404] , and puromycin is active against the infection in man [405]. The mechanism of inhibition of these protozoal infections by the most active drugs, puromycin and the aminonucleoside, is not known. Puromycin and nucleocidin both intertere with protein synthesis, but the aminonucleoside does not. It is known to be demethylated to 3'-amino-3'-deoxyadenosine, which is phosphorylated and interferes with nucleic acid metabolism (see above). Whether puromycin must be converted to the aminonucleoside before it can inhibit protozoa has not been established. Some purine analogues known to interfere with nucleic acid metabolism, however, are less effective as antiprotozoal agents, even in vifro, perhaps because their effects are primarily on the de novo pathway which many, if not all, protozoa do not use [406]. Viruses and cancer
2-Aminoadenosine, the first purine found to possess antiviral activity, inhibits vaccinia [384], spring-summer encephalitis [407], psittacosis [408], and poliomyelitis [409] viruses in cell culture. 8-Azaguanine has been reported a$ both active [410] and inactive [384] against vaccinia virus, and active against psittacosis and encephalomyocarditis. 6-Mercaptopurine interfered with the replication of both RNA and DNA viruses in Lass cells [41 I ] . 9-P-D-Arabinofuranosyladenine has a remarkable inhibitory action on the multiplication of the DNA viruses [41 l a ] , herpes, vaccinia [412, 4131, and cytomegalovirus [414], which also responds to thioguanine. Puromycin is active against a number of viruses in cell culture. In chick embryo cells it delayed the replication of western equine encephalitis [4 151 and inhibits Venezulian equine encephalitis [4 161 . It interferes with the replication
JOHN A. MONTGOMERY
107
of poliomyelitis [417-4191 and western equine encephalitis [419] in HeLa cells. I t is reported to inhibit [420] and not inhibit [421] encephalomyocarditis and t o inhibit reovirus [422] and influenza (4231, but not herpes [424] in L cells. If added early in the eclipse stage it inhibits adenovirus in monkey kidney cells [425]. I t also inhibits polyoma virus in mouse embryo cells [426]. Activity of an agent against a virus in cell culture is only an initial lead. Many false positives are found because there is no measure of host toxicity at viricidal levels or of the many other complicating factors. Unfortunately the purine analogues have shown minimal activity against viral infections in the whole animal. 2-Aminoadenine reduced the mortality of mice infected with springsummer encephalitis [427], but puromycin had no effect on herpes keratitis in rabbits [428]. A number of purine analogues failed t o inhibit Semliki Forest virus infections in mice [ 3721 . 9-p-D-Arabinofuranosyladenine was the only purine of a large number evaluated for in viuo activity against influenza and vaccinia viruses that was inhibitory and its effectiveness was confined to vaccinia 14291. In vivo studies with virus-induced cancers mostly limited t o virus leukemias in mice and the Rous sarcoma in chicks, have been concerned primarily with the anticancer aspect of the problem, and have placed little emphasis on the viral aspects. 6-Mercaptopurine, its ribonucleoside, thioguanine, and azathioprine all prolong the life span of mice infected with the Friend virus leukemia [430,43 1 ] . In addition t o these compounds, 9cyclopentyl-6-mercaptopurine,9-butyl-6mercaptopurine, 6xbenzylthio)purine ribonucleoside, and thioguanosine are also active [432] . 6-Mercaptopurine [433] and thioguanine were active against both the Friend and Rauscher viruses in an in vitro assay system [434]. 6-Mercaptopurine showed only minimal effects against the Moloney virus leukemia [435, 4361, although other purine analogues such as thioguanine and 6chloropurine ribonucleoside are reported t o increase survival time of infected mice [ 3 6 6 , 4 3 7 ] . Although inactive against the Kous sarcoma in the standard post-infection test, 6-mercaptopurine, 2-aminoadenine, and 8-azaguanine inhibited the development of the tumour if given prior t o infection of the chicks [417,418]. Most of the adenine and adenosine analogues discussed in the precedine sections are converted to adenosine triphosphate analogues and are highlY cytotoxic. Unfortunately, their specificity for cancercells is low so that, although they show some activity in sensitive experimental animal systems such as Ehrlich ascites carcinoma, they are not useful agents; and those that have been evaluated clinically (i.e., 2-aminoadenine [363] and 4-aminopyrazolo[3, 4-d] pyrimidine [438] ) are not effective, but are toxic t o man. The ribonucleoside [439] of N-hydroxyadenine [440], an inactive adenine analogue, may be an exception to thisstatement, since it is quite active against L1210 leukemia [439], but haemolysis at low dosage occurred in preliminary clinical trials [439a]. Since other N-substituted adenosines are phosphorylated to the monophosphate stage only, the active form of this analogue is probably N-hydroxyadenylic acid, rather
108
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
than the triphosphate, which may be part of the reason for its selective action on cancer cells. Trimethylpurin-6-ylammoniumchloride [44 11 and some of its derivatives [442, 4431 inhibit the growth of adenocarcinoma 755, but not sarcoma 180 or leukaemia L1210 in mice; little additional information is available on this series of compounds. 6-Chloropurine, as its ribonucleotide, is active against a number of animal neoplasms [444] and human leukaemias [363], but is less effective than the purinethiones, which it resembles in its action. 8-Azaguanine is inhibitory to several experimental animal tumour systems [444], but is not highly active. Clinically its toxicity has been more apparent than its anticancer effects [362,363]. Of the purine analogues investigated thus far, the purinethiones are by far the most effective anticancer agents. 6-Mercaptopurine remains the agent of choice clinically [363, 445-4471 , since other thiopurines, such as thioguanine, 6-(methylthio)purine, azathiopurine, 9-ethyl-6-mercaptopurine, and 6-mercaptopurine ribonucleoside, which are also active in man, appear to offer no real advantage over it. 6-Mercaptopurine is useful in the treatment of acute granulocytic, acute lymphocytic, and chronic granulocytic leukaemia and choriocarcinoma [ 12, 363, 445-4471 . The combination of 6-mercaptopurine and 6(methylthio)purine ribonucleoside, however, is more effective in the treatment of acute adult leukaemia than either drug alone [448]. 6-Mercaptopurine is considerably less effective in the treatment of solid tumours [363] . The reason for the selective toxicity of 6-mercaptopurine remains to be established, but two factors may be of primary importance. 6-Mercaptopurine is anabolized primarily, if not exclusively, to the monophosphate level, and it is readily catabolized by xanthine oxidase, an enzyme that is low in most cancer cells compared to normal cells. Another factor that must be considered is the metabolic state of the target cells. Actively proliferating leukaemia cells are more sensitive to 6-mercaptopurine, as they are to all antimetabolites, than cells in the so-called Go or stationary phase. Although this does not explain the difference between 6-mercaptopurine and other purine analogues, it may explain the ineffectiveness of 6-mercaptopurine against solid tumours, most of the cells of which are in the non-dividing state. Certain derivatives of 6-mercaptopurine, such as 6-(methylthio)purine, 6-mercaptopurine-3-oxide [448a] , and 6-mercaptopurine ribonucleoside and its acylated derivatives apparently owe their activity to their in vivo conversion to 6-mercaptopurine [ 11,131. It would appear, however, that the 9-alkyl derivatives of 6-mercaptopurine, and its arabinosyl and xylosyl derivatives, are not metabolized-except in the case of the 9-alkyl derivatives, t o a limited extent to their S-glucuronides-and that their mechanism of action is quite different from that of 6-mercaptopurine. Thioguanine is 5-30 times as toxic to rodents (depending on schedule) as 6-mercaptopurine and somewhat more effective against rodent neoplasms,
JOHN A. MONTGOMERY
109
although its therapeutic index is not greater. It would seem likely that 6-mercaptopurine and thioguanine inhibit cancerous growths in a similar manner. Changes in the structure of thioguanine also give rise to active structures. but no significant improvement in effectiveness [ 11,131 . THE PROBLEM OF RESISTANCE Mechanisms
Both natural and acquired resistance constitute a serious problem to therapy witH purine analogues, particularly in the case of cancer. Why one acute leukaemia responds well to methotrexate but not to 6-mercaptopurine, whereas a morphologically identical leukaemia responds to 6-mercaptopurine but not to methotrexate, and a third, seemingly identical leukaemia responds to neither is a vexing problem that has so far defied solution [449]. In the case of acquired resistance, a patient may respond well to a drug initially and appear to be completely cancer-free, only to succumb later to a cancer that now does not respond to therapy with the same drug. Such a situation may indicate that the cancer cell population has, before resumption of treatment, multiplied to a size where it can no longer be controlled by a drug dose th?t the patient can tolerate [450], or it may indicate that a drug-resistant mutant population has replaced the original heterogeneous population containing almost entirely drug-sensitive cells. The necessity for most purine analogues to be converted to their nucleotides to show their inhibutory effects has been discussed. Cells deficient in hypoxanthine-guanine phosphoribosyltransferase activity cannot convert 6mercaptopurine, thioguanine, or 8-azaguanine to their ribonucleotides and are resistant to these analogues [8,98, 101,260,451455], but are still sensitive to adenine analogues such as 2-fluoroadenine, 2-aminoadenine, and 4-aminopyrazolo [3, 4:d] pyrimidine [456]. Conversely, cells deficient in adenine phosphoribosyltransferase activity are resistant to the various adenine analogues, such as 2-aminoadenine [ 113, 3041 and 2-fluoroadenine [ 1281, but are still sensitive to cytotoxic hypoxanthine-guanine analogues [ 128, 1471 . Although mammalian cells are naturally resistant to xanthine analogues, because they are deficient in xanthine phosphoribosyltransferase activity, bacteria possess this enzyme and are sensitive to 8-azaxanthine. Bacteria that have become resistant to 8-azaxanthine were shown to have lost their xanthine phosphoribo'syltransferase activity [98]. Resistance to 2-aminoadenine and 8-azaguanine in Salmonella typhimurium is apparently due, in some cases, to genetically controlled alterations of the phosphoribosyltransferases to forms of the enzymes that can still convert the natural substrates to nucleotides but not the purine analogues [457,458]. Cells deficient in adenosine kinase fail to respond to adenosine analogues, unless they are cleaved to adenine analogues that can be converted to ribonucleotides by adenine phosphoribosyltransferase. Cells deficient in both these enzymes fail to respond to adenine and adenosine analogues, but are still sensitive to hypoxanthine-guanine analogues [ 1471 . Resistance to the various purine
110
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
analogues due to these enzyme deletions has been observed in bacteria, mammalian cells in culture, and neoplasms in experimental animals indicating that this is a ubiquitous and an important cause of acquired resistance [8]. Since these enzymes catalyse the so-called 'salvage' pathways of purine utilization they are not essential to cellular metabolism, and their loss does not, in general, affect the ability of cells to proliferate at normal rates, which may explain why resistance by these deletions occurs so readily and frequently. However, acquired resistance is thought to result from chemical selection and overgrowth of specific drug-resistant mutant cells from a heterogeneous population, and hence it is not surprising that more than one type of resistance t o a particular agent has been found. Other mechanisms of resistance to purine analogues that have been advanced are inaccessibility of the nucleotide-forming enzyme system t o the analogue [459, 4601, increased rate of degradation of the analogue or its metabolities [461-463], and a decreased affinity of the activating enzyme for the analogue [ 1001 . Circumventions
One of the first demonstrations that acquired resistance could be circumvented was the inhibition of S. faecalis resistant to 8-amguanine by 8-azaxanthine. Thus, cells that possess xanthylic acid phosphoribosyltransferase activity could form 8-azaxanthylic acid, which was then converted to 8-azaguanylic acid and incorporated in nucleic acids as such 1981 . Early attempts to inhibit H.Ep.-2 cells resistant to 6-mercaptopurine [464J resulted in the finding that a number of 9-alkyl derivatives of 6-mercaptopurine were highly active in this test system. 9-Alkylhypoxanthines and adenines were less effective [465]. 6-Mercaptopurine ribonucleotide is not active against cells resistant to 6-mercaptopurine, presumably because nucleotides cannot penetrate cell membranes intact [466] (its activity in sensitive cells is no doubt due to its cleavage back to 6-mercaptopurine [467] ). This stumbling block led to the synthesis of esters of 6-mercaptopurine ribonucleotide [468, 4691 that might penetrate cell walls intact and then either inhibit per se or be cleaved back to the ribonucleotide. Two such derivatives, bis(thioinosine) 5 ', 5 "'-phosphate [470] and the monophenyl ester of. 6-mercaptopurine ribonucleotide [ 13, 4681 do inhibit H.Ep.-2 cells resistant to 6-mercaptopurine, but some cross-resistance was noted. Because of the relatively low therapeutic index of all known purine antagonists, this cross-resistance did not otter encouragement for in vivo activity against resistant neoplasms, and, indeed, the monophenyl ester did not inhibit leukaemia L1210 resistant to 6mercaptopurine. More successful in this regard was the use of 6-(methylthio) purine ribonucleoside against MP-resistant cells. Thus, this nucleoside, which is converted t o the nucleotide by adenosine kinase, is highly active against both resistant H.Ep.-2 cells in culture and resistant L1210 leukaemia in mice [471]. Furthermore, it is therapeutically synergistic with 6-mercaptopurine in the
JOHN A. MONTGOMERY
111
sensitive line of L1210 [471]. Similar observations were made in the Ehrlich ascites carcinoma system [472]. The clinical utility of this combination [448] has been discussed above. AC KNOWL EDG EMENTS
The author gratefully acknowledges the helpful criticism of Dr. Lee L. Bennett, Jr. Thanks are due to Mr. Vladimir Minic and Miss Linda Scott for checking references to the literature and to Mrs. Frances K. Hoffman for preparation of the manuscript. REFERENCES
1. E. R. Stadtman, Adv. Enzymol., 1966,28,41 2. J. F. Henderson, Progr. Exp. TumorRes., 1965,6,84 3. N. 0. Kaplan and M. Friedkin, Advan. Chemother., 1964, 1,499 4. H. J. Grav, Merhods in Cancer Research (Ed. H. Busch), Vol. 3, Academic Press, New York, 1967, p. 243 5. H. G. Mandel, Pharmacol. Rev., 1959, 11,743 6. R. E. Handschumacher and A. D. Welch, The Nucleic Acids (Eds. E. Chargaff and J. N. Davidson), Vol. 3, Academic Press, New York, 1960, p. 453 7. R. W.Brockman and E. P. Anderson, Annu. Rev. Biochem., 1963,32,463 8. R. W. Brockman, Adv. Cancer Res., 1963.7. 129 9. J. F. Henderson and H. G. Mandel, Adv. Phormacol., 1963,2; 297 10. G. H. Hitchings and G. B. Elion, Metabolic Inhibitors (Eds. R. M. Hochster and J. H. Quastel), Vol. 1. Academic Press, New York, 1963, p. 213 11. J. A. Montgomery, Progr. Drug Res., 1965,8,431 12. G . B. Elion and G. H. Hitchings, Adv. Chernother., 1965,2,91 13. L. L. Bennett and J. A. Montgomery, Methods in Cancer Research (Ed. H. Busch), Vol. 3, Academic Press, New York, 1967, p. 549 14. M. Friedkin and H. Kalckar, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vok. 5 , Academic Press, New York, 1961, p. 237 15. H. L. A.Tan, Can. J. Biochern Physiol., 1958,36,517 16. E. W. Ysmada, J. Biol. C h e m , 1961,236, 3043 17. W. Fiers and J. de Bersaques, Enzymologia, 1962,24, 197 18. A. M. Gotto, A. W. Meikle and 0. Touster, Biochim. Biophys. Acta, 1964,80,552 19. B. Pinto and 0. Touster, J. B i d . Chem., 1966,241,772 20. T. A. Krenitsky,Mol. Pharmacol., 1967, 3,526 21. H. L. A. Tarr and J. E. Roy, Can J. Biochem., 1967,45,409 21a. T. A. Krenitsky, G. B. Elion, A.M. Henderson and G. H. Hitchings, J. Biol. C h e m , 1968,243,2876 21b. R. P. Agarwal and R. E. Parks, J. Biol. Chem., 1969,244,644 22. M. Zimmerman and D. Hatfield, Biochim. Biophys. Acta, 1964,91,326 23. R. Abrams, M. Edmonds and L. Libenson, Biochem. Biophys. Res. Comtnun, 1965, 20.31n 24. A. R. P. Paterson and A. I. Simpson,Can. J. Biochem, 1965,43, 1996 25. T. Sakai,T. Tochikura and K. Ogata, Agr. Biol. Chern, 1965,29,742 26. M. Zimmerman, J. Biol. Chern, 1966, 241,4914 27. R. Caputto, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 6, Academic press, New York, 1962, p. 133 28. L. A. Heppel, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 5, Academic Press, New York, 1961, p. 49
112 29. 30. 31. 32. 33. 34. 35. 36. 37. 37a. 38. 39. 40. 41. 42. 43. 44. 45. 45a 46. 46a. 47. 48, 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 64a. 65. 66. 67. 68. 69.
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES E. R. Stadtman, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 5, Academic Press, New York, 1961, p. 55 G. Schmidt, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 5, Academic Press, New York, 1961, p. 37 J. Lisowski, Biochim. Biophys. Acta, 1966, 113, 321 M. Center and F. J . Behal, Arch. Biochem. Biophys., 1966, 114,414 S. J. Levin and 0. Bodansky, J. Biol. Chem., 1966, 241,Sl C. S. Song and 0. Bodansky, Biochem. J . , 1966, 1 0 1 , S c C. Arsenis and 0. Touser, J. Biol. C h e m , 1967, 242, 3399 P. L. Ipata, Biochem. Biophys. Res. Commun., 1967, 27, 337 H. C. Neu, J. Biol. Chem., 1967,242, 3896 C. Arsenis and 0. Touser, J. Biol. C h e m , 1968, 243.5702 M. R. Atkinson and R. K. Morton, Comp. B i o c h e m , 1960, 2, 1 L. Noda, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 6, Academic Press, New York, 1962, p. 139 J. lmsande and P.Handler, TheEizzyrnes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 5, Academic Press, New York, 1961, p. 281 M. Hori and J . F. Henderson, J. Biol. C h e m , 1966, 241, 3404 M. Hori, R. E. A. Gadd and J . F. Henderson, Biochem Biophys. Res. Commun., 1967, 28, 616 A. W. Murray, Biochem J., 1967,103, 271 A. W. Murray and P. C. L. Wong, Biochern. J . , 1967, 104, 669 A. W. Murray, Biochem J . , 1967, 104,675 T . A. Krenitsky, S. M. Nei1,G. B. Elion and G. H. Hitchings, J. Biol. Chem., 1929,244, 4779 C . E. Carter,J. Amer. Chem. SOC.,1951, 73, 1508 M. Terada, M. Tatibana and 0. Hayaishi, J. Biol. Chern., 1967, 242,5578 H. P. Schnebli,D. L. Hill and L. L. Bennett, J. Biol. Chem., 1967,242, 1997 B. Lindberg, H. Klenow and K. Hanscn, J. Biol. C h e m , 1967, 242,350 M. A. Brewster and E. S. Younathan, Can. J. Biochem, 1 9 6 6 , 4 , 1469 R. J . Haslam and D. C. B. Mills, Biochem J., 1967, 103,773 C.Chiu, S. Su and S. J. Russell, Biochim Biophys Acta, 1967, 132, 361 S. Su and S. J . Russell, Biochirn. Biophys. Acta, 1967, 132, 370 A. Larsson and P. Reichard, Progr. Nucleic Acid Res. Mol. Biol., 1967, 7, 303 P. Reichard, Eur. J. Biochem., 1968, 3, 259 R. C. Hartenstein and I. Fridovich, J. Biol. Cliem., 1967, 242, 740 L. G . Howell and I . €ridovich.J. Biol. Chem., 1967, 242,4930 A. Coddington, Biochim. Biophys. Acta, 1965,99, 442 S. Minato, T. Tagawa and K . Nakanishi, J. B i o c h e m , 1965,58,519 R. Wolfenden, J. Amer. C h e m SOC., 1966,88, 3157 S. Minato, T. Tagawa, M. Miyaki, B. Shimizu and K. Nakanishi, J. B i o c h e m , 1966, 59, 265 M. Rockwell and M. H. Maguire,Mol. Pharmacol., 1966, 2, 574 R. Wolfcnden, T. K. Sharpless and R. Allan, J. Biol. Chem., 1967, 242, 977 B. M. Chassy and R. J . Suhadolnik, J. Biol. Chem., 1967, 242, 3655 V. D. Hoagland and J . R. Fisher, J. Biol. C h e m , 1967, 242,4341 P. M. Murphy, M. Noonan, P. Collins, E. Tully and T. G . Brady, Biochim Biophys Acta, 1969, 171, 157 J. M. Buchanan, The Nucleic Acids (Lids. E. Chargaff and J . N. Davidson), Vol. 3, Academic Press, New York, 1960, p. 303 A. Hampton, J. Biol. Chem., 1962, 237, 529 M. R. Atkinson, R. K . Morton and A. W. Murray, Biochem. J., 1964,92, 398 R. H. Weaver, The Enzymes (Eds. P. D. Boyer, H. Lardy and K . Myrback) Vol. 6, Academic Press, New York, 1962, p. 151 N. Mourad and R. E. Parks, Biochern. Biophys. Res. C o m m u n , 1965, 19, 312
JOHN A. MONTGOMERY
70. 71.
113
N. Mourad and R. E. Parks, J. BioL C h e m , 1966, 241, 271 N. Mourad and R. E. Parks, J. Biol. C h e m , 1966, 241, 3838
72. W. W. Kielley, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback) Vol. 5, Academic Press, New York, 1961, p. 159 7 3 . Y. P. Lee, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback) Vol. 4, Academic Press, New York, 1960, p. 279 74. B. S. Cunningham and J. M. Lowenstein, Biochim Biophys. A c f a , 1965, %, 535 75. A. Razin and J. Mager, Israel J. Med Sci., 1966, 2, 614 76. K. L. Smiley and C. H. Suelter, J. Biol. Chem., 1967,242,1980 77. K. L. Smiley, A. T. Berry and C. H. Suelter, J. Biol. C h e m , 1967, 242,2502 78. A. W. Nichol, A. Nomura and A. Hampton, Biochemisfty, 1967,6,1008 79. H. G. Khorana, The Nucleic Acids, (Eds. E. Chargaff and J. N. Davidson) Vol. 3, Academic Press, New York, 1960, p. 105 80. H. M. Keir, Progr. Nucleic Acid Res. Mol. Biol., 1965, 4, 81 81. N. B. Furlong, Methods in Cancer Research (Ed. H. Busch) Vol. 3, Academic Press, New York, 1967, p. 28 82. H. L. A.Tarr, Can. J. Biochem, 1964,42, 1535 83. E. S. Zimmerman and B. Magasanik, J. Biol. C h e m , 1964, 239,293, 84. R. C. Bray, Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 7, Academic Press, New York, 1963, p. 533 85. A. W. Murray, Biochem-J., 1966, 100,664 85a. T. A. Krenitsky, R. Papaioannou and G. B. Elion, J. Biol. C h e m , 1969, 244, 1263 85b. T. A. Krenitsky and R. Papaioannou, J. Biol. C h e m , 1969, 244, 127 1 85c. J. H. Anderson and A. C. Sartorelli. J. Biol. C h e m . 1968. 243.4762 ' 86. J. Mager and R. Magasanik, J. Biol. Chern., 1960,235,1474 87. H. R. Mahler, Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 8, Academic Press, New York, 1963, p. 285 88. R. Currie, F. Bergel and R. C. Bray, Biochem. J., 1967, 104,634 89. H. Kuramitsu and H. S. Moyed, J. Biol. C h e m , 1966,241, 1596 90. T. T. Fukuyama, J. Biol. Chem., 1966,241,4745 91. R. P. Miech, R. E. Parks, J. H. Anderson and A. C. Sartorelli, Biochem. Pharmacol., 1967, 16, 2222 92. A. Kornberg, I. Lieberman and E. S. Simms, J. Amer. C h e m Suc., 1954, 76,2027 93. A. Kornberg, I. Lieberman and E. S. Simms, J. Biol. Chem., 1955,215,417 94. E. D. Korn,C. N. Remy, H. C. Wasgejko and J. M. Buchanan,.I. Biol. Chem., 1955, 217,875 95. C. N. Remy, W. T. Remy and J. M. Buchanan, J. Biol. C h e m , 1955,217,885 96. J. G. Flaks, M. T. Erwin and J. M. Buchanan, J. Biol. Chcm., 1957,228, 201 96a., T. A. Krenitsky, Biochim. Biophys. A c f a , 1969, 179,506 96b. J . F. Henderson, L. W. Brox, W. N. Kelley, F. M. Rosenbloom and J. E. Seegmiller, J. Biol. C h e m , 1968,243,2514 . , 96c. J. F. Henderson, Can. J. Biochem, 1969,47,69 97. J. G. Flaks, Methods in Enzymology (Eds. S . P. Colowick and N. 0. Kaplan) Vol. 6, Academic Press, New York, 1963, p. 136 98. R. W. Brockman, C. Sparks, D. J. Hutchison and H. E. Skipper, CancerRes, 1959, 19, 177 99. C. P. Kalle, J. S. C o t s and C. Abramson, Fed. Proc., 1960, 19, 310 100. R. W. Brockman, C. S. Debavadi, P. S t u t t s a n d D. J. Hutchison, J. Biol. C h e m , 1961, 236,1471 101. R. W. Brockman, L. L. Bennett, M. S. Simpson, A. R. Wilson, J. R. Thomson, and H. E. Skipper, Cancer Res., 1959, 19, 856 102. M. R. Atkinson and A. W. Murray, Biochem J . , 1965,94,64 103. A. W. Murray, Biochem J., 1966, 100,671 104. R. Pomales, G. B. Elion and G. H. Hitchings, Biochim. Biophys. A c f o , 1965.95,505
114 105. 106. 107. 108. 109. 110. 11 1. 112. 113. 114. 115. 116.
THE BIOCHEMICAL BASIS FOR T H E DRUG ACTIONS OF PURINES W. N. Kelley, F. M. Rosenbloom, J. F. Henderson, and J. E. Seegmiller, Biophys. Res. Comtnun., 1967, 28, 340 R. D. Berlin and E. R. Stadtman, J. Biol. C h e m , 1966,241,2679 A. Bendich, J. F. Tinker and G. B. Br0wn.J. Amer. Chem. Soc., 1948,70, 3109 J. A. Montgomery and I(.Hewson, J. Amer. Chem SOC.,1960, 82, 463 R. K. Robins, J. Amer. Chem. Soc., 1956,78,784 E. N. Shaw and D. W. Woolley, J. Biol. Chem., 1952,194,641 R. 0. Roblin, J. 0. Lampen, J. P. English, Q. P. Cole, and J. R. Vaughan, J. Amer. Chem Soc., 1945,67,290 J. L. Way and R. E. Parks, J. Biol. C h e m , 1958,231,467 J. K. Roy, A. G. Haavik, and R. E. Parks, Proc. Amer. Assoc. Cancer Res , 1960, 3, 146 C. N. Remy and M. S. Smith, J. Biol. Chem., 1957, 228,325 C. N. Remy, Biochem. Biophys. Acra, 1967, 138,258 D. G. R. Blair and A. D. Hall, Can. J. Biochem., 1965,43,1857; Blair, Can. J. Biochem, 1967.45.435
117. G. P. Wheeler and H. E. Skipper, J. Biol. Chem., 1953,205,749 118. L. L. Bennett, D. Smithers, C. Teague, H. T. Baker, and P. Stutts, Biochem. Phartnacol., 1962, 11.81 119. J . F.Henderson and I.G. Junga,CancerRes., 1961,21, 118 120. G. B. Elion, E. Burgi and G. H. Hitchings, J. Amer. Chem. Soc., 1952,74,411 121. D. E. Duggan and E. Titus, Biochim. Biophys. Acra, 1962,55,273 122. C . E. Jamison, J. W. Huff,and M. P. Gordon,Cancer Res., 1962,22, 1252 123. D. E. Duggan, M. G. Weigert, W. E. Grieb and E. 0. Titus, Biochim. Biophys. Acta. 1963,68,519 124. C. N . Remy, J. Biol. Chem.. 1961,236,2999 125. D. E. Duggan, Biochim. Biophys. Acta, 1963,68,319 126. G. B. Brown and V. S. Weliky, J. Org. Chem., 1958,23, 125 127. J. A.Carbon, J. Amer. Chem. SOC.,1958,80,6083 128. L. L. Bennett, M. H. Vail, S. Chumley and J . A. Montgomery, Biochem. Pharmacol., 1966,15,1719 129. 130. 131. 132. 133. 134. 135. 136. 136a. 137. 138. 139. 140. 141. 142. 143. 144. 144a. 145. 146.
M. P. Gordon, 0. M. Intrieri and G. B. Brown, J. Biol. C h e m , 1957,22Y, 641 A. Hampton and A. R. P. Paterson, Biochim. Biophys. Acta, 1966,114, 185 I. W. F. Davidson and J. Fellig, Fed. Proc., 1962,21, 160 G. B. Elion and G. H. Hitchings,J. Amer. Chem. Soc., 1955,77.1676 R. K. Robins,J. Org. Chem., 1956,21,489 L. N. Lukens and K. A. Herrington, Biochim. Biophys. Acta, 1957,24,432 C. E. Carter, Biochem. Pharmacol., 1959.2, 105 A. R. Paterson, Acta Unio Intern. Contra Cancrum, 1964,20,1033 M. L. Meloni and W. 1. Rogers, Biochem.Pharmacol., 1969,18,413 D. W. Woolley and E. N. Shaw,J. Biol. Chem., 1951,189,401 J. A. Montgomery and H. J. Th0mas.J. Org. Chem., 1961,26,1926 A. Hampton and M. H. Maguire, J. Amer. Chem. SOC.,1961,83,150 (a) J.K.Roy,D.C.Kvam, J. L. Dahland R. E. Parks,J. Biol. Chem., 1961,236,1158; (b) J. L. Way, J. L. Dahl and R. E. Parks,J. Biol. Chem., 1959,234, 1241 D. 1. Magrath and C . B. Brown,J. Amer. Chem. SOC.,1957.79,3252 M. F. Utter, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 2, Academic Press, New York, 1960, p. 75 G. A. LePage and I. G. Junga, Cancer R e s , 1963, 23, 739 G. A. LePage and I. G . Junga, Mol. Pharmacol., 1967,3,31 G . A. LePage, Can. J. Biochem., 1968,46,655 K. J. Pierre, A. P. Kimball and G . A. LePage, Can. J. Biochem., 1967.45, 1619; K. J. Pierre and G. A. LePage,Proc.SOC.Exp. Biol. Med., 1968, 127,432 A. Kornberg and W. E. Pricer, J. Biol. Chem., 1951,193,481
JOHN A. MONTGOMERY
115
147. L. L. Bennett, H. P. Schnebli, M. H. Vail, P. W. Allan and J. A. Montgomery, Mol. Pharmacol., 1966, 2, 432 148. W. W. Lee, A. Benitez, L. Goodman and B. R. Baker, J. Amer. Chem. Soc., 1960,82, 2648 149. C. P. J. Gluademans and H. G. Fletcher, J. Org. C h e m , 1964.29, 3286 150. P. Changand B. Lythgoe,J. Chem. SOC.,1950,1992 151. B. R. Baker and K. Hewson, J. Org. Chem., 1957,22,966 152. J. J. Brink and G. A. LePage, Cancer Res., 1964.24.1042 153. D.B. Ellis and G. A. LePage, Cancer Res., 1966,26A,893 154. J. J. Brink and G. A. LePage, Cancer Res., 1964,24,312 155. J. L. York and G. A. LePage, Can. J. Biochem., 1966.44, 19 156. D. B. EUis and G. A. LePage, Can. J. Biochem., 1965,43,617 157. D. B. Ellis and G. A. LePage,Mol. Pharmacol., 1965, 1.23 1 158. J. A. Johnson and H. J. Thomas, J. Amer. Chem. Soc., 1956,78,3863 159. A. Hampton, J. J. Biesele, A. E. Moore and G. B. Br0wn.J. Amer. Chem. SOC.,1956 78,5695 160. J . A. Montgomery, T. P. Johnston, A. Gallagher, C. R. Stringfellow and F. M. Schabe J. Med.Pharm. Chem., 1961,3,265 161. L. L. Bennett, R. W. Brockman, H. P. Schnebli, S. Chumley, G. J. Dixon, F. M. Schabe1,E. A. Dulmadge, H. E. Skipper, J. A. Montgomery and H. J . Thomas, Nature, 1965,205,1276 162. I. C.Caldwell,J. F. Henderson and A. R. P. Paterson, Can. J. Biochem., 1966,44,229 162a. D.H. W. Ho, J . K. Luce and E. Frei, Biochem. Pharmacol., 1968,17, 1025 163. R. M. Bock, The Enzymes (Eds. P. D. Boyer, H. Lardy and K. Myrback), Vol. 2, Academic Press, New York, 1960, p. 3 164. K. G.Cunningham, S. A. Hutchison, W. Manson and F. S. Spring, J. Chem. SOC., 195 1,2299 165. E. A. Kaczlta, N. R. Trenner, B. H. Arison, R. W. Walker and K. Folkers, Biochem. Biophys. Res. Commun.. 1964,14.456 166. W. W. Lee,A. Benite2.C. D. Anderson, L. Goodman and B. R. Baker, J. Amer. Chem. SOC.,1961,83,1906 167. H. Klenow.Biochim. Biophys Acta, 1963,76,347 168. H. Klenow, Biochim. Biophys. Acta, 1963,76,354 169. H. T.Shigeura and C. N. Gordon, J. Biol. Chem., 1965,240,806 170. B. R. Baker, R. E. Schaub and H. M. Kissman, J. Amer. Chem. Soc., 1955,77,5911 171. N. N. Gerber and H. A. Lechevalier, J. Org. Chem., 1962,27,1731 172. A. J. Guarino and N. M. Kredich, Biochim. Biophys. Acta, 1963.68, 317 173. H. T. Shigeura, G. E. Boxer, M. L. Meloni and S. D. Sampson, Biochemistry, 1966,s. 994 174. J. A. Johnson,H. J: Thomasand H. J. Schaeffer, J. Amer. Chem. Soc., 1958,80,699 175. A. Coddington, Biochim. Biophys. Acta, 1962,59,472 176. E.Walton, F. W. HoHy,G. E. Boxer,R. F. Nutt and S. R. Jenkina, J. Med. Chem., 1965, 8 , 659 177. H.T.Shigeura,S. D. Sampson and M. L. Meloni, Arch. Biochem. Biophys., 1966,115, 462 178. G. B. Brown and V. S. Weliky, J. Biol. Chem., 1953,204,1019 179. M. P. Gordon and G. B, Brown, J. Biol. Chem., 1956,220,927 180. G. R. Barker, J. B. Lloyd, M. D. Montague and N. F. Wood, Biochem. J., 1959,72,9P 181. J . F . Paterson, Can. J. Biochem. Physiol., 1959,37,1011 182. H. T.Shigeura,G. E. Boxer, S. D. Sampmn and M. L. Meloni, Arch. Biochem. Biophys 1965,111,713 183. J. Davoll and B. A. Lowy, J. Amer. Chem. Soc., 1951,73,1650 184. T.Naito, K. Ueno and F. Ishikawa, Chem. Pharm. Bull. (Tokyo), 1964, 12.951 185. M. Tatibana and H. Yoshikawa, Biochim. Biophys, Acta, 1962,57,613
'16 186. 187. 188. 189.
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES H. J. Schaeffer and H. J. Thomaa, J. Amer. Chem. SOC.,1958,80,3738 K. Anzai, G. Nakamura and S . Suzki, J. Antibiot. (Tokyo), Ser. A , 1957, 10,201 S. Suzuki and S . Marumo, J. Anribiot. (Tokyo), Ser. A , 1960,13,360 Y. Mizuno, M. Ikehara, K. A. Watanabe, S. Suzaki and T. Itoh, J. Org. Chem., 1963,
28,3329 190. G. Acs, E. Reich and M. Mori,Proc. Nut. Acad. Sci. U.S., 1964,52,493 191. H.Nishimura,K. Katagiri,K.Sato,M.Mayamaand N. Shimaoka, J. Anribiot. (Tokyo), Ser. A , 1956,9,60;K. Ohkuma, J. Antibiot. (Tokyo), 1961, 14,343 192. G. Acs and E. Reich, Antibiotics (Eds. D. Gottlieb and P. D. Shaw), Vol. 1: SpringerVerlag New York, Inc., New York, 1967,p. 494 193. R. J. Suhadolnik, T. Uematsu and H. Uematsu, Biochim. Biophys A c f a , 1967,149, 41 194. H. G. Mandel, P. E. Car10 and P. K. Smith, J. Biol. C h e m , 1954,206,181 195. R. E. F. Matthews and J. D. Smith, Nuture, 1956,177,271 196. H.G. Mandel and R. Markham, Biochem. J., 1958,69,297 197. E.C. Moore and G. A. LePage, Cancer Res., 1958, 18,1075 198. G. A. LePage, Cancer Res., 1960,20,403 199. R. H. Iwamoto, E. M.Acton and L. GoodmanJ. Med. Chem., 1963,6,684 200. S . Bieber, L. S. Dietrich, G. B. Elion, G. H. Hitchings and D. S . Martin, Cancer R e s , 1961,21,228 201. J. P. Scannell and G. H. Hitchings, h o c . SOC.Exp. Biol. Med., 1966, 122,627 202. A. Bloch. R. J. Leonard and C. A. Nichol, Biochim. Biophys A c f a , 1967,'138, 10 202a. K. V. Rao, J. Med. Chem., 1968,11,939 202b. R. J. Suhadolnik, S. I. Finkeland B. M.Chassy, J. Biol. Chem., 1968,243,3532 202c. B. M. Chasay and R. J. Suhadolnik,J. Biol. Chem., 1968,243,3538 203. C. N. Remy, J. Biol. Chem., 1959,234,1485 204. C. N. Remy. J. Biol. Chem.. 1963,238,1078 205. E. J. Sarcione and L. Stutzman, Cancer Res., 1960,20,387 206. P. W. Allan. H. P. Schnebli and L. L. Bennett, Biochim. Biophys. Acfu, 114, 641 207. P. Mazel, J. F. Henderson and J. Axelrod, J. Pharmacol. Exp. Ther., 1964, 143,1 208. J. F. Henderson and P. Mazel, Biochern. Pharmacol., 1964,13,207 209. J.N.Porter,R. L. Hewitt, C. W. Hesseltine, G. C. Krupka, J. A. Lowery, W. S. Wallace, N. Bohonor and J. H. Williams, Anfibiot. Chemother., 1952,2,409 210. B. R. Bake1,R.E. Schaub, J. P. Joseph and J. H. Williams,J. Amer. Chem. Soc., 1955, 77,12 211. B. R. Baker, J. P. Joseph and J. H. Williams,/. Amer. Chem. SOC.,1955,77,1 212. P. Mazel, A. Kerza-Kwiatecki and J. Simanis, Biochim. Biophys. Actu, 1966, 114,72 213. H. T. Nagasawa, K. F. Swingle and C. S . Alexander, Biochem. Pharmacol., 1967, 16 221 1 214. P. Mazel and J. F. Henderson, Biochem. Pharmacol., 1965,14,92 215. J. F. Henderson and P. Mazel, Biochem. Phurmacol., 1964,13,1471 216. H. T. Shigeura and S . D. Sampmn, Biochim. Biophys Actu, 1967,138,26 217. A. E. Farnham and D. T. Dubin, Biochim. Biophys. Act@,1967,138,35 218. G . P. Wheeler and B. J. Bowdon,J. Biol. C h e m , 1966,241,1114 219. M. R. Atkinaon, G. Eckermann and J. Stephenson, Biochim. Biophys. Acra, 1965, 108, 320 220. S. Frederikaen, Biochim. Biophys. Actu, 1963, 76,366 221. G. B. Brown, G. Levin, S. Murphy, A. Sele, H. C. Reilly, G. S. Tarnowski, F.A. Schmid, M. N. Teller and C. C. Stock, J. Med. C h e m , 1965,8,190 222. J. F. Paterson, Can. J. Biochem., 1965,43,257 223. T. A. Krenitsky, G. B. Elion, R. A. Strelitz and G. H. Hitchings, J. Biol. Chem.. 1967, 242,2675 224. M. Friedkin,Biochim. Biophys. Acta, 1955, 18,447
JOHN A. MONTGOMERY
117
225. A. W. Meikle, A. M. Gotto and G.Touster, Biochim. Biophys. Acra, 1967, 138,445 226. J. F. P a t e r m and A. Sutherland, Can. J. Biochem., 1964.42, 1415 226a. T. A. Krenitsky, G. B. Elion, A. M. Henderson and G . H. Hitchhgs, J. Biol. Chem., 1968,243,2876 227. G . A. LePage and I. G. Junga, Cancer R e x , 1965,25,46 228. A. Bloch and C. A. Nichol, Antimicrob. Agents Chemother., 1965,530 229. F. Rottman and A. G. Guarino, Biochim. Biophys. Acta, 1964,80,632 230. J. A . Montgomery and K. Hewson, J. Med. Chem., 1968,11,48 231. J. Davoll and K. A. Kenidge, J. Chem. SOC.,1961,2589 232. J. A.Montgomery,S. J. Clayton and W. E. Fitzgibbon, J. Heterocycl. Chem., 1964, 1, 215 233. J. A. Montgomery and K. Hewson, unpublished 234. J. A. Montgomery and K. Hewson, J. Heterocycl. Chem., 1964, 1,213 235. J. F. Gerster, J. W. Jones and R. K. Robins, J. Org. Chem., 1963,28,945 236. B. R. Baker, K. Hewson, H. J. Thomas and J. A. Johnson, J. Org. Chem., 1957,22, 954 237. H. P. Baer and G . I. Drummond, Biochem. Biophys. Res. Commun.. 1966,24,584 237a. S . Minato, J. Biochem., 1968,64,815 238. J. G . Cory and R. J. Suhadolnik, Biochemistry, 1965,4,1733 239. J. G . Cory and R. J. Suhadolnik, Biochemistry, 1965,4, 1729 240. S . FrederikseqArch. Biochem. Biophys., 1966, 113, 383 241. H. P. Baer, G. I. Drummond and E. L. Duncan, Mol. Pharmacol., 1966,2,67 242. 0 .P. Chilson and J. R. Fisher, Arch. Biochem. Biophys., 1963, 102,77 243. D. A.Clarke, J. Davoll, F. S . Phillips and G. B. Brown, J. Pharmacol. Exp. Ther., 1952. 106,291 244. M. Hori, E. Ito, T. Takita, Y. Koyama, J. Takeuchi and H. Umezawa, J. Antibiot. (Tokyo), Ser. A 1964. 17,96 245. G. Koyama, K.Maeda, H. Umezawa and Y.Iitaka, Tetrahedron Lett., 1966, SY7 246. R. K. Robins, L. B. Townsend, F. Cassidy, J. F. Gerster, A. F. Lewis and R. L. Miller, J. Heterocycl. Chem., 1966. 3. 110 241. S. Frederiksen, Biochim. Biophys. Acta, 1964,87,514 248. Y. Fukagawa, T. Sawa, T. Takeuchi and H. Umezawa, J. Antibiot. (Tokyo), Ser. A . , 1965.18.191 249. T. Sawa, Y. Fukagawa, S. Homma, T. Takeuchi and H. Umezawa, J. Antibiot. (Tokyo) Ser. A , 1967,20,221 250. J. L. York and G. A. LePage, Can. J. Biochem., 1966,44, 331 251. E. J. Reist, D. E. Gueffroy and L. Goodman, J. Amer. Chem. SOC.,1964,86,5658 252. Y. F. Shealy and J. D. Clayton, J. Amer. Chem. SOC.,1966,88, 3885 253. L. L. Bennett, P. W. Allan and D. L. Hill, Mol. Pharmacol., 1968,4,208 254. N. Dickie, L. Norton, R. F. Derr, C. S. Alexander and H. T. Nagasawa, Proc. SOC.Exp. Biol. Med., 1966, 123,421 255. J. J. Brink and G . A. LePage, Can. J. Biochem., 1965,43,1 256. H. J. Schaeffer and R. Vince, J. Med. Chem., 1967, 10,689 257. A. H. Roush and E. R. Norris, Arch. Biochem. Biophys., 1950,29,124 258. J. Kream and E. Chargaff, J. Amer. Chem. Soc., 1952,74,4274 259. P. E. Car10 and H. G. Mandel, Cancer Res., 1954,14,459 260. R. W . Brockman, Cancer R e x , 1960.20, 643 261. B. R. Baker and D. V. Santi, J. Med. Chem., 1967,10, 62 262. M. Dixon and R. Lemberg, Biochem. J., 1934, 28, 2065; F. Bergmann, H. Kwietny, G. Levin and D. J. Brown,-J. Amer. Chem. SOC.,1960,82,598 263. D. E. Duggan and E. Titus, J. Biol. Chem., 1959,234,2100 264. D. E. Duggan and E. Titus, J. Pharmacol. Exp. Ther., 1960,130, 375 265. H. Lettre, N. K. Kapoor and D. Werner, Biochem. Pharmacol., 1967, 16, 1747 265a. H. Lettre and D. Werner,Biochem.Pharmacol., 1968, 17, 1951
118 266. 267. 267a. 268. 269. 270. 271. 272. 273. 274. 275. 276. 217. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 297a. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 308a.
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES P. Feigelson, J. D. Davidson and R. K. Robins, J. Biol. Chem., 1957,226,993 P. Feigelson and J. D. Davidson, Cancer R e x , 1958,18,226 T . Spector and D. G. Johns, Biochem. Biophys. Res. Commun., 1968,32,1039 G. B. Elion, Fed. Proc., 1967,26,898 T. L. Loo, C. Lim and D. G. Johns, Biochim. Biophys. Acta, 1967,134,467 G. B. Elion, S. Callahan, S. Bieber, G. H. Hitchings and R. W. Rundles, Cancer Chemother. Rept., 1961, 14, 93 G. B. Elion, S. Bieber and G. H. Hitchings, Cancer Chemothcr. Rept., 1960,8, 36 T. P. Johnston, L. B. Holum and J. A. Montgomery, J. Amer. Chem. SOC., 1958, 80, 6265 J. A. Montgomery and C. Temple, J. Amer. Chem. Soc., 1957,79,5238 J. A. Montgomery and C. Temple,J. Amer. Chem SOC.,1958,80,409 C. W. Noell and R. K. Robins, J. Med. Pharm. Chem., 1962, 5 , 5 5 8 H. J. Hansen, W. G. Giles and S. B. Nadler, Cancer Res., 1962,22,761 H. J. Hansen,W.G.Gilesand S. B.Nadler,Proc. SOC.Exp. Biol. Med., 1963,113,163 H. G. Khorana, J . F. Fernandes and A. Kornberg, J. Biol. Chem., 1958,230,941 D. E. Atkinson and L. Fall,J. Biol. Chem., 1967,242,3241 F. Rottman and A. J. Guarino, Biochim Biophys. Acta, 1964,80,640 H. Klenow and K. Overgaard-Hansen, Biochim. Biophys. Acta, 1964,80,500 K. Overgaard-Hansen, Biochim. Biophys, Acta, 1964,80.504 J . F. Henderson, A. R. P. Paterson, I. C. Caldwell and M. Hori, Cancer Res., 1967,27, 7 15 H. Yuntsen, K. Ohkuma, Y. Ishii and H. Yonehara, J. Antibiot. (Tokyo), Ser. A , 1956.9. 195 H. Hoeksema and G. Slomp, Tetrahedron Lett., 1964, 1787 A. Bloch and C. A. Nichol, Biochem. Biophys. Res. Commun., 1964, 16, 400 C. T. Carkey, D. M. Ashton and J. B. Wyngaarden, J. Biol. Chem., 1964,239,2570; D. P. Nierlich and B. Magasanik, J. Biol. Chem., 1965,240,358 S . C. Hartman and J. M. Buchanan, J. Biol. Chem., 1958,233,45 1 D. L. Hill and L. L. Bennett, Biochemistry, 1969.8.122 R. J. McCollister, W. R. Gilbert, D. M. Ashton and I . B. Wyngaarden, J. Biol. C h e m , 1964,239,1560 J. P. Henderson and M.K. Y. Khoo, J. Biol. Chem., 1965,240,3104 L. L. Bennett, L. Simpaon, J. Golden and T . L. Barker, Cancer R e s , 1963,23, 1574 M. T. Hakala and C. A. Nichol, Biochim. Biophys. Acta, 1964,80,665 R. W. Brockman and S. Chumley, Biochim. Biophys. Acta, 1965,95,365 E. A. Dulmadge, G, J. Dixon, S. Chumley and R. W. Brockman, Proc. Amer. Asroc. Cancer Res., 1965,6,16 P. W. Allan and L. L. Bennett,Proc. Amer. Assoc. Cancer Res., 1968,9, 2 I.. L. Bennett and D. Smithers,Biochem. Pharmacol., 1964,13,1331 J. Henderson, Cancer Chemother. Rept., 1968, 1, 375 G. A. LePage and M. Jones, Cancer Res., 1961,21,642 A. C. Sartorelli and G. A. LePage, Cancer Res., 1958,18,1329 J . F. Henderson, Biochem. Pharmacol., 1963, 12,551 J. Davoll, J. Chem. SOC.,1958, 1593 F. Rottman and A. J. Guarino, Biochim. Biophys. Acta, 1964,89,465 I. C.Caldwell,J. F. Henderson and A. R. P. Paterson, Can. J. Biochem., 1967,45,735 I. Lieberman and P. Ove, J. Biol. Chem., 1960,235,1765 W. N. Kelley, F. N. Rosenbldom, J. F. Henderson and J. E. Seegmiller, Proc. Nut. Acad. Sci. U.S., 1967, $7, 1735 J. E. Seegmiller, F. M. Rosenbloom and W. N. Kelley, Science, 1967, 155, 1682 M. R. Atkinson and A. W. Murray, Biochem. J., 1965,94,71 A. J. Tomisek, A. P. V. Hoskins and M. R. Reid, Cancer Res., 1965,25, 1925 J. F. Henderson and R. E. A. Gadd, Cancer Chemother. Rept., 1968, 1, 363
JOHN A. MONTGOMERY
309. 310. 311. 312.
119
J. D. Davidson, Cancer Res., 1960,20,225
J. Salser, D. J. Hutchison and M. E. Balis,J. Biol. Chem., 1960,235,429 A. Hampton, Fed. Proc., 1962,21,370 M. E. Balis, P. Pecora and J. S. Salser, Exp. Cell. Res., Suppl, 1963,9,472;J. S. Salscr and M. E. Balis, Cancer Res, 1965,25,539 313. H. T . Baker and L. L. Bennett, Biochim. Biophys. Acta. 1964,80,497 314. H. T.Shigeura and C. N. Gordon,J. Biol. Chem., 1962,237,1932 315. H. T . Shigeura and C. N. Gordon,J. Biol. Chem., 1962,237,1937 316. A. Hampton, J. Biol C h e m , 1963,238,3068 317. A. Hampton and A. Nomura, Biochemistry, 1967,6,679 317a. L. W . Brox and A. Hamuton. . ,Biochemistrv. 1968.7.2589 318. L. W.Brox and A. Hampton, Biochemistw: 1968;7; 398 319. A. C. Sartorelli and B. A. Booth, Biochim. Biophys. Acta, 1962,55,214 320. S . Udaka and H. S . Moyed, J. Biol. Chem., 1963,238,2797 321. H. Yunsen, J. Antibiot. (Tokyo), Ser. A., 1958, 11,244 322. T.E. Eble, H. Hoeksema, G, A. Boyack and G. M. Savage, Antibiot. Annu., 1959,9,
419 W . Schroeder and H. Hoeksema,J. Amer. Chem. SOC.,1959,81,1767 L. J. Hanka, J. Bacteriol., 1960,80,30 L. Slechta, Biochem. Pharmacol., 1960,5,96 L. Slechta, Biochem. Biophys. Res. Commun., 1960,3,596 W . E.Magee and F. S. Eberts, Cancer Res., 1961,21,611 T.T.Fukuvama and H. S. Moyed.Biochemistry, 1964,3,1488 A. J. Guanno, Antibiotics (Fds. Gottlieb and Shaw), Vol. 1: Springer-Verhg, New York, Inc.. New York. 1967.p. 464 329a. R. P.Miech, R. York and R. E. Parks,Mol. P h a m c o l . . 1969,5,30 330. E. C. Moore and S. S. Cohen, J. Biol. Chem.. 1967,242.2116 331. E. J. Reist,A. Benitez, L. Goodman, B. R. Baker and W.W . Lee,J. Org. C h e m , 1962,2
323. 324. 325. 326. 327. 328 329.
3274 332. A.P. Kimball, B. Bowman,P, S. Bush, J. Herriot and G . A. LePage, Cancer R e s , 1966, 26,1337 333. A. P. Kimball, G. A. LePage and P. S . Allinson, Cancer Res., 1967,27A,106 334. A. P. Kimball and G. A. LePage, Cancer Res., 1962,22,1301;Cancer R e s , 1963,23, 1792 335. J. J. Furth and S. S . Cohen. Cnncer Res.. 1967,27,1528 335a. J. J. Furth and S . S . Cohen, Cnncer Res., 1968,28,2061 336. R. E. F.Matthews, Pharmacol. Rev., 1958,10,359 337. J. H. Mitchell, H. E. Skipper and L. L. Bennett, Cancer Res., 1950,10,647 338. H. G. Mandel, Fed. R o c . , 1967,26,905 339. G . A. LePage and M.Jones, Cancer Res., 1961,21,1590 340. G. A. LePage, Cancer Res., 1963,23,1202 341. H. G. Mandel, R. G. Latimer and M. Riis, Biochem. Pha?macol., 1965,14,661 342. L. L. Bennett, personal communication 342a. S. C. Uretsky, G. Acs, E. Reich, M. Mori and L. Altwerger, J. Biol Chem., 1968,243, 306 342b. R. J. Suhadolnik, T. Uematsu and H. Uematsu, J. Biol. Chem, 1968,243,2761 343 H. T. Shigeura and G. E. Boxer, Biochem. Biophys. Res. Commun., 1964,17,758 344. J.G.Cory, R. J.Suhadolnik, B. Resnickand M.A. Rich,Biochim Biophys. Acta, 1965, 103,646 344a. M. Ikehara, K. Murao, F. Harada and S. Nishimura, Biochim. Biophys Acta, 1968, 155, 82 345. S. S. Cohen, Prog. Nucleic Acid Res., 1966, 5 , 1 346. D. Gruenberger, L. Meissner, A. Holy and F. Sorm, Bwchim. Biophys. Acta, 1966, 119,432
120
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES
347. D.Gruenberger,C. O’Nealand A. Nirenberg, Biochim. Biophys. Acra, 1966, 119,581 347a. D. Grunberger, A. Holy and F. Sorm, Biochim. Biophys. Acta, 1968, 161,1A7 348. D. Nathans, Antibiorics (Eds. D. Gottlieb and P. D. Shaw), Vol. 1 : Springer-Verlag New York, Inc., New York, 1967, p. 259 349. N. M. Kredich and A. J . Guarino, J.-Biol. Chem., 1961, 236, 3300 350. A. J . Guarino, M. L. Ibershof and R . Swain, Biochim. Biophys, Acta, 1963, 72, 62 351. A. J. Guarino and N. M. Kredich, Fed. Proc., 1964, 23, 371 352. J. J . Fox, K. A. Watanabe and A. Bloch, Progr. Nucleic Acid Res., 1 9 6 6 , 5 , 25 1 353. G. 0. Morton, J . E. Lancaster, G. E. Van Lear, W. Fulmor and W. E. Meyer,J. Amer. Chem. SOC.,1%9,91,1535 354. J. R. Florini, Antibiotics (Eds. D. Gottlieb and P. D. Shaw), Vol. 1 : Springer-Verlag New York, Inc., New York, 1967, p. 427 3 5 5 . M. R. Atkinson, J . F.Jackmn,and R. K. Morton,Nafure, 1961, 192,946 356. M. R. Atkinson, J. F. Jackson, R. K. Morton and A. W. Murray, Nature, 1962, 196, 35 357. S. Garattini and R. Paoletti, G. Ital. Chemiother., 1956, 3 , 5 5 358. H. E. Skipper and L. L. Bennett,Annu. Rev. Biochem., 1958.27, 137 359. F . M. Schabel, J. A. Montgomery, H. E. Skipper, W. R. Laster and J. R. Thomson, Cancer Res., 1961, 21, 690 365. F. S. Philips, S. S. Sternberg, L. Hamilton and D. A. Clarke, Ann. N . Y. Acad. Sci., 1954,60,283 361. R. K. Shaw, R . N. Shulman, J . D. Davidson, D. P. Rall and E. Frei, Cancer, 1960, 13, 482 362. G. C. Armstead, J. H. Burchenal, D. A. Karnofsky and C. M. Southam, Cancer, 1949, 2,1087 7/13. 1 . H. Burchenal, Current RexCancer Chemother., 1956,4, 3 364. T. L. LOO,J. K. Luce,M. P. Sullivan and E.Frei,Clin. Pharmacol. Therap., 1968,9,180 365. E. B. Fiegelson, J . W. Drake and L. Recant, J. Lab. Clin. Med., 1 9 5 7 , 5 0 , 4 3 7 ;u. c. Dubach,Progr. DrugRes.. 1 9 6 4 . 7 . 341 365a. R. F. Derr, D. K. Loechler, C. S. Alexander and H. T . Nagasawa, J. Lab. Clin. Med., 1968.72, 363 366. D. A..Karnofsky, Cancer Res. Suppl., 1 9 5 5 , 3 , 8 3 367. S. Bieber and G. H. Hitchings, Cancer Res., 1959, 19, 112 368. J . B. Thiersch,Ann. N . Y. Acad. Sci., 1954,60, 220 369. J. B. Thiersch, Proc. Soc. Exp. Biol. Med., 1 9 5 7 , 9 4 , 4 0 370. J . B. Thiersch,J. Reprod. Fert., 1962.4, 291 371. J. B. Thiersch, J. Reprod. Fert., 1962.4, 297 372. R. L. Thompson and C. F. Lavender, Proc. SOC.Exp. Biol. Med., 1 9 5 3 , 8 4 , 4 8 3 372a. C. Kury, S. ChaubL: and M. L. Murphy, Arch. Pathol., 1 9 6 8 , 8 6 , 395 373. G. L . Woodside,Anat. Rec., 1952, 113,551 374. R. Schwartz, J . Stack,and W.Dameshek, Proc. Soc. Exp. Biol. Med., 1958, 99, 164 375. G. H. Hitchings and G. B. Elion,Pharmacol. Rev., 1963, 15, 365 375a. G. H. Hitchings and G. B. Elion, Accounts Chem. R e x , 1969, 2 , 2 0 2 376. Various authors, Fed. Proc., 1967, 26, 877 377. A. P. Kimball, S. J. Herriott andG. A. LePage. Proc. Soc. Exp. Biol. Med., 1966, 121, 929, A. P. Kimball, S. J . Herriott and P. S. Allinson,Proc. Soc. Exp. Biol. Med., 1967 126, 181 378. G. V. R . Born and M. J. Cross, Nuture, 1963, 197,974 319. D. Regoli and V. Clark, Nature, 1963, 200,546 380. S . Clayton, G. V. R. Born and M. J. Cross, Nature, 1963,200, 138 381. G. V. R. Born, Nature, 1964,202, 95 382. G . V. R . Born, R. J. Haslam, M. Goldman and R. D. Lowe, Nature, 1 9 6 5 , 2 0 5 , 6 7 8 383. G. V. R . Born, A. J . Honour and J . R. A. Mitchell, Nature, 1964, 202,761 384. R. L. Thampson, M. L. Price, S. A. Minton, G. B. Elion and G. H. Hitchings.J. Immunol., 1 9 5 0 , 6 5 , 5 2 9
JOHN A. MONTGOMERY
121
385. R. W. Rundles, J . B. Wyngaarden, G. H. Hitchings, G. B. Elion and H. R. Silberman, Trans. Assoc. Amer. Physicians, 1963,16,126 386. J. R. Klinenberg, S. E. Goldfinger and J. E. Seegmiller,Ann. InternalMed., 1965,62, 639 387. D. L. Hill and P.Chambers,J. Cell. Physiol., 1967,69,321 388. G. W.Kidder and V. C. Dewey,J. Biol. Chem., 1949,179,181 389. G. W. Kidder and V. C. Dewey,Arch. Biochem. Biophys., 1957,66,486 390. V. C. Dewey, G. W. Kidder and D. G. Markees, Proc. SOC. Exp. Biol. Med., 1959,102, 306 391. J . F. Fernandes and 0. Castellani, Exp. Parasitol., 1958,7,224 392. M. Nakamura and M. B. James, Exp. Parasitol., 1953,2,19 393. L.H. Silva, S. Yoneda and J. F. Fernandes, Exp. Parasitol., 1959,8,486 394. G. E. S. Moraes, J . L. Faria and J. F. Fernandes, Rev. Inst. Med.Trop. SZoPaulo, 1960, 2,147 395. J. A . Meira, V. A. Neto, J. T. Tartari and R. Sonntag, Rev. BrasilMed., 1954,11,829 396. F. Hawking,Experimental Chemotherapy (Ed. R. J. Schnitzer and F. Hawking), Vol. 1: Academic Press, New York, 1963,p. 129 397. R. L. Hewitt. W. S. Wallace, A. R. Gumble, E. R. Gill and J. H. Williams, Amer. Trou. Med. Hyg., 1953,2,254 398. E. J. Tobie, Amer. J. Trop. Med. Hyg., 1954,3,852 399. E. J . Tobie and B. Highman, Amer. J. Trop. Med. Hyg., 1956,5,504 400. J. J . Jaffe. Biochem. Pharmacol., 1961,8,216 401. R. L. Hewitt. A. R. Gumble. L. H. Taylor and W. S. Wallace, Antibiotics Annual, 1956-195 7 (Eds. H. Welch and F. Marti-Ibanez) Medical Encyclopedia, New York, 1957, p. 722 402. E. J . Tobie, J. Parasitol., 1957,43,291 403. D. E. Eyles and N. Coleman, Antibiot.Chemother., 1954,4,649 183 404. M. Nakamura and S. Jonsson, Arch. Biochem. Biophys.1957,66, 405. G. H. Hitchings, Ciba Found. Symp. Chem. Biol. Purines, 1957,177 406. J . J. Jaffe, Trans. N. Y. Acad. Sci., 1967,29,1057 407. C. Friend, Proc. SOC.Exp. Biol. Med., 1951,78,150 408. H. R. Morgan, J. Exp. Med., 1952,95,277 409. G. C. Brown,J. Imrnunol., 1952,69,441 410. J . Cogniaux-Le Clerc, Brit. J. Exp. Puthol., 1962,43,587 Exp. Biol. Med., 1964,116, 228 411. J. W. St. Geme,Proc. SOC. 411a. F. M . Schabel, Chemotherapy, 1968,13,321 412. M.P.de Garilhe and J. de Rudder, C. R. Acad. Sci., Paris, 1964,259,2725 413. J. de Rudder and M . P. de Garilhe,Anfimicrob. Agents Chemo., 1965,578 414. R. W. Sidwell, G. Arnett and G. J . Dixon, Abs. 7th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 1967,p. 28 415. T. Sreevalsan and R. Z. Lockart, Virology, 1964,24,91 416. V. M. Zhdanov and F. I. Ershov,Antibiotiki, 1965,10,255 417. V.Groupe, F. J. Rauscher and W. R. Bryan, Science; 1956,1073 418. V. Groupe, F. J . Rauscher and W. R. Bryan, Proc. SOC.Exp. Biol. Med., 1956,91,113 419. E. Wecker. Nature, 1963.197.1277 420. G. A. Galegov and N. V. Kaverin, Experientia, 1967.23,83 421. A. E..Farnham, Virology, 1965,27,73 422. H. Kudo and A . F. Graham, Biochem. Biophys. Res. Commun., 1966,24,150 423. K . S. Pilcher and J. N . Hobbs, J. Pharm. Sci., 1966,55,119 424. A. A . Newton, Biochem. J., 1965,94,9P 425. H. D.Mayor,J. Exp. Med., 1964,119,433 426. J . M. Bowen, R. G. Hughes and L. Dmochowski, Texas Rep. Biol. Med., 1966,24,143 427. A . E. Moore and C. Friend, Proc. SOC.Exp. Biol. Med., 1951,78,153 428. H. Neubauer, D. Falke and C. Simonis,Arch. Ophthalmol., 1965,168,256 429. R. w. Sidwell, G . J . Dixon, S. M. Sellers and F. M. Schabel, Appl. Microbiol., 1968, 16,370
122 430. 431. 432. 433. 434. 435. 436. 437.
438. 439. 439a. 440. 441. 442. 443. 444. 445. 446. 447. 448. 448a. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465.
THE BIOCHEMICAL BASIS FOR THE DRUG ACTIONS OF PURINES K. Sugiura, Gann, 1 9 5 9 , 5 0 , 2 5 1 K. Sugiura, Cancer Res. Suppl., 1 9 6 2 , 2 2 , 9 3 R. W. Sidwell, G . J. Dixon, S. M. Sellers and F. M. Schabel, Cancer Chemother. Rep., 1966,50,299 E. A. Mirand, N. Back, T. C. Prentice, J. L. Ambrus and J. T. Grace, Proc. SOC.Exp. Biol. Med., 1961, 108, 360 M. A. Chirigos. Ann. N. Y.Acad. Sci., 1965. 130,56 M. A. Chirigos, J. B. Moloney, S. R. Humphreys, N. Mantel and A. Goldin, Cancer Res. 1961,21,803 J. P. Glynn, A. R. Bianco and A. Goldin, Cancer Rex, 1964,24, 1303 A. Goldin, J. P. Glynn, A. R. Bianco, J. M. Venditti and J. B. Moloney, Proc. 3rd Inter. Congr. Chemotherapy, Stuttgart, 1963, p. 812; A. Goldin, J. P. Glynn, J. B. Moloney, S. R. Humphreys and M. A. Chirigos, Acta Unio Inter. Contra Cancrum, 1964,20, 157 C. A. Nichol, Cancer Res., 1965,25, 1532 A. Giner-Sorolla, L. Medrek and A. Bendich, J. Med. Chem., 1966, 9, 143; J. H. Burchenal, M. Dollinger, J. Butterbaugh, D. Stoll and A. Giner-Sorolla, Biochem Pharmacol., 1 9 6 7 , 1 6 , 4 2 3 I. H. Krakoff and M. R. Dollinger,Proc. Amer. Assoc. Cancer Res., 1969, 1 0 , 4 7 A. Giner-Sorolla and A. Bendich, J. Amer. Chem. SOC.,1958,80, 3932 J. P. Howitz and V. K. Vaitkevicius, Experientia, 1961, 1 7 , 5 5 2 F. R. White. Cancer Chemothcr. Rept., 1963.30,57 J. A. Montgomery, C. Temple, T. P. Johnston F. M. Schabel, unpublished and observations J. A. Stock, Experimental Chemotherapy Eds. R. J. Schnitzer and F. Hawking), Vol. 4: Academic Press. New York. 1966, p. 80 G. Zubrod, Arch. Int. Med., 1960, 106.663 E. Frei and E. J. Freireich, Adv. Chemother., 1965,2, 269 J. K. Luce, G. P. Bodey and E. Frei, HospitalPractice, 1967,42 G. P. Bodey, H. S. Brodovsky, A. A. Isassi, L. Samuels and E. J. Freireich, Cancer Chemother. Rept., 1968.52, 315 K. Sugiura, Cancer Chemother. Rept., 1968, 1, 383 J. H. Burchenal, Cancer Res., 1963,23, 1186 H. E. Skipper, F. M. Schabel and W. S. Wilcox, Cancer Chemother. Rept., 1964, 35.1 R. W. Brockman, M. C. Sparks and M. S. Simpson, Biochim. Biophys. Acta, 1957; 26, 67 1 R. W. Brockman, M. C. Sparks, M. S. Simpson and H. E. Skipper, Biochem. Pharmacol., 1959,2,77 R. W. Brockman,G. G. Kelley, P. Stutts and V. Copeman, Nature, 1961,191,469 P. Stutts and R. W. Brockman,Biochem. Pharmacob, 1963, 1 2 , 9 7 R. W. Brockman, CancerRes., 1963,23, 1191 R. W. Brockman,Clin. Pharmacol. Ther., 1961, 2,237 G. P. Kalle and J. S. Gots, Science, 1963, 142,680 J. C. Adye and J. S. Gots,Biochim. Biophys. Acta, 1966, 118, 344 A. R. Paterson, Can. J. Biochem. Physiol., 1960,38.1117 A. R. Paterson,Can. J. Bwchem. Physiol., 1962.40, 195 A. C. Sartorelli, G. A. LePage and E. C. Moore, Cancer Res., 1958, 18, 1232; D. B. Ellis and G. A. LePage, Cancer Res., 1963.23.436 A. L. Bieber and A. C. Sartorelli, Cancer Res., 1964,24, 1210 L. L. Bennett, P. W. Allan, D. Smithers and M. H. Vai1,Biochem. Pharmacol., 1969, 18,725 G . G. Kelley, M. H. Vail, D. J. Adamson and E. A. Palmer, Amer. J. Hyg., 1961, 73, 23 1 G. G. Kelley, G. P. Wheeler and J. A. Montgomery,Cancer Res., 1962,22, 329
JOHN A. MONTGOMERY
123
P. M . Roll, H. Weinfeld, E . Carroll and G . B. Brown, J. Biol. Chem.. 1956,220,439 J . A . Montgomery, F. M . Schabel and H. E. Skipper, Cancer R e x , 1962, 22,504 J . A . Montgomery, H . J . Thomas and H . J . Schaeffer,J. Org. Chem., 1961, 26,1929 H . J . Thomas and J . A . Montgomery, J. Med. Plzarm. Cllem.,1962,5, 24 J . A . Montgomery, G . J . Dixon, E. A . Dulmadge, H . T . Thomas, R . W. Brockman and H. E. Skipper, Nature, 1963, 199, 769 471. F . M . Schabel. W . R . Laster and H . E. Skipper, Cancer Chemother. Rep., 1967,51, 1 1 1 472. M . C. Wang, A . 1. Simpson and A. R. P. Paterson, Cancer Chemofher.Rep.. 1967,51, 101 466. 467. 468. 469. 470.
3 The Chemistryof Guanidines and their Actions at Adrenergic Nerve Endings G. J. DURANT, B.Sc., Ph.D., A.R.I.C. Smith Kline and French Research Institute, Welwyn Garden City, Herts. A . M . ROE, M.A., D. Phil., F.R.I.C. Smith Kline and French Research Institute, Welwyn Garden City, Herts. A. L. GREEN, B.Sc., Ph.D. Department of Biochemistry, University of Strathclyde, Glasgow. INTRODUCTION THE STRUCTURE AND PHYSICAL PROPERTIES O F GUANIDINES SYNTHETIC METHODS Guanidines Aminoguanidines PHARMACOLOGICAL TEST PROCEDURES Effect o n blood pressure Effect o n the sympathetic nervous system STRUCTURE-ACTIVITY RELATIONSHIPS FOR ADRENERGIC NEURONE BLOCKADE Guanethidine and close analogues Aryloxyalkylguanidines and related structures Araky lguanidines Miscellaneous guanidines Structural requirements for adrenergic neurone blockade OTHER PHARMACOLOGICAL EFFECTS ON SYMPATHETIC NERVES BIOCHEMICAL EFFECTS Depletion of noradrenaline Antagonism of noradrenaline depletion Effect of guanidines o n enzymes involved in noradrenaline metabolism Mechanism of guanethidine-induced depletion Relationship between noradrenaline depletion and adrenergic neurone blockade ADDENDUM REFERENCES I24
125 126 130 130 133 135 135 136 139 139 15 1 160 169 171 174 177 177 185 188 193 196 200 203
G. J . DURANT, A . M . ROE, A. L . GREEN.
125
INTRODUCTION
Guanidines have been studied for many years as a possible source of medically useful compounds, but the recent vast increase in the literature on guanidine derivatives (from about 200 references in Chemical Abstracts in 1958 t o over 1000 in 1965) stems principally from the discovery [ I ] of the potent hypotensive properties of guanethidine (oktadin, Azetidin, Dopom, Eutensol, Guanexil, Guethine, Ipoctal, Ipoguanin, Iporal, Ismelin, Izobarin, Normorif, Octadinum, Octatensine, Pressidin, Sanotensin, Su-5864, Visutensil, I).
Around 40 years ago, the short-lived use of synthalin (11) as a hypoglycaemic drug [ 2 ] led t o numerous studies on guanidines as potential insulin substitutes [3] . Synthalin itself was withdrawn when it was reported that it can cause liver damage [4], and the widespread interest in guanidines eventually lapsed until the introduction of guanethidine nearly 30 years later. It is chastening t o note how often during these early investigations on guanidines, marked cardiovascular actions were reported but not pursued. One such report referred t o phenethylguanidine (111) in the following terms ‘the latter compound, in larger doses, exerts a powerful effect on the flow of blood as Ph(CH2 ) 2 .NH.C=NH
I
evidenced by the difficulty of bleeding the animals: [ 5 ] . Synthalin itself caused a fall in blood pressure, and also had curare-like effects [6] which were subsequently rediscovered in the related compound decamethonium. However, since the object of this early work was t o find drugs which lowered blood sugar rather than blood pressure, these observations were apparently not followed up. During the 1930s several aralkylguanidines were shown by Japanese workers to lower blood pressure [7, 81, but the mechanism of this hypotensive action was not understood a t the time, and again it was not followed up. Synthetic guanidine derivatives have been used successfully in the treatment of a variety of diseases, but the major success has undoubtedly been their exploitation as antihypertensive drugs. Guanethidine has still not been displaced,
126
GUANIDINES A N D ADRENERGIC NERVE ENDINGS
although it now has many competitors such as bethanidine (benzanidine, Esbatal,' Eusmanid, B.W. 467C60, IV), guanoxan (Envacar, V), guanoclor (Vatensol, VI) and debrisoquine (Declinax, VII). The comparative clinical value of some of these compounds has been reviewed recently [ 9 ] . All of these drugs appear to lower blood pressure by blockade of sympathetic
Cl
nerves, and the present review is confined to this particular aspect of the pharmacology of guanidines. The structure, physical properties and synthesis of guanidines are summarized first, and then, after an outline of the methods used for testing these drugs, the relationships between structure and adrenergic neurone blockade are discussed. The relevant biochemical effects connected with these pharmacological actions are surveyed, with particular reference to possible mechanisms of action. The review is written primarily for the medicinal chemist, and detailed pharmacology is generally included only where necessary for understanding the structure-activity relationships. An excellent review of the pharmacological actions of adrenergic neurone blocking agents has been given by Boura and Green [ l o ] . The biochemistry of guanethidine itself has been reviewed by Furst [ 1 I ] , with particular emphasis on tissuz distribution and metabolism; consequently these two topics are not discussed i n detail.
THE STRUCTURE A N D PHYSICAL PROPERTIES OF GUANIDINES
A prerequisite t o a full understanding of tlie nature of tlie interactions of guanidines with living tissue is an accurate expression of the molecular and physicochemical behaviour of both interactants. The molecular arrangement, and hence
127
G. J . DURANT, A. M. ROE, A. L. GREEN.
the physicochemical properties, of the biological surfaces with which this review is concerned are still unknown; but the position with respect to the guanidine partner in these interactions is reasonably well understood. Guanidine (VIII) and those substituted guanidines with which we shall be concerned are strong bases [12-191, and form stable salts with relatively weak acids [ 201 .Table 3.1 lists the published pK, values of some simple guanidines. The increased stability of symmetrical guanidinium ions is reflected in the high basic strength of guanidine and in the still higher basicity of N,N:N':trimethylguanidine. In strong acid, both the guanidinium ion and the aminoguanidinium ion can accept a second proton. The second pK, of guanidine has been estimated [ 151 Table 3.1. THE BASlCITY OF SOME SIMPLE GUANIDlNES*
R'
It2
R3
R4
RS
PK,
H H Me H Me H Me Me Me H
H H H Me Me Me Me Me Me H
H H H
H H H H H Me H Me Me H H H H H H H H
13.65 (131 13.6 (141 13.74 [18] 13.4 1141 13.4 1141 13.6 [ 1 4 ] 13.6 [ 141 13.9 [ 141 13.6 1141 13.9 [ 141 13.8 [ 141 10.8 (171 11.0 1381 10.6 [ 3 7 ] 10.5 (381 12.6 (371 10.85 [ 371 11.4 1381 11.5 i 3 8 j * 9.9 [ 4 1 7 ] 9.8 (4181 11.04 (4191 11.97 1211 11.3-11.4 [ 4 2 0 ]
H
H
Me H H H H H
H Me H H Ph H
H H H Me H Me H H H H H H H
H
Guanethidine ( I )
'The references should be consulted f o r the temperature and other conditions under which these measurements were made.
to be -10.9 on the Ho scale. The very large difference between the first and second pK, values of guanidine is thought to be associated with the loss of symmetry which arises when the guanidinium ion accepts another proton [ 151. The second pK, of (benzy1amino)guanidine is -3.2 on the Ho scale [21].
128
GUANIDINES AND ADRENERGIC NERVE ENDINGS
When the pK, of a guanidine is greater than 13, the ratio of guanidinium ion to guanidine is greater than 1 O6 : 1 under physiological conditions [22] ; aminoguanidine will exist as the protonated ion to the extent of at least lo4 :1, relative to the unprotonated species. In view of the foregoing, the ensuing discussion will concentrate on the structure and properties of the mono-protonated species, that is, on guanidinium ions. There is ample crystallographic evidence that the guanidinium ion is planar and symmetrical [23, 241. Both ions in the crystal of methylguanidinium nitrate exhibit almost perfect trigonal symmetry [25] , and the aminoguanidinium ion has also been shown to be planar [26]. The formal similarity between the guanidinium ion, the carbonium ion, and the carbonate anion has long been recognized [27], and many papers have been devoted to defining the precise electronic structure of guanidinium ions [28-361. Infra-red studies [31] and molecular orbital calculations [33,34] have led to the description of the guanidinium ion as a tri-amino carbonium ion with the nelectron charge distribution shown (IX) Most of the positive charge is located in the vicinity of the central carbon atom. The relevance of this description to the pharmacological properties of guanidinium ions will be discussed later. For typographical convenience, guanidines will be formulated in this review in the unprotonated form. Y
H2N.C-H
I
N H2
H\
, tO.086
rH \
NC+O .7L 2 /1.318
H
N
/
4
(VIII)
Some aspects of the structure and properties of amidines, including guanidines, in relation to their biological properties have been discussed by Fastier [36a] . The formation of relatively rigid amidinium carboxylate ion-, pairs, formulated as eight-membered rings stabilized by two hydrogen bonds, is thought to precede the formation of crystalline salts and is suggested [36b, 36c] as the basis for their biologcal activity. An alternative formulation of a guanidinium carboxylate ion-pair has been proposed [36d]. The affinity of amidinium groups for anionic sites, such as carboxylate and phosphate, has been stressed [36a]. The similarity of the guanidinium ion, in which the distance between the carbon and the hydrogen atoms is about 2.1A, to the hydrated sodium ion [Na(OH,),]+, in which the distance between the sodium and the hydrogen atoms is about 2.3A, has been pointed out [33, 36a], and the physiological
129
G. J . DURANT, A. M. ROE, A. L. GREEN.
properties of these ions have been compared [33, 36al. A comparison, which is more relevant to this review and is pursued later, may be made with the trimethylammonium group. Finally, it has been suggested [21] that the activities of certain aryloxyalkylguanidines depend on their ability to adopt an internally hydrogen-bonded conformation such as (LXXVIII) and (LXXIX) (p. 172 ). The strength of the hydrogen bond in these systems is related to the basicity of the oxygen atom, which in turn is markedly affected by the position and nature of the substituents in the aromatic ring. Although not strictly relevant to the present discussion, some other physico-chemical aspects of guanidines are summarized here, since no review of this subject has been published previously. The structures of aromatic guanidines and their conjugate acids, in which the T-electrons of the ring can interact with the delocalized electrons of the guanidine system, have been studied. From the ultra-violet absorption spectra and acid dissociation constants of pchlorophenylguanidine, structure (X) was preferred [ 371 over structure (XI); in contrast, the most probable structures for phenylguanidine and its conjugate acid were considered [ 171 to be (XI) and (XII). A more extensive study of some para-substituted phenylguanidines, which includes an estimate of the
Ar N H - G N H
1
ArN=C-NH2
I
ArNH-C=hH,
I
Hammett p constant (+ 2.30) for the formation of the conjugate acid and the Up constant of the guanidinium substituent (+0'317 to + 0.443), supported the conclusion [ 3 M ] that the base has the structure (X). A different view [ 391 was based on the fact that since p for substituted anilines is + 2-77, dissociationof the phenylguanidinium ion most likely takes place from the nitrogen atom which bears the aromatic ring. This argument, however, neglects the delocalization of charge in the ion. The directing effect of the guanidinium substituent in electrophilic aromatic substitution is a measure of the interaction of this substituent with an aromatic ring. The guanidinium substituent is not such a powerful metadirecting group as those substituents in which the positive Charge is localized on the atom which bears the aromatic ring [ 4 0 ] . The ultra-violet spectra of guanidines have often been determined in connection with the measurements of dissociation constants [ 17, 38, 411, and other studies have been reported [42-441. There have been many reports on the infra-red spectra [31, 35, 42, 45-48], the nuclear magnetic resonance spectra [ 38, 49-5 1 ) (see also p. 134). the Raman spectra [52-541, force constants [ 35, 361, and mass spectra [SS] of substituted guanidines. Guanidine forms salts with such relatively weak acids as nitromethane, phthalimide, phenol and carbonic acid [ 2 0 ] . lnteractions between carboxylate anions of proteins and added guanidinium ion are thought [19, 561 to be weaker than the interactions with ammonium ions; the role of guanidinium-carboxylate interactions in stabilizing natural protein conformations has been discussed [36c]. A few reports of metal complex formation by guanidines 157-601, and aminoguanidines [61] have appeared.
130
CUANIDINES AND ADRENERCIC NERVE ENDINGS
Much attention has been given recently to the chromatographic behaviour of guanidines [ 62-69), and various techniques for the detection and determination of guanidines are described there and elsewhere [ 70-761.
SYNTHETIC METHODS Guanidines
Guanidines have been prepared by a wide variety of methods, of which two are of much greater importance than the others. These two methods, (a) the addition of amines to cyanamides and (b) the displacement of an alkylmercaptan by an amine from an alkylisothiouronium salt, together with close variants, are discussed first, and this discussion is followed by a survey of less frequently used procedures. Since an excellent summary of some of the methods that have been used to obtain guanidines is available [77] , the following discussion concentrates on those aspects of synthetic chemistry that are likely to be of interest to medicinal chemists. Patents are only cited when the experimental methods described supplement those available elsewhere. It is worth stressing at this point that although many statements have been made concerning the relative merits of one method of synthesis compared with another, there is little consistency and much contradiction to be found. Except where a comparative study by the same workers has been carried out, it is unwise to rely on these generalizations as a guide for preparing novel guanidines. It is probable that much of the confusion arises from the use of inappropriate methods of isolation rather than from anomalous reactivities.
Method (a)
RzNH + RZN-CN + R Z N G N H
I
Guanidine itself was obtained by Erlenmeyer [78] in 1868 from the action of ammonia on cyanamide, a method that soon led to the synthesis of phenylguanidine from aniline hydrochloride and cyanamide [79,80]. This method has been used to prepare many arylguanidines, and the use of substituted cyanamides has given NJ”diary1- [81] , N-aryl-N’-alkyl- (or N-aryl-N:N:dialkyl-) [82], and N-aryl-N‘benzoyl-guanidines[83] . Arylguanidines are sometimes advantageously prepared by using the benzoylguanidine as an intermediate [83]. Reaction between an amine salt and cyanamide has been used successfully for the synthesis of many mono- and poly-alkylguanidines [84-95], and also of alkoxyguanidines [96, 971 and aryloxyguanidines [98]. The reaction is usually carried out in boiling water or ethanol for from 1 t o 24 hours. Higher temperatures have been employedusingsealed tubes [99, 1001 or butanolasasolvent [82,101].
G. J. DURANT, A. M. ROE, A. L. GREEN.
131
Very dilute acetic acid [lo21 and ethyl acetate [lo31 have also been used as solvents. The fusion of amine salts with cyanamide or a substituted cyanamide is often more satisfactory than using a solvent [ 107-109, 2281, particularly for sterically hindered guanidines such as t-butylguanidine [228] . The preparation of alkylguanidines by fusing amine salts with dicyandiamide at 180" for three hours has been advocated [104], however it has been shown that, depending on the conditions, a guanidine or a biguanide can result [105, 106). Odo studied the formation of methylguanidine from cyanamide and aqueous mixtures of methylaminc and methylamine hydrochloride in various proportions [ 1101 . He concluded that the reaction occurred by a reversible nucleophilic attack of the free amine on cyanamide, and that an acid was required t o shift the equilibrium in the direction of the guanidine. This method of formation of guanidines is considered especially suitable for arylguanidines [77] . The dihydrochloride of p-aminobenzylamine (XIII) reacted with cyanamide to give a mono-guanidine which was assumed [ 11 11 to be the arylguanidine (XlV) on the grounds that benzvlamine hydrochloride did not react under the same conditions, whereas aniline hydrochloride did. An isomer was obtained [ 1 1 1] when p-aminobenzylamine reacted with S-methylisothiouronium sulphate, and this isomer was formulated as (XV). However, these structural
assignments need verification. It is relevant to note that the free base (XIII) reacted with cyanamide t o give the bis-guanidine [ 11 I ] . Further, guanidines have been obtained by reaction of cyanamide with salts of benzylamine [82] and p-nitrobenzylamine [87, 1011. The product from the latter was reduced [87, 1011 to authentic p-aminobenzylguanidine (XV) dihydrochloride, which decomposed only 3-5" above the reported [ 1 1 1 ] decomposition point of the dihydrochloride of the isomer assigned structure (XiV).
Method (b)
RZNH + RzN.C=NR
I
X
-
R2 N G N R
I
+ HX
NR2
The most frequently used synthesis of guanidines involves the displacement by an amine of a suitable group, X, from the amidine-type compound shown. The preparation of phenylguanidine from ammonia and phenylthiourea was claimed [ 1121 in 1879 but the authenticity of the product has been questioned
132
GUANIDINES A N D ADRENERGIC NERVE ENDINGS
[79]. The generally recognized originator of this synthesis of guanidines is Rathke who showed that ammonia reacts with S-ethyl-N,N'-diphenylisothiourea to form N,N-diphenylguanidine [ 1131 . That this product can be formulated in two ways: PhNH.C(:NPh)NH, or PhNH.C(:NH)NHPh, was clearly recognized at that time. Similarly, guanidine itself was obtained from S-ethylisothiourea and ammonia [ 1141. Although 0-ethylisourea was reported not t o react with ammonia or with aniline [ 7 9 ] , the synthetic potential of this method became apparent when various polymethylguanidines were prepared from S-alkylisothiouronium hydriodides [ 14, 115, 1161 or, more conveniently, from S-methylisothiouronium sulphate [ 14, 1171. Aniline was reported not t o react with the latter salt [ 1171, but a later paper [ 1181 described its conversion into phenylguanidine. Many different alkvl- and awl-guanidines have been obtained by this procedure [SS, 86, 1 1 1, 119-1321, as have alkoxyguanidines [97, 1331, and benzoylguanidines [ 134, 1351 . It is usual t o carry out the reaction in water or ethanol, or in mixtures of the two, at temperatures ranging from 60" to the boiling point, for from 2 t o 1 2 hours. Butanol has also been used as a solvent [82, 1361 and, exceptionally xylene [I371 and dimethylformamide [138], or even n o solvent a t all [I361 The alkyl mercaptan which is evolved in this reaction can be absorbed in a solution of sodium hydroxide and hydrogen peroxide [135] or in a charcoa1:cupric chloride trap [ 1391 . The guanidines are often conveniently isolated via their relatively insoluble bicarbonates [ 118, 1391 . King and Tonkin [82] used this method t o prepare many guanidines and, more recently, other workers [109, 140, 1411 have studied its scope. I t has been stated [ 141 ] that primary amines are generally more reactive than secondary amines, but there are many exceptions [109, 140-1431. A series of comparative experiments has demonstrated [ 1441 that the structural requirements for a successful reaction are often fairly critical; for example, RCHzCMe2.NH2 gave the guanidine when R = OH, NHPr, or NHBu, but not when R = H or NMez. In spite of this work, and the successful preparation [139] of cr-methyl- and a-ethyl-benzylguanidine, as well as trans-2-phenylcyclopropylguanidine,it has recently been stated [ 1411 that this method is not successful when benzylamines are substituted by a methyl group on the cr-carbon atom. Substitution of two methyl groups on the p-carbon atom of aliphatic amines slows down the reaction with S-methylisothiouronium sulphate [228] ; two methyl groups on the a-carbon atom, as in t-butylamine, prevent reaction altogether [228] . When the amine and the S-alkylisothiouronium group are part of the same molecule, an intramolecular synthesis of a guanidine can occur with great ease [145, 1461. A special effect attributed to the presence of a cyclic system is the reaction between aziridines and S-methylisothiouronium salts t o give 2-methylthioethylguanidines [ 147, 21 51. There have, of course, been many applications of this reaction t o the preparation of guanidino-acids such as arginine [ 6 6 , 9 0 , 149-1561 .
133
G. J. DURANT, A. M. ROE, A. L. GREEN.
An important development of the synthesis described above is derived from the observations of Scott, O’Donovan and Reilly [ 1591, which were taken up by others [ 1091 . l-Guanyl-3,5-dimethylpyrazolenitrate reacts with alkyl- and arylamines in hot water, ethanol, or without solvent to give good yields of guanidines. Use of this pyrazole nitrate or other salt for obtaining guanidines now competes with older methods if yield and ease of isolation of the product are the main considerations [95, 138, 140, 143, 160-1641. The foregoing methods are those most generally applicable t o the synthesis of guanidines. There are many other ways in which guanidines have been obtained, some of which have occasionally been used to prepare compounds whose biological properties will be discussed later. Although there are many claims in patents to the preparation of alkylguanidines by reaction of guanidine with alkyl halides, this method, which was first studied by Schenck [ 1651 ,has only rarely been found satisfactory. Primary and secondary alcohols in 80-85 per cent sulphuric acid react with guanidines to give the monoand di-alkyl derivatives [ 1661 . A process for direct alkylation of guanidine by an alkyl tosylate has been developed [95, 138, 1671. The acylation of guanidines can be controlled more easily than alkylation; and esters, acid anhydrides, and acid chlorides have been used successfully [ 134, 168-1 731 . Guanidines have been prepared by the reaction between an amine, or an amine salt, and a host of other reagents, such as a thiourea in the presence of lead or mercuric oxide [83, 157, 1581, carbodi-imides [140, 174, 1751, calcium cyanamide [ 176, 1771 , isonitrile dichlorides [ 178-1 801 , chloroformamidines [ 18 11 , dialkyl imidocarbonates [ 1821 , orthocarbonate esters [ 1831 , trichloromethanesulphenyl chloride [184], and nitro- or nitroso-guanidines [ 185-1881. Substituted ureas can furnish guanidines, either by treatment with amines and phosphorus oxychloride [ 1891, or by reaction with phenylisocyanate [ 1901 or phosgene [ 191] . Aminoguanidines
Since the synthesis of aminoguanidines has been comprehensively discussed by Kurzer and Godfrey [61] ,only the more recent developments are included in this review. Most of the methods used for the synthesis,of guanidines are adaptable t o the synthesis of aminoguanidines, but the fact that a mono-substituted aminoguanidine can be one of three isomers (XVI), (XVII) or (XVIII) adds interest t o the preparative methods. RN H.NH.C=NH
I
NH2
(XVI)
R.N.C=NH
I 1 H2N NH2
(XVII)
RN HC=N H
I
NHNH2
(XVIII)
134
GUANIDINES AND ADRENERGIC NERVE ENDINGS
Until recently it was thought that mono-substituted hydrazines invariably reacted with S-methylisothiouronium salts t o give compounds of type (XVII) [129, 192, 1 9 3 ) ; however, examples have now come t o light in which the alternative isomer (XVI) has been isolated from this reaction [21, 131, 194, 1951. This formulation is based on (a) the failure of the products t o react with benzaldehyde, [21, 129, 131, 1941, (b) the unambiguous synthesis of the two possible alternative structures [21, 129, 1941, and ( c ) an examination of the nucleai magnetic resonance spectra of the mono- and di-protonated forms of some
RCH2 .NH.NH-
c
=NH
RCH2 .N-C=NH
I I
H2N NH2
NH2
+H']
I
- H'
+H']
(XIXa)
-H'I[
R C H l~
+H'
f - H'
I
+H+1 - H'
j.N H-C ~ +-N ~H~
I
NH2 (XIXb) pairs of isomers of type (XIX) and (XX): in trifluoroacetic acid and in 90 per cent sulphuric acid (XIX) and (XX) exist as the mono- (XIXa) and (XXa), and di-protonated forms, (XIXb) and (XXb) respectively. Under these conditions, the effect of the second positive charge on the chemical shift of the methylene protons is considerably greater when the charge is on an adjacent nitrogen (XIXb) than when on a more remote nitrogen as in (XXb) [21, 1941. This analysis
G. J. DURANT, A. M. ROE, A. L. GREEN.
135
enables a monosubstituted aminoguanidine of unknown structure to be assigned structure (XIX) or an isomeric structure. Compounds of type (XVI) have been obtained by reduction of guanylhydrazones [ 129,1921, by treatment of an N-substituted-N-benzylhydrazinewith 1-guanyl-3,5-dimethylpyrazolesulphate followed by reductive removal of the benzyl group [ 1941, or by reaction of a hydrazine with a substituted cyanamide [ 1961 . An N,N-dialkylhydrazine reacts with S-methylisothiouronium salts unambiguously to give an N,N-dialkylaminoguanidine[ 1971 . Structures of type (XVII) have been obtained by treatment of an N-alkyl-N-cyanohydrazinewith ammonia [ 1941. The use of I-guanyl-3,5-dimethylpyrazolesalts for preparing compounds of type (XVI) originated with Scott [ 159, 1981, and this reaction has also been used by others [ 163, 1941 . Compounds of type (XVIII) have been prepared by reduction of a nitroguanidine [ 1991,by reaction of an amine with S-methylisothiosemicarbazide [ 13 1, 194,199,2001 ,or by reaction of hydrazine with a substituted S-methylisothiouronium salt [ 131, 1931. PHARMACOLOGICAL TEST PROCEDURES Effect on blood pressure
Direct measurement of the effect of drugs on the blood pressure of animals has found little use as a screening procedure. This apparent deficiency in hypotensive drug testing stems mainly from three causes. Firstly, a fall in blood pressure is difficult t o interpret in the absence of considerable background information about the site and mode of action of the drug concerned; it might, for example, result from the liberation of histamine or from a myocardial depressi.on reducing cardiac output, neither of which is of therapeutic value. Secondly, many compounds of established utility as antihypertensive drugs in man, d o not lower blood pressure when administered in single doses t o anaesthetized animals. Thirdly, even when administered over a long period, many established antihypertensive drugs fail to lower the blood pressure of normotensive animals. This last problem can be partly overcome by use of animals which have been deliberately made hypertensive in one of the following three ways, (a) by surgical destruction of the buffer nerves in the regions of the carotid sinus and aortic arch'(neurogenic hypertension), (b) by reducing the blood supply t o the kidney, using clips on the renal arteries or encapsulation of the kidneys in cellophane or latex (renal hypertension), or (c) by giving animals a diet with a high sodium chloride content and administering adrenal corticoids, particularly deoxycorticosterone acetate (DOCA). The argument that such hypertensive animals do not represent a realistic model of human hypertension and that results obtained in them by the use of drugs may have no relevance to the human situation, has some validity; nevertheless, the effectiveness of known antihypertensive drugs can almost always be demonstrated in such animals. In man, the therapeutic value of antihypertensive drugs lies in
136
G U A N I D I N E S A N D A D R E N E R G I C N E R V E ENDINGS
their ability t o lower the blood pressure rather than in removing the underlying cause of the raised blood pressure. Even so, the technical problems entailed in the production of hypertensive animals and the regular determination of their blood pressure are considerable, and the use of such animals is generally confined t o providing confirmatory evidence of an antihypertensive action in drugs which, on other grounds,have been thought likely to possess such an action. A comprehensive and detailed review of methods for measuring arterial blood pressure, and of producing hypertensive animals, has been given by Boura and Green [201]. Effect on the sympathetic nervous system
The more usual methods which have been employed for testing guanidine derivatives as potential antihypertensive drugs depend on detecting some form of interference with the sympathetic nervous system. This.subject has also been reviewed recently in considerable detail [ 7 0 7 ] , and only those methods which have been, or could be, widely applied to elucidating structure-activity relationships are described here. By far the most popular test system is the cat nictitating membrane. In unanaesthetized cats, the nictitating membranes are normally kept retracted, and barely visible, by nerve impulses conveyed along the cervical sympathetic nerves. Abolition of these impulses by surgical denervation, or by sympathetic blocking drugs, causes the membrane t o relax until it covers about 70 per cent of the eye. The extent of relaxation can be measured by estimating the position of the membrane along the lower lid with a ruler or calipers, or by photographing the eyes and estimating the percentage covered by placing transparent paper with a square grid marked on it over the photographs. This latter procedure is often less satisfactory because of the closure of the palpebral fissure which generally accompanies relaxation of the membrane. Whichever method is used, it is better t o aim at a quick approximate result with minimal disturbance of the animals. When using this test, it is desirable for the experimenter to observe the cats at various times up to at least 38 hours after injection of the drug. since the onset of relaxation may be delayed u p to 74 hours or more. Furthermore. a range of drug doses should be used rather than a single arbitrary test dose since some adrenergic neurone blocking drugs also possess a contracting action on the membrane which. at higher doses. masks the sympathetic blockade and leads to anomalous dose-response curves [ 203. 7041 . In comparing results from different laboratories it is important t o note whether they are expressed as percentage relaxation. which generally means percentage cover o f the eyes (maximum about 70). or as a percentage of maximal relaxation (maximum 100). In anaesthetized cats. the tone of the nictitating membranes may be recorded with a writing lever o r strain gauge. Stimulation of the cervical sympathetic nerves at a frequency of 0.1 to 50 pulses/second causes the membranes to contract. The magnitude of the contractions is dependent on the frequency of
G. J . DURANT, A. M. ROE, A. L. GREEN.
137
stimulation, but it does not increase much at rates above lO/second. The potency of sympathetic blocking drugs can be assessed from the extent by which they reduce the magnitude of the contractions. Ideally, all drugs should be tested at a range of frequencies, as some drugs are more effective at low stimulation rates than at high ones, hence the relative potencies of two drugs may depend on the stimulation rate. This is rarely done, but when comparing a group of chemically closely related compounds the error due t o use of a single stimulation rate is probably less than that arising from individual variation among the small number of animals which are generally used. Relaxation of the nictitating membrane in conscious cats, and failure of the nictitating membrane t o respond t o sympathetic nerve stimulation in anaesthetized cats, may be brought about by a blocking action a t the sympathetic ganglia, at the post-ganglionic sympathetic nerve endings, or at the effector organ receptors. A decision as t o the primary site of action of any particular drug can usually be achieved without much difficulty. Ganglion blocking drugs cause mydriasis in conscious cats, by depressing the transmission of parasympathetic impulses through the ciliary ganglion, as well as relaxing the nictitating membrane. In anaesthetized cats, they block contractions of the nictitating membrane in response t o pre-ganglionic stimulation of the cervical sympathetic nerve without affecting responses t o post-ganglionic stimulation. Drugs which prevent the release of noradrenaline from the post-ganglionic sympathetic nerve endings cause relaxation of the nictitating membrane in conscious cats but n o mydriasis:and in anaesthetized cats, they block the contractions of the nictitating membranes produced by pre-ganglionic or post-ganglionic nerve stimulation without affecting contractions due t o injected noradrenaline. Drugs which block the a-receptors on the membrane itself cause relaxation without mydriasis in conscious cats; in anaesthetized cats, they tend t o inhibit the contractions of the nictitating membrane in response t o injected noradrenaline more readily than responses t o nerve stimulation, although these too are blocked a t higher doses. A further distinction can be made between adrenergic neurone blocking drugs such as xylocholine, bretylium and guanethidine, which act a t the post-ganglionic sympathetic nerve endings by inhibiting the release of noradrenaline in response t o nerve stimulation, and those, such as reserpine, which act by depleting the noradrenaline from the nerve endings. The effects of $rugs of the former type on the nictitating membrane can be readily reversed by injection of low doses of amphetamine. These differences are summarized in Table 3.2. Another method for use in unanaesthetized animals, which is akin to studying the relaxation of the nictitating membrane in cats, is the observation of ptosis in mice or rats. These smaller and less expensive animals can be used in much larger numbers than cats, and the method does not suffer from the anomalous doseresponse curves mentioned previously. Ganglion blocking drugs, adrenergic neurone blocking drugs and a-receptor blocking drugs can be simply distinguished by essentially the same means as those used in cats. However, the method has not so far been widely exploited. A full description, with illustrative examples
Table 3.2. DIFFERENTIATION OF SYMPATHETIC BLOCKING DRUGS
Nictitating membrane
Type of drug
Pupil
\
A
/-
Response t o preResponse t o postganglionic stimularion ganglionic srimulation
A
Response to noradrenaline
Reversal of block by amphetamine
Mydriasis
Normal*
Not
Yes
Ganglion blocking (e.g. hexamethonium, pempidine)
Blocked
Normal
Adrenergic neurone blocking(e.g. xylocholine, guanettfidine)
Blocked
Blocked
Normal*
Yes
No
Noradrenalinedepleting (e.g. reserpine)
Blocked
Blocked
Normal*
Not
No
&Receptor blocking (e.g. phentolamine, phenoxybenzamine)
Blocked
Blocked
Blocked
No
No
*The response of the nictitating memhrane may often be potentiated. depending b o t h o n the time the noradrenaline is given after the sympathetic blocking drug and o n the dose o f the latter. t A partial reversal of block may sometimes be encountered. but t h i s effect is short-lived a n d Mock subsequently re-appears.
G . J . DURANT, A. M. ROE, A. L. GREEN.
139
comparing the mouse ptosis and cat nictitating membrane tests, has been published elsewhere [203]. Numerous in vitro preparations, consisting of isolated smooth muscles with attached nerves, have been described for studying the actions of sympathetic blocking drugs, but only one of these, the isolated rabbit mesenteric nerveintestine preparation (or Finkleman preparation) [205] has been used at all extensively as a screening test. This preparation is a short segment (about 3 cm) of intestine, which is removed from a freshly killed rabbit, together with the mesentery containing the branches of the mesenteric artery which supply the segment. This piece of intestine is suspended in oxygenated Tyrode solution in a small jacketed water bath. The lower end of the segment is attached to the base of the bath and the upper to a writing lever. Electrodes are attached to the mesenteric artery enabling the mesenteric nerve, which runs periarterially, to be electrically stimulated. In the absence of stimulation, the segment undergoes spontaneous pendular contractions at a rate of about 10 per min. Stimulation of the mesenteric nerve, or addition of noradrenaline to the bath, inhibits these spontaneous contractions. Adrenergic neurone blocking drugs added to the bath abolish the inhibitory effect of nerve stimulation but not that of noradrenaline, whereas a-receptor blocking drugs abolish the inhibitory effect of noradrenaline as well as that of nerve stimulation.
STR UCTURE-ACTIVITY RELATIONSHIPS FOR ADRENERGIC NEURONE BLOCKADE
For the purpose of examining the effect of chemical structure on the pharmacological activity of guanidines at sympathetic nerve endings, compounds are discussed in terms of three main classes. These classes, namely, guanethidine and close analogues, aryloxyalkylguanidines, and aralkylguanidines (in addition to some miscellaneous guanidines) perhaps represent the attempts of chemists to manipulate a particular type of guanidine or related structure, more than a strict categorization on chemical grounds. Nevertheless,, there are indications of structural prerequisites for biological activity and apparent structure-activity relationships within these subdivisions. However, it is appreciated that compounds discussed in one subsection are often pertinent to others. As an example, the activities of guanethidine analogues containing a fused benzene ring are relevant to the discussion of aryloxyalkylguanidines and aralkylguanidines. Guanethidine and close analogues
Guanethidine (I) (p. 125) is a potent antihypertensive agent of great clinical importance [206]. A detailed discussion of the pharmacology of guanethidine is
140
GUANIDINES AND ADRENERGIC NERVE ENDINGS
beyond the scope of this review and, for further pharmacology, the reader is referred to other sources [ l o , 207-2091. Here, we merely indicate the major factors involved in the action of guanethidine at sympathetic nerve endings so that the activities of related compounds may be compared. The hypotensive action of guanethidine seems most likely t o be attributable t o blockade of transmission at adrenergic nerve terminals, and is associated with the inhibition of the release of the neurotransmitter, noradrenaline [207] .Guanethidine may therefore be classified as an adrenergic neurone blocking agent [ l o ] . As discussed later, the marked depletion of tissue stores of noradrenaline which is produced by guanethidine, appears unlikely to be responsible for the adrenergic neurone blockade. The adrenergic neurone blocking action of guanethidine is accompanied by an initial transient sympathomimetic activity [ 2071 caused by release of free catecholamines. Guanethidine also inhibits the release of noradrenaline induced by indirectly-acting sympathomimetic amines, such as tyramine and amphetamine [2071. ~. A great many compounds have been synthesized which are chemically related to guanethidine. Discussion of the relationship between chemical structure and biological activity withn this class of compound is complicated by the varying criteria of activity used by different workers. For instance, some [ 127, 2 l o ] have compared close analogues of guanethidine in terms of antihypertensive activity, whilst others [ 140,211, 2121 have used adrenergic neurone blockade as their criterion. In this review, most of the data are presented in tabular form which lists, where possible, both antihypertensive and adrenergic neurone blocking activities. Unless otherwise specified, relaxation of the nictitating membrane of the conscious cat is used as the criterion of the latter action. Other relevant features of the action of guanethidine analogues which appear in the literature are described in the text and indications of clinical activity are included. The Tables are compiled on a chemical basis which emphasises different structural aspects of the guanethidine molecule. Modification of the ring
Open chain analogues of guanethidine were originally reported to be devoid of antihypertensive activity [210]. However, it has subsequently been shown that numerous compounds in this category are active as adrenergic neurone blocking agents (Table 3.3). For example, it is reported that, compared with guanethidine, 2-(methylisobutylamino)ethylguanidine (XXI) has a more potent action of longer duration and more rapid onset [211] . 2-Cyclohexylaminoethylguanidine (XXII) was found to be similar to guanethidine when their actions on isolated sympathetically innervated organs were compared [213]. The adrenergic neurone blockade was persistent but could be reversed by amphetamine [213] . 2-Diethylaminoethylguanidine was found to beonlyslightly less active than guanethidine both in virro [213, 2141 and in vivo [140, 21 1,2121.
141
G. J. DURANT, A. M. ROE, A. L. GREEN.
Short andDarby [ 2 151 have recently reported that 2(2-methylthioethylamino) ethylguanidine (XXIII) relaxes the nictitating membranes of conscious cats, and Me2CH.CH2 .NCH2 .CH2-NH-C=NH
I
Me
I
C6H 11.NHCH2-NHC=NH
NH2
NH2
(XXII)
(=I)
has a hypotensive action, similar to that of guanethidine, in the anaesthetized cat. Comparison of closely related compounds indicated a considerable specificity in certain of the structural requirements for activity (Table 3.3). For example, Table 3.3. T H E ACTIVITY OF OPEN CHAIN ANALOGUES OF GUANETHIDINE R1R2NCH2CH2.NHC(:NH)NH2
R' Me Et H H Me Et H Me H Pr Pr. Pr f Pr' Me Me Et Me Pr Bu H H H Et H H
R2
Adrenergic neurone blocking activity
Inactive ( 1 4 0 , 2 1 3 ) Slight activity [211] Active [ 1 4 0 , 211-2141 Inactive [ 2151 Active [ 2 1 1 ] BU' Prf Active 12111 Pr' Active (2111 Ami Active [ 2 1 1 ] But Active [ 2 1 1 ] Active [ 2 1 1 , 2131 C6H11 Pr Active (2111 Slight activity [214] Pr f Active I2111 Pr' Slight activity 1 4 0 , 2 1 4 1 Bui Active 12111 C6Hll Active 1211, 2 41 C7H13 Active [ 1 3 5 , 2 41 C6Hll Active [ 2 1 1 ] CaH 15 Active [ 1351 C6Hll Active [ 2 1 1 ] C6Hll Inactive [ 2 1 1 ] MeS(CH92 Active (2151 EtS(CHd2 Inactive [ 2 1 5 ] MeO(CHd2 Active [ 2151 MeS(CHd2 Active [ 2 1 5 ] MeS(CHd3 Active [ 2 1 5 ] Et*N(CH& Inactive 12151 Me Et Et .
A n tihypertensive activity -
-
Inactive [ 2101 -
Active [ 2 1 5 ] -
Active [ 2151 Active [ 2151 Inactive [ 2 1 5 ] -
replacing sulphur by oxygen in compound (XXIII) maintains the adrenergic neurone blocking activity, although at a lower potency, but replacing the methyl group of (XXIII) by ethyl gives a compound which does not relax nictitating
142
GUANIDINES AND ADRENERGIC NERVE ENDINGS
membranes at 30 mg/kg [215]. The activity of these open chain structures is a clear demonstration that the heterocyclic ring is nof a prerequisite for adrenergic neurone blocking activity within guanethidine-like compounds. The association of peak antihypertensive activity with the eight-membered ring of guanethidine rather than other ring sizes has been discussed previously Table 3.4. THE ACTIVITY OF RING SIZE MODIFICATIONS OF GUANETHIDINE (CH2),N€H2€H2eNHC(:NH)NH2
n 4 5
6 7 8 9
Adrenergic neurone blocking activity
Antihypertensive activity
Active [ 2141 Active [ 2 1 4 ] High activity [ 2 1 4 ] Peak activity [ 2 1 4 ] -
Active [ 1271 Active [ 127, 2101 High activity [ 127,2101 Peak activity [ 1 2 7 , 2 1 0 ] High activity [ 127,2101 Active [ 2101
[127, 2101 (Table 3.4). Recently, Ozawa and Sato [214] have compared the pharmacological properties of several of these analogues in more detail. The activities of the compounds on the isolated rabbit ileum paralleled their reported MeS-CH2CH2.NHCH2-CH2.NH.C=NH R'R2N-CH2CHz.NH-C=NH
I
I
NH2
NH2 (XXIII)
(XXW
antihypertensive activities (XXIV, R'RZ = (CH,), 2 (CH2)6> (CH,),
> Etz
= (CH2)4).
Other compounds tested (for example (XXIV), R' R2 = Pr2; P r i ;C6Hi1, Me) were either very weakly active or inactive. In the anaesthetized cat, contractions of the nictitating membranes induced by noradrenaline or adrenaline were enhanced by the active compounds, but the contractions caused by tyramine were inhibited. The contractions elicited by stimulation of the pre-ganglionic superior cervical nerve were also blocked. Modifications of the moderately active piperidiw analogue of guanethidine (XXIV,RIRz = (CH2)5), in which the guanidinoethyl group is attached to different positions of the piperidine ring, show only very low adrenergic neurone blocking activity [ 1401. The effect of introducing methyl groups into the heterocyclic ring system of guanethidine and related compounds is recorded in Table 3.5. The high adrenergic neurone blocking activity of the methyl substituted piperidine analogues is of interest [211]. A potent unsaturated derivative of this type (XXV), guanacline (cyclazenine. Leron), has been introduced recently [216-2181. The 2,2,6,6-tetramethylpiperidine analogue (XXVI) of guanethidine also has hypotensive properties [129, 2191, but these are probably due to ganglionic
G . J. DURANT, A. M. ROE, A. L. GREEN.
143
blockade rather than toadrenergic neurone blockade. This finding is understandable, since the compound is essentially a derivative of the ganglion-blocking agent pempidine (XXVII) [ 1291 . Table 3.5. THE ACTIVITY OF RING-SUBSTITUTED GUANETHIDINE ANALOGUES RCH2CH2'NHC(:NH)NH2
R
u
e
a
Adrenergic neurone blocking activity
Active [ 2 1 1 ]
-
Active [ 21 11
-
High activity [ 2161 M
e
Antihypertensive activity
High activity [ 2161
0
Ganglion blocking activity [ 1291
Active [ 129,2191
ue Me
0:'
Slight activity 12101 Slight activity [421]
Diazacycloalkane analogues of guanethidine and related structures have been examined for both antihypertensive and adrenergic neurone blocking activity (Table 3.6). In contrast to what is found in the mono-aza series, the sixmembered piperazine ring system is associated with higher activity than the corresponding seven- and eight-membered structures. In the piperazines, the ring N-rnethyl compound (XXVIII) has the highest potency. Larger substituents lead t o loss of adrenergic neurone blocking activity (1401. In contrast to (XXVIII) the related morpholine and hexahydropyrimidinyl compounds are reported to be inactive. The high activity of bridged heterocyclic systems related to guanethidine was first reported by Schlittler, Druey and Marxer 12101 . Subsequent investigations
144
GUANIDINES AND ADRENERGIC NERVE ENDINGS
N.M e
Table 3.6. THE ACTIVITY OF DIAZACYCLOALKANE ANALOGUES OF GUANETHIDINE AND RELATED STRUCTURES R.CH2CH2.NH C ( :NH)NHz
R
R'
Adrenergic neurone blocking activity
Me Ph Me PhCHz
An tihypertensive activity Active [210,422] Slight activity [210,422
Active [ 140,4211 -
-
High activity [ 1401 Inactive [ 1401 Inactive [ 1401 Inactive [ 1401 -
Inactive [ 1401 -
Slight activity (2101 Inactive [210] Inactive [422] High activity [210] Active (2101 -
Active [ 2101 -
Slight activity [210] Inactive [210] Inactive [422] -
Slight activity 14221 Inactive [127, 2101 Inactive [ 127,2101
145
G . J . DURANT, A. M. ROE, A. L. GREEN
r'\
M eN
C H; C H; N H . C = N H
r\l. C H,. C '-I,. N H - C = N H
u
I
I
NHZ
NH2
(XXVIII)
i
sx1x:
Table 3.7. THE ACTIVITY OF BICYCLIC DERIVATIVES OF GUANETHIDINE RCHz €H*.NH €(: NH)NHz
R
Adrenergic netrrone blocking activity
A n tihypertensive activity
-
High activity [ 2 1 0 , 4 2 3 , 4 2 4 1
-
Active 1 2 1 0 , 4 2 3 , 4 2 4 1
Active [ 1 3 5 )
-
-
Slight activity [ 2101
-
Slight activity [ 2 1 0 ]
-
Active [ 4 2 4 ]
Active [ 2201
Active [ 2 2 0 , 4 2 4 1
Active [ 4 2 4 ]
Active [ 4 2 5 ]
I
XXX)
R=CH,.CH,.NH
C ( : N H ) NH,
Active (4251
146
GUANIDINES AND ADRENERGIC NERVE ENDINGS
have confirmed that bicyclic variants of guanethidine, bridged in several different ways, have antihypertensive activity, presumably acting by adrenergic neurone blockade (Table 3.7). The 2-aza-bicyclo [2,2,2] octane derivative (XXIX) has, however, shown undesirable side effects (severe diarrhoea in mice [220] , and the analogue with a three-carbon side chain caused cardiac arrest in dogs [220]. Bicyclic modification of guanethidine containing azaspiro-alkane ring systems (Table 3.8) have been studied in some detail. The most active compounds are comparable to guanethidine as sympathetic blocking agents, and show the following order of potency [221-2231: The total number of atoms in the azaspirocycle is optimally seven or eight, similar to the optimal requirements in the monocyclic guanethidine series. However, an additional factor with the azaspiro-alkanes is that the number of atoms in the heterocyclic ring should be as large as possible consistent with the previous condition. Compound (XXX) has a longer duration of action than guanethidine both in animals [221] and in man [224]. The antihypertensive activity of the seven-membered analogue of guanethidine in which a benzene ring is fused in the 4,5-position was reported in the review by Table 3.8. THE ACTIVITY OF AZASPIRO ANALOGUES OF GUANETHIDINE
k
m
n
1
2
2
Numbef of atoms in heterocycle
8
Adrenergic neurone blocking activity
High activitv 1221-223.4261 Active- [ 122,4271 Active [ 222,4261 Active [ 222,223,428) slight activity [222,223,426] Slight activity [ 222,223,4261 Inactive 1222, 223,4261 Inactive (222,223,4261 .
1 2 2 2
2 2 1 2
1 1 1 2
7 8 9
3
2
1
9
3 4
1 1
1 1
8 9
I
An tihypertensive activity
I
High activity (221-223,4261 Active [ 222,4271 Active [ 222,4261 Active [ 222,223,4281 Slight activity [222, 223,4261 Slight activity [ 222,223,4261 Inactive 1222. 223,4261 Inactive i222,223,426]
.
Schlittler, Druey and Marxer [210]. Subsequently, the analogous variant (XXXI) of guanethidine was shown to be an adrenergic neurone blocking agent [ 225,2261 Compound (XXXI) was found to be more potent than guanethidine on the guinea-pig isolated vas deferens preparation [227] . The sympathomimetic phase following the administration of compound (XXXI) to whole animals is reported to be less pronounced and more transient than that produced by guanethidine, and it has been suggested that the compound has a weaker amine-releasing
G . J. DURANT, A. M. ROE, A. L. GREEN.
147
capacity [226]. Central actions have also been observed with this compound [225].
NH,
Modifications of the side-chain
The ethylene side-chain present in guanethidine was formerly regarded as essential for optimum activity in compounds of this type [210]. However, the effect of introducing methyl groups has been reported only recently (Table 3.9). Rand and Wilson [213] studied the adrenergic neurone blocking potencies of a series of cyclohexylaminoalkylguanidines (XXXII), using isolated sympathetically innervated organs. Derivatives with methyl substituted side-chains (XXXII, R3 or R5 = Me)* were highly active in these preparations, being similar in potency to guanethidine, and they were possibly more active than the compound containing the unsubstituted ethylene linkage. The isobutyl analogue (XXXII, R3R4 = Me2) was also found to be a highly active antihypertensive agent in rats [213]. Short, Ours and Ranus [228] investigated methyl substitution in the side-chain of diethylaminoethylguanidine (XXXIII) and found that the isobutyl derivative (XXXIII, R3R4 = Me,) was considerably more active than the parent compound or other analogues (XXXIII, R3 = R4 = H, R5 = R6 = Me) in relaxing the
(XXXII) R'R2 = CIHll,H
R3 R5
I I
R' R2N-C-C-NHC
= NH
I I
I
R4R6
NH2
(XXXIII) R' R2 = Et
nictitating membranes of cats. Extending this to the hexamethyleneimines, these authors found that the isobutyl analogue (XXXIV, R3 = R4 = Me) was highly active, and in fact caused a remarkably long prolapse of the nictitating membrane (2 16 hours). However, this compound was reported to be disappointing below 10 mg/kg in hypertensive dogs [228]. Increasing the distance between the amino function and the guanidine group in compounds related t o guanethidine results in a decline in activity (Table 3.9) [ 127, 140, 2131. *Here and subsequently R = H unless otherwise specified.
148
GUANIDINES AND ADRENERGIC NERVE ENDINGS
Table 3.9. THE ACTIVITY O F SIDECHAIN MODIFICATIONS O F GUANETHIDINE AND ITS ANALOGUES R*A*NHC(:NH)NH2
R
A
0
High activity [ 127,207,2101 High activity [ 127,207, 2101 Slight activity [ 1271 Slight activity [ 1271 Inactive [210] Inactive [210] High activity [ 2281 Slight activity [ 2281 Active [ 2281 -
((392 (CH2)3
Active [ 1401 Active [ 1401 Inactive [ 1401 Active [ 2281 Active [ 2281 Active [ 228) Active [ 2281 Active [ 2281
-
(CH2)3 CMe2CH2
Active [ 140) Inactive [ 1401 Inactive [228]
-
(CH2)2 CH(Me)CH2 CH2CH(Me) CH(Me)CH(Me) CH(Et)CH2 (CH2)3
Active (2131 Active [213] Active [213] Active [213] Slight activity (2131 Slight activity [213]
(CH2)2
A MeN
N
NH
An tihypertensive activity
(CH2)2 (CH2)3 (CH2)4 CH(Ph)CH2 CH2CO CMe2CH2 CH2CMe2
CH(Me)CH2 CHzCH(Me) CMe2CH2 CH2CMe2 CH2CMe2CH2
Et2N
Adrenergic neurone blocking activity
-
-
-
Active [213] -
Modifications of the guanidine function
Modification of the guanidine function of guanethidine by alkyl group substitution does not seem to have been reported. In the related series of diethylaminoethylguanidines (Table 3.10) it was found that, whereas the analogue containing a methyl substituent on the terminal nitrogen atom had adrenergic neurone blocking properties, all other alkyl substituted guanidines tested were inactive [ 1401 . 2-Aminoimidazolines are cyclized N , N'-dialkyl guanidines: this variation of guanethidine was originally reported to be devoid of antihypertensive properties [210], although some activity has since been claimed for related compounds [ 1861 (Table 3.10). The guanidine function in compounds such as guanethidine is essentially completely protonated at physiological pH, and adrenergic neurone blockade is presumably caused by interactions of the cationic species at hypothetical
G . J. D U R A N T , A.M. R O E , A. L. G R E E N .
149
Table 3.10. T H E ACTIVITY OF G U A N E T H I D I N E A N A L O G U E S A L K Y L A T E D O N T H E G U A N I D I N E FUNCTION
Adreriergic rieuroiie blockirig activity Active [ 1401 Inactive 1401 Inactive 1401 lnac tive 140) Inactive 1401 Inactive 1401
Et2NCH2CH2.NHC(:NMe)NH2 EtZNCH2CH2’NHC(:NBu)NH2 Et2NCH2CH2.NMeC(:NH)NH2 Et2NCH2CH2.NHC(:NEt)NHEt Et2NCH2CH2.NHC(:NMe)NMe2
n
M e N ~ ,N.CH, U
A I I rilij,perretisive activitj,
CHz.NH.CI N B u I N H Z
Cyclic guariidines Active [ 861
Inactive [210]
G
Active 1,1861
N CH, CH, N H C’
.N-
Bu,N CH, CH, NH C
“ J
Active [ 1861
Active [ 186)
‘NH
EI,N
CH, CH, NH C
EL,N
C H 2 CHz NH
Active [ 1401
Inactive [ 1401
C4
receptor sites (see p. 199). It is natural therefore that strongly basic groups other than guanidine should have been incorporated into guanethidine and analogues for investigation of adrenergic neurone blocking activity (Table 3.1 1). Guanethidine was developed from a series of amidoximes (for example XXXV, Su 4029) which were potent antihypertensive drugs. However, compound (XXXV) had n o adrenergic neurone blocking properties when examined for relaxation of the cat nictitating membrane, although tissue stores of noradrenaline were extensively depleted and the pressor effects of amphetamine and other indirectly
C
N-CH,.
CH,. C=NOH
I NHZ
C
N-CH2*CH2*NH.C=NH
I
Me
(XXXV) (XXXVIJ acting sympathomimetic amines were suppressed [230-2321. In this series of amidoximes, peak antihypertensive properties are associated with the sevenmembered ring system. This is in contrast t o the guanethidine series, in which the eight-membered ring bestows maximum activity.
150
GUANIDINES AND ADRENERGIC NERVE ENDINGS
Table 3.1 1. THE ACTIVITY OF GUANIDINE MODIFICATIONS OF GUANETHIDINE AND ITS ANALOGUES RCHzCH2.X
Adrenergic neurone blocking activity
X
R
C(: N0H)NHz C(: NH)NHz / 7~~ NH .C( : NH)NH NH 2 _ ~ NH.NHC(:NH)NHz , S C ( N H )NH NHC(: NH)NHC(:NH)NHz
’
Active (4311 Active [ 2341
-
O.NH.C(: NH)NH2 C(:NOH)NHz C(:NH)NHz NH-C(:NH)Me
Inactive [230-2321 Active [ 2 1 0 , 4 3 0 ] Active [ 2331
N(NH~)C(:NH)NHZ NHC(: NH)NHNHz
Inactive [ 1401 Inactive [ 1401
CN EtzN
Inactive [ 230-2321
Antihypertensive activity Active [ 2 1 0 , 2 3 0 , 4 2 9 3 Active [ 4 3 0 ] Active [ 1 9 9 , 4 3 1 1 Active [ 2341 Inactive [ 2 lo] Inactive 12101 Inactive [ 4 3 2 ] Active [ 2 1 0 , 2 3 0 , 4 2 9 1 Active [ 2 1 0 , 4 3 0 1 Active [ 2331
The corresponding amidines also have antihypertensive properties, but whereas the amidine with the seven-membered ring exerts similar actions to guanethidine, the higher homologue is reported to act more like the amidoxime [210]. Some related N-substituted amidines are reported to be adrenergic neurone blocking agents and the amidine (XXXVI) is comparable to guanethidine in potency [233]. Adrenergic neurone blockade by the amidine (XXXVI) is accompanied by sympathomimetic effects and depletion of catecholamine stores [233]. Peak adrenergic neurone blocking activity within this group of N-substituted amidines is associated with the seven-membered ring system, and the presence of a two-carbon sidechain is essential [233] . Aminoguanidines related to guanethidine form another clas8 of compound with adrenergic neurone blocking properties. The fall in blood pressure due to compounds of type (XXXVII) is reported to be of shorter duration than that caused by guanethidine [ 1991. The isomer (XXXVIII) has antihypertensive actions very similar to those of
NH NH2
IXXXI’I I i
H2N
i XXXVIII 1
guanethidine in several animal species [234] ,the compound acts like guanethidine in causing adrenergic neurone blockade; and the sympathomimetic action of guanethidine is largely eliminated by this modification of the guanethidine molecule. Various other basic terminal groups have been investigated in the
G. J . DURANT,A. M. ROE,A. L. GREEN.
15 1
guanethidine series, but n o appreciable antihypertensive or adrenergic neurone blocking actions have been reported (Table 3.1 I ) . Aryloxyalkylguanidines and related structures
Several years before the discovery of guanethidine, Hey and Willey [23S] had found that choline 2,6-xylyl ether bromide (XXXIX, xylocholine, TbllO) blocked transmission at postganglionic sympathetic nerve terminals. I t was shown subsequently that this blockade resulted from inhibition of the release of the adrenergic transmitter at the nerve endings [236-2381. The clinical us< of xylocholine as an antihypertensive agent was, however, limited by marked niuscarinic effects. A large number of structures related t o xylocholine have been synthesized in attempts to obtain antihypertensive drugs of clinical utility. Although reduction or abolition of the gross muscarinic stimulation, with retention or enhancement of adrenergic neurone blocking activity, was achieved by suitable modification of the xylocholine molecule, n o drug of proven clinical
($-0.Cti2,CH2.&4e3
6r
I XXXIX)
value emerged from this study [ 2 3 9 ] . Erratic absorption is one common disadvantage of orally administered quaternary ammonium drugs and this may have been a problem here. It is interesting that xylocholine has a structure derived from phenoxyethylamine, since the classical work of Bovet and BovetNitti [ 2401 demonstrated that aryloxyethylamine derivatives (XL) have affinity for adrenergic receptor sites (as sympathomimetics or sympatholytics). A later example is the potent adrenolytic action of phenoxybenzamine (Dibenyline Dibenzyline), (XL, Ar = Ph, R' = PhCHz, R2 = CHzCH2CI), which is thought [ 24 I ] t o be due to the cationic species(XL1, Ar = Ph, R' = Ph CH,). As xylocholine acts at sites within the presynaptic nerve terminal and not at a-adrenergic receptors in the effector cells, the significance of this c o F m o n structural feature is uncertain. The discovery of guanethidine, a drug with a structure including the ArO .C H2 .CH .N R
' RZ
ArO-CHz.CH2-y\bH + / CH2 2
y a n i d i n i u m cation, and with a potent blocking action at peripheral sympathetic nerve endings prompted the investigation of compounds related to xylocholine
152
GUANIDINES AND ADRENERGIC NERVE ENDINGS
in which the quaternary ammonium group was -.replaced by the guanidine function. The adrenergic neurone blocking action of 2-(2,6-~ylyloxy)ethylguanidine (XLII) was reported independently by two groups [ 1 3 5 , 2 4 2 ] .
I NH2
(XLJI)
The blockade caused by (XLII) was equal in intensity t o that induced by similar doses of guanethidine and the duration of action was even longer [ 135, 2431. The potency of (XLII) on the Finkleman preparation was much greater than that of guanethidine [243]. The compound had initial sympathomimetic effects and produced a triphasic response on the blood pressure of anaesthetized cats and dogs. The antihypertensive action of (XLII) in man was comparable to that of guanethidine [243], and a mechanism of action similar to that of guanethidine was indicated. Muscarinic properties similar to those exhibited by xylocholine were originally attributed [242] to(XLI1) but Barron, Natoff and Vallance [243] were able to demonstrate that parasympathetic stimulation is not a feature of this guanidine analogue of xylocholine. Thus, replacement of the trimethylammonium head of xylocholine with the guanidine moiety removes the muscarinic properties whilst retaining or enhancing its adrenergic neurone blocking effects. Attempted analysis of structure-activity data in compounds related to (XLII) is particularly complicated since they often give anomalous dose-response curves for their effects on the nictitating membranes of cats [203]. Some results are listed in Table 3.12, and it is apparent that aryloxyalkylguanidines may appear only weakly active at high doses (50 mg/kg, s.c.) but show high activity at much lower dose levels. Also given in Table 3.12 are results from an assay for adrenergic neurone blockade employing ptosis production in mice [203]. It may be deduced from these results that whilst the 2,6-xylyl derivative is a highly potent adrenergic neurone blocking agent, this property is by no means unique to the 2,6-disubstituted structure, but is also possessed to a large degree by some monosubstituted compounds. Unsubstituted phenoxyethylguanidine does not appear to have a marked adrenergic neurone blocking action, and substituents undoubtedly greatly influence the magnitude of the blocking activity. There is evidence of steric factors with 2,6-disubstituted .compounds, since the high activity associated with (XLIII, A = 0 , Ar = 2,6-F2C6H3, 2,6-C12C,H3 or 2,6-Me,C6H,) declines when the size ot the substituent is increased, i.e. (XLIII, A = 0 , Ar = 2,6-Et2C6H3 or 2,6-Pri2C6H3)(Table 3.12). A somewhat similar reduction in adrenergic neurone blocking action associated with an increase in bulk of the groups flanking the ether linkage has been observed with analogues
G. J. DURANT, A. M. ROE, A. L. GREEN.
153
of xylocholine [239] . A recent study [244] of 2,6-disubstituted aryloxyethylguanidines and aryloxyethylammonium salts has shown that in the former series, the 2, 6-difluoro compound was the most active in conscious cats; the order of Table 3.12. THE ACTIVITY O F ARYLOXYALKYLGUANIDINES ArO*(CH2),*NHC(:NH)NHz
Ar
An tihypertensive activity
n Adrenergic neurone blocking activity* Ptosis score f
35% coverage of the eyes
50% coverage of the eyes
2 >SO[244] >SO (1351 0 2 2.5-5 [203] >SO [135] 5.2 2 2.5-5 [203] >SO [ 1351 4.8 2 1 0 [203] >50 [135] 2.0 10 [135] 5 -2 Active [ 135,2431 2 2.5 [203] I 0 [244] 50 (1351 2 2 >50 [135] 2, > 4 0 [ 1351 2 >SO [135] 2 2 0 [ 1351 2 < 5 [23<] 10 [244] 5 [21] 2 5 [244] 2 3-10 [239] 2 >SO [ 135) 2 > 3 8 [135] 2 50 [1351 Active [ 248.249) 3 Inactive (248, 2491 3 50 [135] Active [251] 3 Active [ 25 1] 4 >SO [1351 -
>
*Cat nictitating membrane; approximate dose (mg/kg, s.c.) causing the coverage shown.
Figures in italics represent interpolated data tPtosis assessed 2 h after injection into mice ( 2 0 mg/kg), maximal score usually
4-6 [ 2031
potency in the latter series increased when the 2,6-substituents were H < F < Me < C1 [244]. Related 2,6-xylyl thioethers (XLIII, A = S,Ar = 2,6-Me2C,H3) and amines (XLIII, A = NH or NMe, Ar = 2,6-Me2C,H3) are also highly active adrenergic neurone blocking agents, as evidenced by the nictitating membrane assay, whereas the unsubstitutedcompounds(XLII1,A = S or NMe, Ar = Ph) were apparently inactive at high doses [ 1351 (Table 3.13). However, 2-(methylpheny1amino)ethylguanidine (XLIII, A = NMe, Ar = Ph) is reported to be an adrenergic neurone blocking agent, with an action similar to that of guanethidine [245-2471. Groups flanking the ether linkage markedly affect the adrenergic
154
GUANIDINES AND ADRENERGIC NERVE ENDINGS
Table 3.13. THE ACTIVITY OF MISCELLANEOUS ARYLOXYALKYLGUANIDINES AND RELATED STRUCTURES ArA*NHC(:NH)NH2
Adrenergic neurone blocking activity.
Ar
A
2,6-Me2C6H3 2,6-h!e,C6H3 Ph 2,6-hIe2C6113 2,6-h'fe2C,H3 Z ,6-Me 2C6H 3 Ph
OCH(Me)CH2 S(CH2)2 S(CH2h NH(CH2)2 NMe(CH2)2 NEt(CH 2)2 NMe(CHd2
Antihypertensive activity
2 0 [ 135, 2421 10 [ 1 3 5 ] > 5 0 [ 1351 10 [ 1351 10 [ 1 3 5 ] >SO 11351 10, t [ 245,2461 >[135] 1C10117 O(CH212 >SO [ 1 3 5 ] 2C,Ol17 O(CH2)2 50 [ 1 3 5 ] Ph2CH O(CH212 > 4 0 [135] 2,6ClzC6H3.0.(CH2),.Nh!e.C(:NH)NH? 20 $ [ 211
~
-
~
_
_
_
_
-
Active [ 1351 -
Active [ 2 4 5 , 246) -
Active [ 135) -
_
*Cat nictitating membranes. Approximate dose (mg/kg, s.c.) causing SO% coverage of the eyes. Figures in italics represent interpolated data
administration $.Intravenous Transient activity
neurone blocking properties of homologous phenoxypropylguanidines (Table 3.12). 3-Phenoxypropylguanidine (XLIV, Ar = Ph, n = 3) does not cause ArACH2CH2.NHGNH I NH2 (XLII I)
ArO-(CH2),*NH-C=NH
I NH2
(XLIV)
adrenergic neurone blockade, but does produce hypotension, possibly by depletion of peripheral tissue stores of catecholamines [ 248-2501. The 2,6(XLIV, Ar = 2,6-Me2C6H3 dimethyl- and 2,6-dichloro-phenoxypropylguanidines and 9 , 6 - c I 2 C 6 H 3 , n = 3) however, d o show adrenergic neurone blocking activity [135,251]. I n the series of aminoguanidines (Table 3.14) the 2,6-dichloro- and 2,6dimethyl-phenoxyethyl compounds (XLV, Ar = 2,6-C12C6H3 or 2,6-Me2C6H3), are highly active adrenergic neurone blocking agents, whilst the unsubstituted compound is inactive [21, 2521. In this series, disubstituted compounds containing only one ortho substituent (for example XLV, Ar = 2,5-C12C6H3 or 2,3-Me2C6H3)also possess good adrenergic neurone blocking properties. Inhibition of the release of transmitter substance upon nerve stimulation, leading to adrenergic neurone blockade has been demonstrated with (XLV, Ar = ?,6-C12C6H3),i.e. guanoclor (VI). When examined in conscious hypertensive dogs,
155
C. J. DURANT, A.M. ROE, A. L. GREEN.
ArO.(CH,),.NH.NH.C=NH
I NH2
(XLV) guanoclor caused only slight depression of blood pressure on chronic administration; the analogues (XLV, Ar = 2,6-Me2C6H3and 2,5-CI2C6H3)were slightly more effective in lowering blood pressure. However, an antihypertensive action of guanoclor has been demonstrated in clinical trials (2531. Table 3.14. T H E ACTIVITY OF ARYLOXYALKYLAMINOGUANIDINES
ArO.(CHd;X
X
Ar
n
Ph Ph
2 NHNHC(:NH)NH2 3 NHNHC(:NH)NHz 2 NHNHC(:NH)NHz 3 NHNHC(:NH)NHz 2 NHNHC(:NH)NHz 2 NHNHC(:NH)NH2 2 NHNHC(:NH)NHz 2 NHNHC(:NH)NHz 2 NHNHC(:NH)NHz 2 NHNHC(:NH)NH? 3 NHNHC(:NH)NH2 2 NMeNHC(:NH)NHz 2 NHNHC(:NH)NHMe 2 NHNHC(:NMe)NHMe 2 N(NHdC(:NH)NHz 2 N(NH2)C(:NH)NH2 2 NHC(:NH)NHNH2 2 NHC(:NH)NHNHz
2-MeOC6H4 2-MeOC6H4 ~ C I C ~ H ~ 2-MeC6H4 2,5ClzC6H3 2,6ClzC6H3 2.6-MezC6H 3 3,5-Me&H3 2 ,6-MezC6H 3 2,6-MezC6H3 2,6-Me2C6H3 2 ,6-Me2C6H 3 2,5Cl&H 3 2,6Cl&H 3 2,6-Me2C6H3 2,6ClzC6H3
Adrenergic neurone blocking activity * >20 (21) >20 [21] 2 0 [21] >20 [2l] > 2 0 [21] > 2 0 [21] 5 [211 5 [211 5 1211 > 2 0 [21] > 2 0 [21) 5 [211 > 2 0 [21] >20 [21] > 2 0 1211 2 0 I211 2 0 [ 131) Inactive [ 1941
*Cat nictitating membranes. Approximate dose (mg/kg,
s.c.) to
Antihypertensive activity -
-
Active (211 Active (211 Active [ 2 1 ] -
-
-
-
cause 30-5046 coverage
Of
the eyes.
1 4-Benzodioxans
The affinity of phenoxyethylamines for adrenergic receptor sites is enhanced by cyclization to analogous aminomethyl- 1 ,Cbenzodioxans such as piperoxan (XLVI, R'R2= (CH,),) which block a-receptors [240] . The introduction ofguanidine 194,138, 252, 2541 and quaternary ammonium [94] groups into 2-aminomethyl- 1,4-benzodioxan leads to compounds with adrenergic neurone blocking properties similar t o those of guanethidine and the
156
GUANIDINES AND ADRENERGIC NERVE ENDINGS
openchain aryloxyalkylguanidines and quaternary ammonium derivatives. The pharmacology of the guanidine derivative, guanoxan (Envacar) (XLVII), has been studied in some detail [94, 254, 2551. It has many properties typical of
( XLVI
1
j
XLVII i
adrenergic neurone blocking agents, causing relaxation of the nictitating membrane of conscious cats and abolition of contractions of the nictitating membranes evoked by stimulating the post-ganglionic cervical sympathetic nerve of anaesthetized cats. Experiments o n the spleen indicated that during nerve stimulation, guanoxan prevented the release of noradrenaline from nerveendings, and that this effect was reversed by amphetamine. Long-lasting depletion of noradrenaline following administration of guanoxan has been reported 194, 2541. The antihypertensive action of guanoxan, which is comparable t o that of guanethidine, has been demonstrated in animals and in man [94, 256, 2571. Structure-activity relationships amongst compounds related t o guanoxan have some interesting features (Table 3.15). Introduction of a single methyl group into position 5 of the aromatic ring results in an almost complete loss of adrenergic neurone blocking activity. Moving the position of this substituent to positions 6, 7 or 8 gives rise t o compounds with increased activity. The last of these compounds (XLVIII, R = %Me, n = 1) at a dose of 30 mg/kg, caused the
most pronounced relaxation of the nictitating membranes observed in this series [ 1381 . This apparent enhancement of adrenerBc neurone blockade by orfho substitution is somewhat analogous t o the increase in blocking activity resulting from ortho substitution in phenoxyalkylguanidines. Introduction of more than one methyl group into the aromatic ring giving 5,7-, 6,7-, or 5&disubstituted compounds, resulted in loss of all activity 194, 1381. The effect of chlorine substitution follows a rather similar pattern [ 1381 . The adrenergic neurone blocking activity of guanoxan is maintained in the homologous compound in which the side chain is increased by one carbon
157
G. J. D U R A N T , A . M . ROE, A. L. G R E E N Table 3.15. T H E A C T I V I T Y OF 2GUANII)INOALKYL-1,4-BENZODIOXANS
Formula (XLVIII)
R
n
H 5-Me 6-Me 7-Me 8-Me 5,s-Mez
1 1 1 1
5CI 7CI 6,7432 H H
Adrenergic neurone blocking activity *
10 [94,138,254] >20 [138] 20 [ 138) 5 [ 138) 20 [ 138) > S O (94,1381 >20 [138] 20 [ 1381 20 [ 1381 20 [ 138) 20 [ 1381
1 1 1 1 1 2 3
Antihypertensive activity High activity [94,138,2541
-
Active 1138)
Formula ( X L K )
R'
RZ
H
H H Me
Met H H H
R3
Adrenergic neuronr blocking activity *
Antihypertensive activity
Me 10 (94)20 [138] H 20[95] H >20[95] -CHZ-$ -CHz-*
20 [95]
* >20 1951 Formula (L)
R
H H H H H H H H H H H 5,8-Mez
X NHC(:NH)NHMe NHC(:NMe)NHMe N M e C ( : NH)NH2 ,pCHZ NH.$ 1 NHCHz NHC(:NH)NHNHz N H .C ( :N H N H 2,N H N H 2 NH.NHC(:NH)NHz NHC(:NH)NHC(:NH)NH* $(:NH)NH* NMe3 hEt3 hMezEt
Adrenergic neurone blocking activity*
Antihypertensive activity
>20 [ 1381 >20 [138] > 2 0 [138]
>20[138] > 2 0 [ 1381
>20 [138] >20 [21] > 20 [ 1381 20 [ 1381 25 [ 941 > 25 [94] 10-20 1941
*Cat nictitating membranes. Approximate dose (mg/kg, s.c.) t o cause 30% [ 941 or 30-50% 1 2 1 , 9 5 , 1381 coverage of the e y e s . ?Trans. SSyn. * * Anti.
158
GUANIDINES AND ADRENERGIC NERVE ENDINGS
atom (XLVIII, R = H, n = 2 ) , although amme-depleting power in rat tissue is decreased 11381. The isomeric branched chain structure (XLIX, R' = R2 = H, R3 = Me) also has potent adrenergic neurone blocking properties but causes less depletion of the noradrenaline in mouse hearts than guanoxan I941 . The isomeric 3-methyl substituted compound (XLIX, R' = Me, R2 = R3 = H) (either the pure trans-compound 12571 or the cis-:trans-niixture [ 1381) had a shorter duration of action than guanoxan. Syn- and anti-isomers* of the cyclopropyl analogue (XLIX, R' = H, R2R3 = CH2) have also been investigated [ 9 5 ] . The former was much shorter acting than guanoxan [ 9 5 ] , whilst the latter compound was devoid of adrenergic neurone blocking activity.
N-Methylation of guanoxan leads t o complete loss of activity in the nictitating membrane assay [ 1 3 8 ] . This is similar t o the findings in the open chain phenoxyalkylguanidines [ 1 3 5 , 2 4 2 1 . Analogues containing cationic groups other than guanidine have also been examined (Table 3.15). Various amino- and diamino-guanidine derivatives are reported t o have a very low order of adrenergic neurone blocking activity [21, 1381. Some activity was found with related amidine and amidoxime derivatives [ 1381 . ATongst quaternary a m m o n i u T derivatives, the compounds (L, R = H, X = NMe, and R = 5,8-Me2, X = NMe,Et) caused relaxation of the nictitating membranes in cats, although they were less active than guanoxan [94]. 1.3-Benzodioxoles
1,3-Benzodioxole analogues (LI, R = H, 4-Me, 4,7-Me2, X = NHC(:NH)NH,) of the active 1,4-benzodioxans have been synthesized [94] , but their adrenergic
(LI) neurone blocking activity was less than that of the corresponding 1,4-bemodioxans [94] (Table 3.16). However, the quaternary ammonium compound (LI, *The terms syn- and onti- refer to the configuration of the guanidine group with respect to the methylene group of the dioxane ring.
G. J. DURANT, A. M. ROE, A. L. GREEN.
159
+
R = 4-Me, X = NMeEt,) had a more potent adrenergic neurone blocking action than any of the guanidines in this series [94] . Table 3.16. THE ACTIVITY OF 2GUANIDINOALKYL-1,3-BENZODIOXOLES(LI)
R
X
H 4-Me 4.7-M~ H 4-Me 4-Me 4-Me
N H C ( : NH)NH2 NHC(:NH)NH2 NHC(:NH)NH2 &Me3 kMe3 kMeEtz kEt3
Adrenergic neurone blockingactivity* (941
25-50 10-25 25
>
-t -t
10- 25 50
*Cat nictitating membranes. Approximate dose (mdkg, s.c.) to cause 30% coverage o f the eyes. ?Powerful nicotine-like drug, toxic to conscious cats.
2,3-Dih ydrobenzo furans The guanidine and quaternary trimethylammonium deriva$ves of the 2,3-dihydrobenzofuran (LII, R = 7-Me, X = NHC(:NH)NH2 or NMe3) which
bear a direct relationship to xylocholine (XXXIX) and the corresponding guanidine (XLII) (and also to bretylium and aralkylguanidines) have a prolonged adrenergic neurone blocking action [93]. The release of noradrenaline from the spleen during nerve stimulation is inhibited by both these compounds, but the noradrenaline content of rat hearts is not apprecia6ly lowered 24 hours after a single dose of either of these drugs. In cats the guanidine (LII, R = 7-Me, X = NHC(:NH)NH2) has a sympathomimetic action on the blood pressure and the nictitating membranes resembling that of guanethidine. In large doses the quaternary compound (LII, R = 7-Me, X = NMe3) has a sympathomimetic action that for some time antagonizes the relaxation of the nictitating membranes resulting from the adrenergic neurone blockade. This action, which is probably due to release of catecholamines, causes anomalous dose-response curves when relaxation of the nictitating membranes is used as a method of assay for adrenergic neurone blocking activity [93].
160
GUANIDINES AND ADRENERGIC NERVE ENDINGS
Substituted 2,3-dihydrobenzofuranyl guanidines (LII, X = NH.C(:NH)NH2) were studied for their relative activities in relaxing the nictitating membranes of cats, and the following order of potencies was obtained [93] : R = 5-CI > 7-Me = 5-Me > H > 6-Me (Table 3.17). Quaternary ammonium analogues of the S c h l o r o and 5- and 6-methyl substituted guanidines were inactive as adrenergic neurone blocking agents Table 3.17. THE ACTIVITY OF 3-GUANIDINO-2,3-DIHYDROBENZOFURANS (LII)
R H 7-Me 6-Me 5-Me 5C1 H 7-Me 6-Me 5C1 ?-Me 6-Me 5-Me 5C1 7-Me
X NH€(:NH)NHl NHC(: NH)NH? NHC(:NH)NH2 NH C(:N H ) NH 2 NHC(:NH)NH2 &Me3 kMe3 &Me3 kMe3 kMezEt kMe,Et $MezEt NMezEt kMeEtz
Adrenergic neurone blocking activity* [ 931
0.15 0.35 0.10 0.35 0.65 0.10 0.20 0 0 0.30 0 0 0 0.20
*Relative activities (xylocholine = 1.0) from weight for weight comparisons of the subcutaneous doses necessary t o relax the nictitating membranes of cats t o cover 30% of the eyes.
(Table 3.17) suggesting, perhaps, that in this type of compound substituents ortho t o the ether linkage are more important for activity in the quaternaries than in the guanidines. Aralkylguanidines
Following the discovery that xylocholine blocked transmission at sympathetic nerve terminals, intensive chemical and biological investigations of related compounds revealed that various benzyl quaternary ammonium salts were potent and selective inhibitors of adrenergic nerve function. A review of compounds of this type has been published by Copp [239] . N-2-BromobenzylN-ethyl-N. N-dimethylammonium tosylate (LIII) (bretylium) has been studied extensively [237, 2581, and suppression of adrenergic nerve function has been demonstrated in numerous test situations in various animal species. That adrenergic neurone blockade was caused by inhibition of the release of the neurotransmitter substances during nerve stimulation, was shown by
G. J. DURANT, A. M. R O E , A. L. G R E E N
CH2 ;Mule,
Et
161
Tos
Table 3.18. THE ACTIVITY OF SUBSTITUTED BENZYLGUANIDINES (LIV)
R
'
RZ
R3
H H H H H H H H ti H Ii H I1
I1 H H ti H H H ti H H H li H H I1 H H ti ti ti
H 11
H ti ti H H H H I1 I1 Me H (+)Me H ( )hie H Me H Me H Me H (+)Me H (
)Me
Me Me
H H H
R4
R5
A drenergic neurotie
A ntihyperrensive
blocking activity Cat nictiraring Ptosis in membranes. micet [ 2591
activin
H H H H H H H H H H H ti
> 2 5 $ [ 1391 0 < I S [ 141, 239) 1s [ 1401 > 3 0 11411 > 3 0 [ 1411 10 [ 1411 > 3 0 [ 1411 6 0 [ 141 I 3 - 5 0 11391 + <3U [ 2 3 9 ) . > 3 0 [ 141115[140],>50[139] + > 3 0 [1411 15 [ 1411 I S [ 141) 30 [ 1411 5-10 [ 1391 ++ 30 [ 239. 141 I -
H
> 3 0 [ 141)
H H H
H H I{ H H H
t1
I1
H
H H H H H H H
30[1411 2 5 [ 2441 <15[1411 so [ 2441 >so [ 1391 >50 11391 1.25-2.5 [ 1391 1.25-2.5 [ 1391 1.25-2.5 [ 1391 2.5-5.0 [ 1391 2 . 5 - 5.0 [ 1391 1.25-2.5 [ 139) 2.5-5.0 [ 1391 1.25-5.0 [ 1391
H
H H
H H H H H H H H 11 11
H H tl H H li It t1
H H H H 11
'H
H H H H
H
< <
-
<
Inactive [ 141) -
-
Active [ 1411 -
Inactive [I411 -
-
Active [ 141) -
<
-
+ '
0
++ +++ ++ +++ +++ +++
+++ +++
Hypertensive [ 1391 Active [ 1391
162
GUANIDINES AND ADRENERGIC NERVE ENDINGS Table 3.18. continued
R'
4CF3 2.4-Mez H 4C1 H 4C1 H 2CI 4CI H 2CI 3-Me 3CI 4C1 4CF3 H 2421 H
H
R2
R3
R4
R5
Me
Me Et Et H H H H H H
H H H H Me Me H H H H
H H H H H H Me Me Me Me
H H H H H H H H H Me
H H H H H H H H H
H H H H H H H H NH,
Me Me Me Me Me Me Me Me H
Me Me
Me Me Me Et Et Pr H
Adrenergic neurone blocking activity Cat nictitating Ptosis in membranes* mice? [ 2591
< 15 [ 1 4 1 ] 5-10 [ 1391 2.5-5.0 [ 1391 > 2 5 [139] > S O [ 1391 > 3 0 [ 1411 > 3 0 [239] 10[239] >30 [141] 1-3 [10;239,242,260] <30 [ 141) 3-10[10,239,242,260] <_S_o[239] < 3 0 [239] > 3 0 [141] > 3 0 [ 1411 10 [ 2391 w t (2391 30 [ 2391 > 2 0 1211
-
+++ + 0
-
-
+++** +++** -
Antihypertensive activiv
Active [ 1411 Active [ 2601 Active [ 2601 -
-
-
-
-
-
-
'Approximate dose (mg/kg, s.c.) t o cause-25-30% coverage o f the eyes. Figures in italics represent interpolated data. tEstimated 2 h after injection of 20 mg/kg (0 = negligible, + = slight, ++ = moderate, +++ = marked). $1.~.administration. "Ptosis production in rats [ 3 5 8 1 . ttTransient activity [ 2393.
measurements of noradrenaline release from the spleen of cats 12371. In shortterm experiments in numerous animal species only slight depletion of tissue catecholamines has been found with bretylium. The low capacity of bretylium for releasing catecholamines is probably its major distinction from guanethidine in its pharmacological action. Bretylium has been used for control of hypertension, but its value as a clinical agent is limited by the rapid development of tolerance [ 101 . Cuanidine analogues of benzyl quaternary ammonium salts have afforded a series of compounds with an interesting range of activities. Although benzylguanidine (LIV)* itself causes only barely significant adrenergic neurone *See footnote on P. 147
G. J. DURANT, A. M. ROE, A. L. GREEN.
163
blockade [ 139, 2591, the introduction of substituents into the aromatic ring, on the a-carbon atom, or on the terminal nitrogen atoms, can lead t o compounds exhibiting a high degree of activity. Available data for adrenergic neurone blocking activity and indications of antihypertensive action are summarized in Table 3.18. Where necessary to provide a standard (although very approximate) measure of potency, namely the minimum subcutaneous dose required to produce 25-30 per cent coverage of the eyes, the liberty has been taken of extrapolating or interpolating semiquantitative data on the effects of these drugs on the nictitating membranes in conscious cats. Where available, adrenergic neurone blocking potencies assessed from the production of ptosis in mice are included. The essentially semiquantitative nature of these assessments of adrenergic neurone blocking activity must be emphasized.
(LV. R=H) (LVI, R=CL)
The first published report [242] on the adrenergic neurone blocking activity of aralkylguanidines showed that N , N', N'Lbenzyldimethylguanidine (bethanidine, Esbatal, LV) and its ortho-chloro analogue (LVI) were about twice as active as guanethidine in relaxing the nictitating membranes of cats. Subsequently, the higher potency of bethanidine (LV) in this test was demonstrated [ 2601 . Both compounds resembled bretylium and guanethidine in potentiating the effects of adrenaline and noradrenaline on the blood pressure and the nictitating membranes. The compounds differed in the extent to which they inhibited the response of the nictitating membranes and the blood pressure of cats to tyramine given 24 hours later: bethanidine (LV) was much more active, and comparable to guanethidine in this respect, whereas the weak action of the ortho-chloro analogue (LVI) resembled that of bretylium (LIII) [260] . Again (LV), but not (LVI), caused appreciable depletion of the pressor m i n e content of the spleen of cats on chronic administration. Bethanidine has proved an effective and well-tolerated antihypertensive agent ihn man. A low incidence of side-effects, particularly the diarrhoea which is often troublesome during treatment with guanethidine, has been reported [ 10, 261, 2621. Adrenergic neurone blocking activity is increased when substituents are introduced into the orrho- and para-positions of benzylguanidine (Table 3.18); active compounds include the bromo (a particularly close analogue of bretylium), chloro and trifluoromethyl derivatives (LIV, R' = 2-Br, 2-C1, 2- and 4CF3) [140, 141, 239, 2421. The 4-trifluoromethyl derivative, which has a relaxing effect on the nictitating membrane of cats comparable in intensity and duration to bethanidine, also decreased blood pressure in hypertensive dogs [ 1411 . Certain
164
GUANIDINES AND ADRENERGIC NERVE ENDINGS
ring-disubstituted benzylguanidines, notably 2,4- and 2,6-dichlorobenzylguanidine, are also active adrenergic neurone blocking agents (LIV, R' = 2,4-C12, 2,6-C12) [ 141.2393. Derivatives of 1-phenylethylguanidine (LIV. R2 = Me) are potent adrenergic neurone blocking agents, as has been demonstrated by their effects on the nictitating membranes of anaesthetized and conscious cats, on the Finkleman preparation, and in mice [ 139, 2591. This type of compound is of particular interest as the existence of an asymmetric centre permits the separation and the study of optical isomers. Racemic 1-phenylethylguanidine and also the (+)-isomer are almost inactive in conscious cats, whereas the (-)-isomer is very active both in conscious and anaesthetized cats. The (+)-isomer causes a rise in the blood pressure of anaesthetized cats, in contradistinction to the (-)-isomer which causes a prolonged fall in blood pressure and only a transient increase in heart rate. Furthermore, the (+)-isomer antagonizes the adrenergic neurone blocking action of (-)-1 -phenylethylguanidine, xylocholine and guanethidine in cats and mice [263]. It is this antagonism that accounts for the inactivity of the racemic compound. In contrast, both optical isomers of 1-p-tolylethylguanidine (LIV, R' = 4-Me, R2 = Me) are potent adrenergic neurone blocking agents, as are the racemates of analogues having ortho ring substituents [ 139, 2591 (Table 3.18). Racemic 1-p-trifluoromethylphenylethylguanidine(LIV, R' = 4-CF3, R2 = Me) causes prolonged relaxation of the cat nictitating membrane [ 1411. This compound decreases the blood pressure of renal and neurogenic hypertensive dogs, and is reported to be notable for its lack of side effects [ 1411. Methylation of the terminal nitrogen atoms of benzylguanidine greatly enhances its activity, and retains or enhances the adrenergic neurone blocking activity of ortho- and meta-substituted compounds [239] . However, the activity of para-substituted compounds such as the trifluoromethyl derivative (LIV, R' = 4-CF3, R4 = R5 = Me) is apparently diminished by this substitution [ 1411. A study of structural modifications of the guanidine portion of bethanidine (LV) and its ortho-chloro analogue (LVI) indicates that adrenergic neurone blocking activity is optimized in this system by N, Nrdimethylguanidine substitution (LIV, R' = H or 2-C1, R4 = R5 = Me) [239]. Compared with the potent adrenergic neurone blocking activity displayed by numerous derivatives of benzylguanidine, the activity of derivatives of phenethyl; guanidines (LVII) and longer chain compounds is generally of a much lower order (Table 3.19). The parent compound (LVII) has a very weak relaxing activity on cat nictitatingmembranes and does not produce ptosis in mice [ 139,2591 .P-Hydroxyphenethylguanidine (LVII, Ar = Ph, R' = OH) also has only very weak adrenergic neurone blocking properties [264, 2651 . In contrast, the ortho-chloro derivative of the latter (LVII, Ar = 2.C1C6H4, R'.= OH) has a much stronger adrenergic neurone blocking action in cats and mice. These two guanylated arylethanolamines also differ in that depletion of tissue catecholamines is very marked with the former compound but is insignificant with the latter orthochloro compound [265]. It appears, therefore that the ortho-chlorine atom
165
G. J. DURANT, A. M. ROE, A. L. GREEN. Table 3.19. THE ACTIVITY O F PHENETHY LGUANIDINES AND RELATED COMPOUNDS (LVII) Ar
R'
Ph
H
R2 R3
H
H
R4 Rs
H
H
4C1C6H4 H H H H 3,4-(Me0)2 H C6H3 H H H H 2,6C1&6H3 H H H H 2,6-F2C6H3 H H H 2,6-Me2C6H3 H H H H Ph M e H H H 4-HOC6H4 H H H H 4-MeOC6H4 H Me H H Ph O H H H H Ph (-)OHH H H Ph (+)OH H H H 4ClC6H4 OH H H H 2CIC6H4 OH H H H 3,4Cl2C&3 OH H H H 4-MeOC6H4 OH H H H Ph OH H Me H Ph (-)OHH Me H Ph OH H H Me Ph H H NH2 H PhChIe2CHzNHC(:NH)NH2 4C1C6H4CH2CMe2NHC(:NH)NH2 rrans-PhCHCHNHC(:NH)NH2
H H H H H H H H H H H H H H H H H Me H
Adrenergicneurone blocking activity Cat nictitating Ptosis in membranes* mice?
An rihypertensive
activity
>25 $ [ 139,211 >SO (2441 0 ** [ 2 5 9 ] 3 0 j t [ 141) 3 0 [ 1401 > 2 0 (211 50 12441 25 [ 244) >SO 12441 0 [ 2591 50 [ 1391
>
-
> 2 5 11391 5-25$$ [265] > 2 0 [318] -
5 [2651 -
-
-
>20 30 >30 >25
>
-
0(259] + [ 2651 + [ 2651 + (2651 + [ 2651 + [ 2651 0 [ 2651 0 [ 2651 0 [ 265) tt [2651 0 [265]
-
Hypertensive 14331 -
0 (2591
[21] [ 2283 [228] [139]
\I
CH z Ph(CH2)$4HC(:NH)NHz. cis-PhCH=CH C H 2NHC(: NH)NH 2
> 2 5 (1391 Active [ 266 ]
0 [2591 -
Active [ 266,2671
*Approximate dose (mg/kg, s.c.) t o cause 25-300/0 coverage of the eyes, see text. Figures in italics represent interpolated data. ?Estimated 2 h after injection of 2 0 mg/kg 1 2 5 9 1 , or 100 mg/kg 1 2 6 5 1 (0 = negligible, + = slight, ++ = moderate, +++ = marked) $1.". administration. **Ptosis production in rats has been reported 13581 ransient response Erratic and only partial response
iY
causes a complete change in the mode of action at adrenergic nerve endings.
ArCHCH-N-C = NR4
I 1 II
R' R2 R%HR5 (LVII)
166
GUANIDINES AND ADRENERCIC NERVE ENDINGS
Cinnamyl and phenyl c yclopropyl guanidines
Cinnamylguanidines have antihypertensive properties 1266, 2671 (Table 3.19) and the cis-isomer (LVIII), which is reported t o be more active than the isomer with the trans configuration [266], has an action which is more rapid in onset and of shorter duration, than that of guanethidine [266, 2671. Blockade of adrenergic nerve fibres has been demonstrated and a similar mode of action to guanethidine appears likely [267] . The trans-phenylcyclopropyl derivative (LIX) is inactive as an adrenergic neurone blocking agent [ 139, 2591 ,but it is claimed to lower blood pressure [268]. The cis-phenylcyclopropyl isomer has not yet been described. As pointed out earlier, the cyclopropyl derivatives in the 1,4-benzodioxan series also demonstrate the importance of stereochemical configuration in the action of guanidines at adrenergic nerve endings. CH,.NH.C=NH
I
N H2
Ph
/H
'c-c H'
'1 \NH.C=NH
c H2
I NH2
(L[X)
(LVIII Heteroaromatic alkylguanidines
Various guanidines linked by an alkylene chain to heteroaromatic rings have shown activity at adrenergic nerve endings; the reported activities of compounds in this class are listed in Table 3.20. These include the thenylguanidine (LX) Table 3.20. THE ACTIVITY OF HETEROAROMATIC ALKY LGUANIDINES R'.(CH~~.NHC(:NR~NHR~ A drenergic neurone
R'
RZ
n
hlocking activity*
4-Pyridyl 2-Pyridyl 4-Imidazolyl 2-F~r~l 2-Thienyl 10-Phenothiazinyl 2CFrlO-Phenothiazinyl
H H H H Me H H
2 2 2 1
> 3 0 [ 1401
1
3 3
30 [ 1401
> 3 0 [ 1401 >30 [ 1401 1 t [2391 >40 [ 1351 >50 [135]
A n tihypertensive activity
Inactive [210] Active [ 2101 Inactive [ 1271 -
'Cat nictitating membranes. Approximate dose (mg/kg, s.c.) to cause 25-3096 coverage the eyes. Figures in italics represent interpolated data. +Short acting [ 2391
Of
which has a very potent, but transient, action in cats [239]. In contrast to the activity of (LX), the replacement of benzene by its isostere, thiophene, in benzyl quaternary ammonium derivatives, leads to inactive compounds [2391 .
G. J. DURANT, A. M. ROE, A. L. GREEN.
167
2-(2-Pyridyl)ethylguanidine (LXI) is said to be more active than the Qisomer (LXII) as an antihypertensive agent [210].However, the reverse order of activities
Q-w,.
NH.c=NMe
I
CHI CH,. N H * C= NH
NHMe
I
NH2
(LX)
(L XI)
(LXIII)
(LXII)
is reported for adrenergic neurone blocking activity in cats [ 1401. The related 3-pyridylmethylguanidine(LXIII) has a weak ephedrine-like action [2691 . C H i C=NOH
I
CH,.C=NOH
I
NH2
(LXIV)
(LXV)
The bicyclic amidoximes (LXIV) and (LXV)cause a reduction in blood pressure in various animal species, but apparently they are not adrenergic neurone blocking agents [270].The activity of (LxIV)is thought to be mainly due to catecholamine release and subsequent depletion, whilst the action of (LXV)involves blockade at a-receptors [270].
-.
Tetrahydroisoquinoliner
R
\
l
a
N
- C=N R 2
I
‘Et
(LXVI)
NHR3
(LXVII)
1,2,3,4-Tetrahydroisoquinolineis an example of a cyclized ardkylamine Moderate adrenergic neurone blocking activity has been demonstrated by the
GUANIDINES AND ADRENERGIC NERVE ENDINGS
168
quaternary ammonium derivative (LXVI) [239] (Table 3.21), whereas the corresponding guanidine (LXVII), debrisoquine, has a potent action resembling that of bethanidine (LV). The drug is an effective antihypertensive agent, both pharmacologically and clinically [271-2761 . Appreciable depletion of tissue catecholamines does not occur [271]. Like bethanidine, debrisoquine has a shorter duration of action than has guanethidine, and does not cause diarrhoea, a common drawback with guanethidine. Table 3.21. THE ACTIVITY OF TETRAHY DROISOQUINOLINE DERIVATIVES (LXVII)
R'
RZ
R3
H 6,7-(MeO)z 7-Br H H
H H H Me -CH2CH2-
H H H Me
Adrenergic neurone blocking activity
Antihypertensive activiv
Active [271] Active [ 2771 Active [ 278) Inactive [ 2791
Active Active Active Active Active
[271-2761 [ 1431 [277] 12781 [279]
The ring-substituted derivatives (LXVII, R' = 6,7-(Me0)2 and R' = 7-Br) are also potent anti-hypertensive agents [ 143, 2771 . The pharmacological profile of the latter (guanisoquin) includes adrenergic neurone blocking activity on cat nictitatingmembranes, where it has about one-fourth the potency of guanethidine, pronounced catecholamine depletion and local anaesthetic activity. Although the hypotensive effect is considered to be primarily due to catecholamine depletion and adrenergic neurone blockade, centrally mediated interference with vasomotor tone and peripheral vasodilatation are also considered to be partly responsible 12771. - The dimethylguanidine (LXVII, RZ = R3 = Me) causes vasodilatation but lowers blood pressure as a consequence of adrenergic neurone blockade [278]. Apparently, the related imidazoline (LXVIII) is not an adrenergic neurone blocking agent but a hypotensive, which acts by vasodilatation and blockade of a-receptors [279] .
iL XVlIIl
(LXIXI
The tetrahydrobenzazepine (LXIX) related to debrisoquine (LXVII) is reported to be a potent adrenergic neurone blocking agent (three-fifths as potent as guanethidine in anaesthetized cats) [280] . Marked sympathomimetic activity is not associated with (LXIX) and in this respect it is similar to the hexahydrobenzazo-
G. I. DURANT, A. M. ROE, A. L. GREEN.
cine analogue (XXXI) of sympathomimetic activity.
169
guanethidine, which also lacks appreciable
Miscellaneousguanidines Alkylguanidines
Hypotensive effects caused by simple alkylguanidines such as methyl- and ethylguanidine (LXX, R' = Me, Et), and even by guanidine itself, were recorded by Ales [281] in 1926. More recently, these and other simple guanidines have been shown to affect neuromuscular and ganglionic transmission [282,283]. A review of the general pharmacology of alkylguanidines and related amidines has been published [36a]. Methyl- and N, N -dimethyl-guanidine (LXX, R' = Me, RZ=H or Me) show antagonism against ganglion blocking agents, whereas N,N-diisopropylguanidine (LXXI) is itself a powerful ganglion blocking agent. This last activity is understandable in view of the structural similarity of (LXXI) to pempidine (XXVII). Me
R' NH .C=NH
I
I
CH -M e
\
NHR~
IL XX)
CH -Me
I
Me
(Lxxr)
Short, Ours and Ranus [228] found that,whereas straight chain alkylguanidines (LXX, R' = Bu or CIH1,) were devoid of adrenergic neurone blocking activity, some branched-chain compounds, for example (LXX,'R' = MeJ or Me3CCHz), were active (Table 3.22). The presence of a tertiary carbon atom separated from the guanidine group by not more than one carbon atom appears to be essential for appreciable adrenergic neurone blocking activity in simple alkylguanidines [228] . t-Octylguanidine (LXXII, guanoctine) is an antihypertensive drug with a guanethidine-like action both as an adrenergic neurone blocking agent and as a depletor of endogenous noradrenaline [ 2841 . Unlike guanethidine, t-octylguanidine shows little sympathomimetic activity. A direct vasodilatation has been demonstrated, but it is doubtful whether this plays a very important role in the action of this drug. The possibility of a central
GUANIDINES AND ADRENERGIC NERVE ENDINGS
170
component in the hypotensive action of this guanidine has also been suggested [284]. The compound has been investigated clinically and is reported to be an effective antihypertensive drug with few side effects [285]. Table 3.22. THE ACTIVITY OF ALKYLCUANIDINES R'NHC(:NH)NHR~
R'
R2
Adrenergic neurone blocking activity *
Bu nC8H 17 But But Me 3CCH 2CMe Me 3CCH &Me2 Me3CCH 2 Me3CCH2CH2 E t 3CCH 2 Me 3CCH 2CH(Me)CH 2CH EtC(Me)2
H H H PhCH2 H Me H H H H CN
>30 (2281 >30 12281 <15 (2283 >3b[2283 < 2 (228,2841 30 [228] 15 [ 2281 >30 [228] < 1 5 [228] 30 [ 2283 Inactive [ 2 2 9 . 2 8 6 ]
Antihypertensive activity
-
Active (284,2853
< >
-
Active [ 229, 286, 2871
*Cat nictitating membranes, approximate dose (mg/kg, s.c.) t o cause Z S Q coverage of the eyes.
N-Cyano-N'-t-amylguanidine(LXXIII, guancydine) is reported to be a potent and moderately long-acting hypotensive agent [ 229, 2871 . However, adrenergic neurone blockade is not part of the mechanism of action of this drug, but antagonism of angiotensin, an action not associated with adrenergic neurone blockade, has been found with this cyanoguanidine [229, 2861 .
Ye
Et .C.NH.C=NH
I
Me
(LXXII)
I
NHCN
(LXXIII)
A rylguanidines
Certain aromatic guanidines (and biguanides) are known to cause a reflex fall of blood pressure and heart rate by an action on receptors in the heart [288] . However, there have been no reports of arylguanidines exhibiting activity at sympathetic nerve endings. o-Bromophenylguanidine (LXXIV) does not affect cat nictitating membranes [239] .
G. J. DURANT, A.M. ROE, A. L. GREEN.
171
2-Arylaminoimidazolines (LXXV, R = ArNH) are related chemically to guanidines as well as to 2-imidazolines. Substituted 2-imidazolines exhibit a range of activities varying from vasodilatation, often accompanied by a-adrenergic blockade (for example tolazoline, Priscol, Priscoline, Vasodil, Benzidazol, LXXV, R = PhCH2), to vasoconstriction (for example naphazoline, Privine, Rhinoperd, Niazol, LXXV, R = I -CI0H7CH2). Some 2-arylaminoimidazolines have been investigated by Hutcheon and co-workers [279], who found that the naphthalene derivative (LXXV, R = I-CloH7NH) causes vasoconstriction and a rise in blood pressure, together with some a-adrenergic blockade. Derivatives of 2-anilinoimidazoline(LXXV, R=PhNH) have recently proved to be a very interesting class of hypotensive drugs. The most widely investigated compound (LXXVI, clonidine, Catapres, Catapresan, ST 155) causes a prolonged decrease of blood pressure, accompanied by bradycardia, inhibition of pressor reflexes, and decrease of cardiac output [289,290] .No structure-activity data have appeared, although the structural features required for activity are said to be fairly specific [290]. Compound (LXXVI) has proved effective clinically in the treatment of hypertension [ 29 1-2931 . An initial vasoconstrictor action has been identified with direct stimulation ofa-receptors [294] . The effects of stimulating adrenergic nerves are prevented only at high doses, and no depletion of heart catecholamines takes place following administration of compound (LXXVI) [289]. It appears most unlikely that the compound causes a reduction in blood pressure by blockade of the peripheral sympathetic nervous system, and a central action appears more
I LXXIVJ
(LXXVJ
(
LXXVI 1
likely [295, 2961. Recently, it has been found that the hypotension in dogs and cats is very pronounced following intracisternal administration, and the drug has been classified as an antihypertensive agent with a specific blocking effect on cardiovascular sympathetic centres [ 297,2981 . Thusderivatives of arylguanidines often possess marked antihypertensive activity, although this may not result from an action at sympathetic nerve endings, and the compounds cannot be classed as adrenergic neurone blocking agents. Structural requirements for adrenergic neurone blockade
From the discussion on close analogues of guanethidine, it may be concluded that adrenergic neurone blocking activity requires the structural unit (LXXVIIa) comprising a nitrogen atom linked to the guanidine via an alkylene chain, in which R' - R8 are selected alkyl (or aralkyl) radicals or hydrogen. Depending on
172
GUANIDINES AND ADRENERGIC NERVE ENDINGS
the nature of the groups R' - R8, a further CHz or NH group may be inserted between the guanidine and the carbon atom bearing Rf and R6. In the branched chain structures (LXXVIIa, various R3 - R6 = Me), the side-chain nitrogen atom R3 RS R'RzN.~.~.NH4i=NR7 Ar C-NHC=N R Ar0.C-C .NH-C=NR
II
R4 R6
I I
.-
NHR*
I1
I
1 1
NHR
I
NHR
(LXXVlla) (LXXVIIb) (LXXVIIC) is no longer an essential requirement for activity and may be replaced by hydrogen or an alkyl group. The activity of aralkyl- (LXXVIIb) and aryloxyalkylguanidines (LXXVIIc) demonstrates that adrenergic neurone blockade does not demand the presence of an additional basic centre. The activity of benzylguanidine and phenoxyethylguanidine is greatly enhanced by appropriate substitution or cyclization. However, the complexity of structure-activity relationships is such that no satisfactory general structure-activity theory or receptor model has yet been proposed. A lipophilic group linked to a guanidinium (or similar) ion appears to be the onlycommon feature amongst the active compounds. An attempt has been made by Augstein, Green, Monro, Wrigley, Katritzky and Tiddy [21] to relate the adrenergic neurone blocking activity of aryloxyalkyl-guanidines and
( LXXVIII
1
(LXXIX)
(Reproduced by courtesy of the American Chemical Society)
-aminoguanidines to an intramolecularly hydrogen bonded conformation. In an extension of Belleau's hypothesis [299] concerning the conformational requirements for the blocking activity of 0-haloalkylamines on a-adrenergic receptors, they suggested that, if the conformations (LXXVIII) and (LXXIX) are adopted, the guanidine group is brought to the optimum distance from the aromatic centre required for effective adrenergic neurone blockade. This idea affords one explanatior for the loss of activity caused by methylation o f N ' in the guanidine (LXXVIII, Y- = CI, n = 2) and the retention of activity in compound (LXXIX, Y = R = Me). Hydrogen bonding should be prevented in the former, but
G. J. DURANT, A. M. ROE, A. L. GREEN.
173
should not be affected in the latter. This concept also affords an explanation for the inactivity of 3(2,6-dichlorophenyI)propylguanidine [ 2 I] , since it lacks a suitable group adjacent t o the aromatic ring with which the guanidine group can form a hydrogen bond. In ortho-disubstituted anisoles, steric restrictions lead t o the &-carbon being displaced from the plane of the aromatic ring and the resulting inhibition of resonance will increase the basicity of the ether oxygen. Ortho-disubstitution of phenoxyalkylguanidines should therefore enhance the hydrogen bond donator properties of the oxygen atom and facilitate the interactions shown in (LXXVIII) and (LXXIX), providing a neat explanation for the increased activity of (LXXVIII) and (LXXIX) when Y # H. It should be noted, however, that the relative activities of some bicyclic aryloxyethylguanidines do not support this idea that a hydrogen-bonded conformation can bring the aromatic ring and the guanidinium function into the optimum distance. Thus guanoxan (XLVII) is active, as is the syn-cyclopropyl analogue (XLIX, R' = H, RZR3 = CH2), but the anti-isomer, in which the guanidinium function can hydrogen bond to the 1-oxygen atom, is inactive. (LII) cannot Further, although the active 3-guanidino-2,3-dihydrobenzofurans form a hydrogen bond between the guanidinium function and the oxygen atom, in these compounds the distance between the aromatic ring and the guanidinium function is similar to that found in the active benzylguanidines. The above speculation [21]may be extended to include the related quaternary ammonium compounds such as xylocholine (XXXIX). It is probable that the volumes of the guanidinium ion and the trimethylammonium group are similar. The ionic radius of the guanidinium ion (IX) is about 3A; the ionic radius of the tetramethylammonium ion has been estimated [300] to be 34A, although rather smaller values have also been proposed [301-3031 . Crystallographic analyses of muscarine iodide [304], choline chloride [305] and acetylcholine bromide [306] have revealed that the carbon to nitrogen distance is about 1 .SA,and that a hydrogen bond (C-H--Odistance 2.87-3.07A) exists in the crystals of these compounds. In xylocholine the two ortho subslituents inhibit the delocalization of t h q oxygen 7r-electrons and it is possible that the oxygen atom is sufficiently basic tot cause the hydrogen-bonded conformation (LXXXltp be adopted.* Some correlations have been pointed out between the nicotine-like stimulant activities of substituted aryloxyethylammonium salts and the angle of twist between the side-chain and the aromatic ring (and hence the basicity of the oxygen atom) [307,308). The possibility that 0---H-C bonding might stabilize a conformation that has adrenergic neurone blocking activity has not been suggested previously. This concept could be extended to include alkylamino-
* The conformation (LXXX) has been confirmed [ 306al by a single-crystal X-ray analysis o f xylocholine bromide. The methyl-carbon t o oxygen separation is 2.949 k 0.009A
174
GUANIDINES AND ADRENERGIC NERVE ENDINGS
ethylguanidines, such as guanethidine, where a N---H-M bond can be envisaged.
(LXXX) OTHER PHARMACOLOGICAL EFFECTS ON SYMPATHETIC NERVES
Though the main action of guanidine derivatives is to interfere with the liberation of noradrenaline at adrenergic nerve endings, guanidines may affect the results of sympathetic nerve stimulation in other ways as well. Thus, guanethidine has a transient blocking action on sympathetic ganglia [207, 3091 and reversibly blocks a-receptors [3101 ; guanoxan causes transient blockade of a-receptors in dogs (2541 and rats [311], but not in cats [254] ; phenethylguanidine is also a weak antagonist of adrenaline on isolated rabbit intestine and uterus [3121 .Such actions, which are not confined to these three guanidines [94], are usually elicited only by high concentrations. This has discouraged any extensive study of the structure-activity relationships for these minor actions and makes it unlikely that any of them contribute significantly to the hypotensive action of the drugs. It was first noticed clinically that guanethidine-induced hypotension could be abolished by small doses of methamphetamine [313]. Amphetamine and related compounds have since been shown to reverse the adrenergic neurone blockade produced in animals by guanethidine [314-3161, guanoxan [254], bethanidine [260], (-)-1 -phenylethylguanidine [3151, and many other adrenergic neurone blocking drugs [226,245,3 151 . This reversing effect appears not to be associated with the sympathomimetic effect of amphetamine, since noradrenaline and tyramine are both inactive [3 14, 3 171 . Only very small doses of amphetamine are required (often less than one tenth of that of the blocking drug), and other types of sympathetic blockade are largely unaffected [315]. The specificity of this reversing effect is such that it can be used as a diagnostic test for distinguishing adrenergic neurone blockade from other types of sympathetic blockade (see p. 197). Antagonism of adrenergic neurone blockade by amphetamine has been attributed t o competition by amphetamine for the site on the nerve ending at which the guanidine derivative exerts its blocking action [314, 3161. It might consequently be expected that other guanidine derivatives, which themselves had no blocking action, would exert an antagonistic effect similar to that shown by amphetamine, and numerous examples of antagonism of adrenergic neurone blockade by guanidines have been reported [259, 315, 3181. The relative antagonistic potency amongst the compounds studied is largely independent of the nature of the drug causing adrenergic neurone blockade, although the absolute
G . J. DURANT, A . M . ROE, A. L. GREEN.
175
potency varies with both the nature and the dose of the blocking drug, which is what would be expected with drugs which competed for a common site. The available information on the relationship between structure arid potency in preventing guanethidine-induced ptosis in mice is summarized semiquantitatively in Table 3.23. The most active compounds are aralkylguanidines Table 3.23. ANTAGONISM BY GUANIDINE DERIVATIVES OF GUANETHIDINE-INDUCED PTOSIS IN MICE RNHC(:NH).NH2 R
Poteiicv*
PhCHz Ph (C H 3 2 Ph(CH33 PhCH(Me)CHZ PhCH(Et)CH 2 (+)-PhCH(OH)CH2 (-)-PhCH(OH)CH2 (+)-PhCH(Me) (+)-PhCH2CH(Me)
Reference
t
+ 0
+++ 0
+
0
+
0
+++ 0
+ 0
+ 0
I
Me
Me
PhCHz.NMeC(=NH)NH2 PhCHzCH(Me)NH2(Arnphetarnine)
+++ ++
*Based on dose required t o reduce intensity of ptosis due to by 50%. 0 10 mg/kg; + about 3 mg/kg; ++ about 1 mg/kg;
>
13151 13151
176
GUANIDINES AND ADRENERGIC NERVE ENDINGS
like mans-phenylcyclopropylguanidine(LXXXI) and N-benzyl-N-methylguanidine (LXXXII) which, when given alone, have no detectable effect on adrenergic neurones; however, two of the guanidines in the benzodioxole and benzodioxan series which did not possess adrenergic neurone blocking activity (Tables 3.15 and 3.16) were also inactive as antagonists. It is of interest that although amphetamine is a potent guanethidine antagonist, neither the guanidine (LXXXIII, R = H) directly derived from it, nor i t s p-methoxy analogue (LXXXIII, R = OMe) display any significant effect. Many of the antagonists in this test, such as benzylguanidine and phenethylguanidine, display weak blocking activity on the cat nictitating membrane [ 1391 . (+)-I-Phenylethylguanidine (LXXXIV) is an antagonist in mice and also antagonizes the relaxation of the nictitating membranes produced by adrenergic neurone blocking drugs in
(LXXXII)
conscious cats, but in anaesthetized cats it has a weak blocking action, whilst on the isolated rabbit ileum it is a potent blocking drug [ 1391 . If adrenergic neurone blockade is regarded as the result of an agonist action on an appropriate receptor, compounds like benzylguanidine might be regarded as partial agonists with moderately high affinity and low efficacy, and compounds like N-benzylN-methylguanidine (LXXXII) as pure antagonists with very high affinity and zero efficacy. Ph0.(CH2 ) 3 .NH.C=NH
p-RC,j H4 .CH2 .CH.NH.C=NH
I
Me
I
I
NH2
NH2
(LXXXV)
(LXXXIII)
(LXXXIV) Although this susceptibility to antagonism by amphetamine-like drugs is
G. J. DURANT, A. M . ROE. A. L. GREEN.
177
characteristic of adrenergic neurone blockade. some guanidines can also slightly delay the onset of the sympatholytic signs which follow the administration of reserpine [263.315]. Thiseffect most likely results from the monoamine oxidase inhibition produced by many guanidine derivatives. an action which is discussed later. 3-Phenoxypropylguaiiidine (LXXXV). but not guanethidine. antagonized ptosis due to either reserpine or tetrabenazine when given before. or together with. these drugs, but was ineffective when given 21 hours after reserpine [ 2191. Prevention of reserpine-induced sympathetic blockade is commonly used as a test for antidepressant activity and. on the basis of these observations. phenoxypropylguanidine was given a clinical trial in depressed patients. but without success [319]. It is by n o means certain that the ptosis caused by reserpine is primarily ot central origin [320], and consequentl). the ability to antagonize reserpine-induced ptosis should not be automaticall!. regarded as an indication of a central antidepressant action.
BIOCHEMICAL EFFECTS Depletion of noradrenaline Guanethidine
The characteristic pharmacological action of adrenergic neurone blocking agents istoinhibit responses to stimulation otadrenergic nerves. an action unaccompanied by any similar blockade of responses to injected noradrenaline. The demonstration [321] that the somewhat similar s!-mpathol~.ticaction of reserpine was associated with almost complete elimination of noradrenaline from the tissues suggested that guanethidine might act in a like manner. and only a short time after the antihypertensive activity of yanetliidine was first reported. the drug was indeed shown t o cause a marked fall in tissue noradrenaline [ 3 U . 4371. These original observations have been amply confirmed. Table 3 . 3 . containing a selection from the voluminous literature on the subject. shows that. in a variety of species. guanethidine causes a fa11 in the noradrenaline content of every peripheral adrenergically-innervated tissue examined. In all species, depletion does not appear to reach its greatest extent until at leist four hours after injection. irrespective of the dose of drug. The rate of recover!' is variable. but after large doses of guanethidine the noradrenaline level does not return to normal for several days. Although some depletion of brain noradrenaline has been reported, in this tissue both depletion and recovery are rapid and not dose-dependent [ 3 7 _ 2 ] .Guanethidine, being largely protonated at neutral pH. does not readily cross the blood-brain barrier, and only trace amounts have ever been detected in the brain after injection [323-3251. This is true also of bethanidine (IV) [326] and guanisoquin(LXVI1, R' = 7-Br, R 2 = R3 = H ) [ 3 2 7 ]. In the very young chick, in which the blood-brain barrier is poorly developed. guanethidine does cause
Table 3.24. EFFECT O F SINGLE INJECTIONS O F GUANETHIDINE ON TISSUE NORADRENALINE
Species Mouse Mouse Mouse Mouse Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat Rat Guinea-pig Guinea-pig Rabbit Rabbit Rabbit Rabbit Rabbit Rabbit
Tissue Heart Heart Heart Heart Heart Heart Heart Heart Heart Heart Heart Brain Adrenals Brain Hypothalamus Brain Brain Spleen Intestine Adrenals Heart (atria) Heart Heart Heart Spleen Brain Adrenals Superior cervical ganglion
Dose (mg/kg) and rou re
Time (h) after injection
1.25,25,20 i.p. 0.3,1,3,10 S.C. 10 S.C. 20 S.C. 15 i.p. 15 S.C. 20 i.p. 10 S.C. 35 i.v. 25 i.v. 8 i.v. 10 S.C. 10 S.C. 5 S.C. 5,15 i.p. 5,10,20 S.C. 10 S.C. 15 S.C. 15 S.C. 150,200,400 i.p. 3,10,30 i.p. 30 i.p. 1 2 3 i.v. 1 2 3 i.v. 12.5 i.v. 12.5 i.v. 1 2 5 i.v.
16 4 1 24 2,24 1,2,4,6,18,48 5,24,72 1 4,24,48,72 0.5,1,2 1,5,10,20 1 1 1,3,6
15 i.v.
2 4 1,2,4,6,18,48 2,4,6,18,48 12 24 24 1,2,4,18 48,72,120 18 18 18
Percentage depletion of noradrenaline
Reference
25,40,80 35,60,80,86 51 40 50,o 25,35,65,80,75,30 90,70,30 50 90,95,75,50 10,20,50 10,70,85,80 0 0 48,60,28 0 10,60,15 15 30,40,75,80,95,70 40,80,80,75,15 0,10,50 0,74,83 78 35,61,78,85 5 3,3 7,25 60 0 0
351 259 434 94 383 334 435 340 323 323 349 340 340 436 341 322 322 334 334 323 404 340 437 437 437 437 437
50-60
329
Table 3.24. continued
Species
Tissue
Dose (mg/kg) and route
Time (h) after injection
Percentage depletion of noradrenaline
Reference
~~
Rabbit Cat Cat Cat Cat Cat Cat Cat Cat Dog Dog Monkey Chick Chick (1-5 day) Chick (21 day)
Heart Heart Brain Adrenals Hypothalamus Superior cervical ganglion Heart Spleen Nictitating membrane Heart (atria & yen tricles) Heart (atria) Heart Heart Brain Brain
1.25,5,20 i.v. 15 S.C. 15 S.C. 15 S.C. 15 i.p.
17 24 24 24
35,59,70 75 0 0 0
337 437 437 431 34 1
15 i.v. 10J5 S.C. 10,15 S.C.
18 18
50-60 61,83 73,94
3 29 264 264
10,15 S.C.
18
85,>95
264
10,30 i.v. 15 i.v. 15 10 S.C. 10 S.C. 10 S.C.
2.5 4,24 18 24 24 24
50.60 25,95 95 50 40 0
435 403 284 328 328 328
180
GUANIDINES AND ADRENERGIC NERVE ENDINGS
extensive depletion 13281, but the short-lasting effect on brain noradrenaline in other species is due perhaps t o a prolonged reflex stimulation of the sympathetic system rather than to a more direct action o n the brain [329] . The catecholamines in the adrenal glands are also fairly resistant t o depletion by guanethidine. Direct observation with the electron microscope of rat adrenal medullary granules showed that these were not depleted of their noradrenaline in animals treated with either guanethidine or reserpine, whereas noradrenaline storage granules in the pineal gland and vas deferens were depleted readily [ 3 3 0 ] . This resistance is not due t o any failure o n the part of guanethidine t o enter the adrenals 13231, but it may depend on differences in the catecholamine storage mechanisms in adrenal and nervous tissue. The catecholamine storage granules from chromaffin cells are larger and heavier than the storage granules isolated from sympathetic nerves, [ 3 3 1 , 3 3 2 ] and there are also other differences. Literature o n the effect of guanethidine o n other natural tissue amines is scanty. In rats, u p t o about SO per cent depletion of 5-hydroxytryptamine has been reported in the brain [21 I ] , thyroid [333] , duodenum [21 I ] and small intestine 1334, 33.51, but n o depletion has been observed in the spleen or ileum [21 1, 3341. Guanethidine does not affect rat-heart histamine [ 3 3 6 ] . The noradrenaline normally contained in the storage granules can be partly or completely replaced by structurally related sympathomimetic amines, either by injection of the amine itself, or of suitable precursors such as a-methyl-DOPA or a-methyl-rn-tyrosine. These amines can be depleted from the heart by guanethidine in the same way as the noradrenaline which they had replaced. a-Methylnoradrenaline [337] and metaraminol [338] are depleted less readily than noradrenaline from rabbit or rat hearts, whereas dopamine, octopamine and rn-octopamine are depleted more readily than noradrenaline [339] . The more rapid depletion of these last three compounds was attributed t o weaker binding in the storage granules [ 3 3 9 ] , but could equally well be due t o their greater susceptibility t o destruction by monoamine oxidase, since both a-methylnoradrenaline and metaraminol are resistant t o attack by monoamine oxidase. The effect on tissue noradrenaline levels of repeated administration of guanethidine over a period of several days or weeks differs little from that produced by a single large dose. Thus, repeated dosing failed t o lower brain ,noradrenaline in rats [322, 340, 3 4 : ] , dogs [254] or rabbits [ 2 5 4 ] , although there was some effect in cats [341] ; nor was there much effect on adrenal catecholamines in rats [322, 3401 or rabbits [254]. Adrenal catecholamines in dogs were lowered by about 50 per cent o n daily oral administration of 5 mg/kg of guanethidine for 2 8 days [254].
Other guanidines
Many guanidines, besides guanethidine, will lower tissue noradrenaline, although only two have been found to be more active, namely the spiro analogue
181
G . J . DURANT, A. M. ROE, A. L. GREEN.
(LXXXVI) [342] of guanethidine and P-hydroxyphenethylguanidine (LXXXVII) [264]. Guanoxan (V) has about equal activity, on acute administration, to that of guanethidine [94, 2541 . Structure-activity relationships are summarized in
c
OH
N.(CH2)2.NH.C=NH
I
I
PhCHC H2. NH C=N H
I
N H2
N"2
(LXXXv I )
(LXXXVI I)
Tables 3.25-3.27. As there is considerable diversity in the choice of species, route of administration, and time after injection in these studies, depleting Table 3.25. NORADRENALINE-DEPLETING ACTIVITY OF GUANETHIDINE ANALOGUES AND MISCELLANEOUS GUANIDINES RNHC(: NH)NH2 Depleting potency *
R
c
N (CH7)* (Quanethidine)
tt++
Reference
see Table 3.24
tt
234
t+t+t
342
0
438
+t
438
+t tt